

NATIONAL QUALITY FORUM  
+ + + + +  
POPULATION HEALTH & PREVENTION ENDORSEMENT  
MAINTENANCE STEERING COMMITTEE

+ + + + +  
TUESDAY  
SEPTEMBER 13, 2011

+ + + + +  
The Steering Committee met at the  
Marriott Wardman Park Hotel, 2660 Woodley Park  
Road, N.W., Washington, D.C., at 8:39 a.m.,  
Paul Jarris and Kurt Stange, Co-Chairs,  
presiding.

PRESENT:

PAUL JARRIS, MD, MBA, Co-Chair  
KURT STANGE, MD, PhD, Co-Chair  
RON BIALEK, MPP, Public Health Foundation  
LARRY COHEN, MSW, Prevention Institute  
LINDA KINSINGER, MD, MPH, National Center

for Health Promotion and Disease  
Prevention

FRANK LEONE, MD, MS, Penn Lung Center,  
University of Pennsylvania

SARAH LINDE-FEUCHT, MD, Health Resources  
and Services Administration

KEITH MASON, MS, National Forum for Heart

Disease and Stroke Prevention

RHONDA MEDOWS, MD, UnitedHealthcare

JACQUELINE MERRILL, RN, MPH, DNSc

MADELINE NAEGLE, PhD, FAAN, APRN, BC, New  
York University College of Nursing

ROBERT PESTRONK, MPH, National Association  
of County and City Health Officials

SUE PICKENS, MEd, Parkland Health and  
Hospital Systems

PRESENT(Cont'd):

SARAH SAMPSEL, MPH, WellPoint

JASON SPANGLER, MD, MPH, Partnership for  
Prevention

MATT STIEFEL, MPA, Kaiser Permanente

MICHAEL STOTO, PhD, Georgetown University

ANDREW WEBBER, National Business Coalition  
on Health

NQF STAFF:

HELEN BURSTIN, MD, MPH

KAREN ADAMS, PhD

HEIDI BOSSLEY, MSN, MBA

KRISTIN CHANDLER, MPH

ANN HAMMERSMITH, JD

NICOLE McELVEEN, MPH

ELISA MUNTHALI, MPH

ROBYN Y. NISHIMI, PhD

KAREN PACE, PhD, RN

MARY PITTMAN, DrPH

REVA WINKLER, MD, MPH

ALSO PRESENT:

KEZIAH COOK, Acumen

MEGAN LINDLEY, CDC

DAWN JACOBSON, Los Angeles Department of  
Public Health

ELIZABETH MADIGAN, Case Western Reserve  
University

STEVE TEUTSCH, Los Angeles Department of  
Public Health

## C-O-N-T-E-N-T-S

Welcome and Introductions	4
Disclosures of Interest	5
Ann Hammersmith, JD, General Counsel	
Project Overview and Review of Agenda	16
Elisa Munthali, MPH	
National Priorities Partnership and Population Health	28
Karen Adams, PhD	
Paul Jarris, MD, MBA	
Measure Evaluation for Population Health Measures	103
Helen Burstin, MD, MPH	
Analytic Framework, Principles, and Environmental Scan: Background Commissioned Paper (Annotated Outline)	157
Steven Teutsch, MD, MPH, Chief Science Officer	
Dawn Jacobson, MD, MPH, Director, Performance Improvement	
Los Angeles County Department of Health	
NQF Member/Public Comment	229
Population Health Measurement Issues	243
Paul Jarris, MD, MBA, Co-Chair	
Consideration of Candidate Standards (Immunizations)	358
Kurt Stange, MD, PhD, Co-Chair	
Adjournment	454

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

P-R-O-C-E-E-D-I-N-G-S

8:39 a.m.

DR. JARRIS: Good morning,  
everyone, and now is the most important part  
the meeting, go ahead.

DR. WINKLER: Anthony, are you on  
the line?

OPERATOR: Yes, we have the line  
connected.

DR. WINKLER: Please connect, open  
our lines please. We're getting started.  
Thank you.

DR. JARRIS: We have a script to  
follow here. Good morning and thanks for  
coming from all over. Probably the furthest  
person to come is Mr. Cohen from South Africa,  
dodging lions. Right. I think this an  
exciting initiative that we're beginning here.

It's going to be both conceptually  
and methodologically challenging, I believe,  
as we sort of stretch into the area of  
population health, and it's a great group of

1 folks in the room. So I'm looking forward to  
2 joining you all in this journey.

3 Why don't we begin by  
4 introductions? I'm Paul Jarris. I'm the  
5 Executive Director of the Association of State  
6 and Territorial Health Officials, which we  
7 represent the 50 state, D.C. and the U.S.  
8 Territories and freely-associated states'  
9 public health agencies and departments. We're  
10 based here in Washington, D.C., and it's a  
11 pleasure to be here.

12 DR. BURSTIN: Actually, before we  
13 proceed any further, as we're doing  
14 disclosures, good morning, I'm Helen Burstin,  
15 perhaps we can also introductions with  
16 disclosures would be more efficient. So maybe  
17 if Ann Hammersmith could just briefly describe  
18 what she'd like you to do. She's our general  
19 counsel.

20 DR. JARRIS: Good.

21 MS. HAMMERSMITH: Good morning,  
22 everyone. For those of you who've been to our

1 meetings before, this portion of the meeting  
2 is familiar to you, but I will go over it.  
3 Several weeks ago you should have received a  
4 disclosure of interest form from us, where we  
5 asked you very specific questions, and we then  
6 reviewed your responses.

7           What we'd like to do here today is  
8 have you go around the table and disclose  
9 anything that you think is relevant to your  
10 service on this Committee. I want to  
11 emphasize it's not necessary for you to  
12 summarize your CV. We just want you to  
13 disclose things that are particularly relevant  
14 to your service on the Committee, and that may  
15 well be nothing at all.

16           We'd like you to pay particular  
17 attention to relevant research or grant monies  
18 that you have, that you've had in the last two  
19 years, and also to consulting, including  
20 speaking fees, which you've had in the last  
21 two years, and anything else that you think as  
22 well is relevant.

1 I also want to remind you that you  
2 serve on this Committee as an individual, not  
3 as a representative of your employer or of  
4 anyone who nominated you to serve on the  
5 Committee. You are serving as an expert. So  
6 with that, go back to Dr. Jarris, and have him  
7 disclose, and then if you just go around the  
8 room, introduce yourselves and do your  
9 disclosure at the same time.

10 DR. JARRIS: Okay. So our  
11 organization is a 501(c)(3). We get  
12 substantial funding from Health and Human  
13 Services, largely from Center for Disease  
14 Control and other branches of HHS. I don't  
15 perceive of any of those in particular as a  
16 conflict here, but thank you. Dr. Stange.

17 DR. STANGE: Hi, I'm Kurt Stange.  
18 I'm a family physician and public health and  
19 internal medicine position from Cleveland, on  
20 the faculty of Case Western Reserve  
21 University. I also work at a federally  
22 qualified community health center, have

1 hospital privileges at our three health care  
2 systems, the Cleveland Clinic, Metro Health,  
3 our county system. Is that more detailed than  
4 you want for this -- okay.

5 I have a bunch of grants from the  
6 NIH and a few foundations, and am doing three  
7 quarter time for the next year with the  
8 National Cancer Institute. That's about it.

9 DR. WINKLER: Good morning. I'm  
10 Reva Winkler. I'm a Senior Director of  
11 Performance Measures at NQF. Thank you all  
12 very much for being here.

13 MS. MUNTHALI: Good morning. I'm  
14 Elisa Munthali, a Senior Project Manager at  
15 NQF. Thank you.

16 DR. NISHIMI: Good morning,  
17 everyone. I'm Robyn Nishimi. I was the  
18 former chief operating officer at NQF, but now  
19 I'm a consultant to them.

20 MS. MERRILL: Good morning. I'm  
21 Jacqueline Merrill. I'm an associate  
22 professor in Nursing and Biomedical



1 Informatics at Columbia. I don't think I have  
2 anything to disclose. I have foundation  
3 funding and occasionally small funding from  
4 CDC.

5 DR. KINSINGER: Good morning. I'm  
6 Linda Kinsinger. I'm a general internist of  
7 preventive medicine physician. I'm the chief  
8 of Preventive Medicine for the Veterans Health  
9 Administration. I have no financial  
10 disclosures to report. I do serve as the VHA  
11 liaison to the U.S. Preventative Services Task  
12 Force and the Advisory Committee on  
13 Immunization Practices.

14 DR. LINDE-FEUCHT: Good morning,  
15 excuse me. I'm Sarah Linde-Feucht. I'm a  
16 family physician and the chief public health  
17 officer of HRSA. I don't have anything to  
18 disclose.

19 DR. NAEGLE: Good morning. I'm  
20 Madeline Naegle. I'm a professor at NYU's  
21 College of Nursing. NYU is a private  
22 university in the public service. I have some

1 NIDA funding and a substance abuse education  
2 grant. I also serve as the director of our  
3 World Health Organization Collaborating Center  
4 in Geriatric Nursing Education. No  
5 disclosures there.

6 MR. WEBBER: Good morning. I'm  
7 Andy Webber, president and CEO of the National  
8 Business Coalition on Health. We're a  
9 national association of employer-based health  
10 coalitions around the country, focused on the  
11 triple aim of better health, better care and  
12 lower costs.

13 I have no financial conflicts.  
14 Our group does have a CDC cooperative  
15 agreement, and we have some foundation grants  
16 that relate to population health improvement  
17 at a community level, but I think I'm okay.  
18 Thank you.

19 DR. SPANGLER: I'm Jason Spangler.  
20 I'm the chief medical officer of Partnership  
21 for Prevention, which is a health policy and  
22 research non-profit organization here in D.C.

1 that focuses on clinical prevention and  
2 community prevention.

3 We also have a cooperative grant  
4 with CDC and we get some foundation funding,  
5 some funding from pharmaceutical companies as  
6 well, but I don't have any financial conflicts  
7 to disclose.

8 MR. PESTRONK: I'm Bobby Pestronk,  
9 the Executive Director at the National  
10 Association of County and City Health  
11 Officials, NACCHO. We are a 501(c)(3)  
12 organization located here in Washington, D.C.,  
13 and we represent the approximately 2,700 local  
14 health departments across the country.

15 NACCHO receives grants from the  
16 federal government, predominantly the  
17 Department of Health and Human Services. We  
18 also receive foundation funding as well. I  
19 don't believe I have any conflicts to  
20 disclose.

21 DR. STOTO: Good morning,  
22 everyone. I'm Mike Stoto. I'm a professor of

1 Health Systems Administration and Population  
2 Health at Georgetown University. Most of my  
3 research is funded by CDC, some in partnership  
4 with state and local health departments, and  
5 a little bit of foundation work as well. But  
6 I don't think I have anything to disclose.

7 MR. STIEFEL: Hi. I'm Matt  
8 Stiefel, Senior Director for Care and Service  
9 quality at Kaiser Permanente. No financial  
10 disclosures. I am a fellow and faculty member  
11 with IHI for the Triple Aim Initiative, and  
12 serve on a couple of NCQA committees.

13 DR. PICKENS: Hi. I'm Sue Pickens  
14 with -- I'm Director of Population Medicine at  
15 Parkland Health and Hospital System, a county  
16 -- large health system in Dallas, Texas, and  
17 I don't believe I have anything financially to  
18 disclose.

19 MS. SAMPSEL: Good morning. I'm  
20 Sarah Sampsel, Health Index Strategies  
21 Director with WellPoint. We manage 14 Blue  
22 Cross/Blue Shield plans across the country.

1 Typically, branded by Anthem, and we own  
2 Resolution Health, which we will be reviewing  
3 one of their measures, and then previously, I  
4 was a measure developer at NCQA.

5 MR. MASON: Hello. My name is  
6 Keith Mason. I'm the Executive Director of  
7 the National Forum for Heart Disease and  
8 Stroke Prevention, a 501(c)(3), in which it's  
9 an organization of organizations that care  
10 about cardiovascular disease and prevention of  
11 that. We are a 501(c)(3) that receives funds  
12 from pharma companies, CDC, NHLBI, and AHA,  
13 and I have no conflicts myself.

14 MR. COHEN: Hi everyone. I'm  
15 Larry Cohen. I'm Executive Director at the  
16 Prevention Institute, and despite what I said  
17 earlier about living in South Africa, actually  
18 we're in Oakland, California, and I just was  
19 in South Africa and feel like I should live  
20 there.

21 You know, our work is entirely on  
22 prevention in the first place, ideally before

1 medical services are necessary. So I hope  
2 that's an attribute and not a conflict. But  
3 our funding is to do that and to promote that.

4 MS. HAMMERSMITH: Okay, thank you.

5 DR. JARRIS: Do you want to  
6 introduce yourself? At the end, and disclose  
7 any conflicts.

8 MR. BIALEK: This is Ron Bialek.  
9 I do not have any conflicts related to this  
10 activity, and sorry for being tardy.

11 DR. JARRIS: Who do you work for?

12 MR. BIALEK: I work for the Public  
13 Health Foundation, last I checked.

14 MS. HAMMERSMITH: Okay, thank you  
15 everyone for those disclosures. Do any of you  
16 have any questions of me, or is there anyone  
17 you want to discuss with each other, based on  
18 your disclosures?

19 (No response.)

20 MS. HAMMERSMITH: Okay, thank you.  
21 Have a good meeting.

22 DR. JARRIS: Helen and the staff,

1 could you otherwise introduce yourselves?

2 DR. BURSTIN: Thank you. I'm  
3 Helen Burstin. I'm the Senior Vice President  
4 for Performance Measures at NQF. I thank you  
5 all for being here. Some very familiar faces  
6 and some new ones, which is not surprising,  
7 considering this is definitely a new area for  
8 NQF and we thank you for your patience. It  
9 was a bit of blending of minds and culture and  
10 we recognize that, and hope you can help us  
11 see the path forward. We'll have lots more  
12 opportunity to talk, but I'll pass it back to  
13 Paul.

14 DR. JARRIS: Kristin. Kristin,  
15 did you want to introduce yourself?

16 MS. CHANDLER: My name is Kristin  
17 Chandler, I am a project analyst at the  
18 National Quality Forum.

19 DR. JARRIS: Okay, thank you. So  
20 just a couple of ground rules. The rest rooms  
21 are down the hall to my right here. During  
22 the presentations, if you want to ask

1 questions, just raise your hand. If we're  
2 having a discussion and you have something  
3 that follows on what's been said before, just  
4 jump in.

5 If you want to get into the queue  
6 and we're having an active discussion, go  
7 ahead and put your card up like this, and  
8 we'll recognize you. Paul and I have a list  
9 here that we'll develop for running the  
10 discussion. Elisa's going to give us our  
11 charge and frame for the day.

12 MS. MUNTHALI: Thank you very  
13 much. The Steering Committee has received  
14 much of this information during your  
15 orientation call and during your work group  
16 call. But we thought it was important to  
17 repeat some of this, and I also wanted to just  
18 highlight a couple of housekeeping things,  
19 just to add to what Dr. Stange has just  
20 mentioned.

21 We are recording and transcribing  
22 this meeting. So whenever you're speaking,



1 whether you're providing a comment or a  
2 question, we ask that you make sure your  
3 microphone is on. The transcript and the  
4 recording will be posted to our project page  
5 within the next few weeks.

6 We also just wanted you to know  
7 that we have participants on the phone. This  
8 is an open call. It's open to NQF members and  
9 to our public, who will have opportunity at  
10 several points during the agenda to make  
11 comments, and we've also invited measure  
12 developers, who will be here to add to, to  
13 clarify any questions that the Steering  
14 Committee may have on their measures.

15 So Kristin, if you can advance the  
16 slide, and we've, I think, all introduced  
17 ourselves, so we can go to the next slide.  
18 We've outlined several meeting objectives.  
19 They include the evaluation of the clinical  
20 preventative services and immunization  
21 measures for endorsement.

22 In doing so, if there are any

1 related and competing measures, we're hoping  
2 that the Committee will identify those for  
3 further evaluation of measure harmonization,  
4 or to select the best measure and class among  
5 the competing measures.

6 We're hoping that in doing so as  
7 well, that we identify gaps in performance  
8 measures for the measures that are in front of  
9 us today.

10 We're asking also the Committee to  
11 provide feedback on the population health  
12 annotated outline, and the authors of the  
13 outline will be participating by  
14 teleconference at about 11:00 a.m. They're in  
15 California, so I think they might be still  
16 sleeping at this point. But they will be here  
17 to answer any questions.

18 They'll give a brief update and  
19 they'll be here to answer questions, detailed  
20 questions about the outline. We're also  
21 hoping that we'll be able to identify  
22 measurement principles for endorsement of

1 population health measures, and be able to  
2 assess how NQF's measure evaluation criteria  
3 might apply to population health measures.  
4 Finally, we're hoping to identify measures  
5 that address healthy behaviors, and this will  
6 be part of Phase 2 of the project.

7 With regards to the meeting  
8 format, as I mentioned before, members and the  
9 public will have opportunity to provide  
10 comment. Our measure developers are here, and  
11 what they will do is at the beginning of each  
12 measure topic, whether it's the immunization  
13 influenza measures, they will give a brief  
14 update about three to five minutes. They're  
15 here throughout to be available to answer any  
16 of the questions that you may have. Then the  
17 Steering Committee will discuss and vote on  
18 each of the measures that are put before you.

19 As mentioned before, we are  
20 extremely excited about the project, and  
21 essentially what we're attempting to do is to  
22 expand NQF's portfolio of existing

1       preventative services and healthy behaviors  
2       measures.

3                   In doing so, we're trying to  
4       foster harmonization of these types of  
5       measures at all levels of analysis, especially  
6       at the provider and population level. This  
7       project is very unique, in that the Committee  
8       will not only consider provider level measures  
9       for endorsement, but also population level  
10      measures later on in the project in Phase 2.

11                   This work will be carried out in  
12      two phases. During the first phase, the  
13      Committee will evaluate 19 endorsed and newly-  
14      submitted clinical preventative services and  
15      immunization measures. Also during Phase 1,  
16      the Committee will initiate foundational work  
17      to prepare for Phase 2, which we hope will be  
18      a consensus development project for provider  
19      and population level healthy behaviors  
20      measures.

21                   Those measures would include topic  
22      areas like smoking, obesity, and physical

1 activity. Because this evaluation and  
2 endorsement of population level measures, as  
3 we mentioned before, is relatively new for  
4 NQF, there's a great deal that we have to  
5 learn, define and standardize.

6 So in preparing for Phase 2, the  
7 Committee will identify measurement principles  
8 for endorsement of population health measures.  
9 They will also look at our measure evaluation  
10 criteria as it might apply to population  
11 health, and the Committee will also have  
12 significant input into the call for measures  
13 for healthy behaviors in Phase 2.

14 To further lay the foundation for  
15 Phase 2, we have selected a contractor, the  
16 Los Angeles County Department of Public  
17 Health, who will develop a Commission paper to  
18 include an environmental scan and gap analysis  
19 of population health measures. They will join  
20 us later on, as I mentioned, by phone.

21 I wanted to talk a little bit more  
22 about the time line, and this is the same time

1 line that I shared with you during our  
2 orientation call, and I think during the work  
3 group meetings. Right now, we're probably,  
4 we're nearing the middle of it, and I won't go  
5 into detail, but it's included in your slide  
6 packet.

7 Kristin, the next slide. Also to  
8 share again, we thought it was important to  
9 reiterate the role of steering committees. As  
10 you know, the Steering Committee will act as  
11 a proxy for NQF multi-stakeholder membership  
12 for this project. You will work with us to  
13 achieve our goals and that's us as staff.

14 You evaluate the submitted  
15 measures against our measure evaluation  
16 criteria. These will be the 19 measures that  
17 you're starting off with today. After you've  
18 discussed your measures, you're going to make  
19 recommendations to NQF's membership for  
20 endorsement. During our comment period, which  
21 is open to NQF members and to the public,  
22 you'll respond to those comments.

1                   Your co-chairs, Paul Jarris and  
2 Kurt Stange, will represent you at our project  
3 webinar and at our Consensus Standards  
4 Approval Committee meeting.

5                   The following outlines the eight  
6 steps of the consensus development process,  
7 and right now we are on Step No. 3, which is  
8 the candidate standards review. So the  
9 Committee is going to review, evaluate and  
10 recommend for endorsement the 19 measures that  
11 are in front of you.

12                   This is just a visual schematic of  
13 the CDP, and it shows the important steps  
14 again, and the entire process, including the  
15 current step, which is highlighted for you.  
16 Since this is part of an endorsement  
17 maintenance process, we thought it was  
18 important to outline the significance of this  
19 process.

20                   We recently tightened our  
21 endorsement maintenance process for  
22 consistency, and to allow our measure

1 developers, our members and our public  
2 sufficient time and notice of upcoming  
3 projects. We now have a regular schedule for  
4 maintaining endorsement of NQF-endorsed  
5 consensus standards, to ensure that these  
6 remain current.

7 Our measures are up for  
8 maintenance review every three years.  
9 Developers are notified several months in  
10 advance of their scheduled maintenance review,  
11 and they may opt out of the process. If they  
12 choose to do that, their measure will lose  
13 NQF-endorsed measurement status. If they  
14 proceed with the process, their measure must  
15 be reviewed against all of our current  
16 evaluation criteria.

17 During this process, we have  
18 accepted new and endorsed measures, and with  
19 the increasing number of measures in our  
20 current portfolio, and the new measures.  
21 We're encountering a number of similar and/or  
22 competing measure issues, which may warrant



1 harmonization of measures, specifications or  
2 a determination of which measures is best in  
3 class.

4           So that gives you just a brief  
5 update on the project and where we are within  
6 the context of our evaluation criteria, and  
7 now I wanted to turn into over to Karen Adams  
8 from the National Priorities Partnership, who  
9 will talk about NPP and the work they've done  
10 on population health.

11           DR. JARRIS: Dr. Medows, would you  
12 like to -- welcome, and would you like to  
13 introduce yourself, and if you have any  
14 conflicts of interest, you have to disburse  
15 the money to us and then I'll go on. Go  
16 ahead.

17           DR. MEDOWS: I've missed you,  
18 Paul. I'm Rhonda Medows. I'm a family  
19 physician. I am the executive vice president  
20 and chief medical officer for United  
21 Healthcare. I am charged with improving the  
22 quality and performance for Medicaid and

1 Medicare plans, as well as for commercial  
2 plans. I don't know how else to describe  
3 conflict of interest, other than saying that  
4 I work for an insurance company.

5 DR. JARRIS: There are other  
6 guilty parties in the room. You're okay, and  
7 others of us who used to. Frank, would you  
8 like to introduce yourself, and to let us know  
9 if you have any conflicts?

10 DR. LEONE: Hi everyone. Frank  
11 Leone, pulmonologist at the University of  
12 Pennsylvania. I direct the Comprehensive  
13 Smoking Treatment programs there. I have no  
14 conflicts to declare.

15 DR. JARRIS: Well very good. Just  
16 a comment. We'll have a lot of time this  
17 afternoon to talk about population health and  
18 some of the issues that we have to look at in  
19 there. So just, it's helpful for me to keep  
20 in mind these NQF meetings. In many ways,  
21 these are cross-cultural meetings.

22 When we bring together folks from

1 the clinical sector, insurance, public health,  
2 we often have different world views, and look  
3 at the world differently. So I think it's  
4 very important for us all to be patient as we  
5 share our concepts with each other, and learn  
6 the concepts from the other sectors. By the  
7 end of this, we'll all meet somewhere close to  
8 the middle, and be a lot smarter for it. But  
9 it's going to be quite a process.

10 So with that, I'd like to  
11 introduce Karen Adams, who's the Vice  
12 President of the National Priorities for the  
13 National Quality Forum, and I've worked  
14 extensively with her. A wonderful staff  
15 person here and leader.

16 MR. MASON: I just have one  
17 question about Elisa's slides. You said Phase  
18 1 was over in January, but it didn't really  
19 say anything about Phase 2. Is that Phase 1  
20 and 2? It just indicated Phase 1 on the time  
21 line.

22 MS. MUNTHALI: Phase 1 actually

1 isn't over in January. We're hoping it will  
2 be over in the spring. Phase 2 we're hoping  
3 will be over in the fall, fall 2012.

4 DR. ADAMS: I appreciate the  
5 opportunity to speak with you today, in  
6 particular around NPP's work, National  
7 Priorities Partnership work. We've just  
8 released a report to the Secretary of Health  
9 and Human Services on September 1st, so the  
10 timing is very important, particularly to this  
11 work.

12 Although we're going to offer kind  
13 of an overview of the report, we have played  
14 special attention in particular to the  
15 population health oriented recommendations,  
16 and we certainly welcome your feedback. Allow  
17 me to acknowledge that Paul Jarris did serve  
18 as our co-chair of the National Priorities  
19 Partnership Population Health Subcommittee,  
20 and also Jason Spangler and Matt Stiefel, who  
21 are on the Committee, contributed to that work  
22 group as well. So Matt and Jason, tell us if

1 we get it right. We welcome your input here  
2 as well.

3 So since, as Paul shared, we have  
4 both people who are familiar to NQF processes  
5 around the table, as well as those who have  
6 been involved with the National Priorities  
7 Partnership or other work.

8 I thought I would spend a few  
9 minutes setting some context slides, and then  
10 Paul will go into the details around the  
11 recommendations, and we'll do a little bit of  
12 wrap-up about the next steps and path forward,  
13 because certainly this work will be very  
14 instrumental in connecting the dots, so to  
15 speak, with this national level initiative.

16 So if you can go to the next  
17 slide, please. Just a brief overview on NQF.  
18 Of course, many of you are familiar with our  
19 long-standing history around endorsement of  
20 performance measurement.

21 But we do have a three-part goal,  
22 and about four years ago, our Board did expand

1 our mission, and you see this here, building  
2 consensus on national priorities and goals,  
3 and this is the work of the National  
4 Priorities Partnership, endorsing our  
5 consensus standards, which will be an  
6 important role that you'll be playing, and  
7 then promoting alignment in the goals through  
8 education and outreach programs.

9 Just a little bit of context-  
10 setting around NQF, which is the convener of  
11 the National Priority Partnership, and how  
12 this plays into our broader mission.

13 Next slide, please. A little bit  
14 about the National Priorities Partnership.  
15 Now in your background material, we provided  
16 a list of all the organizations, and certainly  
17 on our website, we have our contact  
18 individuals who serve. But these are  
19 organizational representatives.

20 As I mentioned, the National  
21 Priorities Partnership is convened by NQF, and  
22 it includes 48 organizations across every

1 sector of healthcare. I'd like to emphasize  
2 here that importantly, when we began our work  
3 four years ago, we recognized that we needed  
4 additional representation from our colleagues  
5 in population and public health.

6 So Paul, as well as others, have  
7 been added to this group, to ensure that we  
8 have this broader view of health. You'll see  
9 the various other representatives of  
10 organizations we have on this Committee, from  
11 consumers, through health plans, through  
12 industry.

13 We also have federal partners that  
14 you see listed here. We work very closely  
15 with Peter Briss at the CDC, as well as  
16 others, and our federal partners are ex-  
17 officio, non-voting, and this effort is led by  
18 Bernie Rosof from the physician consortium,  
19 and Helen Darling from the National Business  
20 Group on Health. So a little bit about the  
21 NPP.

22 So let me give a little bit of

1 context, particularly in the realm of health  
2 reform and ACA. Within the ACA legislation,  
3 HHS must develop a national strategy around  
4 this triple aim of better care, affordable  
5 care, and importantly, healthy people, healthy  
6 communities.

7 So it was from the beginning, it  
8 was very strongly felt that the NQF should be  
9 shaped by multi-stakeholder input, that this  
10 is a national strategy, certainly a federal  
11 type of initiative. But it's a national  
12 strategy that requires input across sectors.

13 So it was very important that  
14 there was coordination and alignment around  
15 the various stakeholder groups. So HHS  
16 requested NQF to convene the NQP, which had  
17 already been active for a number of years, to  
18 serve in that role, to provide this input from  
19 across the different sectors.

20 So specifically, last fall in  
21 October, the National Priorities Partnership  
22 provided up front input into the National



1 Quality Strategy. So we were asked to provide  
2 some input around the preliminary framework  
3 that was put forth around this three-part aim.

4 Then, this year, when the National  
5 Quality Strategy was released in March, the  
6 National Priorities Partnership was asked once  
7 again to provide input on the goals and the  
8 measures and strategic opportunities.

9 I'm going to focus a little bit on  
10 these strategic opportunities, because there  
11 is clearly a role for population and public  
12 health, and as will be emphasized, under that  
13 bridging of delivery system and the public  
14 health, population health sector. So this  
15 input was very critical as we moved on. So we  
16 will, of course Paul will speak to the goals  
17 and the associated measure concepts.

18 But I do think that the strategic  
19 opportunities, as we think about this work,  
20 will be critical as well. We just, we  
21 submitted our report to the Secretary, 1st  
22 September. We're happy to provide a PDF or

1 copies of the report for you in detail. I  
2 know you've got a lot of background materials,  
3 so we didn't want to weigh you down too much.

4 So as we speak to these strategic  
5 opportunities, and I'll ask that we go to the  
6 next slide please, and then to then to the  
7 next slide. Thank you. I'm getting a little  
8 ahead of myself. Here are some of the three  
9 strategies. So HHS access. Can you map some  
10 strategic opportunities to each of these  
11 goals?

12 When the NPP was doing their work,  
13 they said you know certainly it would be  
14 fortunate to have 32 strategic opportunities  
15 or however the number of goals were. But we  
16 thought that three really surfaced to the top,  
17 as kind of an organizing framework.

18 One was that we needed a national  
19 strategy for data collection, measurement  
20 reporting that supports measurement-based  
21 improvement. We hear in the field,  
22 particularly this kind of a noise and the

1 cacophony and there needs to be alignment.  
2 Alignment is a huge message that certainly  
3 came through our public comment period.

4 So there's both strategic  
5 opportunity around a national strategy for  
6 data collection, very critical. As we think  
7 about that, how do we integrate and population  
8 health level data into that data collection  
9 strategy will be very critical.

10 The report goes into much more  
11 detail around each one of these strategies.  
12 But in regards to time today, I won't go  
13 through all those. But you know, certainly  
14 the work that you'll be doing now will be very  
15 important to this strategy.

16 The second strategy is around  
17 community infrastructure, and this is public  
18 and private and that, you know, we need to  
19 work with communities. Communities are  
20 innovating. It's not so much about telling  
21 communities what their goals should be,  
22 although certainly we want alignment with the

1 National Quality Strategy, but now do we help  
2 them and support them with the work that  
3 they're doing, and building an infrastructure  
4 for measurement, public reporting and  
5 importantly, a feedback loop for best  
6 practices.

7           So very bidirectional, and we've  
8 been working with our community and regional  
9 based representatives in this regard. Then  
10 the third, which probably will come to no  
11 surprise at all, is around payment and  
12 delivery system reform, and the importance of  
13 primary care. Our report places a lot of  
14 attention on upstream prevention, and looking  
15 at these different types of integrated  
16 delivery models that are under ACA.

17           As I shared, these are played out  
18 further in the report. But we did want to  
19 spend a few moments on that, because  
20 certainly, your role moving forward, around  
21 playing out these recommendations, will be  
22 very critical. So Paul, I'm going to turn it

1 over to you, because of course, this will get  
2 into the goals and strategic opportunities,  
3 and I'm happy to answer any questions.

4 DR. JARRIS: Well thank you,  
5 Karen, and Matt and Jason, please feel free to  
6 help, for we need your help. We made great  
7 conceptual breakthroughs during our meeting.  
8 Both of them contributed significantly. So  
9 overall then, in looking at this, the HHS  
10 National Quality Strategy have come out with  
11 six national priorities.

12 There were three, this is based on  
13 the triple aim or three-part aim. There were  
14 two priorities under what was called community  
15 and population health, three priorities under  
16 patient experience, quality and care, and  
17 another two priorities under affordability,  
18 excuse me, one priority under affordability.

19 For each of those priorities, we  
20 have established three goals, and then look at  
21 measure concepts and measurement gaps, if we  
22 are going to actually establish a consistent

1 national way of looking at quality improvement  
2 across the country.

3 If you'll look, if you can see  
4 that slide, your eyes are better than mine,  
5 but on the top of that slide, you can see that  
6 there's better care, and then again patient  
7 experience, quality of care, and then  
8 affordable care on the bottom right, and on  
9 the left, healthy people, healthy communities.

10 Incidentally, during this process,  
11 we did not have, that I could determine, a  
12 common definition of what we meant by  
13 population health, and frankly, in looking  
14 back, I haven't found one in IHI or HHS in  
15 general. So I think that's something we'll be  
16 talking about in our next session.

17 The priorities established, you  
18 can see that six of them in the middle, or  
19 perhaps you can't see it, health and well-  
20 being, prevention and treatment of the leading  
21 causes of mortality, and by that  
22 cardiovascular health was chosen, the ABCs,

1 person and family-centered care, patient  
2 safety, effective communication and care  
3 coordination and affordable care.

4           So if we could flip to the next  
5 slide. The Healthy People-Communities  
6 Subcommittee, there were several themes we  
7 came up with that we wanted to make sure then  
8 checked back at the end of the process. That  
9 was to see if we had stuck with them. We  
10 really wanted to promote health and well-  
11 being.

12           So the concept of well-being is  
13 introduced, which is gaining further support.  
14 We got an email from Target Corporation today  
15 and health and well-being of their employees  
16 and customers is one of their corporate goals  
17 now. But again, going beyond just disease or  
18 absence of disease, trying to find out what  
19 are the attributes and characteristics of  
20 well-being was important to the group.

21           Health equity was critically  
22 important. We find that many of the

1 publications and documents, wherever they come  
2 from, including the HHS ones, certainly  
3 mention health equity. But when it gets down  
4 to it, there's very little meat on the bones.  
5 We wanted to really introduce this as an  
6 important concept, and that we will not have  
7 a healthy population unless we specifically  
8 address health equity.

9           Recognizing the need for  
10 intervention across the life span, Charlie  
11 Homer was on the committee. So needless to  
12 say, pediatrics was well-represented, and but  
13 also just the notion that for CMS, for  
14 example, there's little they can do if  
15 everyone hits age 65 and enrolls that are very  
16 ill, that we really have to look at what  
17 factors predispose people towards illness, or  
18 in fact the concept of health sustainability  
19 would be an interesting concept. How do we  
20 keep from breaking people in this nation, and  
21 breaking their health?

22           Incorporating community,



1 behavioral and clinical concepts. So in other  
2 words, broad-based notion of what constitutes  
3 health and well-being, not just the physical  
4 and clinical health that we often deal with in  
5 the health care sector, and emphasizing the  
6 importance of composite and outcome measures.

7 So ideally, we would have  
8 composite measures, and we'll talk a little  
9 bit more about this later, that you could  
10 disaggregate into specific behaviors, if  
11 you're looking at what is a measure of healthy  
12 behavior, for example. Next slide, please.

13 So the goals, we set three goals,  
14 and I think this actually may be important to  
15 this group, and could inform some of the work  
16 of this group. Clearly, it appeared to the  
17 committee that much of the concept of what was  
18 around community and population health was at  
19 the clinical level, clinical and preventative  
20 services.

21 In the most limited way of viewing  
22 that, you're talking about a population health

1 as clinical preventative services among my  
2 patient population, or it could be my hospital  
3 service or my insureds or enrollees in the  
4 insurance company.

5 So we wanted to recognize there's  
6 that strong view held by many people out  
7 there, by putting on the bottom, if you look  
8 at the third bullet there, receipt of  
9 effective clinical preventative services  
10 across the life span in clinical and community  
11 settings, acknowledging that clinical  
12 preventative services are important.

13 But then to go above that, and I  
14 think this is perhaps touched on in what's  
15 called Phase 2 of this project. We wanted to  
16 look at healthy behaviors, and behaviors we  
17 don't simply mean pejoratively, you know, if  
18 people only behaved right they would be  
19 healthy.

20 But healthy behaviors means that  
21 people live in a context in which it is  
22 possible to choose healthy behaviors, and that

1 those healthy behaviors become the easy and  
2 perhaps default behavior.

3           If you're living in a food desert  
4 or if you live in a crime-ridden area, you  
5 simply can't get healthy food. You can't  
6 afford it or it's not available in your inner  
7 city or rural grocery store, and your kid  
8 can't walk to school or play on the  
9 playground, because it's full of drug dealers.

10           So again, here the context is how  
11 do we create an environment in which healthy  
12 behaviors become the easy choice? On the top,  
13 the third aspect, goal aspect was community  
14 interventions that result in improvement of  
15 social, economic and environmental factors,  
16 recognizing there are social determinants of  
17 health that are very powerful, and that there  
18 policy levers, both public and private policy  
19 levers that can affect the environments in  
20 which people live, which can make the  
21 difference between being able to live a  
22 healthy life and not.

1           So we introduced this concept of  
2           these three tiers of goals and carried that  
3           through, and I think that might be something  
4           that's made it through the National Priority  
5           Partnership overall. So it is an official  
6           NQF, I think we can say position. So  
7           therefore, I think again we might want to look  
8           at that as we try to conceptualize what we're  
9           doing within this group.

10           Next slide, please. The measure  
11           concepts, I think the importance in looking at  
12           these is that look at how broad-based they  
13           are. Concepts of adequate social support or  
14           social capital, connectivity, has a lot to do  
15           with resilience. You see that a lot within  
16           youth or substance abuse or mental health and  
17           other areas. So it is a very important  
18           concept to start looking at.

19           Mental health. We wanted to make  
20           sure, and there's a substance abuse measure up  
21           here and binge drinking. We wanted to make  
22           sure we were looking at other leading causes

1 of death and disability, and not simply locked  
2 into the physical health that we often spend  
3 our time with.

4 ED visits for injuries. We put  
5 that in there, because injuries still continue  
6 to be one of the major causes of death for  
7 people under age 35, and that can be addressed  
8 both at individual level in the clinic, unless  
9 you live in Florida, which is illegal to ask,  
10 if you have a gun. Excuse me, Rhonda, a  
11 former Floridian.

12 But it can certainly be addressed  
13 at the behavioral level, in terms of getting  
14 people to wear a seat belt, and it can be  
15 addressed at a policy level, in Click It or  
16 Ticket, or in many other ways.

17 We thought it was important, in  
18 looking at behaviors, to try to come up with  
19 some index. Not do you just eat right or you  
20 exercise, but what is the composite measure of  
21 healthy behaviors, to see how people at a  
22 population level, how are they? Are they able

1 to and do they choose to behave in a healthful  
2 manner?

3 Then dental health made it up here  
4 also. Important, because dental health not  
5 only is one of the most common chronic  
6 illnesses, if you look at it from that point  
7 of view, but it certainly affects how children  
8 can learn in school, and it affects people's  
9 employment and employability. If your teeth  
10 are rotten, you can't even work a retail job,  
11 and again, back to social determinants. Your  
12 median family income is probably one of the  
13 major determinants of your health.

14 Then immunizations, which I think  
15 we'll get to today, a very obvious  
16 preventative measure at the population level.  
17 Next slide, please.

18 Gaps. Again, there's a lot of  
19 measurement gaps, we believe probably in this  
20 community and population level, particularly  
21 from NQF's perspective, since this is an area  
22 they haven't worked on. I think those in

1 public health perhaps have different types of  
2 measures that they look at, but they may or  
3 may not fit within the current NQF  
4 methodology.

5 So healthy lifestyle behaviors,  
6 again a composite. Community environmental  
7 assessment. What does it mean to be a healthy  
8 or healthful community that promotes well-  
9 being? How do we measure that, and my guess  
10 is that we don't really have a good measure  
11 right now. We have many measures.

12 Productivity. This concept was  
13 introduced in terms of, you know, if you're  
14 talking about well-being, you're probably  
15 talking about people's functioning as well.  
16 I mean, are kids going to school or are they  
17 absent? At people at work and are they  
18 productive? There's not absenteeism,  
19 presenteeism and other things like that? Are  
20 elderly people able to live a full life in  
21 their retirement years? These are gaps we  
22 think will have to be addressed.

1                   Next slide, please. The second  
2 national priority was promoting effective  
3 prevention, treatment intervention practices  
4 for leading causes of mortality, and HHS  
5 specifically wanted to look at this notion of  
6 cardiovascular disease as the number one  
7 killer in the nation in the disease category.

8                   Again, we applied the goals at the  
9 preventative services, behavioral and  
10 community level. We can go onto the next  
11 slide, and rather than looking at, in this  
12 community and population, at the specific  
13 disease processes, we were trying to look at  
14 the causes, if you will, the underlying causes  
15 of these diseases, which would, of course, be  
16 tobacco, nutrition, exercise, and alcohol and  
17 other things, although we did hit measures in  
18 all three levels of the goals here.

19                   Why don't we go on to the next  
20 one? So population levels, measurement gaps  
21 of some of these clinical things. How do we  
22 measure that? I think we might talk more



1 about that here, as Dr. Stange said. What is  
2 the denominator and how do we use that?

3 The ABCs, we do need good. So  
4 aspirin, blood pressure control, cholesterol,  
5 and smoking. Do we have good aggregate  
6 measures of that at the population level, and  
7 then healthy foods. How do we measure whether  
8 or not an individual or a community has access  
9 to healthy foods in their communities?

10 There's been a lot of work done on  
11 food deserts and all, but I don't think  
12 there's an accepted measurement for that.

13 Next slide.

14 Now we're into the area of patient  
15 experience or it's not called that. We call  
16 that the quality -- and quality area, and a  
17 large emphasis on person- and family-centered  
18 care, engaging people in their care as active  
19 participants, as knowledge participants who  
20 can navigate the system, and also be clearly  
21 involved in leading their own care.

22 I'll let you read through some of

1 these goals and measures. I won't go through  
2 them in the same detail as the prior one,  
3 because they're clearly very important, but  
4 you can read these on your own, if you will.

5 Next slide, please. Patient  
6 safety. Again, a very important area. HHS  
7 has the Partnership for Patients which NQF is  
8 working with them on, which is basically a  
9 patient safety initiative. I'd encourage you  
10 to all look at this.

11 For those of you across the  
12 spectrum, it's another area where there are  
13 active discussions with HHS and CMI, Center  
14 for Medicaid or Medicaid Innovation, about the  
15 role of people outside of the purely clinical  
16 sector and patient safety.

17 It tends to have been launched as  
18 a clinical initiative, and they are starting  
19 to gain an appreciation that much of the work  
20 for patient safety goes on in the public  
21 health sector also, all the way from  
22 preventing health care-acquired infections to

1 hospital licensing and on and on.

2 Next slide, please. Effective  
3 communication and care coordination.  
4 Certainly, culturally competent communication  
5 is important we need to measure and develop  
6 goals around, but also the care coordination  
7 between levels of care, whether that is hand  
8 offs, primary care, specialty care, hospital,  
9 long-term care, nursing home, but also the  
10 notion here that we need to engage the  
11 community and understand how the clinical  
12 sector and the community integrate, and how  
13 that hand off in care coordination occurs.

14 Next slide, please. The final  
15 group, affordable care. Again, a critical  
16 component of everything we do. I'll let you  
17 read these here, but some interesting concepts  
18 about consumer affordability. I'm sorry, my  
19 eyes are failing me and I'm not close to my  
20 slides here, so I wish someone closer would  
21 read some of these.

22 Measures trying to limit the

1 annual percentage of growth in healthcare, as  
2 well as the per capita health care costs, you  
3 know. Can we compare that from one area to  
4 another, and who actually has responsibility  
5 for that, and can we set goals and achieve  
6 them, which will be the real challenge here.

7 Next slide. Karen, I think we're  
8 back to your area here.

9 DR. ADAMS: So we thought we might  
10 wrap up just with kind of a context-setting,  
11 and where this falls in the broader quality  
12 picture, the big picture, so to speak, and  
13 this slide here represents what we refer to as  
14 the functions of the quality enterprise.  
15 There's many important contributors and  
16 stakeholders to this in the various moving  
17 parts, and where do we fit here.

18 We just, if you look at the first  
19 box, we just shared, you know, an important  
20 part of a quality enterprise is to establish  
21 national priorities and goals. So part of the  
22 work of the National Quality Strategy and the

1 National Priority Partnership feedback into  
2 that was one of those critical first steps.  
3 You see in the box we focus that around the  
4 triple aim of better care, affordable care and  
5 healthy people/community.

6 As we go along this flow, the next  
7 box is around identifying measure gaps. Paul  
8 highlighted several of the measure gaps that  
9 were identified for population health. There  
10 are other gaps, particularly as we think about  
11 more cross-cutting measures as well. But  
12 certainly, one of the roles that you'll be  
13 serving is to help us fill some of these  
14 measure gaps that are critical for advancing  
15 the goals around population health.

16 Then certainly there's upstream  
17 measure development. We're looking at  
18 existing measures and how those might be  
19 applied. Now, the green box that we also have  
20 highlighted is the endorsement process that  
21 you're participating in.

22 I'll go through the other ones

1 just quickly, but certainly one of the  
2 strategies we talked about, we're building  
3 data platforms and how do we collect these  
4 various data streams, so that we can get a  
5 good overall picture of health and public  
6 reporting, our next box, and using that for  
7 informed choice and selection and decision-  
8 making.

9 We talked about another strategic  
10 opportunity around payment and alignment of  
11 payment incentives with these various care  
12 deliveries, which certainly translates into  
13 improvement around quality improvement and  
14 performance. We don't want to forget that we  
15 need to have an ongoing feedback loop, and  
16 that evaluation just isn't at the end, that we  
17 have to be -- this has to be built in up  
18 front, and certainly to look for any  
19 unintended consequences as we think of these  
20 measures and they're applied.

21 So a little bit of context as to  
22 where we may fit into this broader quality

1 arena. Then our next slide we have here,  
2 we're starting to refer to this as the  
3 cascade, and I noticed that when I reviewed  
4 your materials over the weekend, there was  
5 some referencing to this cascading, and how do  
6 we get this type of shared accountability  
7 across all levels of the system.

8 So if you think at the national  
9 level, and we use this as an example for  
10 tobacco, and Paul, you talked about different  
11 policies too that would come into place as we  
12 look at these different levels, and what type  
13 of drivers or what type of things would we  
14 look at these each levels to advance towards  
15 these goals.

16 This one gives an example around  
17 tobacco. It could be played out and it's  
18 illustrative, of course. But it could be  
19 played out various ways. So, and this really  
20 builds on some of the early work of the  
21 National Quality Chasm, where they spoke to  
22 different levels and the microsystem, and this

1 is really evolving into the HHS as the  
2 National Partnership at the national level.  
3 What measures and measure concepts would you  
4 want to put forth, to evaluate against the  
5 goals that were identified?

6 But certainly there's a role at  
7 the state and community level health plan. I  
8 would also add, you know, certainly these  
9 emerging areas around ACOs, patient-centered  
10 medical homes, other shared saving models.  
11 Provider level, you know from hospitals,  
12 nursing home, home health, etcetera, and then  
13 the individual provider.

14 We don't want to forget about, of  
15 course, the consumer. So you know, in an  
16 ideal world this would cascade and roll up and  
17 down, and we know that there are many  
18 methodological as well as harmonization  
19 issues. But as we strive for this shared  
20 accountability, this is a concept that's  
21 coming forth, this cascading, and we do speak  
22 to it in more detail in the report.



1           It also ties into some work the  
2 NQF is doing around the Measure Applications  
3 Partnership. HHS has asked us also to convene  
4 another partnership, to look at recommending  
5 measures and measure steps for payment in  
6 public reporting and rulemaking input. So you  
7 know, very important to connect the work we're  
8 doing at the NPP, at the national level with  
9 these various units of analysis.

10           So Paul, I'll turn it back to you.  
11 I think that wraps it up for our background.

12           DR. JARRIS: Good. Jason or Matt,  
13 did you want to add anything, having sat  
14 through this process?

15           MR. STIEFEL: Well perhaps this  
16 comment will just foreshadow the discussion  
17 that we have later today about the  
18 relationship between that work and this work.  
19 One thing that jumps out at me is the framing,  
20 with the three-part framing of this work, of  
21 community, behavioral and clinical.

22           What appears from the pre-reading

1 here is a two-part framing, behavioral and  
2 clinical and not community. And I'm happy to,  
3 you know, defer that to the later  
4 conversation, but I think that's something  
5 that is important to address.

6 DR. JARRIS: Jason? Okay. Other  
7 comments or questions from the group? Dr.  
8 Stange.

9 DR. STANGE: Just to Matt's  
10 comment, I actually have a question for Helen.  
11 So this looks like, the work that Karen and  
12 Paul presented looks like very helpful  
13 background for our work, and we certainly have  
14 the chance to have an influence on this  
15 analytical framework that the subcontractor is  
16 doing.

17 I'm wondering about the things  
18 you're going to present on the measurement  
19 evaluation that we received some stuff about.  
20 Do we have any influence on this, or is this  
21 a done deal?

22 DR. BURSTIN: That is very, very

1 drafty. That was literally just our attempt  
2 to put something in front of you, as we  
3 recognize how difficult it will be to kind of  
4 put some square pegs in some round holes. And  
5 I also just want to briefly respond to Matt's  
6 comment, because I do think as we thought  
7 about how to frame this project, the question  
8 was can we do all of it at once?

9 I think, as we've talked with our  
10 HHS colleagues, for example, and at least  
11 thought it would be helpful in our first foray  
12 out into this area, to try to focus on a  
13 couple of high priority areas, and chose, for  
14 example, at least as the initial starting  
15 point, smoking, obesity and exercise, that  
16 could we potentially use those three as the  
17 way to explore those three levels that emerged  
18 from the NPP?

19 I think our concern was would be  
20 boiling the ocean and then just kind of fail?  
21 If we couldn't at least try to stick to a set  
22 of areas where there is logical overlap

1 between clinical, behavior and community. So  
2 I don't think we meant to exclude community at  
3 all. I think we're just trying to wrap it in  
4 the context of what's doable, and also a big  
5 part of what we do, as we'll talk about going  
6 forward, is a lot of what NQF has been working  
7 on over the last several years is really  
8 harmonization of measures.

9 We've spent an inordinate amount  
10 of time trying to take measures that come from  
11 different stewards, that come from different  
12 sectors, nursing home, hospital, home health,  
13 ambulatory. I mean just the amount of  
14 cacophony out there, just on the clinical  
15 sector alone, has given us a tremendous amount  
16 of work. Reva has gained many gray hairs  
17 through cardiovascular project this year  
18 alone, as you can imagine how many measures  
19 there were to be harmonized.

20 So I think one of the challenges  
21 is going to be is can we at least begin  
22 thinking about that framework of harmonizing

1 a reasonable set of the highest priority areas  
2 in those domains. But by no means do we mean  
3 to exclude community. But I think it's in the  
4 context of those higher priority areas, if  
5 that helps Matt.

6 DR. STANGE: So if I could just  
7 follow up on that. So the incremental steps  
8 that Elisa talked to us about are really about  
9 clinical preventative services in Phase 1, and  
10 then the health behaviors in Phase 2. But  
11 there is potentially a Phase 3 that's not yet  
12 articulated, that's really broader, and then  
13 might involve the community and other things.

14 Our chance to set the frame for  
15 that is when we talk about these evaluation  
16 criteria and then the analytic framework and  
17 principles. Is that --

18 DR. BURSTIN: You know, that's a  
19 good question, Kurt. I guess as we were  
20 thinking about it, I'm not sure that we can't  
21 do two and three together. So I think in some  
22 ways, and Paul isn't going to like this, I

1 think in some ways we -- and that's part of  
2 our challenge here, right?

3 So some of you will think of some  
4 of the community indicators, for example, that  
5 may emerge from BRFSS or some of the other  
6 indicators projects that many of you have been  
7 working on. Isn't there an opportunity there  
8 to think about what those healthy behavior  
9 measures would look like at clinical, as well  
10 as at community?

11 That's why in fact the smoking  
12 measures and the obesity measures were already  
13 submitted to us, and we've made the decision  
14 that you're not reviewing them in this phase,  
15 because there's a critical opportunity, we  
16 think, to think about the harmonization as the  
17 other more community-oriented indicators flow  
18 through. But again, if that's not the right  
19 framing, you know, we're certainly open to --

20 DR. JARRIS: The reason I shake my  
21 head is that it's a very common perception  
22 that, you know, if people only ate right and

1 exercised, they'd be healthy. But when I  
2 worked in the inner city school, those kids  
3 couldn't eat right and they couldn't walk to  
4 school. I saw sexual predators, registered  
5 sexual predators sitting outside the  
6 playground of the school.

7 So you know, you've just got to  
8 recognize there's a context that people live  
9 in, and one of our important jobs is to create  
10 an environment where people can be healthy,  
11 where those poor little kids could grow up and  
12 eat and get out to a playground. So Larry.

13 MR. COHEN: Well, I had a very  
14 specific question, but I am going to jump into  
15 this instead first, and then ask the specific,  
16 which actually relates, based on your comment,  
17 Paul.

18 I think in terms of the notion of  
19 cascading, and in terms of the notion of  
20 unintended consequences, one of the things I'm  
21 very aware of is that when we start from our  
22 comfort zone and say well maybe, you know,

1       there's a limit to what we can accomplish,  
2       that one of the potential unintended  
3       consequences that the emphasis on the  
4       community, which is where most health and  
5       maintaining health takes place, tends to be  
6       diminished or possibly ignored.

7                To say we'll get to the community  
8       later, we'll fold it into behavior, sets an  
9       approach or a context where it really tends to  
10      be minimized, you know. I'm fully  
11      understanding of the notion of we've got to  
12      start with what we're most knowledgeable  
13      about, what we're most comfortable with. At  
14      the community level, the kinds of indicators  
15      that we have are much more difficult to  
16      access. It's much more challenging.

17               Therefore, unless we really  
18      emphasize that, we often end up in a situation  
19      where the community, in effect, is given  
20      second shrift, despite the fact that I think  
21      we probably all share the notion that the  
22      community is probably the focal point for



1 maintaining health and wellness, and also for  
2 maintaining people who are not healthy, but  
3 maintaining their level of injury, illness,  
4 disability, etcetera, as opposed to it  
5 diminishing.

6 So that worries me a great deal,  
7 and I mentioned that in the orientation. But  
8 it really worries me in terms of the structure  
9 and strategy here.

10 The specific question I wanted to  
11 ask was -- well, let me say one more thing  
12 about that, which is that my notion, from work  
13 I've done on prevention over a number of  
14 years, is that the fundamental issue is not  
15 one particular measure or approach, but it's  
16 really community norms change.

17 So even Paul, when you gave the  
18 example before, does the community have access  
19 to healthy food, you know, versus being a food  
20 desert, the question I would ask is, does the  
21 community overall emphasize healthy food?  
22 Where is the balance? What is the level of

1 emphasis, because only by changing norms and  
2 changing environments are we going to change  
3 from a sick culture to a healthy culture.

4 That's going even further and it's  
5 harder to measure. Admittedly, it's very hard  
6 to measure. Therefore, it worries me if we  
7 leave it out, because it's hard to measure,  
8 and say we'll start with where we're  
9 comfortable.

10 So the initial question I wanted  
11 to ask was specifically, when you mentioned  
12 safety, which I was very happy you mentioned,  
13 whether we're also talking about violence  
14 prevention or just unintentional injury.  
15 Because for me, violence prevention is not  
16 only important in and of itself, but it's a  
17 critical trigger in terms of chronic disease,  
18 and more importantly perhaps, in terms of your  
19 comments a critical trigger in terms of equity  
20 issues.

21 If communities are not safe, then  
22 all the other community health factors can't

1       come into play nearly as well, and we start to  
2       have a two-part society, where some  
3       communities are safe and others aren't, and so  
4       there's a different level of attention. So I  
5       mean for me, that would be a high priority  
6       issue here, and I'm not sure whether this  
7       question applies to what you reported or it  
8       applies to later in the conversations that  
9       I've just asked about.

10               DR. JARRIS: Yes, you know, it's a  
11       good point Larry, and what -- within the  
12       earlier work, advising HHS on the National  
13       Quality Strategy, we recognized that injury-  
14       accidents what was important, I think we  
15       looked ER visits, was the concept measure  
16       there. But we didn't specifically get into  
17       type of what led to it, although as I'm  
18       thinking about it, I wasn't thinking about  
19       violent injury. So I don't think we got  
20       there.

21               I have an order here, which I  
22       think is the order in which the cards get up.

1 But if it's not, then it's my own arbitrary  
2 order. Bobby, you go next.

3 MR. PESTRONK: Thanks. I also  
4 like the idea of separating out community  
5 frame from other frames, so that it does get  
6 specific attention.

7 I wonder, given the fact that the  
8 agenda and the process for this group seems to  
9 have been established, perhaps a practical  
10 solution to identifying what the community  
11 could address in the community frame is right  
12 now at the early --

13 While we're in the first steps of  
14 this process, why don't we commission a paper  
15 that could inform our subsequent conversation  
16 about what the community theme and frame  
17 means, and ask that that be done by a group or  
18 groups that are knowledgeable about this area?

19 So at the time we come to explore  
20 the community frame, we're not asking  
21 ourselves what it means. We have the  
22 background materials that we might concur

1 would help inform our discussion. Then, we  
2 don't -- we have a running start on it, rather  
3 than trying to drag it into the conversation  
4 at the last minute.

5 DR. JARRIS: So part of the  
6 challenge, as you underline the question, is  
7 you know, there's a charge to this Committee.  
8 How fixed is that? Where does it come from?  
9 How modifiable, you know, is it, because I  
10 think that's what underlying this conversation  
11 right now.

12 DR. BURSTIN: Just one brief  
13 response.

14 MR. COHEN: You know, are the  
15 resources that commission further work to  
16 inform us on other aspects of this.

17 DR. BURSTIN: And just to respond,  
18 I think if you look at the outline of the  
19 commissioned paper that the folks from LA are  
20 doing, I believe they actually are attempting  
21 to address that. Again, it's just an outline.  
22 They're going to be on the call with us today.

1 I think there is an opportunity. I think they  
2 certainly have that knowledge to potentially  
3 move in that direction.

4 I think you just need to take a  
5 look at that outline, and see if there's a way  
6 to make that work, because that is part of  
7 their charge.

8 DR. STANGE: I'm sorry, if I could  
9 just follow up on that. So that was actually  
10 the genesis of my question. So what are the  
11 outputs that we have, and certainly that  
12 commissioned paper is one. What about this  
13 measurement criteria that you described? Do  
14 we have a way to influence this and what's the  
15 mechanism for that?

16 DR. BURSTIN: Absolutely. You  
17 will be doing that today, as a matter of fact,  
18 having that discussion, helping us think  
19 through. Just to put this in context, and we  
20 can do this in a little bit, but we've done  
21 this recently when we did resource use  
22 measures for the first time. It was very

1 clear. Some of these just didn't quite fit  
2 into our old mind set, Sarah's smiling, of how  
3 difficult it is to evaluate those kinds of  
4 measures.

5 So we recognized we needed to go  
6 back, offer additional guidance, perhaps give  
7 some different terminology that does resonate  
8 with the different communities engaged in that  
9 part of measurement. So our expectation is  
10 we'll need to do the same thing for population  
11 health. So that is wide open, Kurt, for your  
12 input.

13 DR. STANGE: So we actually have  
14 two mechanisms now. One thing we can do is  
15 look to see how adequately we feel those  
16 mechanisms have captured the issues, and if  
17 not, then we can look at whether we need to  
18 recommend other mechanisms perhaps.

19 MR. BIALEK: I'd like to  
20 understand the framework that we're using a  
21 little bit better. For instance, if the  
22 priorities really are smoking, obesity and

1 exercise, if one were to construct a logic  
2 model and look at what really can impact that.  
3 For smoking, for instance, taxation and  
4 smoking laws, in terms of secondhand smoke,  
5 will impact that far greater than what can be  
6 done in the clinic.

7 For obesity and exercise,  
8 similarly, far greater impact can be achieved  
9 outside of the clinical setting than in the --  
10 far greater will be achieved in the community,  
11 excuse me. So I'm just wondering the  
12 framework, because we're starting --  
13 everything seems to be very clinically-based.  
14 We're starting with the clinic. We're  
15 starting with the clinical intervention, and  
16 then we're cascading down to other  
17 interventions.

18 It seems to me that I would like  
19 to see laid out, again, where are we achieving  
20 the greatest impacts, and then look at  
21 measures within those areas of greatest impact  
22 that may be clinical or may be population-



1 based. But I don't think separating it the  
2 way that we're doing is necessarily going to  
3 get us to where we want to be.

4 DR. JARRIS: It's a good point,  
5 and I think that probably what we're -- the  
6 area we should look at is where is the  
7 interface between the clinical and the  
8 community. Back to the comment of this is a  
9 cross-cultural experience, NQF has  
10 historically been a clinical measures  
11 organization, and now they're inviting public  
12 health people to the table. So we've got to  
13 start where NQF is, and then try to move NQF  
14 or perhaps expand the sphere that they work  
15 within.

16 So I think it could be dangerous  
17 for us to go right to community, because there  
18 might not be a context in which it's  
19 understood. Which is why we came up with the  
20 three levels of measures, to say let's start  
21 at the clinical and then let's walk toward the  
22 others.

1                   But I think it's going to be  
2                   important, at least from my point of view,  
3                   that we understand that path includes going  
4                   toward the community.

5                   MR. BIALEK:   Paul, I'm not  
6                   suggesting we start with community.  I'm  
7                   suggesting we start by looking at what has the  
8                   greatest impact, and then based on what has  
9                   the greatest impact, where do we actually have  
10                  measures.  It may be clinical; it may be  
11                  community.  But it just strikes me again, if  
12                  we're looking at the objectives of improving  
13                  quality, cost, efficiency, et cetera, that  
14                  separating the way that we're separating it  
15                  may be very unnatural.

16                  I understand the perspective, that  
17                  we really, you know, starting at the clinical  
18                  may be just a necessary piece.  But I think we  
19                  need to be thinking about where's the greatest  
20                  impact as we go along.

21                  DR. JARRIS:  Could I -- I just  
22                  want to asking a clarifying, thank you, Ron,

1 clarifying question. You mentioned that  
2 smoking, obesity and exercise were the focus.  
3 I didn't see that in the pre-read. Did I just  
4 miss that, or where did --

5 DR. BURSTIN: It's just been some  
6 of the discussions we've had with HHS, that we  
7 recognize again, we can't do everything, and  
8 they thought given that those are among the  
9 highest priorities for the Department, and  
10 those are the ones we think, going to your  
11 point, where there is the greatest interface  
12 potentially between some of the measures in  
13 the clinical space and some of the measures in  
14 the community space, that would be a good  
15 place to start.

16 I'm not sure that's in conflict  
17 with the idea of doing a logic model and  
18 thinking about where those greatest impacts  
19 are, perhaps in those areas.

20 DR. JARRIS: You know, the top  
21 three underlying causes.

22 DR. BURSTIN: Exactly.

1 DR. JARRIS: So maybe it makes  
2 sense. I think I had Linda next.

3 DR. KINSINGER: Hi thanks. I  
4 wanted to go back to the National Quality  
5 Strategy, the report that you mentioned. I've  
6 been involved with developing the National  
7 Prevention Strategy, also in the ACA, and  
8 there hasn't been any discussion of this  
9 report there, nor did I hear any really  
10 discussion of the Prevention Strategy report  
11 here.

12 So I'm wondering how these two  
13 reports are intersecting or if they are,  
14 because it doesn't seem to me that they are,  
15 and how could they?

16 DR. ADAMS: So Linda, thank you  
17 for raising that, because certainly this  
18 speaks to the alignment issue, and I  
19 apologize. I really should have emphasized  
20 that in my opening remarks, because one of the  
21 alignment issues, of course, is working  
22 closely with colleagues at HHS, you know, not

1       only across the various programs, but even  
2       within HHS, and then how that also links with  
3       private sector initiatives.

4               So as well as Paul, George Isham,  
5       Peter Briss, have been very involved, and very  
6       much want to have this synching up an  
7       alignment with the National Prevention  
8       Strategy. But we also need to think there's  
9       lots of strategies coming out. We have the  
10      National Prevention Strategy. We have the  
11      Partnership for Patients in regards to the  
12      safety initiative.

13             Today, the Million Hearts campaign  
14      is going to be launched around the ABCs. So  
15      I think there's a critical need here, and  
16      we've tried, as we went through this, as you  
17      see, the safety goals synching up. I think  
18      it's really important that we have this  
19      synching and we have this synergy, because  
20      these strategies all interconnect and they're  
21      not competing strategies.

22             I'd like to see them as

1 reinforcing strategies, whereas for example,  
2 the Partnership for Patients. You know,  
3 clearly the readmissions focus, the hospital-  
4 acquired conditions, of course, but being the  
5 community is very important as well. You  
6 know, how do we fill these population health  
7 kind of gap areas as well, and of course the  
8 prevention strategy.

9 I'll also add the SAMHSA  
10 framework, which is very much built on the  
11 priority areas framework. So I think it's a  
12 critical message of the synching and the  
13 aligning. Of course, now that the report is  
14 released but really more upstream, we'd be  
15 happy to work with you in the QuIC -- there's  
16 a new name for it.

17 It used to be the QuIC Two, but  
18 the QuIC Group, the quality agency, inter-  
19 agency group. There's like -- there's  
20 supposed to be like a quality inter-agency  
21 group amongst HHS that is looking at some of  
22 this. So we're happy to work with that.

1 MR. COHEN: Would it be  
2 appropriate to ask that, in terms of  
3 particularly the National Prevention Strategy,  
4 which I think is key, to ask that the LA group  
5 look at that as part of their work, and really  
6 incorporate that in terms of measures?

7 DR. JARRIS: There's also the  
8 National Action Plan to End Health  
9 Disparities, which doesn't seem to be  
10 integrated. That's a critical one. It should  
11 be foundational to every one of the others.

12 DR. ADAMS: I remember at our  
13 first meeting, we had several people come from  
14 HHS. Of course, different things were in  
15 different stages of development, but to kind  
16 of see how up front we might work on that  
17 synching, since we're going fast in a parallel  
18 track. But thank you for raising that.

19 DR. JARRIS: Remember?

20 MS. MERRILL: Do I remember?  
21 There's well a number of things I could say.  
22 But one, to your point of coordinating. Is

1 ASPE still in existence, and do they have any  
2 interest in creating an overarching framework,  
3 and should they be included in these kinds of  
4 meetings? Assistant Secretary for Evaluation  
5 and Planning at HHS.

6 DR. JARRIS: It does exist.  
7 Sarah, do you know their involvement here? I  
8 don't, because I think --

9 DR. ADAMS: ASPE is our project  
10 officer for the -- they're the coordinating  
11 link. So Kate Goodrich is our project officer  
12 at ASPE, who oversees the contract which this  
13 National Priorities Partnership work was  
14 under. So ASPE is part of this process.

15 MS. MERRILL: I hope she's a  
16 powerful personality.

17 DR. BURSTIN: Peggy Honore from  
18 the Office of the Secretary has been one of  
19 our other links, and I believe she's going to  
20 be joining us at some point today.

21 MS. MERRILL: Good, okay. So the  
22 initial thought that I had was this. I'm a



1 professor at Columbia and so I teach. I teach  
2 the medical students three times a year, and  
3 I go in. This is a sophisticated group, so  
4 you probably know the answer to the question,  
5 but they don't.

6 So I ask them if the health care  
7 system is part of the public health system or  
8 if the public health system is part of the  
9 health care system, and I ask them true or  
10 false. That simple framing of the health care  
11 system is the major system, is really how they  
12 think, and I see that we are -- whether we  
13 want to or not, are starting to fall into that  
14 way of thinking, and it's deeply inculcated.

15 So I think that that's something  
16 that we need to be aware of, that simple true  
17 or false when we're thinking about things. So  
18 it is -- the health care is part of the public  
19 health system. That is really where we are.  
20 So that kind of speaks to your concerns.

21 Then there's another point. I'm  
22 trying to weave together a lot of disparate

1 threads, is this idea that you got the call  
2 from Target. I'm just thinking well, the  
3 corporate culture in this country does drive  
4 decisions at community level, how money is  
5 spent, how actually municipalities actually  
6 spend money to respond to decisions that are  
7 made at the corporate level, in terms of waste  
8 packaging, salts, all kinds of things.

9           So that's another part of the  
10 puzzle that we're dealing with then. I'm also  
11 thinking that perhaps representatives from  
12 that community, it would not be a bad idea to  
13 include some kind of corporate representation,  
14 because corporate culture really does rule.  
15 When you're talking about root causes, they're  
16 right there.

17           DR. JARRIS: Very interesting.  
18 Andrew, Andy?

19           MR. WEBBER: Bobby actually took  
20 my comment, and I just want to endorse doing  
21 some early work on the community framing. You  
22 know, I think we have a fabulous opportunity

1 to bring worlds together here through this  
2 Committee, and I don't want to lose that  
3 opportunity.

4 But I think some early work on the  
5 community framing, I think was a good  
6 consensus of that's where a lot of the gaps in  
7 the thinking reside right now, particularly as  
8 it relates to the history of NQF. So I think  
9 that would be an important early signal.

10 I think part of that, Helen,  
11 looking at sort of the measure development  
12 enterprise, if you will, is to do some early  
13 work on identification of measure gaps in  
14 terms of community conditions for health,  
15 would be important, as part of that work.

16 And let me, you know, I think I'm  
17 the only representative of the business  
18 community here. So let me say, in terms of a  
19 response to the last comment, that you know,  
20 mea culpa, in terms of the business  
21 community's impact, both negative.

22 But I think we also need to think

1 of the leverage of the business community, and  
2 their ability to impact all the conditions for  
3 better health. I think the best way to  
4 approach the business community is not to lead  
5 with, you know, "you create unhealthy products  
6 and stressful work environments," but to talk  
7 about the fact that the business community,  
8 when they look at the goal of health and  
9 productivity as a business imperative for  
10 them, we've got an opportunity to really  
11 engage the business community in very useful  
12 ways.

13 So I think that's another part of,  
14 I hope, the bringing together of different  
15 parts. The wonderful thing about NQF, and why  
16 I've spent so much time -- I sit on the board  
17 of NQF, by the way -- is that it's a wonderful  
18 representation of partnership capability and  
19 different stakeholders coming together.

20 So I just want to again say that  
21 the key to partnerships is finding common  
22 denominators among all the key stakeholders.

1 I think all the stakeholders have a lot more  
2 in common, in terms of the goal of population  
3 health than we have, you know, what divides  
4 us, of which there are many issues, I will  
5 recognize. So anyway, just --

6 DR. JARRIS: You know, I think  
7 there's also some real leadership. If you  
8 look at, for example, Target doesn't sell  
9 cigarettes. They've made that determination.  
10 Walmart is now the second or third largest  
11 organic grocer in the country.

12 (Off mic comments.)

13 DR. JARRIS: Largest, bringing  
14 organic foods to poor people who shop. I mean  
15 they have made, they have a huge footprint, in  
16 terms of doing good things in our community.  
17 So I think we, I agree. We should welcome  
18 them in.

19 I'm curious, Frank and Sue, I  
20 don't know a lot about your procedure, coming  
21 from a clinical orientation, and I'd like to  
22 hear your thoughts about this. Is this

1 resonating? Does this make sense? Is it like  
2 are you looking at it and saying what are  
3 these crazy people talking about?

4 (Laughter.)

5 DR. LEONE: Well, there's a little  
6 of that. No, I mean I'm actually learning  
7 quite a bit. So there's some ideas that have  
8 been floating around that I hadn't really  
9 thought too much about, that have been  
10 crystallized for me this morning, so I  
11 appreciate that.

12 It's true, that I feel like the  
13 health care system is sort of the 800 pound  
14 gorilla in the room. It's the machine that  
15 just keeps moving forward and it sort of sucks  
16 all the other perspectives out, the oxygen out  
17 of all the other perspectives. I think that  
18 it's good to look around the table and see all  
19 the various perspectives, trying to keep that  
20 in check.

21 I actually sort of agree. I sort  
22 of heard the words "community perspective,"

1 "community frame" thrown around. I'm having  
2 trouble understanding exactly what that means.  
3 I think it would be a good idea if we -- well,  
4 if somebody could educate me over lunch, that  
5 would be great. But otherwise, if we could  
6 maybe sit down and just sort of come up with  
7 some standard definitions of what the  
8 community frame really means that might be a  
9 good idea.

10 I would encourage the group to  
11 sort of think outside the box. We have a lot  
12 of information that's already pre-existing  
13 about what works, what doesn't work, what the  
14 relative impacts are of different things. But  
15 this, I feel like this group represents an  
16 opportunity to take systems that may be  
17 broken, and maybe not previously as effective  
18 as they could be, and try and stimulate some  
19 change in systems, to make them even more  
20 effective than they've been in the past.

21 So I'm pleased to be part of this  
22 discussion, and it is definitely resonating

1 for me, Paul.

2 DR. PICKENS: Well, I definitely,  
3 like Frank, have learned a ton this morning  
4 already, and I represent a very large public  
5 health system working in community, where if  
6 we have a community, a healthy community, we  
7 make money, because they don't come to us.  
8 They don't have to be in the hospital.

9 I've spent my last 18 years trying  
10 to work and figure out how to measure what  
11 that is, as well as what kind of interventions  
12 work, both from the clinical into the  
13 community and back and forth. I've looked  
14 forward to participating in the discussion,  
15 and trying to help figure this out.

16 DR. JARRIS: And similarly Matt,  
17 you sort of walk two worlds there with Kaiser  
18 Permanente. So you may be one who can help us  
19 bridge some of this. Any other comments?  
20 Anyone we didn't hear from who would like to  
21 take a chance to speak?

22 DR. BURSTIN: I have a question.



1 It's actually interesting, because I think  
2 that if you look at the framing of the LA  
3 Department Public Health folks' outline, and  
4 they'll be on when it's almost morning on the  
5 West Coast with us, is I think they mainly  
6 framed it, trying to understand the clinical  
7 care system and more the public health system  
8 as their frame.

9 I think one thing that might be  
10 helpful as they come, you know, before they  
11 come I think actually would be useful for us,  
12 Paul and Kurt, to actually spend a little bit  
13 of time trying to do some definitional work,  
14 make sure we're all on the same page. Because  
15 I'm not sure everybody's using the community  
16 frame in the same way or public health in the  
17 same way or health care system in the same  
18 way. I think it's actually a worthy exercise.

19 DR. JARRIS: I am sure they're  
20 not.

21 DR. BURSTIN: I know. We ought to  
22 do it.

1 DR. JARRIS: Michael.

2 DR. STOTO: I was going to save  
3 this for when they get on the line. But I  
4 think the relevant point here is that in the  
5 clinical world, we spend a lot of time  
6 thinking about accountability as associated  
7 with these measures.

8 The focus, I think, of the LA  
9 paper, is on the shared responsibility for  
10 health outcomes, and they actually kind of, I  
11 think, shy away from the accountability of  
12 health departments and other organizations in  
13 the community, from actually doing something.

14 I think that's what we have to  
15 work on, is how do we look at, you know,  
16 holding different organizations, not just  
17 clinical, but all these other organizations,  
18 and not just health departments, but all the  
19 other organizations including companies and so  
20 on, accountable for what they contribute to  
21 the overall outcome.

22 DR. JARRIS: This is a critically

1 important point Mike's bringing up, and it's  
2 something we really probably need to spend  
3 some time on. I think actually Andy, NQF as  
4 a whole needs to spend some time on this. It  
5 really is one of those grass is greener type  
6 pictures, because I know there's a couple of  
7 people here who have been appointed officials  
8 in government, and the fact that you can get  
9 fired in an instant for a story in the  
10 newspaper, or that you may or may not have had  
11 anything to do with, is a real level of  
12 accountability.

13 The fact that you are sued  
14 multiple times per week for things that are  
15 going on, because you're a figurehead is a  
16 level of accountability. I basically went for  
17 an umbrella policy recently, had to list all  
18 the lawsuits. Diana Bonta from California had  
19 a lien put on her home and couldn't sell it,  
20 because of a lawsuit against her in her  
21 official capacity.

22 So there are levels of

1        accountability that are scary when you step  
2        into the public sector, and often, and we hear  
3        this, and I came from the clinical sector.  
4        When you hear from people in the clinical  
5        sector saying well, how are any of those  
6        people held accountable? I think they are,  
7        and I'd love to hear from the Targets and the  
8        Walmarts. Why is Walmart selling organics?  
9        There's somebody on Wall Street holding them  
10       accountable for their product line at some  
11       level.

12                        So this conversation of  
13        accountability is going to be a very important  
14        one. But I would say that we have to move  
15        beyond what I've heard now for a couple of  
16        years at NQF, is that well, you know, those  
17        public health people, this is pretty close to  
18        a quote. Nobody knows what they do and nobody  
19        knows how to hold them accountable.

20                        That's a view from somebody  
21        outside of the field, not from somebody in the  
22        field. Rhonda, you're shaking your head. I

1 don't know how many lawsuits you have still  
2 hanging around you from Georgia.

3 DR. MEDOWS: Enough to keep my  
4 grandchildren busy for many, many, many years.

5 DR. JARRIS: It was three and a  
6 half years before my final lawsuit in a  
7 professional and personal capacity was  
8 dismissed after I left an appointed position  
9 in government. So there's real  
10 accountability.

11 DR. STOTO: So in the clinical  
12 quality area, I think long ago we moved away  
13 from this idea about finding out the bad  
14 apples, and to kind of measuring overall  
15 performance of systems. It strikes me what  
16 you're describing about public health is the  
17 old way, and we need to find a way to kind of  
18 measure performance in a kind of statistical  
19 way, that's parallel to the health care  
20 provider system.

21 DR. JARRIS: Right, we do.  
22 Tomorrow, at the National Press Club, there

1 will be an announcement of the formal  
2 unrolling of the Public Health Accreditation  
3 Board, to accredit state and local public  
4 health agencies. There hasn't been a process  
5 before. We've been working on it for five  
6 years now.

7 So at least we can put that  
8 criticism aside, in terms of certification of  
9 the competence of departments.

10 MS. MERRILL: Earlier in the year,  
11 there was the IOM Report on Measurement. We  
12 have a reference in that as well? Is that  
13 coming into this discussion? Because I didn't  
14 see that mentioned. You know what I'm talking  
15 about?

16 DR. BURSTIN: Yes, and actually  
17 Dawn was one of the -- Dawn and Steve were one  
18 of the authors of one of the chapters of that  
19 report. So they'll be bringing that in as  
20 well.

21 MS. MERRILL: Okay, good.

22 DR. STANGE: I'm particularly

1 anxious that we're not just having a nice  
2 conversation that will look at the action  
3 steps, and I've really heard two action steps.  
4 One's the commissioned papers. So if we want  
5 to affect that, I think we should save our  
6 comments from when the people are on the line.  
7 Otherwise, we'll feel good about it, and it  
8 won't appear in the output.

9           The other action steps that I've  
10 heard is the quality measurement criteria that  
11 Helen's going to talk to us about, and Helen's  
12 in the room. So I'd like to suggest that we  
13 focus our efforts on that, and think about how  
14 are we going to affect that, what's the  
15 feedback loop for us, what's likely to happen  
16 with that.

17           But I also would like to make sure  
18 that we save some time, before we go on to the  
19 more mundane work, of going through the  
20 existing measures, that we say okay, do we  
21 have, are we satisfied with where we are for  
22 the next steps, or doing it to suggest

1 something else?

2 But I think the next steps, since  
3 Helen's in the room, is to look at the measure  
4 evaluation criteria, that are the drafting of  
5 measurement criteria.

6 DR. JARRIS: Very good, but Larry  
7 first.

8 MR. COHEN: I mean I feel like  
9 there's some kind of action step about  
10 reconsidering the agenda and strategy to bring  
11 community in much earlier, and in a much more  
12 consistent and significant way. I feel like  
13 that's the implication of a lot of what people  
14 have been saying.

15 I don't know exactly how the  
16 action step gets translated, whether it's by  
17 the staff or how. But I definitely don't  
18 think that that was just idle conversation.

19 DR. STANGE: So Larry, that's what  
20 I'm actually trying to do. I'm suggesting we  
21 have two steps on the table right now. One is  
22 Helen's work here with the measures; one is



1 the commissioned paper. I think after we've  
2 done that, I think we have to re-ask your  
3 question, is that enough.

4 MR. COHEN: Okay.

5 DR. JARRIS: Rhonda, a final  
6 comment.

7 DR. MEDOWS: I was going to say  
8 can I just second that motion, and then we  
9 vote, what Larry just suggested?

10 DR. JARRIS: So what Larry's  
11 suggesting, to paraphrase that I've got it  
12 right, is that we actually look seriously, if  
13 you will, the goal or charge of this group, so  
14 that it does include community as one of the  
15 measurement points, and that we start looking  
16 at that early on, and preparing, as Bobby  
17 suggested, before we get there.

18 Now I don't know if that requires  
19 a vote, or if there's a consensus. Is there  
20 anybody here who strongly feels that that's  
21 not an approach we should take? Silence means  
22 assent.

1 MR. COHEN: Yes. I just feel like  
2 it's not based on your comments, Kurt, and I  
3 want to just acknowledge I have very little  
4 understanding of exactly how this process  
5 works, and it's fairly new to me. But I  
6 wasn't clear of what the implications would  
7 be, in terms of, for example, our work over  
8 the next two days.

9 To me, it says that our work over  
10 the next two days should look somewhat  
11 different than the current agenda, and that  
12 the way in which we approach things and the  
13 kinds of conversations we have, and the kinds  
14 of questions we answer around what do we mean  
15 by community, what do we mean by a definition  
16 of population health, which in terms of what  
17 you were saying, Jacqueline, that you know,  
18 many people see the medical first, that I was  
19 actually very surprised very recently frankly,  
20 to learn that population health often was  
21 about people with a medical condition, rather  
22 than about the overarching population.

1 I think that really getting into  
2 some of those issues, the implications of  
3 those issues in terms of looking at things  
4 like the National Prevention Strategy, as  
5 central to the way we think, and not just as  
6 oh, we'll get to that eventually. That may,  
7 as I say, be totally implicit in what you were  
8 saying, and I just didn't understand it.

9 But that's why I suggested it's a  
10 very clear action step, and requires some  
11 transition in the work we do here over the  
12 next couple of days.

13 MS. MERRILL: Just in that  
14 definition of community, we want to bring in  
15 the business work life aspect of it. It  
16 definitely has to be --

17 DR. BURSTIN: Let me just try to  
18 respond to Larry. I think we heard you loud  
19 and clear. I think the way the day has been  
20 set up is in fact all just discussion of these  
21 exact issues, in terms of what the scope of  
22 the paper should look like. You're going to

1 have the chance to talk to Dawn and Steve  
2 shortly. They completely get this. This is  
3 not alien to them at all, for those of you who  
4 know them.

5           You'll have a chance. We've got a  
6 several hour block this afternoon. We're  
7 going to have just community, just discussion  
8 among the Committee about what is population  
9 health, what are we really talking about here?  
10 So I think we have the opportunity to  
11 influence, as Kurt said, the framing of that  
12 paper, which is commissioned, and they're  
13 going to be doing that work. We can kind of  
14 move them to make sure it fits the needs of  
15 the Committee as it's emerging.

16           I think also, as Kurt mentioned,  
17 these evaluation criteria are wide open. You  
18 can really say, you know, this really works  
19 for a very clinically-oriented measure. It  
20 would never work for these kinds of measures.  
21 I think we'll kind of get closer to what we're  
22 talking about.

1 I would still find it useful, and  
2 maybe that's more something we'll get to,  
3 after the discussion with Steve and Dawn, to  
4 actually do some definitional work, because I  
5 think it probably help us all, to make sure  
6 we're all on the same page. But I think that,  
7 you know, all of that will be useful.

8 We do, as a matter of course, just  
9 need to, because some of these measures are  
10 getting quite old. We need to look at those  
11 clinical preventive services and immunization  
12 measures. That's part of our process.

13 We thought it would be useful to  
14 actually look at some measures that are the  
15 more traditional ones, as we then think about  
16 how we're going to kind of shift over to the  
17 more community-oriented measures in population  
18 health.

19 So I think we're saying the same  
20 thing. I think we can get there.

21 DR. JARRIS: Yeah, I think so too,  
22 and Rhonda, I'd ask you, you know, since you

1 asked to vote. I think we hear enough  
2 consensus here to move forward.

3 We were charged by NQF, among  
4 other things, to look at these measures, and  
5 I think we should do our housework, as asked.  
6 Also the benefit to that is that will allow us  
7 to look at how NQF goes through their  
8 processes. So as we stretch into new areas,  
9 we at least understand where we're coming  
10 from.

11 So I mean I agree. It would be  
12 unsatisfying if that's all we did and left.  
13 But if we can do that, re-look at the scope of  
14 what we're doing, and then start from the  
15 basis of how NQF approaches things, and again  
16 try to move into new areas, I think then we'll  
17 really have done a service. Bobby, this is  
18 the final last comment.

19 MR. PESTRONK: Yes. This is just  
20 a very -- and this is a very quick one. It  
21 seems to me that somewhere here a picture  
22 would be helpful to orient us to our approach,

1 and it might help us both the logic behind the  
2 approach that we're taking, and give us a way  
3 to focus on what we think the most important  
4 sets of measures around population health  
5 would be.

6 It might suggest to us in a  
7 different way than trying to pore through a  
8 lot of pros, what's most important and what's  
9 least important, and give others who are  
10 trying to understand the work that we're  
11 doing, easy access to the approach that we are  
12 taking.

13 DR. JARRIS: So Helen, I believe  
14 our next step is to move to you for measure  
15 evaluation for population health measures, and  
16 we're six minutes over, so we're doing pretty  
17 well.

18 DR. BURSTIN: Great. Thanks,  
19 everybody. So here's your chance to see  
20 where we've been, and help us think about  
21 where we go.

22 So NQF traditionally, the measures

1 we have endorsed to date, have primarily been  
2 measures that affect various sectors of the  
3 health care system, with clear accountability  
4 to those providers, individual clinicians,  
5 health systems, and again, in some ways as  
6 we've been thinking about a lot of the  
7 movement towards ACOs, I think it's going to  
8 be very similar kinds of issues about  
9 denominators and populations that I think will  
10 continue to be important, even beyond this  
11 context of community as well.

12 So what we thought would be  
13 helpful is actually to walk through the  
14 current NQF evaluation criteria, and you have  
15 that packet. It's Attachment 4 in your  
16 folder, or sent to you electronically as well.  
17 So we thought it would be useful to actually  
18 go through each element of our evaluation  
19 criteria, and see the applicability of those  
20 criteria for measures at population levels,  
21 including the community.

22 NQF always uses the same criteria



1 for all of our projects generally. As I  
2 mentioned, we've modified them slightly for  
3 certain projects like resource use, and we  
4 think we're going to do the same thing for an  
5 area like population health.

6 But, you know, essentially the  
7 four cornerstones remain the same. Importance  
8 to measure and report, which I think gets to  
9 the issues Bobby and others brought up about  
10 trying to think about what are those most  
11 important areas we absolutely want to take  
12 care of and address; the evidence base as  
13 being really critical for the measures;  
14 scientific acceptability of the measurement  
15 properties, i.e., are they reliable, are they  
16 valid, are the specifications precise? Is it  
17 usable and is it feasible.

18 So those four cornerstones, I  
19 would argue, probably still work, and I think  
20 the issue is really definitional and adding  
21 the guidance to make this work. So let's just  
22 walk through this. Yes, Kurt.

1 DR. STANGE: So in the things we  
2 were given in the opening memo, that those  
3 criteria are actually prefaced by saying NQF's  
4 existing measure evaluation criteria appear to  
5 be appropriately specified for population  
6 performance measurement.

7 I think what we're hearing from  
8 the discussion is that assumption might not be  
9 true. So I think these are good criteria. I  
10 think there is, what we're hearing is let's  
11 think of what that means for community. Let's  
12 think about what that means when you actually  
13 specify denominator, and that actually might  
14 turn out that these are good but not  
15 sufficient.

16 DR. BURSTIN: I think what we're  
17 saying there is just a very general framing,  
18 those broad concepts of importance, evidence,  
19 the reliability of the measures, the fact that  
20 they're usable and feasible in whichever  
21 context you're talking about, we think, would  
22 still logically apply.

1                   There's a whole lot of words  
2 associated with that that could change  
3 dramatically when you're talking about a  
4 community context versus clinical context, I  
5 think.

6                   MR. PESTRONK: Are we open to  
7 science from other places?

8                   DR. BURSTIN: Absolutely.

9                   MR. PESTRONK: Because the science  
10 and the conceptual frames that orient science  
11 are different in different countries and in  
12 different cultures. The Canadians, for  
13 example, have reached, have historically taken  
14 an entirely different approach to how they  
15 orient their both public health and medical  
16 care system, and their approach to having a  
17 healthy population.

18                   For some reason, that orientation  
19 doesn't take place. That kind of orientation  
20 doesn't happen here, and I'm wondering whether  
21 that has something to do with how we accept  
22 evidence, or whether -- well, so the question

1 is what are we open, what is NQF open to, and  
2 what is NQF historically open to, and is that  
3 another door that needs to be opened?

4 DR. JARRIS: I suppose those  
5 Canadians just don't know how to make money.

6 (Laughter.)

7 I'm sorry. The other issue is  
8 even -- the sciences of public health are not  
9 the same as the sciences of clinical medicine  
10 and bench science. So that's the other issue  
11 we're going to have to look at is -- and I've  
12 had that discussion in some of the IOM  
13 committees about, you know, are observational  
14 studies science or not?

15 Well, if you're dealing at the  
16 level of a population, they may be the best  
17 you have.

18 DR. BURSTIN: And actually, I  
19 think as you'll see, as we walk through each  
20 of the criteria, every single one of these  
21 issues is going to come up. We're going to  
22 come up to it as soon as we get to the

1 importance criterion. So do you want to hold  
2 or go or --

3 DR. STOTO: Well, I guess I have a  
4 thought that there may be something important  
5 that's not in those four. But maybe it comes  
6 in under importance, and that's the question  
7 about who's accountable, following what I was  
8 saying before.

9 So I think that implicit in all  
10 the standard NQF measures is that the health  
11 care system is responsible for doing this for  
12 the patients, and I think that in the  
13 population health realm, it's not quite clear  
14 who is responsible for doing various things,  
15 and sorting that out may be important.

16 DR. JARRIS: So how is it that  
17 only somewhere between 40 and 50 percent of  
18 people with diagnosed hypertension are  
19 controlled? Who's accountable? If you take  
20 five diabetic parameters, 20 to 25 percent of  
21 the diabetics have them controlled. Who's  
22 accountable?

1                   So that's my issue with that.    I  
2                   mean, what does accountability mean if our  
3                   care is so bad?

4                   DR. STOTO:   Well, that's the  
5                   question that I think the measures have to  
6                   address.  I mean, I think that any health plan  
7                   would say, well, we're not accountable for  
8                   those people who aren't in our plan.  
9                   Sometimes they'll say we're not accountable  
10                  for the ones who don't come to see us.  And so  
11                  on.  But you know, the community may feel a  
12                  responsibility for getting that to happen, and  
13                  then you can say, well, who's going to do  
14                  something about that?

15                  Well, it may be that someone needs  
16                  to do some screening, or it may be that  
17                  someone needs to do some education, or it may  
18                  be that somebody else needs to do something  
19                  else about that, or it may be that the  
20                  facilities aren't there for doing the testing;  
21                  someone needs to provide that.  Or it may be  
22                  that health, the employers may need to say

1 that's part of the package that we buy, that  
2 that be done.

3 So you can imagine that different  
4 entities in the community have different  
5 things they could do to reach that goal, and  
6 I think that part of what we need is how to  
7 sort that out.

8 DR. BURSTIN: We've tried to  
9 actually weave that through, as you'll see  
10 here. Oftentimes, the criteria would have  
11 said "organizations or providers," and we've  
12 just said the accountable entity or entities.  
13 I mean, I think that's going to be one of the  
14 issues, and I think increasingly, if you look  
15 at the measures we've been trying to move  
16 towards like, for example, readmission  
17 measures, there is a movement towards trying  
18 to move towards measures that reflect shared  
19 accountability.

20 I think what we're really trying  
21 to get at is: where is that shared locus of  
22 the high priority areas where we could share

1 that responsibility, and I think it will  
2 oftentimes be more than one accountable  
3 entity. Did you want to say something?

4 DR. NAEGLE: Yes, I just wanted to  
5 comment, because Mike led us to a way of  
6 thinking that really hasn't been reflected in  
7 our framework, even though it is inherent, and  
8 that is the whole notion of the cultural norms  
9 of the community, and I don't mean culture in  
10 a very narrow way, ethnicity or race.

11 It's how are things done within  
12 our community around health? That determines  
13 so many responses to what we consider are  
14 larger system initiatives all across this  
15 country. I do think that you're right, that  
16 Canada identifies that more clearly, in  
17 looking at their approach to evidence-based  
18 practice, where the consumer has much more to  
19 say about what he or she wants to pay for,  
20 what he or she prefers as a mode of treatment.

21 So as we're thinking about  
22 community, I want to be sure that we get all



1 those normative factors somewhere in our  
2 assessment process looking at measures.

3 DR. STANGE: I'd like to suggest  
4 that this is actually one of our lever points.  
5 The NQF has given us their draft evaluation  
6 criteria, and I think we need to budget our  
7 time. My understanding is that Helen's going  
8 to go through this chunk by chunk.

9 Let's budget our time so we get  
10 through each chunk, and get the major comments  
11 down, because I think with some of the  
12 specifics here, we can really start to move  
13 the needle. Then we do want to come back to  
14 these general comments, after this and the  
15 next session, to say what's not there.

16 But so, Helen, how about if you go  
17 through these chunks, and let's feel free to  
18 say you know, these are good comments. Let's  
19 have some people to write them down and send  
20 them to you, so at least we get to discuss all  
21 the aspects.

22 DR. BURSTIN: And I believe Nicole

1 and Elisa are up there in fact to capture  
2 those comments, that will return to our  
3 parking lot. So thank you, ladies. So okay,  
4 it's on the screen. I must admit, I must need  
5 new contact lenses or that's unreadable.

6 But you do have this. The exact  
7 thing we're working off of is in your packet.  
8 It's called Attachment 4, the NQF Measure  
9 Evaluation Criteria. Let's just walk through  
10 it.

11 So the first thing is that we have  
12 a set of conditions for consideration. Before  
13 we'll even look at the measures, there are  
14 several conditions that are always met. I  
15 don't personally, I mean these, I think, would  
16 be similar. We want to make sure that a  
17 measure's in the public domain or a steward  
18 agreement's been signed.

19 We need a responsible entity to  
20 maintain these measures. Part of what we try  
21 to do is the science changes; somebody's got  
22 to update these measures, bring them back to

1 us every three years, which is why you're  
2 going to get to look at some of these other  
3 measures coming up.

4 C there is an interesting one, and  
5 I think it's one we may need to spend a little  
6 bit of time on, which is that the intended use  
7 of the measure is both for public reporting  
8 and those other accountability applications  
9 like pay for performance or accreditation, as  
10 well as quality improvement. So we've  
11 recognized there are many, many measures that  
12 have been used in the QI space only. They  
13 work beautifully in that space.

14 But if they're not rising to the  
15 level of actually being used to compare or  
16 provide, you know, used for accountability, we  
17 have not traditionally brought them into the  
18 NQF portfolio. So I think that's one thing.  
19 You may just want to think about how that  
20 plays in the context. Yes.

21 DR. STANGE: So just on this  
22 chunk, I'd like to suggest as a general thing

1 that could be looked at throughout. So it  
2 says -- the "both/and" is really good. But  
3 the idea that it might not be the same measure  
4 that's used for both/and. So there might be  
5 some measures that need to be different.

6 Then in (b), where it says  
7 "clinical intervention," wherever there's  
8 clinical it should be a serious look at what  
9 needs to be in the right column. So there  
10 could be community and population health  
11 interventions.

12 With the both/and idea under (e),  
13 in the right column it says "Provider level  
14 versus population level." So I think what  
15 we're hearing here it's probably provider,  
16 community and population level, and not  
17 versus. But probably that's a both/and among  
18 those three domains.

19 I think that's one of the ideas  
20 we're hearing here. Yes, the provider level's  
21 good, the population level. But the  
22 population level is more than the aggregation

1 of those clinical measures. So thinking about  
2 provider, community and population is  
3 something to -- is a way to reframe it.

4 DR. JARRIS: I also think that  
5 what do we mean by harmonization, because it  
6 shouldn't mean that in my practice, everyone  
7 has an A1C of less than seven, in my hospital  
8 service area, in my community, and that's what  
9 it means to line up. That's going to state  
10 two clinical differences.

11 There may be, for example, in  
12 tobacco, there may be a measure of at the  
13 provider level, of how many people are  
14 identified as smokers and counseled. At the  
15 behavioral level, how many people access quit  
16 lines, and at the community level, are there  
17 clean indoor air laws, what are the tobacco  
18 taxes, and things like that.

19 So those are harmonized, but  
20 they're not the same measure added up and down  
21 the system.

22 DR. BURSTIN: And that's actually

1 not what we are intending. Truly, it's  
2 harmonization, and some of this really comes  
3 down to harmonization, and some of this  
4 reflects the science issues that have been  
5 brought up. So if there's one consensus way  
6 of measuring smoking, would it be useful to  
7 have the community surveys match in some ways?

8 I think there are opportunities  
9 there to make sure that we in fact are all  
10 offering off that same, you know, reading off  
11 that same hymnal of saying -- funny thing for  
12 me to say -- but, you know, being able to  
13 actually understand that we're talking about  
14 the same thing.

15 DR. JARRIS: So one is a matter of  
16 scale. Can you take an individual measure on  
17 the scale to the population, and the other is  
18 really harmonization. Are these complementary  
19 measures, designed to achieve the same end?

20 DR. BURSTIN: Exactly, and  
21 avoiding when there's competing, which is what  
22 we often encounter. So you may get -- it's

1 also not helpful if there are two standardized  
2 measures that may be using those different  
3 levels, but give you a very different message,  
4 if you're the provider in that community,  
5 versus thinking of yourself as a community  
6 provider.

7 So I think we're just trying to --  
8 I mean, I think there's a lot more to do here,  
9 and this is probably a good area to come back  
10 to, as we try to further explore that framing  
11 of what's community. Did you have a comment  
12 back there, Bobby?

13 MR. BIALEK: Well, since we were  
14 talking about E, just an observation. It  
15 strikes me that the harmonization piece  
16 requires the population measure to not compete  
17 and to be harmonized with all of these other  
18 types of measures that are clinical, as well  
19 as community we just spoke of.

20 But when I look at the clinical  
21 measure, that harmonization of the population  
22 and community measure is not a requirement.

1 So it just strikes me that the burden, if you  
2 will, on the population measure is far  
3 greater.

4 DR. BURSTIN: And that's not our  
5 intent. Our intent is in fact that the  
6 clinical measure should have the equivalent  
7 burden, and in fact, the harmonization goes  
8 both ways. That's really the intent of this  
9 discussion.

10 MR. BIALEK: Okay. So then, would  
11 the wording in that left column change as  
12 well, since you added wording in the right  
13 column, requiring that harmonization?

14 DR. BURSTIN: Potentially. NQF  
15 does re-look at its overall evaluation  
16 criteria on an annual basis, and I think part  
17 of what we've been seeing is we've gone into  
18 these newer areas. We've emerged with newer  
19 guidance, and at times I think some of that  
20 newer guidance needs to get built into the  
21 overall criteria for NQF, as these become more  
22 mainstream. Yes, exactly. That's exactly,



1 I think, where we are. That's very helpful  
2 framing.

3 DR. JARRIS: Larry.

4 MR. COHEN: Again, forgive me if I  
5 don't fully understand how the process works.  
6 But it seems to me that harmonization is  
7 between the clinical measures and the  
8 community measures. But there's another  
9 element, which is the measurement of  
10 inequities. I'm not sure whether that's a  
11 separate piece, or whether that gets included  
12 here, how to incorporate it.

13 But I think -- oh, it's here  
14 already? Oh, okay.

15 DR. BURSTIN: All right. So we're  
16 going to keep moving, and actually I would  
17 jump us ahead to the very first real set of --  
18 the first criteria. The rest of this is sort  
19 of more boilerplate.

20 Let's go to number one there, sort  
21 of the middle of page two, which is actually  
22 our -- this is a must-pass criterion for NQF,

1 which is importance to measure and report.

2 Importance to measure and report has three  
3 elements to it.

4 The first is that it's high  
5 impact. The second is that there's a  
6 performance gap, and the third is that there's  
7 an evidence base for the measure focus. So  
8 we'll go through each of them in detail. But  
9 that's the broad framing of this.

10 We don't evaluate measures  
11 further. We actually don't care if they're  
12 reliable, usable or feasible if they're not  
13 important. So this is the must-pass. In our  
14 hierarchy, we then look at the science of the  
15 measure, in terms of reliability and validity,  
16 and if that is not there, we also stop. So  
17 those are our two stop points.

18 But importance is probably, I  
19 think, the most important framing for us  
20 today, as it relates to the discussion we've  
21 had before. So in the overall discussion up  
22 top here, we specifically said improving

1 health care quality and outcomes. The  
2 question was, should we add population to that  
3 or community, and see if you think the draft  
4 language that's in here is helpful.

5 Then there was this question that  
6 keeps coming up about accountability, and we  
7 thought, since it's been brought up a couple  
8 of times, that it would be useful to put that  
9 in here. Again, these are just straw men,  
10 language for you to react to. Paul's got his  
11 pen out, so please let us know.

12 DR. JARRIS: You know, I'm looking  
13 across from one in Column B there, and it's  
14 again very health-care-oriented. Importance  
15 to making significant gains in health care  
16 quality, and improving health care outcomes of  
17 a specific population, by which that means to  
18 me like a diabetic or hypertensive, for a  
19 specific high-impact aspect of health care,  
20 where there's variations.

21 This is all still purely aimed at  
22 health care, it seems. So we really again

1 have to -- if in fact we're looking at  
2 population health, then we need to introduce  
3 that concept.

4 DR. BURSTIN: Right, and specific  
5 population here was not intended to be  
6 diabetic or anything like that. It was  
7 supposed to be literally getting at a  
8 community. That was not the intent of at  
9 least our draft language here.

10 DR. JARRIS: Because it also  
11 could, it could mean by specific population,  
12 my population as a hospital or as a doctor or  
13 as an insurer. So we have to really be clear  
14 what we mean.

15 DR. STANGE: The other thing that  
16 Paul's getting at is health care quality.  
17 There are other aspects of quality. So  
18 there's, we have a community guide, and we  
19 have public health community preventive  
20 services. So there could be quality that's in  
21 both, more than health care.

22 MS. MERRILL: There's this problem

1 with this word "population." It's creating so  
2 much difficulty everywhere. People are so  
3 confused about it, everywhere I go. So you're  
4 saying here a specific population, but you  
5 mean a community, a defined community.

6 DR. JARRIS: Even the word  
7 "community" is one of those meaningless words,  
8 so.

9 DR. STOTO: I think that what we  
10 need to do is be specific about what we mean,  
11 and understand that it could mean different  
12 things in different contexts, that  
13 traditionally in NQF work, it's referred to as  
14 a group of people who are part of a plan or  
15 see a doctor in a given year. But in  
16 population health work, it could be people who  
17 live in a certain place, or I can imagine it  
18 being defined another ways.

19 But it's important just to be  
20 specific about what we mean by it in any given  
21 setting.

22 DR. JARRIS: Maybe we can -- let's

1 park this up there, because when we talked to  
2 the LA group again, they attempted some  
3 definitions. Let's see if what they came up  
4 with is good enough. But I have a feeling  
5 this is going to be something we're going to  
6 keep going back at, and hopefully we'll get  
7 right.

8 DR. STANGE: Well, this is  
9 something that will need more work. So Robert  
10 suggested earlier the idea of a logic model.  
11 So when you're talking about impact, the  
12 impact here is beyond health care quality. So  
13 the impact has to start looking at population  
14 measures of health.

15 You can define that as the whole  
16 country, a state, a community. You can define  
17 that in different ways. But it's raising the  
18 gaze from the health care of the individual to  
19 other determinants of health for groups of  
20 people.

21 MS. MERRILL: So maybe that's all  
22 it needs.

1 DR. STANGE: So we're not going to  
2 solve this here, but this is where a logic  
3 model about how would you measure an impact  
4 for, and what does quality look like at the  
5 population and community level for the things  
6 that we can measure and the things that we can  
7 then intervene on, that meet your other four  
8 criteria, that have an effect on health at  
9 that group level?

10 Then that's going to beg the  
11 denominator question of how do you define the  
12 group.

13 MS. MERRILL: So would it help  
14 just to say, I mean, that word "specific."  
15 Instead of saying specific, just say for a  
16 defined population group.

17 DR. STOTO: Maybe just define  
18 population.

19 DR. STANGE: Helen, what we're  
20 going to do here is we're going to get a sense  
21 from the group discussion. Will there be a  
22 chance for people to send things, and then

1       there'll be an aggregation of this? This is  
2       going to take multiple iterations. We're not  
3       going to be able to wordsmith this here, this  
4       group. Is that the process we're engaged in?

5               DR. BURSTIN: Absolutely, and that  
6       was part of the logic. Again, I don't want  
7       people to feel like we're sort of putting  
8       community second. I don't think we were ready  
9       to ask for community measures right now,  
10       because I think we need to get this  
11       straightened out first.

12               So that was the idea of doing the  
13       foundational work, while we kind of do our  
14       more traditional kind of measurement. Think  
15       through these issues, and then be able to call  
16       for measures and actually be able to evaluate  
17       them in the second phase, or else I wouldn't  
18       know how to evaluate these measures.

19               DR. JARRIS: Now there's one  
20       aspect of this that we're way ahead of  
21       everybody else. Is that, as we've already  
22       called into question, what we don't know?



1 Because how many groups have you been on where  
2 they just keep using the word population and  
3 community, all talking about different things,  
4 and nobody says we're all talking about  
5 different things. So at least we flagged it  
6 at the beginning.

7 There's one other thing across  
8 from 1). The notion of specific accountable  
9 entity, because you know, it's going to be  
10 hard in population health. It may have to be  
11 entities. For example, an accountable care  
12 organization is an entity made up of an  
13 insurer, providers, hospitals, all kinds of  
14 other things.

15 There are also like through some  
16 of the new ACA initiatives, Communities  
17 Putting Prevention to Work, which is actually  
18 before ACA, where it's a consortium that's  
19 held accountable, sometimes led by the  
20 political leadership, sometimes by clinical,  
21 sometimes -- in Iowa it's led by the business  
22 leadership.

1                   But some entity has to say okay,  
2                   we're going to be held accountable for that  
3                   and achieve it. But it's not likely to be one  
4                   legal incorporated entity. Matt, and then  
5                   Bobby after that.

6                   MR. STIEFEL: That was going to be  
7                   my point as well, but just to elaborate a bit.  
8                   Watching the evolution of IHI's Triple Aim  
9                   initiative, it started with a hodgepodge of  
10                  organizations, some governmental, some  
11                  insurers, some providers.

12                  Almost in all cases, in order to  
13                  achieve the Triple Aim, these groups realized  
14                  that it required the efforts of a multi-  
15                  stakeholder collaboration, to achieve  
16                  population health especially.

17                  So they've all moved in the  
18                  direction of, some very explicitly, in a  
19                  multi-stakeholder coalition. So I think it's  
20                  important enough. While you could say the  
21                  specific accountability entity is the multi-  
22                  stakeholder coalition, that doesn't lead you

1 necessarily to that. I mean, it's so  
2 important in population health that it's worth  
3 specifying.

4 DR. BURSTIN: How would you  
5 specify it differently, Matt? I'd just be  
6 curious as to your thoughts.

7 MR. STIEFEL: The notion of shared  
8 accountability among different stakeholder  
9 groups is a notion here that I think is so  
10 critical for population health improvement.  
11 That's a very different concept than the  
12 language here, of a specific accountability  
13 entity.

14 MR. BIALEK: Well, on the last  
15 point, I think it's both/and rather than  
16 either/or. Shared accountability doesn't mean  
17 that nobody's accountable. At least that's  
18 the frame that I have in my head. Shared  
19 accountability and a partnership model can lay  
20 out within that partnership and that  
21 collaborative approach, who's got  
22 responsibility within their own domains for

1 doing specific things.

2           The successful partnerships, the  
3 ones that actually produce better health  
4 outcomes, do that. They don't just say let's  
5 go -- they say first of all, and that's -- we  
6 do an assessment in our community, and we  
7 understand something about the status, health  
8 status, life status, quality of life status of  
9 people in our community, and we recognize --  
10 we not only have what our status is, but we're  
11 able to contrast it with some other community,  
12 to say there's a difference here, and that  
13 difference leads to conversations about there  
14 shouldn't be that difference and we'd like to  
15 do something about that.

16           Everybody goes around the table  
17 and says, well, okay, yes, that's right. So  
18 there's the first consensus.

19           MR. PESTRONK: First step.

20           MR. BIALEK: The second step is to  
21 say okay, now they have that difference, what  
22 are we going to do about that? And everybody

1 says okay, that's right. So there's a look  
2 around the table and everybody holds hands  
3 through a very difficult process, and they say  
4 here's what I'm going to do.

5 If you've got a real quality  
6 improvement process, you don't get stuck on  
7 trying to do the best thing first. You just  
8 get started and establish a process where  
9 you're constantly contrasting differences over  
10 time, recognizing whether those differences  
11 are shrinking or not.

12 So it's a both/and process. It's  
13 shared, and there are specifics within it.  
14 The reason -- specific obligations within it,  
15 and it works. The reason why I raised my  
16 placard before is to make suggestions to the  
17 chairs and to the staff.

18 Because of the way the agenda has  
19 been framed, to look at what are clinical,  
20 preventive, and I emphasize the clinical, it  
21 might be wise as one or all or several are  
22 discussed, to reserve a few minutes in that

1 discussion, to ask ourselves: how does this  
2 translate to community? Because it's the  
3 discussion over time that will help us take  
4 the kinds of approaches that are being  
5 suggested here.

6 We won't -- we're not going to,  
7 for the ease of the chairs and the staff, we  
8 don't have to reach consensus on what the  
9 community measure would look like. But it  
10 will begin to give us a peek into what does it  
11 mean to think about something in a clinical  
12 way -- in a community way?

13 If we were looking at obesity or  
14 heart disease or some other, what in essence  
15 is a clinical outcome, we could ask ourselves  
16 what do we think from a community perspective  
17 are really causing those outcomes, and it  
18 isn't the clinical intervention measure that  
19 we're looking for.

20 It's the measure on the community  
21 side. So it's a suggestion of how to begin to  
22 weave into the discussions here what will be

1 useful for the staff, because you're so  
2 clinically oriented.

3 That's not a criticism. It's  
4 just, you know, the nature of the work that  
5 you've been doing. It gets to your point,  
6 Paul, which is this is -- it could potentially  
7 be a conflict of cultures, and if we're  
8 successful, it would be a blending of the  
9 cultures, and what we accomplish is the push  
10 from NQF, which is seen as a reputable entity  
11 on the clinical side, becoming a reputable  
12 entity pushing on the community side, which is  
13 what those of us on the community side, I  
14 think, would like to have happen.

15 DR. JARRIS: So Bobby, it's a  
16 great suggestion, as always, and one thing I'd  
17 like to suggest is we also look at it from --  
18 I mean, what's labeled behavioral in that NPP  
19 concept, and I don't like that term  
20 necessarily. But there are those questions  
21 about, you know, we could have clinical set,  
22 community set, but people don't take advantage

1 of it.

2 So we really want to look at,  
3 okay, what are the social norms, the drivers,  
4 the other things that will enable people to  
5 make the healthy choice once available. So I  
6 think looking at all three levels could be  
7 important. I had Ron, then Larry, then Matt.

8 DR. STANGE: And just a process  
9 thing. After we do these questions, Helen, I  
10 wonder if some of these other ones, the  
11 comments that will come up are similar to the  
12 general points that we've had, except for 2C  
13 on disparities. I wonder, since we have ten  
14 minutes left, I think we should end this at  
15 quarter of, if we want to make sure after we  
16 do these comments, if we jump to that and save  
17 a little time, so that we at least get a group  
18 discussion of that.

19 If there are important things  
20 people have to say on some of the other ones  
21 that didn't come up, you'll tell us how to get  
22 those to you.



1 DR. BURSTIN: I'd like to quickly  
2 do evidence as well, because I think it's an  
3 important one that's already been raised.

4 MR. BIALEK: I'd like to build on  
5 Bobby's comment for a moment, and I'm  
6 wondering if under the population health  
7 measure evaluation, the additional guidance  
8 and context, if we could benefit from there  
9 being two columns, one column being the  
10 clinical preventive services, and the other  
11 being the community preventive services and  
12 interventions.

13 Because when I think about  
14 changing all of this language and all the  
15 wordsmithing, it may become incredibly  
16 confusing and provide less guidance, because  
17 the way we think about the clinical preventive  
18 services may be different than the way we  
19 think about the community preventive services.

20 It's just a thought to throw out  
21 there, rather than trying to fit everything  
22 into the same set of criteria, same set of

1 guidance for us.

2 DR. JARRIS: Larry? Okay, Matt.

3 MR. STIEFEL: It's probably gotten  
4 a little out of phase, but Helen asked about  
5 a suggestion for accountable entity. I  
6 actually think there's nothing wrong with  
7 being specific and clear about accountability.  
8 The idea is just to make sure that it's broad  
9 enough.

10 So maybe just a parenthetical  
11 statement, specific accountability, including  
12 multi-stakeholder groups. It's not sufficient  
13 just to have the stakeholders at the table.  
14 There still needs to be clear accountability.

15 DR. BURSTIN: Okay, moving right  
16 along. So let's quickly, page three there.  
17 Let's just quickly keep going through  
18 importance, and again, this is not your last  
19 look at it. Disparities is specifically  
20 listed under performance gap as well. So I  
21 just want to mention that there.

22 There is a requirement, as part of

1 our evaluation, that there's a demonstration  
2 this a problem. There's a performance gap in  
3 this area, and it does include specifically  
4 quality. Again, this is quality of care.  
5 We'll need to potentially round that out. But  
6 quality of care across providers and/or  
7 population groups.

8 So I think that's something we  
9 wanted to specifically understand, this issue  
10 of variation. How would you look at variation  
11 across communities, for example? How is that  
12 a different framing of whether there's a  
13 performance gap in a given measure?

14 DR. JARRIS: It's also within  
15 communities. So we could have two  
16 communities.

17 DR. BURSTIN: Yes, yes. That's  
18 why it specifically says included, but not  
19 limited, to disparities, of trying to look  
20 within communities at populations as well.

21 MS. SAMPSEL: And I think my  
22 comment is probably more global about this

1 section specifically, but probably goes all  
2 the way through, and that's the use of the  
3 word "patient." It doesn't communicate well  
4 in communities, as well as I don't think  
5 that's what we're getting at with a full  
6 population.

7 So that would be the one thing  
8 and, you know, especially in disparities, you  
9 don't always consider someone a patient, and  
10 there's a lot of nomenclature issues in those  
11 populations in talking about patient.

12 MR. STIEFEL: Yes, and along the  
13 same lines, maybe a global search and replace  
14 for things like "care" and "patient." So  
15 disparities in care is too narrow. It's also  
16 disparities in the determinants and outcomes  
17 of health that we care about.

18 DR. JARRIS: Michael, then Larry.

19 DR. STOTO: My point was actually  
20 going to be similar to that, that this idea  
21 about performance works well in the world when  
22 you think about process measurement primarily.

1 But I think that outcomes is more important to  
2 bring in here, and maybe even --

3 MR. COHEN: The reason I brought  
4 this up earlier, in our organization, we do a  
5 lot of work on health equity, as kind of a  
6 fundamental element of our work, and always  
7 with the community as the level of analysis.  
8 One of the things we found commonly is that  
9 the indicators that are available are the  
10 indicators that are not measuring the things  
11 that our thinking indicates are most  
12 important.

13 That troubles me, and that's why I  
14 brought this up actually at the beginning, in  
15 terms of the overarching, rather than as a  
16 subset of this. I don't know what the purview  
17 of this group is in terms of one of the  
18 criteria being kind of available measures.

19 But I think somewhere in some way,  
20 as part of the credibility of this, it's  
21 important to indicate that there are some very  
22 important measures that are lacking, or at

1 minimum, that are inconsistent between  
2 different communities.

3 For example, some of the work that  
4 was done recently by Robert Wood Johnson  
5 called MATCH, which is looking at counties  
6 that I'm sure Bobby's probably one of the most  
7 familiar with. Because it's looking at a  
8 county-wide level, Oakland/Alameda County,  
9 where I came from, come from rated very, very  
10 high.

11 When I look at what's going on in  
12 Oakland, there are horrible inequities that  
13 are not showing up, because of the measure of  
14 the data that's used. I think it's a really  
15 good example of unintended consequences. So  
16 I just want to note this. I don't know,  
17 Helen, exactly where it fits here. But I  
18 think it's an issue of critical importance, or  
19 otherwise we'll continue to drive things in  
20 the wrong direction, and say see, we're making  
21 progress.

22 DR. JARRIS: You know, Larry, we

1 really tried to address this issue with the  
2 NPP process, in which we introduced the World  
3 Health Organization concept from 2002, which  
4 is that you need to have a measure of goodness  
5 and a measure of fairness. The measure of  
6 goodness is the average performance; the  
7 measure of fairness is the difference between  
8 the healthiest and least healthy, or the most  
9 and least disparate group.

10 We could not get that through the  
11 NPP. They couldn't, it was considered a  
12 quote, "new concept," and they didn't want to  
13 introduce a new concept. But I would want to  
14 bring that back here to say, you know, a  
15 perfect measure would not only tell you the  
16 average infant mortality, but it would also at  
17 the same time tell you the difference between  
18 let's say the Caucasian and African American,  
19 Caucasian and Native American, whatever the  
20 appropriate population is.

21 Without that, you know, like you  
22 said, how could Oakland possibly be considered

1 a healthy place if you walk through much of  
2 it, or at least --

3 MS. MERRILL: So it's the  
4 equivalent of the confidence interval.

5 DR. BURSTIN: Some of that will  
6 come up as we talk about the signs of  
7 acceptability in the measurement of  
8 properties. We talk a lot about the precision  
9 of the specifications to get at a level of  
10 analysis most appropriate, to be able to see  
11 what's, where you want to be, and that might  
12 be an interesting issue, is it to the most  
13 granular level to be able to see the  
14 differences.

15 DR. JARRIS: Well, but even  
16 forcing the -- because again this is -- we all  
17 awfulize about health equity. But until we  
18 actually force the system to look at it, and  
19 you can force the system by saying your  
20 measure has got to have an average goodness  
21 and a disparity component at the same time.  
22 Now there's going to be a gap, because we



1 don't have it. But if we don't require it or  
2 push it, it's just never going to happen.

3 DR. BURSTIN: Yes.

4 MR. COHEN: And I think also, on  
5 that point, that there are some, when we  
6 looked and we did research on this, on what  
7 the underlying community health factors are  
8 that relate to the key behaviors and most  
9 important, to the leading causes of death, and  
10 we looked at the ten leading causes of death,  
11 most of which are also the ten leading places  
12 of inequity and cost and disability and  
13 hospitalization, and we came up with 13  
14 community factors that we've laid out and have  
15 identified, we had a very, very hard time and  
16 we're working on it again.

17 But identifying indicators. It's  
18 not even a question -- it's a different set of  
19 indicators that we need, if we're going to  
20 talk, for example, about quality of social  
21 interaction. You know, you can guess things.  
22 You can say, well maybe it's percentage of

1 people voting. But it takes us very, very far  
2 afield when we talk about harmonization, from  
3 patient-oriented.

4 It's not just replacing the word  
5 "patient," but it's a very, very different way  
6 of thinking. I really think it's important,  
7 and it's one of the main reasons I'm here, to  
8 emphasize this very important paradigm shift,  
9 even if we can't get there right away, but to  
10 be very clear that at least from my  
11 perspective, that's the goal that has to be  
12 reached.

13 Not only in population, but as  
14 someone said before, in starting to shift the  
15 clinical measures as well, so that clinical  
16 thinking starts to think more about the  
17 community factors that make people sick or  
18 injured in the first place.

19 DR. JARRIS: Reva, and then Mike.

20 DR. WINKLER: Just to respond to  
21 Larry's comments about available measures, in  
22 the last decade that NQF has been doing this,

1 this has been a common theme, of whenever we  
2 do these projects, the measures we have  
3 available are usually, almost invariably, less  
4 than what people want. There is this general  
5 shared sense of yeah, okay, but they're not  
6 what we're looking for, and that has just been  
7 a common theme. So there is nothing new  
8 happening here.

9           We have seen evolution over time.  
10 It is slow. But ten years ago, the idea of an  
11 outcome measure just was not even considered,  
12 and now they are pretty much what we do. So  
13 things do change, but availability of measures  
14 is one of our serious issues for everybody,  
15 and it really would depend on the measure  
16 development world, you know, who is creating  
17 those measures, and what are the incentives  
18 for them to develop those measures, so that  
19 you have them.

20           It's going to be the same issue for  
21 you all that we've certainly seen in pretty  
22 much everything else in the measurement world.

1 So the one avenue you have is certainly to  
2 identify what those measures are. Be specific  
3 about what you're looking for and what we  
4 need.

5 DR. JARRIS: Matt, you've put yours  
6 down, so maybe Sue and then Bobby, and we have  
7 like two minutes left. So let's be --

8 DR. PICKENS: So I'm going to be  
9 quick, and I hope what I have to say is  
10 relevant. I think what Larry said is  
11 extremely important, because when we do these  
12 broad-based measures of what the community  
13 looks like, how many people have heart  
14 disease, what is the asthma rate, and we take  
15 it to the community, they raise their hand and  
16 say yes, we know that, but that's not what's  
17 important to us.

18 What's important to us is livable  
19 wage jobs, our kids graduate from high school  
20 and nobody gets shot on the way. So those are  
21 kind of the measures that we, in order to make  
22 this even acceptable, I guess, to the

1 communities we're writing it for.

2 DR. JARRIS: And we're moving more  
3 towards that concept of well-being and less  
4 clinical illness.

5 MR. PESTRONK: Helen, what you were  
6 doing was walking us through Attachment 4 and  
7 pointing out to us how the typical NQF  
8 evaluation criteria have been modified or  
9 could be modified to better address the  
10 population health measure context.

11 This conversation has been about  
12 that it needs further revision in order to be  
13 useful. Yet later on today, we're going to be  
14 looking at what are ostensibly population or -  
15 - so my assumption was, let me start there,  
16 that we're going to be looking at what some  
17 people might think are population health  
18 measures, and that's the reason why that's  
19 what this group is.

20 So if in fact the guidance and  
21 context need to change further, how are we  
22 accomplishing the work we're supposed to be

1 accomplishing here, if in fact, we don't have  
2 the criteria and guidance correctly specified  
3 before we go about doing our work?

4 DR. BURSTIN: I think the measures  
5 that are before you today are clinical, and I  
6 think they fit our usual paradigm, which is  
7 why we actually held off on giving you any of  
8 the ones that were submitted, that look more  
9 population-health-oriented, until you have an  
10 evaluation criteria that will effectively  
11 allow you to look at those measures.

12 MR. PESTRONK: So what we shouldn't  
13 be thinking we're doing today, or over the  
14 course of these meetings, is actually the real  
15 work of this group, or --

16 DR. JARRIS: I think we could look  
17 at ourselves as grounding ourselves in the NQF  
18 methodology, so we have that foundation as we  
19 try to go forth. You know, and frankly, if we  
20 all sat down in the room and tried to take  
21 population health on now -- what an immensely  
22 complex task. So let's, I'm glad we're

1 starting somewhere, that some of this has been  
2 worked out.

3 So I've been negotiating with Kurt  
4 on your behalf, Matt. You may get the last  
5 comment here.

6 MR. STIEFEL: 1(c), I'm not sure  
7 which page that is. I think that framework is  
8 not sufficient for the work of this group, in  
9 that evidence, sort of causal pathway of  
10 outcomes, intermediate clinical outcomes,  
11 patient experience and efficiency is not broad  
12 enough for the work of this group. That's a  
13 very clinical focus.

14 It, for example, doesn't include  
15 behaviors, and also it doesn't include the  
16 social and environmental determinants. So in  
17 the causal pathway for this work, it, I think,  
18 needs to explicitly include and articulate  
19 that we're talking about -- I mean, behaviors  
20 is one of the stated purposes, and the  
21 community or social and environmental  
22 determinants are critical in the causal

1 pathway that we're talking about but aren't  
2 listed here.

3 DR. JARRIS: It might be a critical  
4 and a clinical pathway. I mean, if you look  
5 at a patient with chronic illness that sees  
6 their doctor every quarter and pretend it's  
7 half an hour, that's .02 percent of their  
8 life. 99.98 percent of life, they're  
9 determining the care and their health. So it  
10 really ought to be part of the clinical  
11 measures also.

12 DR. BURSTIN: Just to tee up for  
13 our last second, if we could, just if you  
14 could look at 2(c), and we can return to it  
15 this afternoon as we have our discussions, but  
16 2(c) on page six is what we currently have for  
17 disparities, and since it's been so prominent,  
18 I want to at least put it on the table here.

19 We have traditionally been trying,  
20 and again this has been a bit of a forcing  
21 function on our part, to ask that measures be  
22 stratified, Nicole and Robyn have been leading



1 our efforts here, by race, ethnicity, SES,  
2 whatever the case may be. What we're often  
3 finding is it's more dependent on the data  
4 platform than it is the measure itself.

5 I think it would just be helpful  
6 for us to have a discussion, maybe not right  
7 now, but maybe in the afternoon discussion,  
8 after we figure out what population and  
9 community are, and how disparities fits into  
10 that. Perhaps we could just talk about: is  
11 there ever a justification, for example, for  
12 not including stratified data?

13 DR. JARRIS: There are two sides to  
14 that, so we should talk about it. Because  
15 let's take the Alabama Health Department that  
16 doesn't have two nickels to rub together and  
17 a really sick population, and then compare it  
18 to LA, where everyone's too skinny and goes to  
19 health clubs. Who's doing a better job?  
20 Which community is doing a better job?  
21 So there may be a place to look at, you know,  
22 risk adjustment.

1 DR. STANGE: So let me make a couple  
2 of summarizing comments and suggest we  
3 actually do take the break, because we need  
4 to clear our heads, and the next part is  
5 really another high impact thing that we're  
6 doing, that's about the stuff we all care  
7 about. So what I heard is some of the charges  
8 that we've received, is to just, there's kind  
9 of a searching function, looking for key words  
10 like patient care, health care, and just  
11 thinking about people and health and well-  
12 being, for some of those things about disease  
13 and patients.

14 Another is actually to start with the  
15 right column and think about that, about the  
16 similarities, rather than transferring over  
17 from the left column. So starting with  
18 populations and think about how you want to  
19 measure that, what level you measure that.  
20 Think about community as a participation  
21 community. Starting in that right column,  
22 what would that look like?

1           The really important points that we  
2 actually heard from Andy, Robert and Matt  
3 about who's the responsible entity. So they  
4 talked about shared responsibility,  
5 partnership, accountability that includes a  
6 multi-stakeholder group. That's a huge  
7 reframe from one organization that you can  
8 hold their toes to the fire.

9           But if you look at how to make things  
10 useful and feasible, that's going to be the  
11 transformative stuff. So that's a huge  
12 reframe. So think about what that means for  
13 the right column. Thinking about some of  
14 these, what's there, this little word of  
15 disparity, what that means for equity and how  
16 you think about that for the different  
17 populations.

18           So that's a ton of work to do for a  
19 next draft, and then I assume if we have other  
20 comments, we should email those to Elisa or --  
21 and then you will give this back to us  
22 sometime, and we'll have a chance to revisit

1 this and read this? Okay.

2 DR. JARRIS: Okay. So eleven  
3 o'clock, the LA folks are calling in. So  
4 let's take a five minute break and be back at  
5 11:00.

6 (Whereupon, the above-entitled matter  
7 went off the record at 10:51 a.m. and resumed  
8 at 11:12 a.m.)

9 DR. JARRIS: Okay. Well, thank you  
10 very much for joining us. In the room, I'd  
11 say there's about 25 different folks from both  
12 public health, clinical, insurance, as well as  
13 business groups and others, governmental  
14 positions, HHS.

15 We're very interested in hearing  
16 about the paper you've begun to work, and I  
17 think very interested in providing feedback,  
18 as we all stretch to really define better some  
19 of these terms and some of the concepts here.

20 I want to thank you, Steve and Dawn,  
21 for taking this first stab at it in what is a  
22 very complex area, to actually try to nail

1 down these definitions.

2 We were actually thinking this  
3 morning that the work you're doing here is a  
4 good start forward, because many groups have  
5 these discussions without even attempting to  
6 define what they're talking about. So I want  
7 to thank you for taking a stab at this, and  
8 please lead off.

9 MR. TEUTSCH: Great. Thank you so  
10 much, Kurt, and thanks to all of you for  
11 allowing us to work with you on this project.  
12 Dawn and I have been now involved with  
13 performance measures for a long time, but we  
14 were first asked by NQF to consider working on  
15 this paper just about three weeks ago, two-  
16 three weeks ago, and it wasn't till last week  
17 that we actually were told to go ahead.

18 So what you are having from us is  
19 some of our initial thoughts about this work,  
20 and it's an area that we're excited to work on  
21 and we're excited to work with all of you. I  
22 do know many of you, and sorry that we cannot

1 be there with you. So thanks for allowing us  
2 to do it by phone.

3 The person who is going to be doing  
4 the lion's share of the work at our end and  
5 drafted most of the outline that you saw is  
6 Dawn Jacobson. So she'll be doing the  
7 presentation this morning, and I hope most of  
8 you have had the chance to review that,  
9 because the slides obviously are only going to  
10 be able to do a synopsis, have a brief  
11 synopsis of some of the ideas.

12 Then we're looking forward to hearing  
13 from you what you're going to need, so that we  
14 can flesh this out and modify it to meet your  
15 needs. So with that, I'm going to turn it  
16 over to Dawn, and hopefully you all can see  
17 her slides. Do you have her slides up, Kurt?

18 DR. STANGE: Yes.

19 MR. TEUTSCH: Great. So Dawn, why  
20 don't you go ahead?

21 MS. JACOBSON: Okay. Good morning,  
22 everyone. It's very good to be part of this

1 project. Just so you know, I cannot see the  
2 slides on the webinar, so I'm just using my  
3 own slide sets, and I will be try to sure to  
4 say advance slide. Elisa, if you can just let  
5 me know periodically if we're in sync, that  
6 would be great.

7 So before I even begin, we definitely  
8 acknowledge there's a lot of different  
9 terminologies, and a lot of different ways  
10 that the concept can be defined. So we  
11 definitely look forward to hearing how you  
12 choose to define them. Next slide, please.

13 The proposed analytic framework is  
14 really based on a gentleman who created an  
15 approach to measurement maybe in the late  
16 90's, by the name of Mark Friedman. Some of  
17 you may have heard of him.

18 DR. STANGE: Yes.

19 MS. JACOBSON: He worked at the State  
20 of Maryland Department of Finance. He had a  
21 long career in the public sector, and created  
22 an approach that we think is very helpful, in

1 that it clearly distinguishes sort of what  
2 these population health big picture goals for  
3 various levels of community are, from these  
4 sort of organization-specific, provider-  
5 specific, program-specific goals, but links  
6 them very nicely. Again, the concept that  
7 Friedman has proposed is that any public  
8 agency and really any system that would  
9 consider improving population health as a  
10 primary objective, could then apply this sort  
11 of framework.

12 Next slide, please. So then it sort  
13 of begs the question then of what system, how  
14 do we define system, what types of providers  
15 work in these systems, and, again, we all know  
16 this is very complex. We all work in  
17 different aspects of these different systems.

18 What this slide shows, and what the  
19 proposed framework would be, is really taking  
20 the Institute of Medicine definition of the  
21 public health system being this network of  
22 partners, and you'll see on sort of the left



1 the third bullet. "The public health system  
2 is very large, could be work site, schools,  
3 other sort of public agency systems that might  
4 have health as an objective, especially in  
5 social determinants related to health."

6 So loosely connected non-profit  
7 systems, and there's others, you know, we  
8 could list there, and I'm sure everybody will  
9 have something else they want to put in that  
10 sort of catch-all category.

11 But what we thought would be helpful  
12 for framing is that we would focus on then the  
13 two systems, the clinical care system, health  
14 care system, medical care system, whichever  
15 term we choose to use, and sort of this  
16 network of units that deliver governmental  
17 public health activities, because those are  
18 really the two systems that clearly have  
19 health and wellness as a part of their vision  
20 and mission.

21 Then by keeping those three  
22 categories very distinct where possible, then

1 there would be providers or practitioners, and  
2 again choose your term, that would then  
3 reflect delivery of services within those  
4 system, so we propose sort of three systems  
5 and three types of providers.

6 Next slide, please. This is a way of  
7 very simply showing the connections that Mark  
8 Friedman really created. So what you'll see  
9 in the next few slides is that the sort of  
10 linkage for population health improvement and  
11 what an organization or system that we propose  
12 would do, the types of activities that would  
13 lead to planning, getting to agreement on what  
14 collectively we do to improve population  
15 health through shared accountability, shared  
16 work, who does the types of planning, who does  
17 the types of measuring.

18 We didn't quite get into quality  
19 improvement with our examples, but really  
20 again, the clinical care system, the public  
21 health system has been doing these things,  
22 sort of separate but in parallel, and I like

1 the comment earlier this morning about  
2 complementary activities and metrics that  
3 might not be identical.

4 So if you focus on the blue box for  
5 a moment, we can -- population health means.  
6 But if we think about sort of even the U.S.  
7 Constitution and the delegation of who does  
8 the health and welfare of the country, we  
9 consider this sort of the public good, the  
10 common good of population health, that  
11 different systems would then work together to  
12 ensure and move forward.

13 You'll see inside the blue box we put  
14 health outcomes, which we'll talk about in a  
15 minute; behaviors; and then social  
16 determinants. So the more upstream  
17 determinants that would then influence the  
18 health and welfare of populations.

19 Who directs that planning? I heard  
20 comments about who the owners of these types  
21 of activities? A lot of these sort of common  
22 good, public health planning activities have

1 really been done by the governmental public  
2 health system, in some areas of the country in  
3 partnership with the clinical care system or  
4 the non-profit system, as part of this, you  
5 know, state community health assessments or  
6 improvement plans.

7 Part of the framework we'll be  
8 getting a handle on, sort of what different  
9 areas and levels of community have really  
10 prioritized over time, and kind of do a scan  
11 and better understand that.

12 But then you have this green box, of  
13 which whatever system you choose to focus on,  
14 which we'd like to focus on the two primarily,  
15 you have organizational sort of performance  
16 and things you want to do well, and then  
17 really provider level.

18 These are oftentimes reflected in an  
19 organization's strategic plans, the vision  
20 operational plans, and even very specific work  
21 plans or quality improvement efforts that  
22 would happen in a clinic or a public health

1 program, and these activities are occurring,  
2 measurement improvement really in both of  
3 those systems.

4 But it's at the planning, of course,  
5 and sort of understanding who might have  
6 ownership, and how we would integrate those  
7 over time. Next slide, please.

8 This is just a quick reminder that  
9 when you think about population health  
10 improvement, there's a lot of competing, if  
11 competing's the right word, indicator sets.  
12 You have at the national level things like,  
13 you know, the new strategic priorities coming  
14 out of health reform. You have Healthy  
15 People, which has been around for four  
16 decades.

17 You have Trust for America's Health.  
18 You have sort of national level priorities for  
19 population health improvement, and then they  
20 report and measure things in certain ways.  
21 But that cascades down to maybe a state plan,  
22 and then if you go to the very top of the

1 pyramid, I put county or community-based  
2 organization.

3 But you could put accountable care  
4 organization plans. Kaiser, you know, has a  
5 lot of sort of population health improvement  
6 activities they do for their immediate  
7 population and sometimes the broader  
8 population of a county or state.

9 But there's this complex cascading  
10 that I know you're well aware of, that really  
11 starts with planning. Part of this would be  
12 understanding sort of who was prioritizing  
13 what at different levels. Next slide, please.

14 Then you get to then really the  
15 organization level planning. I don't want to  
16 worry about this box so much. That's Mark  
17 Friedman's box of how you would sort of write  
18 structure, process, and output measures for an  
19 organization that's targeting, we use the word  
20 "client," that's -- in public health sometimes  
21 you don't use the word "patient." Sometimes,  
22 you know, organizations have very specific,

1 you know, ways that they discuss the people  
2 they serve.

3 But on the left, then, is just sort  
4 of, you know, what Mark Friedman puts out, is  
5 how you would target then provider-level  
6 metrics, and really assess how well the  
7 organization is performing. That planning  
8 often is very internal to an organization.  
9 Next slide, please.

10 So then it gets to well, how are you  
11 going to select then ways to measure  
12 performance at these two levels. Reports come  
13 to some agreement on what types of things  
14 you'd be measuring, and so I put some examples  
15 of categories of things you could decide to  
16 measure.

17 So on the left again, we have this  
18 population health level, and this is a  
19 reminder, it's health outcomes, behaviors and  
20 social determinants. Then the types of things  
21 that are traditionally measured in the public  
22 health community.

1           Life expectancy, quality of life. We  
2 talked about disparities in equity, which you  
3 can really take any health outcome or behavior  
4 and sort of break it down by race, ethnicity  
5 or income, and get an idea of equity.

6           Disease, morbidity measures, of  
7 course mortality metrics, early mortality  
8 metrics, and then you get to, you know, the  
9 bottom of the list there, which really gets  
10 into more upstream things. You get into  
11 behaviors, environments, homes, social  
12 environment, built environment, that can  
13 sometimes plan at the population level,  
14 depending on your data set.

15           Since for every sort of thing you  
16 would prioritize at that population level, you  
17 could sort of decide which category is the  
18 most relevant to your work. Then you would  
19 move over to the green side, and really decide  
20 then what priority, high value clinical and  
21 community intervention that would then deliver  
22 and measure, really within or maybe across the



1 systems, if there is some commonality.

2 So of course what the public health  
3 departments measure, you know, we look at  
4 policies that are created and cover a  
5 percentage of the population. People informed  
6 coalitions, stakeholders that are engaged,  
7 timeliness and completeness of surveillance,  
8 you know, outbreak investigations, and we're  
9 moving into social and built environment  
10 metrics.

11 Then what we added to the bottom is  
12 really, then, what I currently see as sort of  
13 the provider community. Access might have  
14 some overlap, screening, treatment received,  
15 patient safety. It would be a way of sort of  
16 again having these complementary measures  
17 across the systems that would then  
18 collectively improve population health.

19 Next slide, please. So how do we  
20 help you do some of this? We'd like to look  
21 at the current health assessments and  
22 improvement plans, and see if there are

1 certain party topics that we could advise you  
2 sort of rise to the top. Examples of that  
3 would be like the ten leading health  
4 indicators in Healthy People, which have been  
5 put forth in the past. There's the State of  
6 the USA indicators.

7 But again, there's competing sort of  
8 groups that want to put forth the top ten  
9 things, and I want to put a little bit of a  
10 joke in here. All you have to do is sort of  
11 do what Friedman did with CDC, and pick six  
12 winnable battles, and the advocates are lining  
13 up to create numbers seven, eight, nine, ten.  
14 So prioritization is hard, but if we could  
15 work with you to get to sort of a priority set  
16 of again, these population of impact topic  
17 areas, I think would really move understanding  
18 of population health forward and what we do to  
19 change it.

20 Then we obviously have certain  
21 systematic reviews, clinical guides, community  
22 guides which should help inform how we

1       prioritize our interventions then to improve  
2       health. Then we move into measurement of what  
3       we prioritize, and again if we can sort of  
4       work with you to decide if these two levels  
5       work, to keep them sort of in their separate  
6       box and if these sort of proposed three  
7       systems, with focusing on two of those, is  
8       something that would be the way to move  
9       forward.

10               Next slide, please. I'm moving into  
11       a few examples now of how, you know, working  
12       at the local level, how we would sort of, I'm  
13       not even getting to define community. But  
14       once we define community and who would be  
15       working towards those, which will vary, of  
16       course, all across the country, how to  
17       identify common data sources.

18               What I wanted to introduce to some of  
19       you who have not worked in the public health  
20       arena, is that similar to the clinical care  
21       system, we have performance databases. Some  
22       of them are getting integrated with meaningful

1 use, you know, requirements. But some of them  
2 are just simply if you go to the right column  
3 for a second, some of it is less surveillance,  
4 and we have a stand-alone database in LA that  
5 really lets us understand our activities and  
6 performance in that area.

7 It's not simply measuring percent of  
8 children who have an elevated blood lead  
9 level. It's actually our case management  
10 measures, what we would consider our public  
11 health intervention and how we measure  
12 performance of our staff that go out and do  
13 those types of case management activities.

14 Of course it leads into, you know,  
15 home investigation, mitigation of lead and  
16 lead abatement. But we do have these data  
17 sets, in other words. So we have to do some  
18 sort of scan to really at least put forth what  
19 we think large urban health centers, or I'm  
20 sorry, health departments, would have  
21 available to provide measurement of their  
22 systems.

1           The health care system has had about  
2           30 years' lead time on this. They've had of  
3           course more money in some way that's been more  
4           high profile. But we really have to start  
5           looking at then how we measure with the new  
6           systems, and link it back to these population  
7           data sets. The example that I put there is  
8           just to really show you how in certain  
9           communities, like LA County, we have robust  
10          data sets, and we have to choose if we're  
11          going to use the National BRFSS data, if we're  
12          going to use our California Health Interview  
13          Survey, or own LA County health survey. New  
14          York City is similar to this.

15                 So vital records, you know, is  
16          obviously available at different levels. But  
17          we have competing data sets sometimes. Now  
18          those of you that have worked in the county  
19          health rankings know that a lot of small  
20          counties don't have that. They're lucky to  
21          get a data point out of BRFSS, you know,  
22          period.

1           But we really want to do a scan and  
2 understand where in the country we could start  
3 moving towards this real integrated shared  
4 accountability approach with data. Next  
5 slide, please.

6           Then for moving towards improvement,  
7 again we have sort of competing benchmarking  
8 sources. In public health, we often look to  
9 Healthy People to see what the national target  
10 is. But there is again, state, county.

11 There's professional association,  
12 benchmarking, and again you can divide these  
13 into these two levels, sort of a population  
14 level benchmark and then, you know, again a  
15 system provider level benchmark of  
16 performance, which could give a nice picture  
17 of how to improve over time within these  
18 systems and collectively across the system.

19           Next slide, please. So then how do  
20 we start thinking about these investments  
21 we're making in both of these systems, and  
22 this is very preliminary. This is something

1 I pulled together a couple of years ago. We  
2 can move into much more complex logic modeling  
3 and systems modeling.

4 But the idea is that if we can have  
5 ownership, some sort of ownership of who does  
6 what. It's not going to be easy to figure  
7 that out, but at times, they're going to very  
8 clear, clinical preventive services that  
9 really the clinical care system will do. That  
10 being said, of course, there's some health  
11 departments in this country that still do  
12 primary and specialty care services, and how  
13 do we acknowledge that? So there's going to  
14 be some overlap.

15 But certain metrics will fit nicely  
16 into one of the two systems. So in this  
17 schematic, obviously clinical criticism is on  
18 the left and more of the -- what the health  
19 department tends to have, they feel they have  
20 sort of ownership and direction over is on the  
21 right.

22 Then there's this idea of overlap

1 within the systems, and then delivery  
2 enhancements, which may or may not have  
3 overlap. So again, the schematic is not  
4 perfect. It's meant to stimulate discussion.

5 But then there's going to be system  
6 changes, whether it's meaningful use, IT  
7 integration, whether it's deciding  
8 collectively that a certain policy has to be  
9 implemented in concert with changes throughout  
10 the clinical care system to, you know,  
11 increase maximum impact. It's those types of  
12 things that we want to try to capture in a  
13 logic model.

14 So next slide, please. So how does  
15 that, might that play out? Now granted these  
16 aren't measures yet. We can start writing  
17 measures for these things as well, but we'd  
18 like to hinge this on evidence, just like we  
19 all do, and again, this A and B recommendation  
20 from the clinical guide, if there's  
21 recommended interventions in the community  
22 guide.



1 I just took tobacco and put them in  
2 the Venn diagram. We can start assigning  
3 ownership and then who would measure them and  
4 the data sources that would measure that, if  
5 possible. We probably can't measure  
6 everything, but we can, you know, address that  
7 as the issue comes up.

8 But then look at system changes, that  
9 you know, who really is responsible for  
10 reducing client out of pocket costs? Is that  
11 health plans? Is that a policy that the  
12 health department -- you know, it could be a  
13 series of interventions. But it ends up being  
14 sort of big paradigm shifts or system changes  
15 that would go in those yellow boxes, and you  
16 know, I kind of put sort of the types of  
17 system changes below. I know they're  
18 obviously recommended in the treatment guide.

19 That's tobacco. Then if you go to  
20 obesity on the next slide, it's a bit more  
21 difficult. There's a lot more, and you'll see  
22 then, if you go to the community side for a

1 moment, that could be the governmental public  
2 health system or other system partners. It  
3 starts feeding into work sites, school days,  
4 urban design, which, you know, who owns that.

5 But if we can move toward again  
6 putting it in those three systems, both the  
7 evidence-recommended interventions, and then  
8 move towards understanding how we measure that  
9 complementary together, I think we can really  
10 move measurement and performance and impact to  
11 the population health level forward.

12 DR. JARRIS: Dawn, I'm sorry to  
13 interrupt, but your voice is falling a little  
14 bit. It's probably fatiguing from speaking so  
15 loud.

16 MS. JACOBSON: Yes, and we're almost  
17 done. So we're just on the last couple of  
18 slides. So I'll hang in there. Next slide,  
19 please.

20 So then this is, you know, Steve can  
21 definitely. He's worked in this area for  
22 quite a while. We can take this sort of

1 clinical guide and community guide to to the  
2 next level, and I think the work of the  
3 Steering Committee can then get into other  
4 facts, you know, contextual factors that have  
5 been brought up.

6 I mean is this of value to the  
7 community? Is it feasible? Is it measurable?  
8 You know, there's all sorts of things that can  
9 play into how this Committee would then  
10 prioritize a set of interventions that's  
11 doable. There's one word of caution that from  
12 working in measurement and quality improvement  
13 in a public health department, measures can  
14 get out of control quickly because everybody  
15 has their favorite metric.

16 Part of what we'd like to do for you  
17 is sort of provide some guidance on that.  
18 However, if you pick ten population  
19 indicators, for example, population health  
20 outcomes, just ten, and we recommend that at  
21 least there's one then performance measure  
22 that would be seen as influencing that

1 outcome.

2 Then if you have the clinical care  
3 system and the public health system and the  
4 other system measures, you'd have, you know,  
5 quickly get to hundreds of measures very  
6 quickly. So as you work through those issues,  
7 I'd be glad to talk through, you know, how  
8 we've tried to limit measures, you know, but  
9 keep them essential over time in LA County.

10 But there's different ways that you  
11 can then prioritize these things. And the  
12 final slide, please. How would we like to  
13 help you with some deliverables? That you'd  
14 create a matrix, you know, that would really  
15 show the synergy for how to prioritize,  
16 implement and measure prevention activities  
17 across the two systems.

18 We could recommend three or four  
19 priority areas. You could recommend them to  
20 us, you know, but the idea is that we'd start  
21 making, you know, a more complex logic model  
22 of how this cascades, and yet is complementary

1 across the system.

2 I say two here. You may decide that  
3 you want us to do all three and bring in some  
4 of these other public health system partners,  
5 and we're open to that. It makes the scope of  
6 it bigger, however.

7 And then really then strategies for  
8 how you would collect data and report them,  
9 and maybe even do quality improvement  
10 projects, complementary ones across the two  
11 systems. We very much look forward to a  
12 robust discussion. Thank you.

13 DR. JARRIS: Thank you, Dawn. This  
14 is Paul Jarris. So while we were here, Kurt  
15 and I and Helen just had a brief interchange,  
16 to discuss really the purpose of the paper and  
17 the purpose of the work.

18 As I understand it, the work by Steve  
19 and Dawn is really done to inform us, the  
20 Committee, and be a group that can research  
21 things or look for things that we need  
22 research between meetings and to inform us.

1           So it's not really for an external  
2 audience. It is for us, so hopefully that can  
3 frame part of our conversation. I did have,  
4 if -- I have a comment, and not specifically  
5 regarding the presentation, thank you for  
6 that, Dawn, but more about the paper.

7           We appreciate the first stab at  
8 definitions because that came up again this  
9 morning and hopefully you were able to listen  
10 to part of that. But mine in particular is  
11 about the definition of population health from  
12 Turnock because I think that although that's  
13 a simple, concise definition. I think it  
14 loses some of the other definitions out there,  
15 and in particular, it loses the whole aspect  
16 of health equity, in that this is again  
17 talking about overall goodness. It's not  
18 talking about goodness and fairness.

19           I think the three other measure  
20 definitions which I have been aware of,  
21 whether it's Kindig or Young or Dunn and  
22 Hayes, each hit that. The Dunn and Hayes

1 definition of '99, the Canadians, actually  
2 gets much more into the areas of social  
3 determinants and environmental, as well as  
4 does include clinical.

5           So I'd ask you to take a look at  
6 those definitions again because this one,  
7 although it's simple and concise, doesn't  
8 really capture all the depth of population  
9 health. I'm happy to read -- why don't I do  
10 that for you?

11           So this Dunn and Hayes in '99, I  
12 believe they were two Canadians, as the  
13 Canadians were trying to figure out how do you  
14 define population. It's a little bit long. It  
15 says "The health of a population, as measured  
16 by health status indicators, and as influenced  
17 by social, economic and physical environments,  
18 personal health practices, individual capacity  
19 and coping skills, human biology, early  
20 childhood development and health services.

21           "As an approach, population health  
22 focuses on the interrelated conditions and

1 factors that influence the health of  
2 populations over the life course, identifies  
3 systematic variations in their patterns of  
4 occurrence, and applies the resulting  
5 knowledge to develop and implement policies  
6 and actions to improve the health and well-  
7 being of those populations."

8 So it's pretty broad, it's pretty  
9 long, but I think it actually is a great  
10 conceptual definition.

11 MS. JACOBSON: We're open to other  
12 definitions. I think that one thing I've  
13 learned in public health practice is keep it  
14 short and sweet. But I would say that, you  
15 know, to sort of take that definition, I think  
16 that very nicely, within the Turnock  
17 definition, puts more specifics on extend  
18 beyond medical treatment, and it really then  
19 puts socio-environmental factors and it lists  
20 them. Yes, we can look at finding a way to do  
21 that, yes.

22 But also, I mean I guess one thing



1 I'd like to ask the group is, and I know this  
2 from experience. We could start putting  
3 definitions out there, and we can advise. But  
4 even early in this discussion, I think this  
5 group needs to figure that out. You know, we  
6 can find a list of like ten different  
7 definitions and have you talk through that.

8 Is that something that you would find  
9 helpful, just to give you, like every sort of  
10 the, you know, the major definitions so you  
11 can work through them?

12 DR. JARRIS: Larry.

13 MR. COHEN: Hi, Dawn. This is Larry  
14 Cohen from Prevention Institute, and I'd like  
15 to just make general comments, as well as  
16 responding to that. The general comments are  
17 I just found your presentation really, really  
18 helpful, and also I'm a very big admirer of  
19 Mark Friedman's work, and I'm really glad you  
20 based it on that.

21 I mean I do think we have, I don't  
22 know if the right word is consensus, but we

1 have a general perspective about the kind of  
2 definition we're looking for, and I think it's  
3 a definition that's a bit broader. I really  
4 like your notion of short and sweet and  
5 concise.

6 But at least I'm not -- well, I hope  
7 I'm speaking for a lot of people when I say  
8 that we need a definition which includes a  
9 sense of equity, and also a definition that  
10 includes a broader sense of social  
11 determinants. I was struck, when you were  
12 using Mark's work, Mark Friedman's work, you  
13 know, I don't know whether he's been doing  
14 more recent thinking on these kinds of  
15 efforts.

16 But the public health field has  
17 evolved a lot, and in particular has evolved  
18 in its emphasis on health and well policies  
19 and multi-sectoral work, which goes beyond  
20 medical care and public health as the two main  
21 players.

22 I think a lot of the analyses need to

1 go beyond that. So I would go beyond, for  
2 example, community service guide, you know,  
3 the things like that that are very helpful,  
4 and I would look particularly at the National  
5 Prevention Strategy and the National Equity  
6 Strategy as places where we really need to  
7 bring in content.

8 You know, I thought that the, you  
9 know, the Venn diagrams, at least the way they  
10 were pictured, there was very, very little  
11 overlap between health care and public health.  
12 It was kind of two almost -- well, I wouldn't  
13 say competing, but separate and parallel  
14 measures, sets of measures.

15 The thinking I've been doing and  
16 related to the Center for Medicaid and  
17 Medicare Innovation, and how public health and  
18 medical services linked, is the health care  
19 playing a much stronger role in identifying,  
20 advocating and intervening in community  
21 health. You know, I see that as a shift, and  
22 I would hope the indicators would be

1 indicative of that kind of shift.

2 I'm realizing it's a paper we wrote  
3 called "Community-Centered Health Homes" is  
4 something I want to share with the whole  
5 group, as well as you, Dawn and Steve. But  
6 that I think that the, at least from my  
7 perspective as one Committee member, that a  
8 movement to a certain extent, from the  
9 paradigm of the public health system and the  
10 medical system as the two systems, and from  
11 kind of what they traditionally do, is  
12 absolutely required if we're going to be  
13 defining quality and best practices in  
14 community health.

15 So I would hope for that kind of  
16 reconfiguration, and I think there are a  
17 number of people here, and that it could be  
18 very, very worthwhile to have some of the  
19 discussions about what that looks like,  
20 because I'd hate to just kind of toss that  
21 back into your lap and say it's your problem  
22 to figure out what I'm talking about.

1 I actually, you know, my tendency  
2 would be to revise the agenda in some way so  
3 we could have some of that kind of  
4 conversation here in depth, at least as a  
5 subcommittee, and really start to define that  
6 kind of way of thinking much more effectively.

7 MR. TEUTSCH: This is Steve again.  
8 Thank you for those comments. The recent IOM  
9 report that was released on measurement really  
10 looked at two different levels of population  
11 health developed, you know, in fairly narrow  
12 terms, one was sort of the sum of individual  
13 health, which is traditionally how we've done  
14 it in public health, and the other was really  
15 looking at the overall health of the  
16 communities, which really were not those  
17 individual level indicators summed, but really  
18 looking at community well-being.

19 I think one of the questions I would  
20 have for you, and it sort of relates to what  
21 you were saying, Larry, is how broadly do you  
22 want to get into the measures of community

1 health broadly written, that is the health of  
2 the community, as opposed to simply the sum of  
3 the health of the people in those communities.

4 DR. JARRIS: I think, and I'll watch  
5 the Committee's reaction, the sense this  
6 morning is we very definitely want to get into  
7 the health of the community, and that one of  
8 the things to consider are the three tiers of  
9 community preventative services measured at  
10 the community level, patient behavior and  
11 behavioral choices, and then third, the  
12 community, and I shouldn't say patient, excuse  
13 me, individual people's choices, and at the  
14 third level, the community factors which will  
15 address both self-determinants of health and  
16 the environment which will provide people the  
17 opportunity to make healthy choices. So I  
18 think we want to hit all three levels of  
19 those.

20 DR. STANGE: Dawn, excuse me. This  
21 is Kurt Stange. If I can intuit your approach  
22 using Friedman's results accountability

1 paradigm, that made you focus on the clinical  
2 system and the government public health  
3 system, and it made some sense. Those are  
4 both systems. They both collect data and they  
5 both have resources to then do something with  
6 that data toward their somewhat overlapping  
7 goals.

8           So I noticed in your Venn diagram not  
9 terribly overlapping, which probably reflects  
10 the reality of the current system, but not  
11 where we need to be. There was a really  
12 helpful idea in the morning discussion that I  
13 think could help you think of a third system  
14 that doesn't have that kind of rigid  
15 accountability, but the idea of shared  
16 responsibility, accountability or partnership  
17 among multi-stakeholder groups.

18           For the types of problems we're  
19 trying to solve here, if we just stick with  
20 classic clinical systems, public health  
21 systems, and just try to work at the interface  
22 between those two, we're not going to get at

1 the social determinants of health very well.  
2 We're not going to engage the power and  
3 potential of participatory community groups,  
4 of the business community.

5 Multi-stakeholder groups have the  
6 potential to do that and start to address  
7 that. So if you're looking to engaging the  
8 business community, they want some shocking  
9 things. They are surprising to some people,  
10 advocates for the social determinants of  
11 health, and for controlling the big sucking  
12 sound of the health care system.

13 So the business community wants us to  
14 spend less for health care. If you look at  
15 the decisions that state governors and county  
16 executives and so on are having to make,  
17 they're really spending so much for health  
18 care that they are not able to do anything to  
19 help businesses provide jobs, they're not able  
20 to do anything for education and other social  
21 and environmental, and other social  
22 determinants of health.



1           If we just stick with the clinical  
2           and public health and try to inch forward from  
3           those platforms, which we need to do, we're  
4           not going to engage the really transformative  
5           partnerships. So if you just take that  
6           results accountability platform, and think  
7           about multi-stakeholder groups, that might  
8           unleash a lot of really creative stuff.

9           MS. JACOBSON: Let me just clarify  
10          here. I don't know if you can go back to  
11          Slide 8, but that is sort of where these other  
12          public health system partners land.  
13          Obviously, there's coalitions or  
14          collaborations that would crack, you know, and  
15          it's going to be highly variable, depending on  
16          your community and who has championed this  
17          much funding and who has grants to do what as  
18          we all know.

19          It sounds like this is a vote in  
20          favor of including sort of this group of other  
21          partners, and potentially seeking that down,  
22          what the work site business committee would do

1 with the education system. It makes the scope  
2 of this project much bigger, to figure out  
3 what the education system's doing at the state  
4 and local level. I don't know if we can even  
5 get that information to you.

6 DR. STANGE: So the thing that I  
7 wrote down, Andy and Robert and Matt this  
8 morning told us, though, is to think about not  
9 just as an "other" category, not about them as  
10 individuals, but what happens when they start  
11 working together. What that lets you do, and  
12 there are good examples of this, is it lets  
13 you take a whole systems approach.

14 Otherwise, you end up just looking  
15 under the light post, rather than looking over  
16 in the darkness, where the real problems and  
17 the real transformative solutions are. So if  
18 you just add that as a third bullet, you've  
19 got public health, you've got clinical health  
20 care, don't make it an other. When you're  
21 thinking about accountability and  
22 actionability, thinking about the multi-

1 stakeholder groups. I think that really  
2 changes a lot of -- changes a lot.

3 MS. JACOBSON: I think that we'll get  
4 into the strategies for then working across  
5 systems. Does that make sense? I mean  
6 there's a way that -- and the reason I say  
7 that is these systems, as we all know, have  
8 designed these stand-alone sort of performance  
9 assessment systems that don't talk to each  
10 other.

11 So there's stakeholder groups that  
12 get together. They don't even talk about  
13 measurement. They just talk about the ten  
14 things they want to do together, and they  
15 don't measure anything, because it doesn't  
16 move in that direction.

17 I guess I'm trying to find a way  
18 that, you know, multi-stakeholder is sort of  
19 the strategy, then, to link the systems.

20 DR. JARRIS: Maybe it falls under  
21 this health and all policy concept, you know,  
22 in terms of -- because there's amazing work

1 being done in economic development, in  
2 transportation, in education and many other  
3 groups, that they would never consider  
4 themselves public health partners. They're  
5 doing this work independently.

6           You know, we need to get to the table  
7 with them, and I think some of these multi-  
8 stakeholder consortiums are an attempt to  
9 bring those parties together. But we have to  
10 go, I agree. More broadly beyond this  
11 clinical and public health, and start looking  
12 at this health and all policy.

13           MR. TEUTSCH: Right. I couldn't  
14 agree more. I think again, the measurement  
15 committee at the IOM really tried to talk  
16 about two different kinds of accountability  
17 here. One was the direct accountabilities,  
18 through contracts, through performance  
19 measures, payments, things like that. But the  
20 other was what they called a compact  
21 accountability, where you really looked at all  
22 the stakeholders, their roles, their

1 commitments that they make to achieving some -  
2 - to contribute to a common end, and then how  
3 do you actually measure that.

4 The devil was in the details, because  
5 you can find some of these groups, and there  
6 are several, and I think you mentioned some.  
7 There's some sustainability activities that  
8 link transportation and housing and energy and  
9 the things of that nature that really deal  
10 with many of these issues, and then each of  
11 them make a commitment as to what they're  
12 actually going to do that you can actually  
13 measure, so that they hold themselves jointly  
14 accountable, rather than having kind of direct  
15 accountabilities.

16 I think that this is all fairly  
17 nascent stuff, but we can certainly lay out  
18 what some of those are, and the kind of  
19 measures that they actually try to use or have  
20 begun using.

21 DR. JARRIS: I had Ron, Matt and  
22 Michael, although Matt, you may have retired

1 your question.

2 MR. BIALEK: Hi Dawn and Steve. This  
3 is Ron Bialek. I very much appreciated your  
4 presentation, the good thinking and the  
5 approach that you're taking. A couple of  
6 quick thoughts. In the written document that  
7 we received prior to the meeting, you answered  
8 a lot of questions that I had in your slide  
9 presentation.

10 I just want to be sure that in your  
11 report to the committee, that you're as clear.  
12 For instance, it wasn't as clear to me your  
13 emphasis on policy, and it wasn't as clear to  
14 me your consideration of the community guide,  
15 etcetera.

16 So I think it's important just to be  
17 sure that we don't make assumptions, that all  
18 of us will take for granted that those are  
19 being considered. I thought it was great how  
20 you integrated that into your presentation.

21 Just some specifics. Something I  
22 didn't see mentioned at all was the National

1 Public Health Performance Standards Program,  
2 which really has established metrics, has been  
3 studied for reliability and validity, has been  
4 looked at in terms of impact on performance  
5 and outcomes at the public health system  
6 level. I'd just encourage you to look into  
7 that program a little bit, with regard to the  
8 paper.

9 Community assessment, as it is  
10 referenced, and you did talk about it. I just  
11 want to be sure that when we're talking about  
12 community health assessment, it's not only  
13 needs but also looks at community assets. In  
14 the recent definition or recent guidance from  
15 the Internal Revenue Service, it's more  
16 focused on needs.

17 So again, I just don't want us to  
18 assume that we're all having a similar  
19 understanding. Then lastly, on your last page  
20 of the written document, you spoke to the nine  
21 public health aims from a consensus statement.  
22 I was just wondering how, what your thinking

1 is to date on how you may integrate that into  
2 this work. I've been struggling a little bit  
3 with that, and just would love to hear your  
4 thoughts thus far on how you integrate those  
5 aims into this. Thank you.

6 MS. JACOBSON: Sure, and --

7 DR. JARRIS: Louder.

8 MS. JACOBSON: Obviously in this  
9 overview, we couldn't touch on every aspect  
10 we're going to do in the scan. But someone  
11 earlier this morning --

12 DR. JARRIS: Dawn, we can barely hear  
13 you.

14 MS. JACOBSON: Okay. Someone this  
15 morning mentioned that there are entities that  
16 are, you know, establishing sort of  
17 performance metrics and standards in the  
18 public health community, and I definitely want  
19 to include that as part of the scan. And of  
20 course then, you know, the various sort of  
21 again, organizations that are setting sort of  
22 measurement and performance centers for the



1 clinical care system as well.

2 So thanks, Ron, for the reminder. I  
3 mean we'd throw in the accreditation domains  
4 there as well. But going back to sort of  
5 these nine proposed quality categories that  
6 came out of HHS, I wouldn't say that I have a  
7 strategy in mind right now. I really put that  
8 in as, you know, work to be done and to be  
9 fleshed out, you know, in greater detail, as  
10 we work through the commissioned paper.

11 What I like about the nine  
12 characteristics is it brings it back again to  
13 this, you know, the concept of transparency  
14 and equity, and different types of things that  
15 we in the public health community sort of --  
16 again, you think of the public good, the  
17 common good of health that we think about.

18 I think there is a way to integrate  
19 them. I have to cogitate on it a bit more.

20 DR. JARRIS: Thank you. Matt, are  
21 you passing over? Michael?

22 DR. STOTO: Thanks. Thanks, Dawn and

1 Steve. This is Mike Stoto, and I share Ron's  
2 comments about how valuable I think this  
3 paper's going to be and already is.

4 One of the things that we spoke about  
5 this morning, and Kurt mentioned, I think, is  
6 this idea about thinking through  
7 responsibility and accountability a little  
8 more carefully. We actually worked on the  
9 report, when I worked at the Institute of  
10 Medicine a long time ago, that fleshed that  
11 out.

12 I think you got the slides. I sent -  
13 - I emailed a couple slides to you just this  
14 morning. The idea there was that health  
15 outcomes were a shared responsibility of  
16 health care providers, health departments,  
17 lots of other organizations in the community,  
18 and we needed to sort of measure those, how  
19 well we're doing in terms of our shared  
20 responsibility.

21 But in addition to that, we need to  
22 measure the performance, the actions of a

1 variety of different players, and hold them  
2 accountable for that. So we're talking about  
3 measuring accountability of health care  
4 providers and measuring the accountability of  
5 health departments. But also of employers,  
6 schools and parks departments and all those.

7 This framework kind of lays out a way  
8 to sort of jointly measure shared  
9 responsibility for health outcomes, and the  
10 individual accountability for what these  
11 different entities do towards that goal.

12 MS. JACOBSON: Actually, could you go  
13 to Slide 7?

14 DR. JARRIS: Volume again.

15 MS. JACOBSON: Whoever's managing the  
16 slides.

17 DR. JARRIS: Dawn, please speak up.

18 MS. JACOBSON: The phone is right by  
19 my mouth. Can you hear me better? Can you  
20 hear me now?

21 DR. JARRIS: Yes, we can, much  
22 better.

1 MS. JACOBSON: I guess the microphone  
2 has to be right up close, I guess, in the  
3 phone today. If you go to Slide 7, if someone  
4 who's managing the slides can go to that  
5 slide.

6 DR. BURSTIN: It is.

7 MS. JACOBSON: That's really what  
8 we're getting at there, is that we would want  
9 to propose ownership of the types of  
10 activities on, you know, in the green box. If  
11 you give us leeway, you know Steve and I, and  
12 the folks we're working with, we will happily  
13 put forth who we think the owners are, and  
14 knowing it will stir a lot of controversial  
15 discussion.

16 But we can do that, and I think you  
17 could start writing measures, then. Of  
18 course, there's types of measures that a  
19 health department would feel they do that  
20 reflects their activities, and that the  
21 clinical person would do. I think you will  
22 find that it can be aligned quite nicely

1 within, for example, a disease outcome or a  
2 behavior outcome or a social determinant or  
3 built environment outcome, that's, you know,  
4 kind of listed over under the blue box.

5 DR. STOTO: So if I could just  
6 respond, I think that is the idea that we had  
7 in mind, and the question then becomes, you  
8 know, is it appropriate to assign specific  
9 responsibilities in a report that NQF might  
10 do, or is that something that needs to be done  
11 at the individual community level, because  
12 who's responsible for doing so and so may well  
13 be very different from one community to  
14 another.

15 So maybe there could be suggestions  
16 about potential accountable parties.

17 MS. JACOBSON: Right, and I think one  
18 thing that Steve and I will keep in mind is,  
19 you know, I've worked on healthy people, I've  
20 seen from the national perspective and I'm at  
21 a local health department.

22 Definitely, it varies and I love the

1 comment on a population case mix or risk  
2 adjustment. I think that, you know, I'm  
3 waiting for a major biostatistical breakthrough  
4 that some researcher does, that's going to  
5 start moving us in that direction. Because  
6 then sort of a percent contribution to a  
7 health outcome if we could move in that  
8 direction would be great.

9 But in the meantime, we sort of have,  
10 you know, at least at the local level, you  
11 know, local priorities will play out, and my  
12 concern is that Steve and I will default to  
13 the local perspective too much, and we would  
14 need to be reminded that there's a national  
15 sort of general relevance that has to be  
16 maintained.

17 But any guidance from the steering  
18 committee on how much, like across the levels  
19 of national and state and local, and even  
20 subcounty analysis sometimes. Any feedback  
21 you have on how you want us to break that down  
22 would be helpful, or what's important to you

1 would be helpful.

2 DR. JARRIS: Okay, and can you tell  
3 me, is Jacqueline or Jackie?

4 MS. MERRILL: Jackie. So this is  
5 Jackie Merrill. Hi Dawn. One of the things  
6 that I'm thinking about with this is the  
7 problem of non-linearity, and the idea of the  
8 logic model.

9 So I would encourage thinking that is  
10 not logic model-based, and that is, has a  
11 component of non-linearity. Because when you  
12 do that, and you start seeing the factors, the  
13 multiple factors that are influencing any  
14 single area of your diagram, that's where you  
15 can -- that will suggest the levers that may  
16 be appropriate.

17 So when you're thinking about-- what  
18 we're aiming for is we want to get some kind  
19 of indicators, and in our case, some of these  
20 indicators may come from unusual sources. So  
21 the stewards of the indicators may actually be  
22 groups that don't appear to be aligned

1 proximately in a logic model, but actually in  
2 a systems diagram would make sense. Do you  
3 understand what I'm saying, the idea that it's  
4 not a linear relationship?

5 MR. TEUTSCH: Jackie, are you  
6 suggesting just to show the complexity of the  
7 relationships and interactions, and the  
8 multiple influences, rather --

9 MS. MERRILL: I'm suggesting more  
10 than that. I'm suggesting that that actually  
11 can be a tool to help clarify some of the  
12 competing interests that you're talking about.

13 Now to actually diagram the  
14 complexity might be useful, because it's  
15 certainly something that I struggled with, and  
16 it's -- I mean it's not an easy approach, but  
17 I actually think it's the only approach that  
18 we need to use.

19 So that's just my suggestion, you  
20 know. I think I'm taking issue with the idea  
21 of the linear logic model versus the complex  
22 system dynamics approach.



1 MR. TEUTSCH: You know, I think  
2 you're right, because certainly if you look at  
3 the community guide, U.S. Preventive Service  
4 Task Force, they have a fairly linear model of  
5 how you get from some intervention to some  
6 outcome, as opposed to the more complex, as  
7 you said, systems dynamics models, which do  
8 understand not only the multiple factors, but  
9 the interaction of all of those that influence  
10 things.

11 So I think we can -- we obviously  
12 can't build those models, but those are the  
13 kind of things we can certainly comment on.

14 MS. MERRILL: Well, you might not be  
15 able to build a measurable model, but you  
16 could think about that when you're diagraming  
17 out your own work, because the point I'm  
18 making is that those kinds of models can  
19 suggest a lever. They can suggest the place  
20 where the intervention might, or some action  
21 or some suggestion might make a difference.

22 That might not be obvious when you're

1 doing it linearly. That's what I'm saying.  
2 It's sort of a tool to guide your thinking.

3 MS. JACOBSON: Jackie, let me ask you  
4 one question, that definitely we could, in our  
5 methods section, add that to our scan, and  
6 sort of basically say that types of system  
7 dynamic models exist, and sort of can help  
8 inform especially chronic disease management  
9 and synergistic population, you know, typical  
10 public health population-based interventions  
11 and then clinical care measures, and they're  
12 together in sort of this dynamic feedback  
13 group model.

14 We can add that to the scan as far as  
15 methods. But it also can be used very  
16 practically as a way to prioritize then  
17 interventions at various levels. What I found  
18 very exciting is in the putting communities,  
19 you know, to work.

20 In some of the systems models that  
21 Bobby Milstein and Jack Homer have designed  
22 through CDC, have actually been applied, and

1 a part of that grant process is to apply the  
2 local data in, to then help prioritize at the  
3 state level plausible futures.

4 So let me ask you this. I mean part  
5 of it could be scanned for methods that can  
6 help perform measure selection across the  
7 system. Then too it could be discussed as a  
8 prioritization tool as well. Is that what --  
9 would you like to see it applied in that way  
10 as well?

11 MS. MERRILL: Yes, yes.

12 DR. STANGE: So at the beginning of  
13 this discussion, Helen and Paul suggested that  
14 one of the purposes here is for us to suggest  
15 to Dawn and Steve how they can do work that  
16 would help us in our work. What just they --  
17 Dawn asked a minute ago, asked for our help in  
18 what levels would be helpful. It's worth  
19 thinking about what community means, what  
20 community interventions mean.

21 What levels are we thinking about  
22 that data would be helpful on is the question

1 they're asking us? How can they help us in  
2 that? But so let's get some back and forth.  
3 They're asking how they, you know, what input  
4 they can have from us that would help them  
5 frame it, and what other things could they be  
6 doing that would help as we're going and maybe  
7 expanding the charge a little bit here?

8 MR. COHEN: I actually want to lay  
9 out a question I have on this, what levels of  
10 data would be helpful, and a challenge to  
11 myself and to the group, as well as to those  
12 of you in LA.

13 Recently, I gave a large funder the  
14 advice that if anyone could take complete  
15 responsibility for an achievement, that they  
16 shouldn't be funded again, because my  
17 understanding of community-wide change is it  
18 must be contribution, not attribution.

19 I think that has a lot of  
20 implications for what we're talking about now  
21 in terms of accountability. For example, the  
22 health and all policies approach, Paul, that

1 we've been talking about, would say for  
2 example that transportation can have a  
3 fundamental impact on people's physical  
4 activity.

5           Earlier you used the word "exercise."  
6 But I would prefer to use the word "physical  
7 activity," because I think it involves a lot  
8 of things that don't traditionally get thought  
9 of when we think about exercise. I would like  
10 -- clearly, we could hold the transportation  
11 authority accountable for that, and that's  
12 already as you pointed out Dawn, a hard  
13 stretch and makes the paper more challenging.

14           But from my perspective, it's a  
15 clinical responsibility. I had an experience  
16 with a physician who I met, who was in tears  
17 when we had a conversation about prevention,  
18 because she talked about telling someone that  
19 day that he had pretty serious diabetes, and  
20 urging him, in addition to taking his  
21 medication, to be more physically active and  
22 eating better food.

1                   Broke into tears when he left the  
2                   room, because she knew that was a farce,  
3                   because she knew the neighborhood he lived in.  
4                   It just wasn't safe to be physically active,  
5                   and he too, nodding his head and saying "yes,"  
6                   said he knew it was a farce. She felt she  
7                   needs to speak up and do something about the  
8                   physical activity in that neighborhood.  
9                   That's part of what I would say is a  
10                  community-centered health home.

11                  The implication of that, I think, is  
12                  that the data needs to be data when we talk  
13                  about data being useful and contributing to  
14                  quality. The data we ask for needs to be data  
15                  that when we say something's not working well,  
16                  we don't have the quality, that then moves the  
17                  system to move in a way that's more effective.

18                  I would say part of being more  
19                  effective is physicians as advocate for  
20                  walkable communities, for example, safe,  
21                  walkable communities. I'm not sure exactly  
22                  how to do that, which is why I'm describing it

1 as a challenge.

2 But I think it goes to the core of  
3 some of our thinking. How do we get the  
4 medical care system admittedly primarily doing  
5 patient care, but also taking some of the  
6 broader responsibility for people's health,  
7 because the medical care system has almost all  
8 of the credibility and has almost all of the  
9 money?

10 DR. JARRIS: Thank you. Matt. Matt  
11 has the answer, so that's why he's going next.

12 MR. STIEFEL: I think this follows  
13 Jackie's comments about systems dynamics, and  
14 looking at Slide 7. I have a little trouble  
15 sort of reconciling this framing of population  
16 indicators and performance measures, and I  
17 think that one thing that would be very  
18 helpful to the group, on the population  
19 indicator side, I mean that's obviously not  
20 just a heap of indicators, but there's a  
21 causal pathway there, of determinants and  
22 outcomes of population health.

1           In that causal pathway are the social  
2           determinants, the behavioral determinants and  
3           health care system determinants, that lead to  
4           the outcome, some of the outcome measures that  
5           you're talking about there. So I think  
6           helping us in the framing of that model of the  
7           causal pathway of indicators would be  
8           extremely useful. Then, where I get to the  
9           struggle of sort of reconciling the framework,  
10          the performance indicators are measures of the  
11          components of that causal pathway.

12                 So it's not a separate set of  
13          measures, that the performance of the two that  
14          you pick, the health care delivery system and  
15          the governmental health system, which we've  
16          broadened, I think, in our conversation, are  
17          elements of the determinants of health that we  
18          would want to capture in that causal pathway.

19                 So I guess I don't see this dichotomy  
20          as framed here, and that the causal pathway  
21          for the population indicators would include  
22          the performance of the components of the



1 system.

2 MS. JACOBSON: Yes, I totally  
3 appreciate that comment. That was Matt,  
4 correct, and I think that is the brilliance of  
5 Mark Friedman, and I can't believe he's still  
6 in relative obscurity, you know, as far as  
7 sort of being this measurement guru.

8 We can work on a way of sort of  
9 definitely showing the linkages between sort  
10 of upstream determinants, you know, the actual  
11 sort of then behavior and outcome definitely,  
12 and what I would like to propose that we could  
13 try to do for you is show how interventions  
14 then influence stuff in that causal pathway.

15 I think this is one of the biggest  
16 areas of confusion within the public health  
17 community, is we'll move an intervention,  
18 which is policy creation, and say it's a  
19 social environment measure. By creating a  
20 policy, you either influence the health  
21 behavior and environment, or ultimately a  
22 disease and a causal pathway.

1                   But I'd like to step up to the  
2 challenge of seeing them separate, but showing  
3 you how these are really then levers, as  
4 Jackie was saying, levers that sort of  
5 dynamically are created and like influence  
6 behaviors and health, environment, behaviors  
7 and health.

8                   DR. STOTO: So Dawn and Steve, this  
9 is Mike Stoto again. I'm sitting next to  
10 Matt, but rather than just talk to him  
11 directly, I agree that this causal pathway  
12 really is the critical thing. But I would say  
13 there really is a distinction between the  
14 measures on the left and the one on the right,  
15 and that the ones on the left are things that  
16 the community shares the responsibility for;  
17 that the ones on the right are things that one  
18 or more entities can be held accountable for  
19 doing, so that we eventually get to where we  
20 want to be.

21                   MS. JACOBSON: And I think on the  
22 challenges, seeing policy development and

1 enforcement as an intervention rather than a  
2 social outcome. I mean it's tricky, but we  
3 can -- I think it's in the ten essential  
4 public health services and accreditation  
5 demands, which I know everyone on the Steering  
6 Committee's familiar with.

7 But does that help Mike? I mean  
8 these things are sort of like surveillance is  
9 an intervention that leads to improved health.

10 MR. STIEFEL: Yeah, right, I mean I  
11 agree with that, that you know, somebody  
12 creates those policies. I could be the City  
13 Council or something like that. Those are  
14 parts of the community that intervene to  
15 create health.

16 DR. JARRIS: Andy.

17 MR. WEBBER: This is Andy Webber with  
18 the National Business Coalition on Health. I  
19 thought the presentation was great, and I  
20 actually like sort of how we framed this.

21 I'm a little concerned about the  
22 scope of our activity, I mean we've obviously

1 said, and I think we're in agreement, that we  
2 want to get beyond government public health  
3 and providers.

4 But I mean we could put together a  
5 very long list of entities, organizations,  
6 where we would like to develop performance  
7 measures, you know, ones that are really  
8 focused on that individual entity or shared  
9 among different entities. So I wondered, just  
10 to give Dawn some guidance here, do we need to  
11 put some parameters around that? I mean you  
12 know, we've mentioned employers, we've  
13 mentioned transportation systems, we've  
14 mentioned, you know, public health. Do we  
15 need to identify them all here?

16 DR. JARRIS: I think we're still in  
17 an early phase of trying to discover how we're  
18 going to scope this. So I think it might be  
19 premature to do it now. But we are perhaps in  
20 the phase of creating confusion, as opposed to  
21 reining confusion in.

22 But I found at least like some of the

1 other groups, it was typically when we hit  
2 that point of there is no answer to this, that  
3 some breakthrough thinking came through.

4 So let's expand it a bit now. We  
5 will, what's probably important is what are  
6 the important measures of population health,  
7 and then secondarily to that, and then  
8 therefore who would be accountable for those  
9 things, as opposed to starting out with the  
10 accountability.

11 I think one of the, as a distant  
12 observer to some of the other NQF processes,  
13 one of the issues that's been faced over time  
14 is you may have one measure for, you name it,  
15 surgical site of infection or some other, and  
16 yet one objective to measure that.

17 But there's a different one from  
18 physician's office, from an ambulatory  
19 setting, from a hospital setting, from a  
20 nursing home, and we certainly want to avoid  
21 that.

22 So the issue to me is what's the

1 important thing to measure, and then later,  
2 who has responsibility.

3 MR. TEUTSCH: Could I push back a  
4 little bit on that, because some of the -- as  
5 you link sort of what are the resources and  
6 capability that can then be used to implement  
7 various processes include some various  
8 intermediate and long-term health outcomes, if  
9 you look at the proximal side of this, which  
10 are the resources and capabilities, you can  
11 look at, whether it's the education system or  
12 the employer or organized public health. But  
13 it often is the people who are actually making  
14 decisions about what those allocations should  
15 even be, the politicians and the other leaders  
16 who are making those choices.

17 So we do have to figure out a little  
18 bit where the accountabilities are actually  
19 going. Who is going to be making these big  
20 allocation decisions about health care versus  
21 public health versus education, versus taking  
22 the transportation money and putting it out

1 into safe streets and complete streets.

2           These are very upstream kinds of  
3 accountabilities. If we look very much, you  
4 know, at specific interventions in specific  
5 things, we're going to get to different types  
6 of measures and different kinds of  
7 accountabilities. I think it's one of the  
8 things that we've got to wrestle with if we're  
9 going to not only bridge these population in  
10 clinical areas, but then figure out how we're  
11 going to get the right resources to bear on  
12 them.

13           MS. JACOBSON: Yes. I often say in  
14 my measurement work, if decision-makers, and  
15 I mean that loosely, whether it's  
16 organizational, political, you know, health  
17 care or otherwise, if some decision-maker  
18 would just say we're looking at the data and  
19 there's four leading behaviors, it's the whole  
20 3-4-50. Three diseases or the three risk  
21 factors that lead to four diseases, that lead  
22 to 50 percent of deaths.

1           If someone were to say as a nation  
2           we're just flat-out going to fund that and do  
3           that, it would all cascade down very easily.  
4           Of course, it doesn't happen. So we're left  
5           with we could take the four leading behaviors  
6           and really integrate this for you, and show  
7           how it would fit into this framework and be  
8           very useful, I think, over time.

9           And depending on the issues, for like  
10          physical activity, that would bring in  
11          probably all the public health system  
12          partners, you know, over time. For tobacco,  
13          maybe the same thing.

14          You know, I guess it's sort of the  
15          chicken or the egg. To me, it doesn't really  
16          matter where we start. Just know that if we  
17          start with system partners and what their  
18          specific priorities are, we're going to end up  
19          with 1,000 indicators to measure.

20          That gets back to the scope of which  
21          no organization can, you know, expect them to  
22          track and improve 1,000 indicators, you know,



1 of organizational performance or public  
2 health, population health and performance.

3 When I sit with managers and talk  
4 through this, they're like oh, it's easy.  
5 We're just going to improve, you know, chronic  
6 disease. That's 100 to 200 indicators right  
7 there of population health improvement that  
8 you could pick. What are your priorities, you  
9 know?

10 So it's really, it's harder to go  
11 from not bottom up but system back to  
12 priorities. It's easier if the National  
13 Quality Forum and the Committee would just  
14 pick four, five, six of your own winnable  
15 battles, you know, whether they're freedoms or  
16 not, and use the framework to show how it's  
17 integrated and cascades down.

18 DR. JARRIS: Okay, thank you. Bobby,  
19 did you have a comment?

20 MR. PESTRONK: Actually, I'm not sure  
21 if I do. I think, Paul, your observation  
22 before that starting from outcomes would be a

1       useful way to work back. I think that what's  
2       just been shared is sort of along the same  
3       lines, and I'm struggling myself with whether  
4       it makes a difference where one starts, so  
5       long as one gets started.

6               Then the last thought I have is the  
7       present analytic frame for this, which I like  
8       as it's described here, but it starts from  
9       documents that are already in the context of  
10      the U.S., and I understand why one would want  
11      to do that, because we're in the U.S. and  
12      we're trying to influence the U.S. system, and  
13      so it's a question of starting where we are.

14             The question I have is whether it  
15      might be useful to start from documents that  
16      have been produced in other cultures, because  
17      they'll tell us something different than what  
18      we already know, and it would give us a  
19      completely different place to start.

20             I don't know whether that's a good  
21      idea or not, but I'm struggling with whether  
22      when we get this, we're going to -- on the one

1 hand we'll have, if it's framed in the way it  
2 was just framed, which is okay, here's I won't  
3 say winnable battles, because that says it's  
4 these five or six things.

5 But if we pick a couple of outcomes,  
6 then what we're saying is okay, we're going to  
7 try and walk back into the existing system and  
8 define what everybody needs to do, which is  
9 kind of what everybody's been trying to do for  
10 the last 20 to 30 years. The other approach  
11 is to say how we really want to do this  
12 differently, and what does it mean to do it  
13 differently.

14 The only way to learn how to do it  
15 differently is to look at somebody who's doing  
16 it differently and see how they went about  
17 doing it. Does that make any sense to  
18 anybody? I don't even know if it makes any  
19 sense to me.

20 DR. JARRIS: Yes. I personally think  
21 the 37th in the world is good enough. One  
22 other thing, and we're out of time, but just

1 for Dawn and Steve. We also have to look at  
2 this concept of what do we mean by the term  
3 "community," because it's another word that  
4 means so many different things, and we may not  
5 come up with one definition, but at least  
6 quantify or qualifying it, so we know when we  
7 use the word what we're talking about.

8 Is it a geographic block? Is it a  
9 county, is it a state? Is it a type of  
10 person, based on socioeconomic, racial, you  
11 know, disease, whatever it happens to be. But  
12 we need some better definition around the word  
13 "population" and the word "community."

14 We are out of time, so we probably,  
15 we were supposed to have a period now where we  
16 have public comment. I'll ask NQF staff how  
17 we will do that, and we welcome any public  
18 members who may be on the phone or in person.

19 MS. MUNTHALI: Operator?

20 DR. JARRIS: Thank you Steve and Dawn  
21 very much. We'll be back in touch.

22 MR. TEUTSCH: Thank you. We'll look

1 forward to working with you.

2 MS. MUNTHALI: Operator, Anthony.

3 Public Comment

4 OPERATOR: I'll open up for public  
5 comment at this time.

6 DR. JARRIS: Is there anybody here  
7 who would like to make a comment who's in the  
8 room in person? Peggy, come on up and we have  
9 15 minutes. So I guess we'll give you two  
10 minutes, Peggy.

11 MS. HONORE: In 2008 --

12 DR. JARRIS: Tell us who you are, for  
13 the folks on the phone.

14 MS. HONORE: Oh, sorry. This is  
15 Peggy Honore in the Office of Health Care  
16 Quality, in the Office of the Assistant  
17 Secretary for Health, Howard Koh.

18 In 2008, in that office, the Office  
19 of the Assistant Secretary of Health, we  
20 embarked on a very pioneering effort that some  
21 of you in the room participated in, and that  
22 was the establishment of the HHS-wide public

1 health quality forum, with input from all of  
2 the major public health stakeholder  
3 organizations.

4           What was produced at the time was a  
5 consensus statement on quality in the public  
6 health system, that laid out the nine  
7 consensus aims for what we considered is what  
8 should be characteristics of quality, when  
9 performing a public health mission. Not by a  
10 governmental public health agency exclusively,  
11 but what should be the characteristics of  
12 anyone contributing to that system.

13           We also defined public health  
14 quality. We had a follow-up convening in  
15 2010, where we established priority areas for  
16 the improvement of quality in the public  
17 health system. In designing this project with  
18 NQF over the last two years or so, we very  
19 much had in mind that those initiatives would  
20 be folded into the conversation in some way,  
21 in the design of whatever is going to emerge.

22           So I appreciate Ron Bialek's mention

1 of those this morning, and we very much would  
2 appreciate those things be considered as this  
3 process evolves and deliberations continue.

4 DR. JARRIS: Thank you, Peggy.  
5 Anyone on the line? Anyone else wishing to  
6 make a public comment?

7 (No response.)

8 DR. JARRIS: Okay. I think that  
9 would conclude that section, and next on our  
10 agenda is a lunch break, which looks like it's  
11 about ready. I'll turn this over to people  
12 who know what they're talking about.

13 MS. MUNTHALI: It looks like we have  
14 to give the hotel staff about five minutes to  
15 set up, and then we'll have lunch and we'll  
16 reconvene at 1:00 p.m.

17 DR. JARRIS: Go ahead, Matt.

18 MR. STIEFEL: I'll take advantage of  
19 the five minutes. Just very briefly, back to  
20 the framing for the report. I think one thing  
21 that would be useful is to clearly distinguish  
22 between health outcomes measures and health

1 determinants measures. I don't know that  
2 we've been clear about that so far, and even  
3 in looking at the measure evaluation criteria.

4 I think there are different criteria  
5 for measures of health outcomes and measures  
6 of determinants of health. When you're  
7 looking at length and quality of life measures  
8 or disparities, the criteria for measurement  
9 seem very different. They seem very different  
10 types of measures than when we look at the  
11 behavioral, social and health care  
12 determinants of health.

13 So I think the background paper would  
14 be very useful in helping us to distinguish  
15 between those two different types of measures,  
16 how they fit together, and how they differ  
17 from each other.

18 DR. JARRIS: Very helpful. Ron.

19 MR. BIALEK: This might get into this  
20 afternoon's discussion or even tomorrow's, but  
21 when I think of measures, in terms of  
22 selection of measures as what's the right



1       measure, right, what has impact and what can  
2       have impact, but then I also think about who's  
3       going to use it.

4                I've been thinking all morning about  
5       that, which is we can come up with lots of  
6       right measures that if applied would have  
7       great impact. But I'm not really clear on  
8       once we complete our work who the target  
9       audience or audiences are for the measures  
10      that we will be selecting.

11               It would help to have some clarity on  
12      that, because that should, I think, go into  
13      the thinking about what we choose.

14               DR. JARRIS: Well, you know, we  
15      should ask Helen to comment on this, because  
16      the other thing it's my understanding NQF  
17      doesn't develop measures; they endorse  
18      measures. So can you answer?

19               DR. BURSTIN: I think it's a great  
20      question. Again, NQF doesn't develop  
21      measures. We really just are the neutral  
22      convener and evaluator of measures. So once

1 you guys set the standards for what those  
2 should look like, we'll do a call for the  
3 measures hopefully in those prioritized areas.  
4 We don't always know what the uptake of  
5 endorsed measures will be. They do tend to  
6 get picked up for accountability purposes, and  
7 again, this is such a new space.

8 I think the real question would be,  
9 you know, might some of these get picked up by  
10 broader, newer entities like ACOs? Might  
11 communities or states looking for measures  
12 pick these up for accountability? I think  
13 it's a really good discussion, and I think  
14 it's part of what we framed for this  
15 afternoon.

16 DR. JARRIS: Any others? So I think  
17 ACOs, should they ever get off the ground,  
18 would be a very nice target, because you know,  
19 potentially if we can create it, they'll be  
20 held accountable for both cost savings and  
21 quality.

22 So if we can create some population-

1 based quality parameters, they can then be  
2 held accountable for what's the incidence of  
3 obesity or the incidence of diabetes, so just  
4 what's the A1C.

5 The other area this could be helpful  
6 in is the community benefit that the non-  
7 profit hospitals have to develop, based on new  
8 IRS regulations. If we have some quality  
9 measures, perhaps they can start being held  
10 accountable for community benefit that's a  
11 more population level.

12 MS. MERRILL: So if we were to follow  
13 these characteristics of quality in the public  
14 health system as our guideline, we would say  
15 ostensibly call for measures that are risk-  
16 reducing measures. So that we would have to  
17 come up with some criteria for what is risk-  
18 reducing, and then that could be applied  
19 broadly across different areas.

20 So what is risk-reducing for obesity?  
21 What is risk-reducing for smoking? Is that --

22 DR. JARRIS: I think we're going to

1 have to keep looking. It seems to me it's a  
2 set of principles, and as we work, we should  
3 be informed by those principles, and when  
4 we're done, we're going to pull them back out  
5 to say have we missed anything.

6 MS. MERRILL: But we have to refer  
7 back to -- so when we're creating measures at  
8 this level, or when we're asking for measures  
9 at this level, somehow, if they're going to  
10 reflect quality for public health or  
11 population benefit or all these other terms  
12 that we're considering, we must have some way.

13 These must be some criteria somehow  
14 involved in that, the same way we've got  
15 impact and gap, performance gap. We have to  
16 have some kind of risk-reducing criteria. See  
17 what I'm saying? So it's not just performance  
18 gap. If it's quality and public health that  
19 has to have risk-reducing component. I'm  
20 getting nitty-gritty maybe.

21 DR. STOTO: This doesn't relate  
22 exactly to what Jacqueline was saying, but to

1 the point before that, and it brings us back  
2 to this idea that somebody said earlier, we  
3 may have these thousands and thousands of  
4 measures. So I think that maybe one way we  
5 can think about what we're doing is thinking  
6 about a framework for which specific measures  
7 can be -- within which specific measures can  
8 be developed.

9 Well, what I would say is, going back  
10 to what Matt says. You know, we need to think  
11 about this logic model. How are -- is what  
12 we're doing going to eventually contribute to  
13 the health of the community? But we may be  
14 talking about what's the ACO going to do in  
15 that context? What's the health department  
16 going to do in that context? What somebody  
17 else may be doing in that context?

18 Not expecting that the ACO will do  
19 everything that needs to be done to inform the  
20 healthy community, but what can they do in  
21 that context? How does it relate to the goal  
22 that you eventually want?

1 DR. JARRIS: You know, some of the  
2 discussion about accountability, like for  
3 example, would the ACO actually be held  
4 accountable? It reminds me of the early  
5 discussions with the physician groups around  
6 quality measures, and their response, I can't  
7 be held accountable for that. I don't control  
8 it.

9 Well, nobody controls anything. I've  
10 got teenagers. So it's, but they can be held  
11 accountable for being at the table and being  
12 involved in the conversations.

13 MR. COHEN: And that's good, in terms  
14 of the question I was asking before, which is  
15 that we really need to be clear that  
16 accountability needs to be shared, but that we  
17 start to tease out what at least we want to  
18 look at as the part of accountability for  
19 different sectors or different players, and  
20 you know, in particular what is the health  
21 care accountability, which I think then flips,  
22 in terms of some of the patient-oriented

1 measures as well.

2 For example, I think that if we have  
3 a patient-oriented measure, where part of it  
4 is someone is not saying what are the  
5 community factors that are changeable, that  
6 are leading to it. Someone's coming in, for  
7 example with lead poisoning, and you don't ask  
8 about the community environment, but you just  
9 treat the lead poisoning.

10 There have to be measures that say  
11 that's unacceptable, if we're concerned about  
12 population quality. You know, I actually  
13 don't like logic models, and I really like the  
14 comment that Dawn made earlier about simpler  
15 is more elegant. But I do feel, and I don't  
16 know how exactly how it fits into the  
17 afternoon's discussion.

18 We're talking about 15 or 20  
19 different documents and national initiatives,  
20 and I feel like in a way we should be  
21 building, using all those as building blocks  
22 and as resources for us, as opposed to saying

1 "oh, let's look at one or another and  
2 basically have the same level of conversation.  
3 I don't even understand what they will all be  
4 or what their contributions would be.

5 But I feel like, and I think  
6 particularly some of the people from the  
7 federal government, understand at least many  
8 of those better. But I feel like as part of  
9 moving this agenda forward in the most  
10 effective way it would be helpful, and I don't  
11 just want to turn this over to LA, because I  
12 think it's unfair. I don't know what level of  
13 resources we're giving them, but I feel like  
14 we're asking for a huge amount, and I hope  
15 they can provide at least some of that.

16 I feel like in a way it would be  
17 helpful to delineate what all these different  
18 efforts are, you know, categorize them or  
19 cluster them in some way. How do we put them  
20 to use? What answers have they already  
21 provided in terms of outcomes or the kinds of  
22 data associated with outcomes?



1                   For example, we talked about the  
2                   prevention strategy this morning, and I  
3                   brought it up on a few occasions. I know they  
4                   work very, very hard on outcome measures, to  
5                   come up with population-based outcome  
6                   measures. I don't have those at my disposal,  
7                   but it seems to me that as a group, that would  
8                   be one of the places we'd most want to go, to  
9                   population-based outcome measures, because  
10                  they include 17 different federal agencies.

11                  They're looking at transportation,  
12                  they're looking at agriculture, they're  
13                  looking at economic development, and us kind  
14                  of proceeding in the wilderness, without all  
15                  that information at our disposal, you know.  
16                  It feels like we need to be, move the agenda  
17                  forward using every tool we have possible.

18                  DR. JARRIS: A new Ph.D. thesis is  
19                  born. No, it's very important. You're right.  
20                  If somebody can do a table or cross-walk that  
21                  for us at some level, it would be so helpful.  
22                  Michael, is that? Okay. So why don't we take

1 a lunch break and be back at 1:00, which I  
2 think is when the big hand is on the 12 and  
3 the little --

4 No. Let's really try to be back here  
5 at 1:00 if we can. Thank you.

6 (Whereupon, the above-entitled matter  
7 went off the record at 12:34 p.m. and resumed  
8 at 1:09 p.m.)

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

1 A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N

2 1:09 p.m.

3 DR. JARRIS: Okay. So it's a little  
4 after one. For the afternoon, the next  
5 couple of hours, we're going to have some  
6 discussion, and then finish off the day, I  
7 believe at three o'clock, on picking a few of  
8 the measures to take a look at, for the  
9 purpose of understanding the process, learning  
10 the NQF methodology as a basis for us then to  
11 look forward to how do we extend that beyond  
12 clinical measures into perhaps behavioral and  
13 community health measures, and there will be  
14 some of the methodologists calling in, I  
15 believe, on the phone, to help us with that.

16 I believe we'll start with  
17 immunizations, which might be an easy way. Is  
18 that true?

19 MS. MUNTHALI: Yes.

20 DR. JARRIS: An easy to really look  
21 at not only the clinical, but think about  
22 behavioral and population health, since I mean

1       there are certain states where nearly all the  
2       vaccinations in the state are given by the  
3       state health department down south.  So they  
4       might wonder what the clinical role there is,  
5       for that matter.

6               So first all, some housekeeping.  
7       Reva, did you want to talk about dinner for  
8       tonight?  Oh, I'm sorry.

9               DR. WINKLER:  Oh.  We just wanted to  
10       remind everyone, if you're interested in  
11       having dinner with your colleagues tonight,  
12       our colleague Sheila Crawford is outside, and  
13       she will make arrangements.  So just make sure  
14       you stop by and see her.

15              DR. JARRIS:  Okay.  So an important  
16       question, I think, for this next section,  
17       discussing population health measures, is what  
18       is the outcome we're seeking?  What is the  
19       product we need to develop when we're all  
20       done, finished and done?  So we thought we'd  
21       ask Helen to speak about that a little bit, so  
22       we can keep the end in mind.

1 DR. BURSTIN: Great, thanks. So our  
2 end goal is obviously is to think about  
3 bringing in what you would view as high  
4 priority population health measures that we  
5 can bring in for endorsement in the second  
6 phase of this project.

7 So part of our goal today has been,  
8 for example, just have at a little bit of an  
9 initial review of our evaluation criteria and  
10 think about how those fit the discussion we  
11 had earlier about our definitions, perhaps, of  
12 population health.

13 But I think the issue for us now, as  
14 you kind of face this next set of questions,  
15 is if our end goal is to get to a set of  
16 endorsed population health measures in some  
17 prioritized areas like obesity, smoking and  
18 physical activity, we need to write that call  
19 for measures essentially.

20 What are we going to ask the broader  
21 measurement community to respond to? What are  
22 we going to ask them to submit? Once it gets

1 to us, how are we going to evaluate it, which  
2 is why we'll return to the discussion we had  
3 this morning, after people have had a chance  
4 to, I think, reflect on some of our reviews of  
5 the measures this afternoon.

6 We want to be able to call for a set  
7 of measures, and we need to be able to be  
8 crisp and explain what we mean. We've already  
9 done some of this work, and it might be  
10 helpful. It hasn't been done in a way that  
11 has allowed us the luxury of having this very  
12 thoughtful foundational work first.

13 But for example, Reva just led our  
14 child health quality project, where we all  
15 endorsed numerous measures at the state level,  
16 for example. There's a low birth weight  
17 measure, for example, that is a state level of  
18 analysis.

19 There are multiple measures that came  
20 out of the National Children's Health Survey,  
21 that got at issues like missed days of school  
22 and some of the more classic population health

1 measures that currently have only been able to  
2 have been analyzed to the state or community  
3 level.

4 So we've already done this. We've  
5 brought in many of the AHRQ prevention quality  
6 indicators, for example, the preventable  
7 hospitalization measures that are supposed to  
8 reflect community capacity for primary care.

9 So we've gone down this path a bit,  
10 and I think what we'd like to do with this is  
11 be a bit more purposeful as we go into this  
12 next phase of work and help you have us write  
13 that call in a way that brings in the measures  
14 you're going to want to see put out there.  
15 Does that help?

16 DR. JARRIS: So one thing you said  
17 that I heard you say is that the scope really  
18 or that is around tobacco, either towards  
19 tobacco, obesity and physical activity. So is  
20 that in fact where HHS is funding NQF, or  
21 where NQF intends to have these population  
22 measures focused around?

1 DR. BURSTIN: We have had discussions  
2 with HHS about what they thought were the  
3 prioritized areas, and those seemed to rise to  
4 the top. Again, that's not set in stone per  
5 se. If there's obviously something we've left  
6 off that you think would be really important.

7 I think the concern was this is such  
8 a different area. We should do this in a way  
9 that we have confidence that this is the right  
10 foray. Will we learn from it? Might we do  
11 something different the next time we call for  
12 measures?

13 I think, you know, this isn't our  
14 first and only, you know, attempt at looking  
15 at pop health measures. I think this will be  
16 hopefully the focus of all of our projects  
17 going forward. I mean ultimately what we hope  
18 is sort of like the way, you know, two years  
19 ago we did a framework for how to evaluate  
20 composite measures, and brought in composite  
21 measures to that project.

22 Now all of our measures bring in



1 composite and individual level measures. I  
2 think in the same way, we're starting to think  
3 about in two years, when the cardiovascular  
4 measures are up again, how would the call for  
5 measures look different? What kinds of  
6 measures do we bring in that won't have that  
7 more narrow clinical view you'll see today,  
8 but how do we get that broader expanse?

9 So it's not just a one-time project.  
10 Our thought was should we pick a few areas for  
11 this project, get our feet wet, see how it  
12 goes, and then really move on to standardizing  
13 this into every project we do.

14 DR. JARRIS: Just for clarification,  
15 were the words "tobacco, obesity and physical  
16 activity," or "tobacco, nutrition and physical  
17 activity"? I'm just curious.

18 DR. BURSTIN: It was not that  
19 precise. I think it literally just said  
20 smoking, physical activity and obesity. But  
21 again, I think there's a lot of degrees in  
22 there. We just thought it would be helpful to

1 have three areas. Whether those are the right  
2 three. We know the other advantage of those  
3 areas is we are trying to get somewhat at that  
4 Venn diagram.

5 Those are also areas where there are  
6 clinical measures. So we thought it would be  
7 interesting to have the opportunity to have a  
8 project where we could actually try to  
9 harmonize some of those concepts as well.

10 MR. MASON: So there's no plan to  
11 just go through the existing clinical  
12 measures, and add or look at it from a  
13 population health component, as opposed to  
14 calling for all brand new measures? That's  
15 the first question.

16 DR. BURSTIN: We will, as part -- our  
17 expectation is, at least in those three areas,  
18 we will look at the clinical measures in those  
19 areas when we're looking at the population  
20 health measures. We already have measures in  
21 some of those areas, both for new and  
22 existing.

1           So for example, Joint Commission just  
2           did a whole new series of smoking measures for  
3           hospital. It would be logical that we look at  
4           those in the broader context of whatever comes  
5           in in the second phase of work. So it won't  
6           be that there's an expectation that the  
7           population health measures just have to be an  
8           aggregation of the clinical measures, but we  
9           also want to have that opportunity, and this  
10          came up this morning, to make sure that one  
11          set of measures is not put at a disadvantage  
12          or, you know, that one has to lead the other  
13          necessarily.

14                 MR. MASON: And then the second  
15          component is you said that the cardio measures  
16          aren't open again for another two years, and  
17          one in three. So heart disease and stroke,  
18          the biggest killers. Two years seems like a  
19          long time to apply population measures or  
20          population aspects of a measure, if indeed  
21          that's one in three on killing U.S. citizens.

22                 So I wonder if there's an opportunity

1 even to re-look at that, to say hey, we just  
2 got done redoing cardio, but two years is way  
3 too long. What work we do in here is really  
4 going to have an impact, and cardio being a  
5 great place to do that.

6 DR. BURSTIN: All those things are  
7 certainly open. We just have our usual  
8 schedule where we know we're going to look at  
9 all the measures. That's a certainty. If  
10 there's other opportunities, we'll try to meet  
11 them. I think that was also the logic of the  
12 ones we chose. They're obviously a huge  
13 impact on cardiovascular disease as well.

14 DR. JARRIS: I suspect if we wanted  
15 to have population measures in cardiac  
16 disease, we'd have to start now anyway to  
17 catch back up in two years.

18 MR. STIEFEL: This is a refrain that  
19 will probably begin to get annoying to other  
20 Committee members, but it's about again, the  
21 distinction between determinants and outcomes.  
22 Smoking, nutrition and exercise are not

1 measures of health. They're measures of  
2 determinants of health.

3 I'm just curious if the charge to  
4 this group is about coming up with measures of  
5 health. It's an important question, because  
6 I think if we start with measures of health  
7 and health outcomes, that is, in my mind, the  
8 appropriate way to frame the work, to go back  
9 to those things that have the biggest  
10 influence on health.

11 But starting with the things that  
12 have, that we think are the determinants,  
13 leaves a gap, at least in sort of the model  
14 that we're trying to use.

15 DR. JARRIS: Larry was next, and then  
16 --

17 MR. COHEN: I mean I think I want to  
18 build on that point, because as I said, I  
19 think if we're thinking about where we want to  
20 get and how to measure what we want to get so  
21 the outcomes are right, from my perspective as  
22 I've worked in community health prevention and

1 equity work, we end up with community  
2 determinants.

3 One of the things we've discovered is  
4 often a good solution solves multiple  
5 problems. So for example, if we talk about an  
6 issue like walkability, you know, we're  
7 talking about health. We're talking about  
8 physical activity; we're talking about safety  
9 at the same time.

10 I mean in terms of lives, clearly  
11 we're talking about chronic disease. In terms  
12 of years of potential life lost and some of  
13 the broader equity issues, I think we have to  
14 talk about chronic diseases, and that would  
15 include asthma at times, because I think  
16 there's enormous opportunity there, and we  
17 also have to talk about injuries.

18 So I guess I'm questioning a little  
19 bit the assumption, and I definitely wouldn't  
20 talk about obesity, I'd talk about healthy  
21 eating. But I'm questioning the not  
22 necessarily that it's the best place to start,

1 but that there could be better thought about  
2 whether the best place to start is  
3 automatically healthy eating, active living or  
4 even physical activity and tobacco, or whether  
5 there are a couple of other things that are  
6 just as compelling.

7 But from my mind, a broader  
8 definition, if we're going to talk about  
9 population health, that doesn't say that  
10 that's the determinant, but really looks more  
11 broadly at what, you know, what the underlying  
12 determinant. You know healthy food in stores,  
13 for example, takes in healthy eating and  
14 tobacco at the same time.

15 MS. MERRILL: You're actually  
16 starting to respond to these criteria, because  
17 these criteria are actually saying those kinds  
18 of things, do measures kill more birds with  
19 one stone. That's kind of what this is, in a,  
20 you know, in a more equitable proactive way.

21 DR. STANGE: I just have a question  
22 for Helen that's kind of a follow-up to Matt

1 and Larry's question. In your talking with  
2 HHS, because there is some overlap in the  
3 framing between certainly the obesity and  
4 physical activity frames, do you have the  
5 opportunity to go back to them and say you  
6 know, we decided we were going to choose two  
7 of those three or lump those in some way.

8 Because those have the advantage that  
9 they have clinical measures, but we might  
10 choose one that really is more something that  
11 would be a health outcome, that would be  
12 different that way, and that maybe might not  
13 have any corresponding clinical measures, and  
14 just see what we learn from that, to maximize  
15 our learning. Is that something that's  
16 possible?

17 DR. BURSTIN: It's certainly  
18 possible. Yeah, I think it would also be  
19 helpful for me to actually have Matt or  
20 somebody, I think to make sure again, we're  
21 all talking about the same things. It would  
22 be helpful to actually try to distinguish what



1 are determinants versus a health outcome.

2 I think actually a few examples of  
3 that might be -- I'm not sure we're all  
4 thinking of it in the same way.

5 DR. JARRIS: Yes, because when you  
6 said "determinants," I thought of social  
7 determinants, not proximal measures for  
8 outcomes. So there's another language.

9 MR. STIEFEL: But we've talked about  
10 the notion of this causal pathway between  
11 determinants and outcomes, and you can think  
12 of the social, environmental, genetic factors  
13 leading to behavioral factors, which lead to  
14 physiological determinants, which lead to  
15 disease factors, which lead to functional  
16 status, which lead to quality of life, in an  
17 intricate sort of causal pathway, that has  
18 feedback loops and the rest.

19 But I think just important  
20 distinctions between those things at the  
21 right-hand side of that, that have to do with  
22 life expectancy and quality of life, and the

1 distribution of health in the community,  
2 versus those things that affect or determine  
3 those outcomes.

4 DR. JARRIS: Go ahead, Mike, before  
5 you explode.

6 DR. STOTO: Yes. So I think that the  
7 causal pathway is the way to think about this.  
8 But I'm not unhappy with these obesity and  
9 activity and nutrition, because they are, in  
10 a way, the result of the different kind of  
11 activities, that different health care  
12 sectors, other sectors, public health do.

13 So I think if you want to make a  
14 distinction between the activities that we,  
15 different parts of the health system do, and  
16 the results that come from that, it's okay,  
17 and these are three things that people care a  
18 lot about, even though they may not be the  
19 ultimate goals. They gather attention. We  
20 can then think, you know, how can the  
21 different entities within the broader health  
22 system make a difference in those?

1 MS. MERRILL: Is anybody else an  
2 informaticist on the panel, because I'm just  
3 thinking of an informatic solution that might  
4 help us. So informatics is involved with  
5 knowledge management. So basically what we're  
6 talking about is concepts that have parents  
7 and children, right.

8 So some of these -- so when we talk  
9 about some of these bigger ideas, the idea  
10 that something could be the parent of a number  
11 of different children health conditions.

12 So like you're saying the walkable  
13 environment, actually children of that,  
14 outcome measures of that would affect cardiac,  
15 obesity, work life. You know, so it would be  
16 a variety of things, all going up to one, sort  
17 of in a hierarchy of conceptual framework. Do  
18 you understand what I'm saying?

19 It's because there's such an overlap  
20 involved. Some of these measures, they would  
21 all sort of stem up to the same idea.

22 DR. JARRIS: I think we, considering

1 who our audience is, that both NQF and I would  
2 even say many of the components of HHS, are  
3 very clinically-oriented. So if we can frame  
4 something in terms of, you know, major  
5 underlying causes of death, tobacco, if you  
6 want to call it obesity or nutrition and  
7 exercise, I think they'll get that.

8 If we lead with walkability, they'll  
9 say where's this come from? I mean I still  
10 think if we talk about these three things,  
11 walkability is going to be a clear measure  
12 with many cascading benefits to it. But at  
13 least it's in a context that will be received.

14 MR. COHEN: I agree with you. I do  
15 think, though, there's a question about short-  
16 term change versus making statements that  
17 promote the kind of change we really need to  
18 see in this country.

19 I'm fearful of continuing to go with  
20 the status quo at a time when our health care  
21 is really, really struggling, and we have  
22 virtually no prevention and continuing to

1 affirm the old way of thinking.

2 DR. JARRIS: So the first question  
3 for this afternoon is what is a population  
4 health measure, and I think that we're getting  
5 into that. So one way of answering that  
6 question might be a population health measure  
7 is one that's set in the context of a causal  
8 pathway, that will connect the actions of  
9 different entities, including health care  
10 providers and others, to population health  
11 outcomes that we're concerned about.

12 So some of the things that we do,  
13 like the prevention measure we'll be talking  
14 about later, if seen in that context could be  
15 seen as population health measures. It's just  
16 a way of framing the issues maybe.

17 MR. PESTRONK: Will we have at some  
18 point a, and I don't know whether the LA  
19 document is going to do this, we all have  
20 different ways of wanting or thinking about  
21 framing what the group is going to do, and how  
22 it will approach its work, because we're all

1 coming from different points of views and  
2 frames.

3 Even when we're talking, as we said  
4 before, using the same language, we're still  
5 talking about different stuff, different  
6 things, or understanding it differently. Is  
7 there any way between now and some next  
8 meeting, to lay out the alternative ways in  
9 which this might be approached, so that we  
10 could reach consensus on the approach that  
11 we're taking here? Rather than starting down  
12 a path, without having had the opportunity to  
13 decide, though, that's really the path that we  
14 want to move down.

15 I'm thinking, so that's the first  
16 thing. Then I'm thinking about the HHS  
17 consensus statement on quality in the public  
18 health system, and asking myself how does that  
19 apply?

20 Is that the set of metrics that we  
21 should be using to determine whether any  
22 measure, in addition to the frame that NQF

1 usually uses, which Helen, is what you were  
2 describing earlier, is that another lens to  
3 which we should be looking at any measure that  
4 we pick, that it fits in one or more of those  
5 categories, because HHS has already consensed  
6 around those being the aims for the public  
7 health system?

8 If they have, then there's already  
9 consensus. So we ought to be using it and  
10 promoting it.

11 DR. JARRIS: Well, the corollary to  
12 that would be do the clinical measures look at  
13 the five attributes, the safe, effective,  
14 patient-centered, dah dah dah, and I don't  
15 know that it does. But specifically, do they?

16 DR. BURSTIN: Everything will track  
17 to essentially the National Quality Strategy  
18 or previously the aims of the IOM. So yeah,  
19 we do specifically look at measures in each of  
20 those buckets, yes.

21 DR. JARRIS: I'm sorry, Madeline. Go  
22 ahead.

1 DR. NAEGLER: I like those three areas  
2 for a lot of different reasons, because of  
3 course they address measures of mortality.  
4 But I think there is a lot of overlap with  
5 previous work that's been done, and I would  
6 agree that we are not as well-established as  
7 we would like to think we are in the area.

8 But in smoking and performance  
9 evaluation for smoking cessation, where we  
10 need to be certainly. And in the area of  
11 exercise, there's a tremendous amount of work  
12 which has appeared in the research literature,  
13 which is not getting translated at all into  
14 performance evaluation standards.

15 I really think there's some important  
16 work that we need to do there. Being new to  
17 the process, I'm still struggling about where  
18 we look at outcomes versus determinants. I  
19 liked what Michael said about does it really  
20 matter, as long as we set it in that causal  
21 pathway.

22 DR. JARRIS: So the other way to look



1 at what we're doing is in a sense, it's a  
2 proof of concept. NQF hasn't done this  
3 before. So the smoking, I'll say obesity and  
4 exercises; it irks me. I'll say that instead  
5 of nutrition and activity, but those are  
6 things that are clearly understood. They are  
7 major underlying causes of death and  
8 disability in this country. They also,  
9 tobacco's a pretty clear example of how  
10 alignment of the public health and clinical  
11 sector actually did something important.

12 So it's a really good one to pick as  
13 a proof of concept. So you know, and the same  
14 I think with physical activity and nutrition.  
15 Clearly, there can't be a greater need in this  
16 country. We haven't yet gotten to the same  
17 place, where the case is as clear as it is in  
18 tobacco about aligning public health and  
19 clinical medicine, although there's a lot of  
20 good work going on there now. So that's a  
21 little bit more of a stretch.

22 So those three things may be a very

1 good proof of concept, so that NQF and HHS  
2 comes back and says yeah, this makes sense.  
3 Let's broaden how, you know, the areas in  
4 which we do this. Matt and then Linda.  
5 Larry, is that just a standing? I call on you  
6 every third person. Okay, you can put it  
7 down.

8 MR. STIEFEL: It's just a small  
9 point, but just in our conversation, people  
10 speaking in support of smoking and nutrition  
11 and exercise argue that those are good  
12 measures because they're major contributors to  
13 death and disability.

14 So that mental model suggests that  
15 death and disability are the population health  
16 outcome measures that we care about, and that  
17 smoking, nutrition and exercise are along the  
18 causal pathway, determinants of those  
19 outcomes.

20 So you know, perhaps -- I mean I  
21 agree. They're important measures. But I  
22 think we at least need to have the discipline

1 of saying this is our framework. These are  
2 the population health outcomes, and even in  
3 people's language, in this conversation, it's  
4 death and disability.

5 So the question that I still have is  
6 where are death and disability, or functional  
7 status, in this framework, and how do we make  
8 that linkage in the causal pathway, without  
9 just jumping into smoking and nutrition?

10 DR. JARRIS: Do you have a suggested  
11 answer to that question?

12 MR. STIEFEL: That we have outcome  
13 measures, as well as these measures, and if  
14 what we're saying underlying why we believe  
15 smoking is important, is because we believe  
16 death is important, then death may be a  
17 measure of mortality or mortality amenable to  
18 things we can fix, is a population health  
19 outcome measure that we start with, and then  
20 we say we're going to focus on smoking,  
21 because smoking is the biggest improvable  
22 contributor to that.

1 DR. JARRIS: Rhonda, I don't know if  
2 you recall, but the United health rankings,  
3 and this may not be your area, but there is a  
4 measure that is used for years of preventable  
5 life lost or something like that, and it's  
6 actually looked at among different  
7 populations, African-American, Caucasian-  
8 American. So is that the type of thing you're  
9 talking about?

10 MR. STIEFEL: As a measure of  
11 mortality, yes. It's years of potential life  
12 lost, I think. You start, you know.

13 MR. WEBBER: The LA discussion this  
14 morning, I think Matt talked about health  
15 status indicators, and then having performance  
16 measures that are more on the causal factors  
17 of contributing to that indicator. Then so  
18 yeah, I do think we've got some terminology  
19 issues here.

20 DR. JARRIS: I believe Linda was  
21 next.

22 DR. KINSINGER: I'm not sure where

1 this point fits into this discussion, but I  
2 was just going to make the point that I think  
3 an advantage of looking at physical activity  
4 and nutrition is that those are areas for  
5 which there's really less clarity about the  
6 role of clinical systems, and they're probably  
7 much more addressable at a community or  
8 population level.

9 So I think those two particularly  
10 really do stretch things more into that side  
11 of the, you know, the picture, because while  
12 there are clinical ways of addressing them,  
13 they're probably less effective overall than,  
14 you know, than non-clinical ways of addressing  
15 those issues. So I think it really does help  
16 to move things into that direction.

17 DR. JARRIS: And I think it's  
18 bariatric surgery centers per thousand  
19 population is the measure, yes.

20 DR. PICKENS: Well, we mentioned it  
21 earlier this morning, the work that RWJ has  
22 done with accounting health rankings, and you

1 mentioned it briefly. They have that, you  
2 know, policy is the base and it's sort of a  
3 cyclical policy, health risk factors that  
4 include the social determinants.

5           So what he's talking about as a  
6 determinant are actually risks to the outcome,  
7 which is mortality, quality of life and years  
8 of potential life lost, or I think they  
9 actually use quality life years lost, which is  
10 different.

11           MS. MERRILL: So can I just bring  
12 this back to what we practically will have as  
13 our outcome? So say we decide on this  
14 framework, and we call for measures. Who  
15 would be submitting measures and what would  
16 that mean? So in other words, would we come  
17 up with our framework, call for measures, and  
18 then Kaiser Permanente would come and say we  
19 want to rate ourselves on one of these  
20 measures?

21           Is what we are saying practical for  
22 the people who are invested in getting

1 measures from NQF? So how would a Kaiser  
2 Permanente use a population level measure?

3 DR. BURSTIN: I think it could be  
4 used at a lot of levels. I'll let that answer  
5 that. But I think it could also be used at  
6 the community level. I think that's the  
7 point, is we're trying to get out of the box  
8 of it only being a healthcare --

9 MS. MERRILL: I'd just like to see,  
10 you know, have it explained, so that we could  
11 make the links. That will help our thinking.

12 MR. STIEFEL: Well, we could, but I  
13 think it goes back to the important  
14 conversation we had earlier, probably when I  
15 was talking about the evolution of the Triple  
16 Aim, IHI's Triple Aim, is that single entities  
17 joined Triple Aim Collaborative and quickly  
18 realized that single entities couldn't achieve  
19 the Triple Aims.

20 So if we're talking about population  
21 health outcomes, Kaiser Permanente can't do it  
22 alone, and needs to participate in a broader,

1 multi-stakeholder collaboration with schools  
2 and employers and public health and social  
3 services and the rest, to achieve these  
4 outcomes.

5 MS. MERRILL: So you would select a  
6 measure, and then get some measurement with  
7 your partners?

8 MR. STIEFEL: Yes.

9 MS. MERRILL: And then you would say  
10 we have reached this level of measured  
11 population level performance with our  
12 partners.

13 MR. STIEFEL: And that we could  
14 measure our contribution to the determinants  
15 as performance measures for our organization.  
16 So you know, I think it's in that causal  
17 pathway, where the healthcare organization can  
18 contribute, would be a performance measure as  
19 well. That's a determinant performance  
20 measure, as opposed to an outcome.

21 DR. JARRIS: So then the Communities  
22 Putting Prevention to Work, which is part of



1 the American Recovery and Investment Act, did  
2 fund around 50 communities to look at tobacco  
3 and obesity, and that did require a large  
4 consortium being put together. There was no,  
5 as you said, no single entity can deal with  
6 those issues at the community preventative  
7 level.

8 So there is some experience. The  
9 evaluation of that is ongoing, although I've  
10 heard the evaluation may not obviously turn  
11 out to be quite what's expected. It's hard to  
12 prove these things. Mike.

13 DR. STOTO: Two quick things about  
14 the focus on smoking, obesity, nutrition,  
15 whatever. One is from the proof of concept  
16 point of view, those are areas where the  
17 evidence is pretty good for the kind of non-  
18 clinical, as well as clinical intervention.  
19 So that's another reason for starting there.

20 The other thing is, another reason  
21 for kind of starting there and not ignoring  
22 these outcomes, but focusing on measures of

1 those things is because sometimes, say take  
2 lung cancer, that's the result of smoking, you  
3 don't see changes right away because of the  
4 latency period. But you see changes in the  
5 smoking behavior sooner, and I think that's a  
6 useful property of remission.

7 DR. JARRIS: Sarah.

8 MS. SAMPSEL: I think I wanted to  
9 build upon Matt's response a little bit,  
10 because I think health plans are looking for  
11 this type of measure for a number of reasons.  
12 One is resource direction, and you know,  
13 health plans either have a foundation or other  
14 mechanisms that we're working in communities.

15 In order to evaluate our efforts in  
16 the communities, we need to look beyond our  
17 membership, and in order to do that, we need  
18 some kind of public basis for measurement, so  
19 we can say this is how we're tracking, when it  
20 isn't our internal data.

21 So I specifically run an entire  
22 health index off CDC data. Not ideal, you

1 know, sometimes due to periodicity, sometimes  
2 due to, you know, just other data aspects of  
3 what we get out of our public health system.

4 But we need something like HEDIS for  
5 the public health side, and then, you know,  
6 and exactly what Matt said, is there has to be  
7 a way to evaluate our efforts on each of these  
8 essential areas of population health or public  
9 health or health determinants, that aren't out  
10 there right now.

11 And even the existing measures in  
12 obesity and public health, I mean, they're  
13 very much down the road of did you measure  
14 BMI, not what is BMI.

15 DR. JARRIS: Larry and then Kurt.

16 MR. COHEN: I was really interested  
17 in your comment, Helen, about that communities  
18 could respond to these issues, as well as  
19 medical institutions. The first question that  
20 came up is how would they know about them, why  
21 would they be interested in responding, why  
22 would this in any way feel relevant to them.

1 I feel like the comments about  
2 Kaiser's partnership in CPPW provided at least  
3 some of the answer that I think we really need  
4 to think about, if we're going to move this  
5 constructively, which is that the best way to  
6 reach them probably is through linkages, and  
7 to really then think about what's going on in  
8 those community benefit efforts of Kaiser, for  
9 example, or in CPPW or soon in community  
10 transformation grants, and how do we align  
11 with that, and with that way of thinking.

12 So for example, the word "obesity,"  
13 which probably brings up BMI notions and, you  
14 know, certainly kinds of goals, versus the  
15 word "nutrition," versus the word "food  
16 system." Food system of the three is the  
17 furthest from the medical side.

18 But in some ways, it's going to bring  
19 up the most constructive community solutions,  
20 because food system will then talk about the  
21 work Frank and I were discussing earlier in  
22 Philadelphia, of you know, using economic

1 development dollars to increase the number of  
2 supermarkets, which has now been adopted by  
3 the Obama administration and it's going  
4 nationwide.

5           You know, in that case it may be kind  
6 of tied to obesity, because obesity has kind  
7 of become a national theme. But I think we  
8 have to consider very carefully what frame  
9 we're looking at, because I personally don't  
10 want the frame to be measurement of BMI.

11           I think that's a terrible mistake  
12 which has misguided community, because it  
13 leads people very much to an individual  
14 solution, and we already have a medical  
15 individual paradigm. In order to make  
16 community-wide change, thinking again about  
17 the fundamental question of what outcomes we  
18 want to achieve, you know, I think we have to  
19 flip that.

20           But I do think that the partnerships  
21 and the work going on there may be really  
22 instructive to us.

1 DR. JARRIS: Kurt.

2 DR. STANGE: I wanted to ask Andy a  
3 question. If we take Matt's idea of thinking  
4 about outcome measures in addition to these  
5 determinants of health process measures, what  
6 would be measures that would be engaging to  
7 the business community?

8 Helen gave an example actually of one  
9 that was about missed school days. So  
10 something like missed work days would be  
11 relevant for employed people. But I'm  
12 thinking even beyond that, like in Cleveland  
13 where we have less than half of our students  
14 graduate from high school, we don't have a  
15 very prepared workforce.

16 Is there something that could be  
17 measured as an outcome measure, that would  
18 engage partners that we don't currently have  
19 at the table, just thinking about the clinical  
20 systems and the public health systems, the  
21 things that could engage other sectors of  
22 government, the voluntary agencies and

1 particularly the business community?

2 MR. WEBBER: Yes. Well thanks. You  
3 know, I think it's the two levels, because I  
4 do think, you know, there is a defined  
5 population for an employer itself, you know,  
6 and that is their workforce, their dependents.  
7 You could create accountability measures for  
8 employers, working with other partners,  
9 including healthcare plans, Sarah, the  
10 provider community, community resources that  
11 could really impact the health improvement of  
12 that defined population, that a lot of  
13 employers feel responsible for.

14 In fact, they would say is  
15 increasingly a business imperative for them to  
16 be competitive. Health and productivity,  
17 workforce health and productivity improvement  
18 is related to competitiveness of their  
19 industry.

20 When you start to move into, you  
21 know, community-wide measures, I do think  
22 things like overall economic development

1 issues, things like the quality of the school  
2 system, again because in the minds of business  
3 leaders, there's a direct relationship there  
4 to, again, their enterprise and creating the  
5 conditions for them to be successful in a  
6 marketplace. I do think you can engage them  
7 at that level too.

8 So, you know, I think it's much  
9 easier right now, and we're seeing huge  
10 investments by employers in workforce health  
11 and productivity issues. It's a bit of a leap  
12 to get business leaders more involved in  
13 community-wide collaboratives, although Matt  
14 and others, that's exactly where our business  
15 and health coalitions are focused.

16 I mean, we've done a lot of work on  
17 worksite activities, and by the way, some  
18 measures on worksite activities, though, would  
19 be very useful to the employer community. You  
20 know, what is, what are the best practice  
21 intervention strategies for employers at the  
22 worksite.



1                   But again, I think our larger  
2                   interest here is to get community involvement  
3                   at community level, employer involvement.

4                   DR. JARRIS: There are though, in  
5                   Iowa, there's a very large coalition organized  
6                   by the business community. WellPoint is one  
7                   of them, but then other non-health business  
8                   community, to create a coalition to create  
9                   healthier people. They're going after  
10                  obesity, tobacco and other things like that.

11                  So there are, as you said, they see  
12                  it as a business imperative, and then Oklahoma  
13                  City, the mayor has taken it on, a  
14                  revitalization project designed to make  
15                  walkable, livable communities instead of  
16                  Target. I can't remember how many millions of  
17                  pounds the people would lose in that city, and  
18                  there's about 800,000 pounds they've lost or  
19                  something.

20                  So political leaders see it, business  
21                  leaders see it. So I think there would be  
22                  pretty broad-based interest in the right

1 measures.

2 MR. WEBBER: I think there are plenty  
3 of examples where actually the business  
4 community is taking a leadership role in  
5 community collaboratives. I mean, you know,  
6 one of our -- Jason just mentioned, one of our  
7 coalitions, Mid-America is in charge of the  
8 Healthy Community project and effort.

9 DR. JARRIS: So Jackie and Sarah.

10 MS. MERRILL: In terms of practical  
11 measures and, you know, users of these  
12 measures, so you think that the business -- in  
13 the same way that we have those LEED  
14 buildings, that a business would be interested  
15 in using an NQF criteria to be an NPP employer  
16 or something like that, that kind of a --

17 DR. JARRIS: You know, there actually  
18 is an employer wellness certification process  
19 like the LEED. It's called Health Lead, that  
20 has gone through an alpha testing. It's going  
21 through beta testing now with some major  
22 corporations. Andy's on the board; I chair

1 that board or that group.

2 It's funded actually largely by the  
3 private sector. Target's put in a million  
4 dollars a year to fund it. United has --

5 MS. MERRILL: Is there a public  
6 reporting capacity to it?

7 DR. JARRIS: It's a certification  
8 process for employers. We went through it as  
9 an alpha test, and I thought we were good. We  
10 got a provisional. So it is a really robust  
11 system around wellness, not just around --  
12 because the hierarchy I see with employers,  
13 they first start out with how do we lower our  
14 premium, and then they start doing health  
15 fairs, and then they start perhaps doing  
16 disease management.

17 Then they start to develop  
18 comprehensive programs for their employees,  
19 and then ultimately, the most sophisticated  
20 ones recognize that their dependents, retirees  
21 are living in the community. Their customers  
22 aren't, so they actually branch out and reach

1 out to the entire community.

2 You have to be pretty high up on that  
3 scale to get the certification. So the  
4 process is in place. Sarah.

5 DR. LINDE-FEUCHT: Excuse me. Dawn  
6 mentioned this in her slide presentation, and  
7 also in the paper. But I'd just like to, you  
8 know, remind folks that Healthy People 2020  
9 seems to be another big body of work, where  
10 there are targets on population health  
11 measures.

12 I know the Office of Disease  
13 Prevention and Health Promotion, where I  
14 formerly worked, I don't work there now, is  
15 doing a lot of work on implementation, and the  
16 idea is to get this down to the community  
17 level. So I don't know if that's another  
18 source where we could look for some population  
19 health measures.

20 Let me mention that they, you know,  
21 that work has all been based on social  
22 determinants of health, disparities and equity

1 issues, and it doesn't address just clinical  
2 issues.

3 But there are, you know, all kinds of  
4 things on access and other issues. I think  
5 worksite is part of that. So again, just  
6 something else that exists that might be  
7 helpful.

8 DR. JARRIS: So, you know, that's  
9 common. There are so many products out of HHS  
10 that are released in parallel. So somehow we  
11 have to think about whether anyone in HHS  
12 could sort of do a cross-walk of all those  
13 things, or whether the LA group could, or  
14 whether someone has a Ph.D. student who could,  
15 because it's a huge body of work.

16 DR. BURSTIN: I believe Dawn has  
17 indicated to us that that's actually been part  
18 of what she's already been working on, is that  
19 cross-walk. So we'll make sure that's part of  
20 this paper.

21 DR. JARRIS: So it seems to me that  
22 there is some perhaps consensus around this

1 notion of whatever the words are, smoking,  
2 obesity, exercise were the original words  
3 used. I think we should pick the words we  
4 want to use, if we want to decide that's the  
5 place to begin. Forget the words. Is that  
6 the right, do people agree with that as a  
7 starting point? Matt?

8 MR. STIEFEL: I think if we have a  
9 model or a framework in which those measures  
10 sit, that describe influence on population  
11 health outcomes, just selecting them without  
12 explicitly articulating that framework, I  
13 think, would be very problematic.

14 DR. JARRIS: I think I'd call these  
15 topical areas from which to do the work  
16 within, not --

17 MR. STIEFEL: Well, but what I'm  
18 saying is, I think, something different, in  
19 that we picked these because of their causal  
20 influence on population health outcome  
21 measures that we care about.

22 I guess I would still be

1       uncomfortable with only selecting those  
2       determinants, without articulating the  
3       downstream population health outcome measures  
4       of mortality-related or disability-related.

5                 DR. JARRIS:  So the CDC, I don't know  
6       when they first publish it, but they do have  
7       a chart frequently referred to in public  
8       health sectors, where you have the leading  
9       quote "causes of death," you know, heart  
10      disease, cancer, stroke, diabetes and those.

11                Then they have the underlying causes  
12      of death, of which tobacco, actual cause of  
13      tobacco, and then it is nutrition -- excuse  
14      me.  Poor diet and then physical activity.  I  
15      think alcohol abuse is the next.  So that is  
16      well-established, at least within the public  
17      health work, and I have to assume there was a  
18      research base behind coming up with that.  I  
19      can't quote it.

20                So that is the framework that's, at  
21      least in the public health world, very well  
22      established.

1 DR. STOTO: It's a pair of articles  
2 by McGinnis and Foege that did that. But I'd  
3 like to build on what Matt said, that we need  
4 rationale for choosing these things, and part  
5 of it is embedded in a causal framework that  
6 leads to outcomes that are important, and  
7 that's part of the evidence there.

8 But it's also looking upstream. We  
9 know that there are interventions that could  
10 make a difference, and there's evidence there  
11 as well. So it's really part of a causal  
12 framework that we know that we can do  
13 something about, and that will get us to where  
14 we want to be.

15 DR. STANGE: I wonder if we're  
16 serious about the idea of this is a proof of  
17 concept, if there's something else besides  
18 even embedding those in a causal framework  
19 that we should do, and that's to maximize the  
20 diversity of the types of approaches.

21 I still wonder if, this is probably  
22 a question for you, Helen, if it would be



1 worthwhile to think about a different kind of  
2 thing that is more of an outcome, that's not  
3 about us saying okay, we're really smart. The  
4 folks at HHS are really smart, and these are  
5 three really good things to do, that good  
6 things will happen if you intervene on them.

7 If it's about saying let's see how it  
8 could reframe everything if you chose  
9 something that's a functional health type of  
10 measure, and said we're going to develop  
11 measures of this.

12 We're going to say here's the  
13 concept. Here's some measures that are  
14 available, not over-specifying who uses the  
15 measures, saying that there will be different  
16 levels of groups that will use this. Some  
17 could be community measures. Some could be a  
18 whole state might decide to use some measures.  
19 Some of them might be an employer. Some of  
20 them might -- it might be a health plan.

21 And say we're going to look at the  
22 functional health status of our people. We're

1 going to measure that, and then we're going to  
2 get together and take a whole systems approach  
3 and say who needs to be at the table to, at  
4 our whatever level, whatever community,  
5 whatever group, to do something about that?

6 I just wonder if that would be an  
7 interesting contrast to these others, that we  
8 might learn something interesting that could  
9 inform the next steps.

10 DR. BURSTIN: I was actually going to  
11 say something similar, and that was making a  
12 comment, that there's also nothing that says  
13 that we can't, as part of this call, ask for  
14 both the determinants as well as outcomes.  
15 But I think we just need to be tight in what  
16 we're asking for, because I think otherwise  
17 the universe could stream in, and you'll be  
18 working on this committee for the next six  
19 years.

20 So I just think really being focused  
21 would be helpful. So actually our staff had  
22 done a sort of quick and dirty review of what

1 we thought were out there, in terms of  
2 population health measures. Again, measures  
3 like these, there's a measure that CDC has on  
4 avoidable mortality, 45 to 64.

5 I mean, might that be a nice framing,  
6 to bring in some of the determinants, and  
7 allow some of these more general measures that  
8 could be used at a community level in these  
9 consortia, to get at the outcomes piece?

10 I think the functional health status  
11 stuff is a little more difficult because it's  
12 patient reported. There's a whole other  
13 project beginning on that. There's so many  
14 other feasibility issues, etcetera. I think  
15 some of these -- I just maybe it would  
16 intrigue me to have you guys just think about  
17 whether you'd want to actually consider a  
18 small set of those outcomes as well.

19 DR. STANGE: Well, it doesn't have to  
20 be patient-reported. I mean there are, there  
21 are community reports of this kind of measure.

22 MR. STIEFEL: Nor do I think we

1 should rule out patient-reported. My favorite  
2 quote from John Ware is if you want to know  
3 how Mrs. Smith is doing, unfortunately you're  
4 going to have to ask her.

5 That single question of self-  
6 perceived health, reliable, valid, predictive,  
7 easy to gather, used in all of the national  
8 health surveys, including BRFSS. Why not  
9 consider something like that? We're talking  
10 about measuring health. What about a measure  
11 directly of health?

12 DR. JARRIS: I think the United  
13 health rankings do have a couple of questions,  
14 one on perceived health and one on mental  
15 health, I think.

16 MR. PESTRONK: They do, and so do the  
17 county health rankings.

18 DR. JARRIS: Yes. Those are derived  
19 from United, so --

20 MR. PESTRONK: We've been talking  
21 about two, at least two things simultaneously  
22 or sort of in parallel.

1           One is what to measure, which is the  
2           determinants and outcomes conversation, and  
3           then sort of woven in that conversation has  
4           been how will we determine whether they're  
5           good measures or not?

6           There have been two or three  
7           different sets of criteria proposed, for how  
8           we would determine whether they were good  
9           criteria or not. One are the criteria that  
10          NQF has traditionally used, and then there are  
11          other -- there's at least one other set of  
12          criteria, which are the consensus standard on  
13          quality in public health systems.

14          The aims that are there is the second  
15          one, and maybe there are some others that have  
16          been mentioned as well, because the work of  
17          this Committee is to, from whatever population  
18          of measures are proposed to it, to use some  
19          structured framework to arrive on what the  
20          Committee will ultimately endorse, to be used  
21          by whoever chooses to use them.

22          So both of those things have to be

1 created, before we're able to get to that last  
2 step of being asked whether we want to endorse  
3 them or not. Is that sort of what's been  
4 going on here?

5 DR. BURSTIN: I think so. I mean, I  
6 think that's part of how we began the  
7 discussion about the NQF evaluation criteria.  
8 We then talked about how the influence of the  
9 public health criteria fit in.

10 I think our goal would be that at the  
11 end of this process, you would have a version  
12 of the evaluation criteria we review, because  
13 we are NQF, that incorporate in some of those  
14 key elements you think are going to be really  
15 important to assess public health measures.

16 So I think it's going to be a  
17 blending, which is why we just started the  
18 discussion today about the evaluation  
19 criteria. But you're obviously right. You  
20 can't look at these measures until you have  
21 some basis to figure out how you're going to  
22 determine if they're a good measure.

1 DR. STANGE: So I'm not sure a  
2 process matches the outcome. I don't quite  
3 know how you get from a large group discussion  
4 with 20 people, to the how-to. I mean that  
5 seems like it's a smaller group activity. How  
6 can we help get there?

7 DR. JARRIS: We are an hour into this  
8 two hour conversation, and I was at the same  
9 point. I would love to know what people  
10 think. Why don't we just conclude,  
11 accomplish, move on in the last hour, and if  
12 we are going to take the next hour, and we  
13 need it, where should we be going in the next  
14 hour? Does anybody want to take a crack at  
15 that?

16 MS. MERRILL: So given that this  
17 document, the DHHS characteristics of quality  
18 in the public health system have been  
19 developed by consensus, could we look at these  
20 nine and say which of them we think are  
21 suitable to be NQF criteria?

22 Are there some that are better than

1 others and that would help us, that would be  
2 worthy of including? Does that seem  
3 reasonable? Because this has been -- work  
4 has been done on this thing.

5 (Off mic comments.)

6 DR. JARRIS: It's like the five aims,  
7 and it's the corollary for public health of  
8 the AIMS for clinical medicine, and I think  
9 we, over time, want to make sure we hit each  
10 of those.

11 DR. STANGE: So Bobby and Jackie are  
12 suggesting, Bobby really and Jackie now  
13 suggest a process where some group does,  
14 either we take existing work or subgroups do  
15 some work and present us with a set of  
16 alternatives.

17 I mean, it's hard for a group this  
18 large to do -- we've kind of given the lay of  
19 the land, but to really nail it down to  
20 something we're going to choose between and  
21 weigh the alternatives, there needs to be some  
22 intuitive work done, it seems.



1 MR. COHEN: I'm in favor of  
2 subgroups.

3 DR. STOTO: To what degree are the LA  
4 folks going to do that?

5 DR. BURSTIN: It's not clear how much  
6 they're going to engage specifically in the  
7 evaluation criteria, but it's something we  
8 should follow up with them, to make sure we're  
9 not being duplicative. The other question is  
10 whether it's the group who actually could help  
11 work with LA on some of these issues as well.

12 DR. JARRIS: Yes. I think we should,  
13 I mean, worry about sending LA off by  
14 themselves to come back with something. We  
15 really need to meet together with them. It's  
16 a shame they can't be here today, really to  
17 hear what's going on and inform it. But I  
18 don't think they're going to be the sage that  
19 comes back to us with the answer.

20 MR. PESTRONK: What was the third  
21 area, you know. I described two things that  
22 we've been talking about. The other, and

1 maybe what we're doing is framing out what it  
2 is we'd like to receive. That's what we  
3 talked about at the very start of the  
4 conversation. We don't know what we're  
5 talking about, because we don't share a set of  
6 definitions, and we don't use language the  
7 same way.

8           So we want to make sure that what we  
9 get back, at least has those three parts to  
10 it, so that Kurt then when the group is  
11 ultimately doing its work, it knows exactly  
12 here's what we're talking about, here's how  
13 we're going to -- here's the frame through  
14 which we'll select measures, and here's the  
15 process that we'll use to do that, to do that  
16 selection. We don't, and that's not all  
17 nailed down yet, it seems to me.

18           DR. JARRIS: Matt.

19           MR. STIEFEL: I guess I just lifted  
20 my tent up to agree. But it's, I think, a  
21 framework or a model, on which we could hang  
22 measures, and distinguish between determinants

1 and outcomes, and show how the measure set  
2 that we prioritized or how we prioritize the  
3 measure set, it's with that framework. It  
4 seems fundamentally important.

5           Otherwise, it just seems like a  
6 laundry list, or random, you know. So it  
7 likely leads to measures of things like  
8 nutrition and smoking and exercise, but it  
9 seems much -- I'm much more comforted in sort  
10 of arriving at that conclusion after a  
11 framework in which we can point to how these  
12 fit in the causal pathway.

13           DR. STOTO: You know, I think that  
14 there's probably something like that in most  
15 NQF measures that's implicit, you know,  
16 structure, process, outcome kind of thinking.  
17 But given that the nature of this population  
18 health, I think it helps to be explicit about  
19 these kind of things. So I would support that  
20 as well.

21           DR. JARRIS: And so thoughts about  
22 the framework in which to hang the measures

1 on, distinguish between determinants and  
2 outcomes and prioritize among them, thoughts  
3 about where we would derive such a framework?  
4 Is this the small group to go away and do  
5 that, or would be easier to do the nine aims?

6 MR. MASON: I mean, I think part of  
7 my issue is I'm a very visual person. I hear  
8 a lot of stuff, but I can't see it. I don't  
9 see like charts and boards. I think it might  
10 be interesting to get those charts back.

11 I think they were here earlier, and  
12 start writing what would be in the framework  
13 for population health, and everybody just  
14 starts throwing everything up on the wall.  
15 Then we can start kind of cutting some things  
16 out, piecing them together, linking them. But  
17 it's just really hard to look right in the  
18 middle when you can't see it.

19 DR. JARRIS: Yes. It's also a lot  
20 easier to react to something, than to create  
21 it, especially in a big group like this. So  
22 it may be that subgroups are the step that we

1 need.

2 So let's think about where we go now  
3 in the next hour, which could be on with the  
4 agenda, we finish an hour earlier, or is there  
5 a way we can use this time now to move forward  
6 on this notional framework?

7 DR. MEDOWS: Well, could I also ask -  
8 - I'm sorry, over here.

9 DR. JARRIS: I just didn't know where  
10 the voice was coming from.

11 DR. MEDOWS: It's the voice of God.  
12 Do we want to answer these questions, to help  
13 decide about the next step, or do we want to  
14 do the next step, in terms of breaking out?

15 DR. JARRIS: What's the pleasure of  
16 the group? Take a look down at these five, I  
17 believe, questions?

18 (Off mic comments.)

19 DR. JARRIS: We're deciding where to,  
20 and this is an open process, okay. I just got  
21 appointed to, like a few hours ago, to chair  
22 this thing. So you're all more qualified than

1 me. So let's talk about where we want to go  
2 on this.

3 I mean we, you know, if it's the  
4 framework we're looking at, I mean, we pretty  
5 much either can adopt an existing one if we  
6 want, or think about what attributes would a  
7 framework have.

8 (Off mic comment.)

9 MR. COHEN: I wonder whether if we  
10 have maybe three different groups and three  
11 different measures, and gave the groups the  
12 ability to focus specifically on the measure,  
13 say nutrition for example, or food or whatever  
14 we want to call it, or the ability to kind of  
15 raise some of the meta-questions, and we each  
16 took a half hour in our groups to kind of --

17 Because it feels like if we had some  
18 dialogue, we could come up with some real  
19 constructive ideas, and then we could mesh it.  
20 It feels like we're a little stalled here,  
21 because on one hand we're dealing with very  
22 big ideas, and on the other hand we're dealing

1 with a lot of specificity.

2 DR. JARRIS: Sue.

3 DR. PICKENS: Well, I'm kind of  
4 struggling with, I guess like you, where to go  
5 next. The American Health Care rankings and  
6 the county health rankings have a really nice  
7 framework that you can look at, put on the  
8 wall, and I'm not saying we have to use that  
9 one.

10 But that's one to start with, where  
11 you could put the measure framework, each of  
12 the measures in there, and you'd know where  
13 they sit and what the causal pathway would  
14 look like. I have it on my little iPhone.

15 DR. SPANGLER: And I would say maybe  
16 the county health rankings have a similar type  
17 thing, yes, both. But I would also, I thought  
18 you were going to mention this before, but  
19 another -- it is community; it's also  
20 personal. But another index, and it goes  
21 along with not just health but also well-  
22 being, is Healthways and Gallup's Well-Being

1 Index, which really gets down, and we've  
2 talked about this at NPP, but I mean really  
3 gets down to individual level, but also can be  
4 brought up to the community level.

5 It's also the one thing that has --  
6 one of the huge benefits, it's real time. I  
7 mean, this happens daily, every single night,  
8 and a lot of changes can be done with that as  
9 well.

10 So I mean that's another -- those are  
11 really the three, I think, that we have now,  
12 the state health rankings, the county health  
13 rankings and the well-being index, that  
14 actually look at community health and well-  
15 being.

16 I'm not sure, besides the BRFSS and  
17 the other data and stuff like that. But all  
18 those derive from BRFSS, but the bigger  
19 frameworks.

20 DR. STANGE: Some of the questions --  
21 if we were going to spend the next half hour  
22 in small groups, people can talk and chew on



1 things. Some of the questions we have on the  
2 table are the what, and we've chewed on that  
3 a fair amount, about the three health  
4 behaviors.

5 The how, which involves perhaps  
6 developing a framework that's more  
7 theoretical, and then the how also about the  
8 measures. Then there's implied here of who.  
9 If we were -- let's take a few minutes. If we  
10 were going to do a small group, what would the  
11 small groups be about? What would the charge  
12 be?

13 (Off mic comments.)

14 DR. JARRIS: Postprandial narcosis.

15 DR. MEDOWS: What if each of the --  
16 what if we broke into three separate groups,  
17 used either the county or the state health  
18 rankings as the framework, and then just used  
19 it as something to bounce ideas off of, to try  
20 to work it through for each of the individual  
21 areas?

22 Then the three groups come back

1 together to report out on what they were able  
2 to find that they thought needed to be  
3 changed, what needed to be added, what would  
4 work well, and what additional ideas they  
5 generated? We should, perhaps, I guess go eat  
6 some more cake and be quiet for a few more  
7 minutes.

8 DR. JARRIS: No. I'm beginning  
9 thinking about what is the outcome we're  
10 trying to reach here, and yes, we really do  
11 need to know from NQF what is it you're  
12 looking for here. Because the community,  
13 United Health rankings and the county health  
14 rankings are based on United Health rankings.

15 So that's a fairly complex framework  
16 that's weighted and has attributes under it  
17 that may change from year to year, hopefully  
18 not. So I'm not sure -- to me, that's not  
19 striking as exactly what we're looking for  
20 here.

21 DR. MEDOWS: I think I don't mean for  
22 us to mirror them. I'm just trying to get

1       them to use them as something to get the  
2       conversation going to the next step. We seem  
3       to be stopped.

4               MR. COHEN: I mean, I think what  
5       we're looking for is a shared vision of the  
6       criteria to use with rankings, and by actually  
7       doing the rankings, it may make it more  
8       concrete, which is why I agree with that  
9       recommendation.

10              I don't think we'll exactly do that.  
11       I think what's important is to have open  
12       conversations, where we kind of work at this,  
13       and then kind of come back and hopefully the  
14       clarity of different groups will support and  
15       mirror one another.

16              If we do that for a half hour, we  
17       then have some time to kind of have some  
18       shared conclusions.

19              DR. JARRIS: Mike and Bobby.

20              DR. STOTO: Maybe this is just what  
21       you were just saying, but in a different way  
22       again. The question could be what do the

1 county health rankings, can they serve as the  
2 framework that we need for this activity? Why  
3 or why not? I mean, that would help us think  
4 through what attributes we like and don't  
5 like.

6 DR. JARRIS: Good.

7 DR. BURSTIN: I also think it would  
8 be useful to actually have -- I mean, I think  
9 it would be useful to have that, a group that  
10 wants to think about framework, and whether  
11 some of the existing frameworks exists. I  
12 think one group could do that, and whether  
13 it's applicable to what we're trying to do  
14 today.

15 I still think it would be useful to  
16 have a group who would like to help us think  
17 through this issue of how you would evaluate  
18 these, and how do we kind of reconcile what  
19 we've already got on the NQF side, perhaps for  
20 public health side.

21 Then I guess the third thing is, is  
22 it also potentially going to have a group

1 that's going to think about scope, because we  
2 keep having this discussion about how broad we  
3 want to go. Maybe that's just a simple way to  
4 get something quite concrete out of it, that  
5 might be useful in a half an hour discussion.

6 DR. JARRIS: The groups are  
7 framework, how do we evaluate, and scope?

8 MR. STIEFEL: I've become a collector  
9 of these frameworks just for fun, and have  
10 developed my own sort of synthesis of them.  
11 So I think sharing the frameworks, including  
12 the county health rankings is, going back to  
13 Evans and Stoddart, probably would be useful,  
14 and would be a way for this group to take a  
15 framework and build and adopt one.

16 I don't know that we can do that  
17 during the next 15 minutes, but I'd be happy  
18 to work with a subgroup.

19 DR. JARRIS: You know perhaps,  
20 because again, we're going to need to provide  
21 people with something to look at, something to  
22 react to, and I don't know that again, that we

1 can do that in the next 15 minutes either. So  
2 maybe we should think about, as a next step,  
3 a subgroup maybe telephonically or a webinar,  
4 the meeting might be a webinar, and perhaps  
5 using these are the three groups you propose;  
6 one to look at the different frameworks, and  
7 we already have a co-chair for that one, a co-  
8 chair for that subgroup. Now the other two  
9 groups you mentioned --

10 DR. BURSTIN: Evaluation and scope.

11 DR. JARRIS: Evaluation and scope.

12 Are there those who have an interest in those?

13 DR. BURSTIN: Especially since we  
14 need to look forward to having a call for  
15 measures and a way to evaluate them. So those  
16 seem like the two other very concrete things  
17 we'll need to have people engage in.

18 MS. SAMPSEL: I think just because I  
19 do a lot of work on how to choose measures,  
20 what measures to use, where we get them,  
21 evaluating measures is an area I'd really like  
22 to be involved.

1 DR. JARRIS: Okay. We have Sarah as  
2 chairing that one. Who's the next person who  
3 wants to speak?

4 MS. MERRILL: Are you next in line,  
5 Ron? Okay. So when I was evaluating the  
6 measures, you know, that we had to score, the  
7 question that was the most meaningful to me,  
8 coming from a public health background, was  
9 the feasibility question on the usefulness for  
10 public reporting.

11 That question really puzzled me,  
12 because it didn't seem like the meaning of  
13 public reporting for that question was can a  
14 health plan or anybody else who's using this  
15 measure, put up on their website. That's the  
16 public reporting idea. I thought that that's  
17 what that meant for these measures.

18 But that's not the public reporting  
19 idea that I have in my mind, coming from the  
20 public health system. It's what value would  
21 these things have for the public to know  
22 about. Not how do I evaluate this health

1 plan, but how am I going to -- you know, what  
2 does this mean for me living in society and my  
3 health, you know. This idea that how am I  
4 doing as a person living in society, as I make  
5 my choices.

6 So many of these measures aren't,  
7 they don't really have a lot of meaning for  
8 people living in communities. They have more  
9 meaning for entities that are providing  
10 services.

11 DR. JARRIS: Which is interesting,  
12 because looking around the room, I don't think  
13 we have a consumer representative here.  
14 Obviously, we're all consumers per se, and  
15 it's interesting that most of the NQF clinical  
16 measures are designed for clinical entities  
17 who are steeped in this kind of work.

18 If we're going to do population  
19 health measures, one of the consumers of this  
20 ought to be consumers and the general  
21 population, or parks and recreation,  
22 transportation, mayors, people like that. Yet



1 we don't have those people at the table.

2 MS. MERRILL: It's just I didn't have  
3 any way to like, to compute that question.  
4 That question really puzzled me and bothered  
5 me a lot in this. So anyway, that's another  
6 one of those --

7 DR. JARRIS: So we have our third  
8 chair of the evaluation.

9 DR. BURSTIN: That's Sarah. Sarah's  
10 doing Scope.

11 DR. JARRIS: Oh scope, okay. So  
12 Evaluation, you're on that committee, it  
13 sounds like. Scope in terms of where is the  
14 appropriate entity to be measured or measure  
15 themselves by these. We've scared everyone  
16 away now.

17 (Simultaneous speaking.)

18 MR. BIALEK: I think I belong in the  
19 remedial class, because I'm still struggling  
20 on question number one. Well, I'm thinking  
21 about the measures and their application, and  
22 I'm thinking about the issue of one of the

1 criteria, which is disparity, another  
2 feasibility in terms of data.

3 So if I had a measure around  
4 nutrition, and I were Kaiser Permanente, and  
5 I have my defined community, I'm likely to  
6 have my data and I probably could define  
7 disparities within my own community. I might  
8 be able to, maybe, and I can address that.  
9 The measure would be fine, and I could use it  
10 and I could make something of it.

11 On the other hand, if I were a county  
12 and my data sources are quite limited and I  
13 have the BRFSS, and I cannot really tease out  
14 of that disparities, and I can't really tease  
15 out of that more real time data to deal with  
16 the particular issue, the measure might not be  
17 all that meaningful to me.

18 So I'm wondering how we deal with  
19 this issue, you know, which population or  
20 populations are we focusing on? I came into  
21 this thinking, the population of a community,  
22 defined potentially geographically. Then

1       there's the community that's defined by a  
2       business or defined by a health plan.

3               I think the measures really the  
4       feasibility issue, the disparity issue, the  
5       nine HHS aims, whether it's vigilant or  
6       whether it's proactive, etcetera, really do  
7       vary a great deal by the type of community  
8       we're talking about.

9               Again, so I don't know, I don't know  
10      how to deal with that. But that's just  
11      something that's been going through my head  
12      for the past hour as we've been talking,  
13      because measures mean many different things to  
14      many different communities.

15              DR. JARRIS: So this is the scope  
16      question. You're not chairing? Michael.

17              DR. STOTO: So two things. One is I  
18      want to be on that committee, the framework.  
19      But two, to Jackie's point. I think about  
20      this, these measures as tools for managing the  
21      population health system, not for thinking  
22      about how I behave as a person, to improve my

1 own health.

2 I think that it's important that they  
3 keep that in mind. I mean, I worked on  
4 Healthy People 2000, so that was quite a long  
5 time ago. But one of things that kept on  
6 coming up was this was a way to communicate to  
7 the public about how they should behave with  
8 respect to diet and so on.

9 I don't really think that's true. I  
10 really think it's about how we manage the  
11 system that we then should be focusing on.

12 DR. JARRIS: Great.

13 DR. STANGE: If we were going to have  
14 these three committees, Framework, Evaluation  
15 and Scope, let's just see who would be on  
16 them. Who would be on Framework?

17 (Show of hands.)

18 DR. STANGE: Yes. Just from what  
19 you've heard. So Framework, Evaluation and  
20 Scope. No, but I just wanted to -- I don't  
21 want to make a big deal of this. I didn't  
22 want to do a 30 second straw vote. So who'd

1 be on Framework, based on what you know?

2 (Show of hands.)

3 DR. STANGE: So we've got about six  
4 people. How about Evaluation, Evaluation  
5 Measures?

6 (Show of hands.)

7 DR. STANGE: Really, only three?  
8 Okay, four. Okay. So four or five. Scope?

9 (Show of hands.)

10 DR. STANGE: So not a bad split. So  
11 it could work.

12 MR. STIEFEL: You know, it's probably  
13 okay, because we'll all come up with  
14 interesting things. They are related to each  
15 other, fundamentally related to each other.  
16 But it's all right. It may just be we, you  
17 know, fuel this fire.

18 DR. JARRIS: But also perhaps  
19 subsequent to the meetings, then, the chairs  
20 of those might get together with Kurt and I,  
21 and talk about them.

22 MS. MUNTHALI: That's a great idea.

1 That's a great idea.

2 MR. STIEFEL: Then there could be  
3 another iteration actually to say wait a  
4 minute, we can't compare to what they said.  
5 We're all off or we're 100 percent correct.

6 DR. STANGE: So and not to  
7 procrastinate that, but we do have, I guess,  
8 contractors that will be on the phone at  
9 three. We've been working hard and deserve a  
10 break before that. What if we started a  
11 little bit late tomorrow and had a breakfast,  
12 you know, groups -- breakfasting of these  
13 groups to get a start tomorrow morning?

14 DR. BURSTIN: I don't know that you  
15 have to be precise about the three o'clock.  
16 I think we're probably okay. Elisa, you want  
17 to give us some guidance then?

18 MS. MUNTHALI: You want to start it  
19 a little bit earlier today?

20 DR. BURSTIN: I'm just saying, I  
21 think we should just do it if we can.

22 MS. MUNTHALI: Yes. They'll be here

1 at three. So they'll be waiting, listening  
2 in. So it's fine.

3 DR. BURSTIN: It's fine. That's what  
4 I'm saying, is I think it's fine to take a  
5 little bit longer this afternoon on this  
6 discussion if it's important, before we get to  
7 the measures.

8 DR. STANGE: Do people have energy  
9 for that now, to break out, or would you  
10 rather do it over breakfast?

11 DR. BURSTIN: I think we're also  
12 losing some folks tomorrow. So I'd prefer to  
13 get some of this foundational work done today.

14 DR. STANGE: Okay, go ahead.

15 MR. MASON: So basically what you're  
16 saying is get the groups together right now  
17 and kind of define what their scope is for  
18 their group, right?

19 DR. STANGE: So to speak, yes.

20 MR. MASON: It's their charter,  
21 whatever.

22 DR. STANGE: Right.

1 MR. MASON: Yes. I think that's good  
2 idea.

3 DR. JARRIS: So we can have --

4 DR. STANGE: Why don't we do that?  
5 Your group meets for 25 minutes or so, take a  
6 little break after that. If we come back at  
7 three and do a brief report back, and start a  
8 little bit late, is that doable?

9 MS. MUNTHALI: Yes.

10 DR. JARRIS: Okay. So Matt, you were  
11 doing the Framework; Sarah was the Evaluation  
12 Methods or Evaluation Measures; and Ron was  
13 doing the Scope. Okay. Do each of you want  
14 to find a spot here?

15 MS. MUNTHALI: I was going to say,  
16 you guys are all right there. Why doesn't  
17 somebody come over to this side.

18 DR. JARRIS: We have the areas back  
19 here, and back here, yes.

20 DR. BURSTIN: About 30 minutes is  
21 fine.

22 DR. JARRIS: Right. Let us know



1 where you're going and let us know --

2 DR. STANGE: So Framework's already  
3 clustered over there. How about Evaluation  
4 here and then Scope over here? So Scope to  
5 your right, Evaluation to your left over here,  
6 and Framework over there.

7 (Whereupon, the above-entitled matter  
8 went off the record at 2:23 p.m., and resumed  
9 at 3:08 p.m.)

10 DR. STANGE: So let's go ahead and do  
11 two minute report backs from each group for  
12 three minutes each. Any volunteers? Rhonda,  
13 you ready for the Scope group? Whoa, visuals.  
14 For the folks on the phone, we're reporting  
15 back from some small groups. We have three  
16 small groups to do brief report backs, and  
17 you're missing phenomenal visuals here.

18 MR. BIALEK: For the Scope group, we  
19 looked at three different -- I'm going to  
20 start singing in a moment, and you're really  
21 going to be in trouble. For the Scope group,  
22 we looked at scope in terms of the actors and

1 stakeholders. Secondly, the population that  
2 the measures would apply to, and thirdly, the  
3 scope in terms of the scope of the measures  
4 themselves, what they should address.

5 So for the actors and stakeholders,  
6 oh by the way, members of the group, just  
7 raise your hands so folks know that I was not  
8 responsible for this, but you all were. Okay.  
9 So the actors and stakeholders. You know, we  
10 determined it's healthcare providers,  
11 insurers, payers, businesses, governments,  
12 community-based organizations, et cetera, et  
13 cetera, et cetera.

14 It really applies to organizations,  
15 individuals even, who wish to use and apply  
16 the measures. Which then gets to well, what  
17 is the defining, what's the population we're  
18 looking at, and the group decided we really  
19 should be looking at geographically defined  
20 populations, not populations defined by  
21 individual organizations.

22 There was some discussion around

1 that, and part of the rationale for that was  
2 that whether an individual is part of the  
3 health plan, whether an individual is in a  
4 business, the entire community, the  
5 environment of the community, the policies  
6 that affect the community, et cetera, affect  
7 the health of the individuals within the  
8 business, within the health plan, et cetera.

9 So the group came to consensus pretty  
10 quickly, that the community that the measures  
11 apply to should be geographically defined, not  
12 defined by organizations. Last but not least,  
13 scope of the measures. Clinical measures,  
14 behavioral measures and community measures.

15 Community, broadly defined, is  
16 environmental, socioeconomic,  
17 intervention/community services and policies  
18 fall into that as well, and even community  
19 assets all fall into the community scope here.  
20 Then -- pardon? Oh.

21 Then the group -- and the group ended  
22 up posing a question, which the question was

1 more of a statement than a question. The  
2 question was given scope, given geographic  
3 population distinctions, maybe NQF should  
4 focus on community preventive measures, that  
5 that really should be the focus, because so  
6 much work has been done on the clinical side.  
7 This is the time to make a case for, and make  
8 a real mark and a real statement on community  
9 measures.

10 What does community measures mean?

11 Community measures could be things that affect  
12 the environment, policy, others. Not clinical  
13 services. The Guide to Community Preventive  
14 Services, yes, yes. Yes, the Guide to  
15 Community Preventive Services would have some  
16 of those measures in it. The group member  
17 wish to add, wish to say I missed the boat?

18 (Simultaneous speaking.)

19 DR. STANGE: Sarah, do you want to  
20 talk about how do you evaluate?

21 MR. STIEFEL: Can we ask questions?

22 DR. JARRIS: Why don't we take one

1 question?

2 MR. STIEFEL: I have a three-part  
3 question.

4 (Laughter.)

5 MR. STIEFEL: Okay. I have to pick  
6 one. In the Scope discussion, did you talk  
7 about the denominator, what the population is  
8 and specifically if the population could be  
9 something other than a geographically-defined  
10 population? Whoever was in the group.

11 MR. BIALEK: We didn't discuss that  
12 explicitly. However, if one were to define  
13 the population geographically, then the  
14 denominator would be the, I would think the  
15 population within that geographic area,  
16 whether it's a block, whether it's a state,  
17 whether it's the nation, etcetera. But we did  
18 not discuss that specifically within the  
19 group.

20 MR. MASON: I think they said it  
21 would be cutting it too fine. Matt, over  
22 here. It would be cutting it too fine if you

1 said a subgroup within a geographic group. I  
2 mean you get two down to a level that you  
3 couldn't measure.

4 DR. JARRIS: Although if you were  
5 looking at disparities within a population,  
6 you might have to do it more defined, to  
7 identify --

8 MR. MASON: But you start it in  
9 geographic, and then you could do subgroup  
10 analysis after that.

11 DR. JARRIS: Yes. Okay next, Sarah.

12 MS. SAMPSEL: You really don't have  
13 three parts to your question?

14 DR. JARRIS: Submit them in  
15 triplicate.

16 MS. SAMPSEL: You know, we just  
17 didn't do the written report, but basically  
18 what our group was talking about would be  
19 starting the conversation about the evaluation  
20 criteria, and how they might look different  
21 for population health or community health  
22 measures.

1                   And, you know, what we agreed to do  
2                   is start with the criteria, you know, that  
3                   Helen started discussing this morning, and  
4                   seeing how we may have to adapt those, when  
5                   evaluating population health measures.

6                   Because for some of you who have  
7                   performance measure background, in looking at  
8                   the measures that we reviewed for today and  
9                   tomorrow, some things just don't fit as well.  
10                  So we have to find this point of fit and unfit  
11                  and how to define those types of things.

12                  One way that we're going to do that  
13                  is by looking at the consensus statement on  
14                  quality in the public health system, although  
15                  in our quick review, that obviously has a lot  
16                  of overlap with what we're already looking at,  
17                  as well as crossing the quality chasm. So  
18                  trying to bring those all together, to really  
19                  define what we're going to look at.

20                  We talked a little bit about we're  
21                  going to have to change, I don't want to say  
22                  "change the language," but maybe address the

1 language disparities between the typical  
2 performance measurement, translation of things  
3 to the public health type domain, and on the  
4 way down to consumers, and how do we make this  
5 all transparent, to make it actionable.

6           What we had started to do at the very  
7 end was using, you know, one of the examples  
8 of a public health measure. So from the  
9 National Vital Statistics report, the  
10 percentage of premature death, and thinking  
11 about when you're looking at something that  
12 historically may have been a surveillance  
13 measure, and we want to convert it, or there's  
14 an interest in converting it into being  
15 something that tells us a story that we can  
16 translate, that we can do something about  
17 improvement, how does that translate into  
18 criteria to evaluate?

19           We had just started that discussion.  
20 So we'll have much more to report later.

21           DR. JARRIS: Thank you. Matt. You  
22 can embed your questions in your presentation.



1 Can you use the mic, Matt?

2 MR. STIEFEL: I mentioned that I  
3 collected these models and, you know, a lot of  
4 them you can trace historical roots to Evans  
5 and Stoddart. I came up with this just  
6 because there was something missing in all of  
7 them, and so this is just a framework that,  
8 you know, might be useful.

9 So it moves basically from upstream  
10 to downstream, starting with these upstream  
11 determinants of genetic endowment,  
12 socioeconomic factors, physical environment,  
13 and then the first potential contribution of  
14 health care and prevention and health  
15 promotion upstream.

16 You know, when we were discussing it  
17 in our group, I think it was Larry that first  
18 said you know, it's kind of cheating to have  
19 this box called socioeconomic factors, because  
20 it's like everything else goes in this box,  
21 and the group was talking about maybe having  
22 government programs and policies called out,

1 and maybe affecting the entire continuum.

2 But those are the upstream factors  
3 leading to individual risk factors shown here,  
4 behavioral risk factors which lead to  
5 physiologic risk factors that can be measured  
6 in a health system, like blood pressure and  
7 glucose and BMI and things like that, and also  
8 leading to resilience and also affected by  
9 resilience. All of these factors influenced  
10 by the upstream determinants.

11 These individual risk factors  
12 influence further downstream disease and  
13 injury, and that's mitigated, for better or  
14 worse, by medical care, the second potential  
15 contribution of the health care delivery  
16 system.

17 So far, we're not talking about  
18 population health in this entire framework,  
19 and then downstream from there are the  
20 measures of population health. States of  
21 health described here as death or self-  
22 perceived health and functional status, and

1 even further downstream from there, well-being  
2 or quality of life.

3 I think important to distinguish and  
4 important to distinguish the measures of  
5 health from the intermediate outcomes, two  
6 people with the same disease state or injury  
7 status may have very different levels of  
8 functioning or self-perceived health, and two  
9 people with the same functional status might  
10 have quite different self-perceived quality of  
11 life.

12 There are feedback loops all  
13 throughout this framework that are important  
14 to take into account, that it's not a linear  
15 model, that for example, well-being obviously  
16 has influence on socioeconomic status, and  
17 then over to the right, it's just for sort of  
18 graphical purposes, to show the distinction  
19 here between individual and population health,  
20 is that all of these factors, this bar says  
21 disparities, for all of these factors you can  
22 measure the distribution of health, or

1 distribution of these factors.

2           It's not just the goodness but the  
3 distribution, as we talked about earlier. So  
4 that's a framework, and you know, it's one of  
5 many, I'll admit, but a framework on which you  
6 could hang the measurement activity that we're  
7 talking about. So in the agenda so far, we've  
8 picked two boxes, this prevention and health  
9 promotion box, and the behavioral risk factors  
10 box.

11           But you can see in the broader  
12 framework there are only two of the broader  
13 set of determinants and outcomes in health,  
14 and it might be useful, even if we land on  
15 things like nutrition and physical activity,  
16 to show that sits here, that influences this  
17 sort of causal pathway of influencing  
18 physiology and resilience, downstream  
19 determinants, disease and functional status,  
20 and then the things, probably even more  
21 importantly, the things that affect those  
22 behavioral risk factors.

1           In our discussion, we talked about if  
2           you pick a measure like what we talked about  
3           in terms of nutrition or smoking, you could go  
4           through the discipline of seeing how that, in  
5           each of these domains, how measures in each of  
6           these domains have an influence and relate to  
7           the measure of smoking or physical activity.

8           There's one last thing I'd add, is  
9           that this is still obviously a highly  
10          simplified model, and really still in the  
11          level of a logic model. There was some  
12          discussion earlier about the work of Bobby  
13          Milstein and Gary Gersh and Jack Homer to  
14          develop a real functioning model, a simulation  
15          model of population health, that we're now  
16          experimenting with in a couple of the Triple  
17          Aim communities.

18          So that actually measures what  
19          influences smoking status, and what impact  
20          smoking status ultimately has on downstream  
21          outcomes over a period of 20 years in the  
22          community. So that's a much more

1 sophisticated model. I think it's harder to  
2 use as a framework than this more simplified  
3 logic model.

4 I just wanted to point out that those  
5 more sophisticated models are out there as  
6 well.

7 DR. JARRIS: Larry, did you have a  
8 comment, and then we probably should move on?

9 MR. COHEN: Sure. Thanks, sorry. I  
10 just thought this was very, very constructive.  
11 One of the questions that came up about it,  
12 and also about the Los Angeles report, was  
13 about the purpose of the documents, because  
14 there's a different, and I think this works  
15 very well for our purposes.

16 One of the questions we had is the,  
17 you know, the credibility factor, and you  
18 know, so it probably depends. Is this to  
19 inform our thinking, in which case I think it  
20 works very, very well. Is it to disseminate  
21 more broadly to explain our thinking, and our  
22 bias was that we need to explain our thinking,

1 and also that all the work that LA is doing,  
2 that a lot of that is valuable thinking and  
3 resource for the field.

4 I think someone commented earlier  
5 it's just internal. But I would certainly  
6 think that a lot of it should be disseminated,  
7 you know, or at least, you know, as part of a  
8 statement that's broader than that. I think  
9 that's important to understand from the onset.

10 In terms of the dissemination, I  
11 think one of the problems with this framework  
12 is that on the left hand side, there's a small  
13 line, and that line is supposed to represent  
14 inequities and all the work that's done on  
15 inequities.

16 There are a number of groups,  
17 Prevention Institute being one of them, Policy  
18 Link another, and a couple of others, who  
19 really looked at the underlying community  
20 issues to focus on inequities. I would think  
21 we would want kind of a, some kind of diagram  
22 that talked about the inequity strategy, maybe

1 as an accompanying piece, if it's going to go  
2 beyond this room, because I think it's very,  
3 very important that we say dealing with  
4 inequities is incredibly important at the same  
5 time that we're dealing with overarching  
6 quality.

7 I really think the arrow, you know,  
8 is intended to do that. But from a visual  
9 perspective, I could see it as very  
10 diminishing to people who are not just  
11 thinking conceptually. There is work, and as  
12 I said, interesting. At one point Policy Link  
13 and Prevention Institute were funded  
14 separately and didn't know about it, to  
15 delineate the community factors related to  
16 equity, and came up with almost the exact same  
17 list of factors.

18 So it was almost like the scientific  
19 experiment. We did completely separate  
20 research, but came up with the same answers.  
21 I think it would be easy to turn those into a  
22 chart, or something to kind of lay out kind of



1 the community, the community efforts that  
2 require measures, to have impact.

3 DR. JARRIS: Thank you. Thanks  
4 everyone, for your flexibility in putting that  
5 together. I think that will inform our work  
6 as we go forward. Shall we move on at this  
7 point to next steps?

8 Yes. Let's keep in mind. We're  
9 going to go through this next section here as  
10 a way of -- well, first of all, immunizations  
11 are a nice bridge between individual and  
12 population care, but also as a way for us to  
13 learn the NQF methodology so we may apply it  
14 more broadly. Keith.

15 MR. MASON: Maybe we don't answer it  
16 right now, but what's the now what of forming  
17 those three groups and then putting this out  
18 in the larger group? What do we do now?

19 DR. JARRIS: Well, let me ask the  
20 folks on the group. Would it make sense for  
21 you to get together for an hour on a call, and  
22 finalize this a little bit more, so that you

1 can then present it back to the larger group?  
2 So that we can have that scheduled between the  
3 chairs and the committees. Did anybody  
4 capture who was on what group, or maybe we  
5 could just send a sign-on list around.

6 MR. COHEN: I still think there's a  
7 bit of a question, based on what Keith was  
8 saying, of and then when we do that. It's  
9 kind of how do we get traction from it? Where  
10 does it fit with other work?

11 DR. BURSTIN: Right. I think some of  
12 that will be our next steps, about developing  
13 the call for measures. I think we'll also  
14 want to feed all this information back to the  
15 folks in LA, to make sure that all -- we don't  
16 want them going off in a very different  
17 direction. So we'll be sure to share all this  
18 with them.

19 One question might be whether one of  
20 these groups or multiples want to actually  
21 have a conversation with them as well. I  
22 think the Framework Group, in particular,

1 might be very useful.

2 Measure Consideration

3 DR. WINKLER: Okay. All right.

4 We're going to move you into sort of NQF's  
5 traditional work, and by looking at measures  
6 of influenza immunization. Now because we  
7 know the slides were difficult to read  
8 earlier, we've also given you a printed  
9 version. So Sheila should have handed this  
10 out to you.

11 So for those of you, we really do  
12 want you to be able to read this. So you'll  
13 have, you have both the screen, which I think  
14 is a little closer and a little easier to  
15 read, but also you have a written version and  
16 you can make notes.

17 Also what should have appeared at  
18 your seat is one of these little gizmos, okay.  
19 These are actually going to be little voting  
20 tools, and we'll show you how to use them when  
21 we get to that point. But it's a way of  
22 capturing a group vote on things.

1           So as we go through this, there will  
2           be opportunities to vote on things. So take  
3           note, that that's what this is for. Please  
4           don't take it with you, just leave it at your  
5           seat when we're done today.

6           All right. So what we'd like to do  
7           is talk about the first six measures of the 19  
8           that are part of this project, and they all  
9           speak to influenza immunization. If you  
10          notice, there are even two more on there,  
11          which at the bottom are two additional  
12          measures that are in the NQF portfolio, that  
13          were recently evaluated, that are influenza  
14          immunization measures as applied to the  
15          nursing home population, both short stay and  
16          long stay.

17          I think the first thing that becomes  
18          very obvious is we're measuring one thing with  
19          eight different measures. Last week, we  
20          created the work groups to look at these  
21          measures more in depth, in preparation for  
22          this meeting. The work group members for this

1 group were Jason and Mike, Amir, Jacqueline  
2 and Linda.

3 We talked a lot about, you know,  
4 what's the deal with so many measures. So  
5 we're going to be looking at these, but I  
6 think in the back of your mind, those are the  
7 kind of questions we want to ask. So you'll  
8 see that there are measures for influenza  
9 vaccination for health care personnel, for  
10 immunization and hospital patients, for home  
11 health patients, for outpatients, for the ESRD  
12 population, and then in populations over age  
13 50.

14 So there are different approaches,  
15 and it wasn't always quite, you know, this  
16 crazy. This actually is better than it was.  
17 But I'd like to pull out a table for one of  
18 NQF's more recent task force reports on  
19 harmonization, about related and competing  
20 measures.

21 I think we just looked at a group of  
22 measures that are certainly related, and if

1 you look at the first column in the second  
2 row, which is about measures with the same  
3 focus but with different target populations,  
4 these are related measures. Sort of the  
5 directive or general sense or goal of NQF  
6 would be to combine into one measure with an  
7 expanded target population, or justify why  
8 different harmonized measures are needed.

9           There is definitely a conversation  
10 and a need for trying to reduce this  
11 multiplicity of measures. NQF has worked in  
12 this space before. Three years ago, we had a  
13 project funded by CMS to look at immunization  
14 measures for influenza and pneumococcal  
15 disease.

16           At the beginning of that project,  
17 there were 16 measures for influenza  
18 immunization, and that was just kind of  
19 craziness. Some of the measures were  
20 assessment measures; some were how many  
21 patients were offered, and some were about how  
22 many actually were vaccinated.

1                   But the fact that there were all  
2 these variety of measures was just kind of  
3 crazy. Certainly the need for harmonization,  
4 by which we mean that the way it's measured,  
5 the specifications are all aligned, regardless  
6 of how you might use it in different settings  
7 or different populations, but that the  
8 measures could work together because they are  
9 aligned.

10                   Well, with 16 measures on the table,  
11 the committee was really forced to ask the  
12 question align to what? So they looked at  
13 essentially the current guidelines and the  
14 evidence, and created sort of a basic what  
15 should a good measure look like, and those are  
16 what's known as standard specifications. They  
17 created standard specifications for influenza  
18 immunization, health care personnel influenza  
19 immunization, as well as pneumococcal  
20 immunization.

21                   Essentially, the characteristics of  
22 those standard specifications were based on

1 current ACIP guidelines and the evidence.  
2 They were focused on being comprehensive  
3 measures, to include all recommended  
4 populations to the extent that they're  
5 measurable. So in other words, big  
6 denominators.

7 Then they chose to specify numerator  
8 categories, and we're going to talk a little  
9 bit about why in just a minute. But within  
10 the numerator, rather than aggregating all of  
11 these types of patients, they recommend that  
12 these are separated and computed and reported  
13 separately.

14 Those that actually receive the  
15 vaccine, those that decline the vaccine and  
16 those with contraindications, and then the  
17 standardized time window of October through  
18 March. It was amazing the number of flu  
19 vaccination measures that had totally  
20 different time frames, you know, September,  
21 July, February. Everybody was in there, and  
22 that was kind of very, very difficult to sort



1 out.

2 The numerator categories resulted  
3 from really a thinking about comparing  
4 different approaches to typical measurement.  
5 Examples within those 16 measures had all of  
6 these. This is a comparison of two sample  
7 providers with 100 patients. The first row  
8 talks about what happens if you include in  
9 your numerator all patients that were  
10 vaccinated, those that declined a vaccination,  
11 or had a contraindication to the vaccination,  
12 all combined together without separating them.

13 In other words, did the provider do  
14 the right thing? So one of those three things  
15 is a yes, they did the right thing. As you  
16 can see, these two hypothetical providers had  
17 identical scores. But let's see what happens  
18 to those identical scores when we look at  
19 things slightly differently.

20 When you look at the second row, it's  
21 the first row measure broken out into  
22 numerator categories, where you specifically

1 break out those that actually received the  
2 vaccine, those that declined, and those that  
3 had contraindications, and report these  
4 individually.

5 As you can see, suddenly your two  
6 providers that look the same with the first  
7 row, don't really look the same in the second  
8 row. Clearly, one of the most important goals  
9 and targets of measurement is to increase the  
10 number of patients who get the vaccine.

11 You can see that despite equal  
12 performance in one measure, many more patients  
13 got the vaccine with Provider 2 than Provider  
14 1, even though if you were measuring the  
15 aggregated performance, they looked the same.  
16 This was an important characteristic that this  
17 previous committee felt was an important  
18 aspect and attribute of the measure, to  
19 provide this detailed information. Michael,  
20 did you have a question?

21 DR. STOTO: A comment actually. I  
22 like this example. I'm going to use it in my

1 teaching on Thursday.

2 DR. WINKLER: Okay.

3 DR. STOTO: But the other assumption  
4 here is that decline is a good outcome, and  
5 that may not be so.

6 DR. WINKLER: Right. Well, I think  
7 that was a large part of the discussion.  
8 Clearly this idea of specifying with numerator  
9 categories was really the focus of much of  
10 their discussion, because it was felt that the  
11 declined is something that's potentially  
12 actionable.

13 But if you bury it in the aggregated  
14 score, like in Row 1, you really won't know  
15 that or won't be able to identify the  
16 actionability.

17 DR. STOTO: Right, and you know, as  
18 we get more into population, which obviously  
19 we're doing here, that becomes more important  
20 than you know, things like if they hadn't been  
21 to the doctor, you may want to exclude them.  
22 But we may want to think about them very

1 different in a population setting.

2 DR. PICKENS: Can I intervene with  
3 that declined and give a personal example,  
4 because I work at a health care institution,  
5 and walked down the hall to our health group  
6 in the hospital, and they gave me my flu shot  
7 in our auditorium. Then I had a cold and went  
8 to the doctor, and he said do you want your  
9 flu shot, and I said I already had it. So I'm  
10 in the declined category.

11 DR. WINKLER: No, no. No, you're  
12 not.

13 DR. PICKENS: Yes, I am.

14 DR. WINKLER: No, not in the way the  
15 measures are constructed. Well, that's why  
16 we're going to go into more detail. So but if  
17 you look at Row 3, which is a very common way  
18 for constructing measures, is to take your  
19 exclusions for things like decline and  
20 contraindications, and remove them from the  
21 denominator, and you can see what happens to  
22 the measure calculation.

1           Not only does your denominator shrink  
2           and you don't have a way of really monitoring  
3           how many people actually were assessed,  
4           offered or attended to for flu vaccine, it  
5           really does affect the measure results. So  
6           you can see that having different approaches  
7           to measure construct gives you very different  
8           results.

9           So standardizing the approach was an  
10          important milestone, if you will, towards  
11          aligning all of these different measures, if  
12          they're going to be coming from different  
13          settings or different data sources, to at  
14          least the construct is the same, so that  
15          ultimately, maybe if we move to common data  
16          sources, it should be a nice transition,  
17          because the constructs are the same.

18          So it was because of this that the  
19          steering committee landed on standardized  
20          specifications for influenza immunization, and  
21          essentially the numerator is the patients who  
22          fit into those three categories and report

1       them separately, during October through March.  
2       They had to pick the time frame, because  
3       again, they were not at all standard in the  
4       measures brought to us.

5               The denominator were the number of  
6       patients in, you know, whatever you're  
7       measuring, whether it's a facility, an agency,  
8       a practice or a defined population such as a  
9       health plan, during that time frame, and at  
10      the time, this was prior to the 2010 change in  
11      the recommendations for flu vaccine. But I've  
12      updated it so it's greater than age six  
13      months.

14              So this is what the steering  
15      committee three years ago felt was a good  
16      representation of the type of measure, and  
17      they evaluated the existing measures against  
18      that.

19              Very few measures actually met this  
20      standardization, and some of the measure  
21      developers at the time adjusted their  
22      measures, and some of them did not but were

1 told at their next maintenance review, which  
2 is now, that they would need to do so, to  
3 maintain their endorsement.

4 So there is a standard spec for  
5 influenza immunization, and is there one for  
6 health care personnel.

7 DR. JARRIS: Have you looked at the  
8 October one, because I think it probably ought  
9 to August one at this point.

10 DR. WINKLER: That's something, I  
11 think, that can be discussed. At the time  
12 that it was created, a lot of the discussion  
13 was around availability of the vaccine.

14 DR. JARRIS: It's now available, at  
15 least in the community, in actually July in  
16 some cases, but certainly by August.

17 DR. WINKLER: Yes. Karen was  
18 actually the staff who struggled through this,  
19 and she can probably speak to that part better  
20 than I can.

21 DR. PACE: I just want to mention  
22 that the way that they looked at it is that

1 they would select the denominator population  
2 from October through March, but there would be  
3 a look-back. So that if the person actually  
4 received it in August, they would be  
5 considered as having received the vaccine.

6 So I mean that certainly could have  
7 some adjustments, but I just wanted to assure  
8 you that they did count people who had  
9 received the vaccine earlier and, you know,  
10 they recognized that, you know, it's becoming  
11 available earlier and earlier.

12 DR. WINKLER: Does that answer your  
13 question?

14 DR. JARRIS: Yes, the unintended  
15 consequences, it may not drive providers to  
16 start offering the vaccine or offering a  
17 referral to a place who has a vaccine as early  
18 as August.

19 DR. WINKLER: Okay, noted. Michael.

20 DR. STOTO: I've got a question about  
21 the other end. I mean this can't -- two  
22 things. One is this can't be calculated until



1 April, right? Is that an issue, of the next  
2 year, because --

3 DR. WINKLER: Right. I think that  
4 you're right, you do wait until the time frame  
5 is over. But at the same time, the fact that  
6 not calculating it, you know, after a time  
7 frame has gone on is very typical of measures  
8 in general. It's usually encounters during  
9 the year or something.

10 So there usually is some kind of lag  
11 period that's just very, very typical of  
12 measures. It's rare that you have a measure  
13 that can be done in real time.

14 DR. STOTO: Yes. Well I mean, some  
15 measures you can measure, it can be done on  
16 January 2nd. But this one, this one can't be  
17 done by April 1st. That may not be a big  
18 issue. But the other thing is that this gives  
19 as much credit to someone who gets his shot on  
20 February 28th, as someone who gets it on  
21 October 1st, which obviously there's not as  
22 much protection from the flu. I guess there's

1 nothing you can do about that.

2 DR. JARRIS: Was there any discussion  
3 around populations who are traditionally  
4 under-served with regard to influenza vaccine,  
5 whether those are African-American, Native  
6 American, lower socioeconomic status?

7 DR. PACE: There was discussion  
8 around that, but in terms of changing the  
9 measure, you mean, or stratifying --

10 DR. JARRIS: A way to capture that  
11 health equity issue.

12 DR. PACE: It's not reflected here,  
13 and that's a good question. It's something we  
14 struggled with with all measures, of how best  
15 to display that. Certainly, the way we've  
16 looked at it to date is to try to report  
17 measures, based on those particular population  
18 characteristics. But, you know, frankly  
19 that's not happening consistently. A lot of  
20 times, those kinds of data are not available  
21 in the same place as the clinical data. So  
22 you know, certainly we're always looking for

1 suggestions and recommendations regarding  
2 that.

3 Measure 431

4 DR. WINKLER: So with that  
5 background, our task today is to look at these  
6 six measures, and this work group has looked  
7 at these, and we actually have some  
8 preliminary ratings from them that we'll share  
9 with you as we go through this.

10 So on our agenda, the first measure  
11 we're going to look at is Measure 431. It's  
12 the Influenza Vaccination Coverage Among  
13 Health Care Personnel. And as I said, there  
14 is the standard specifications for that, that  
15 is projected right now. But this measure  
16 looks at the percentage of the health care  
17 personnel who received the influenza  
18 vaccination.

19 I just want to take the opportunity  
20 to briefly talk about the evaluation criteria  
21 very, very quickly.

22 DR. STANGE: So just, as we're doing

1 this, as Reva said, this is the kind of the  
2 normal work of NQA, and I'm new to this  
3 process. A number of you have been through  
4 this before. I think when we were setting  
5 this up, we talked about thinking about this  
6 as a way that we can learn about the process  
7 to which the population measures that we've  
8 been talking about, the other population  
9 measures that might be new, might be  
10 subjected.

11 Bobby asked us to, as we're going  
12 through these, to think about how does this  
13 translate to the community. So we can even  
14 think about the extensions, which is part of  
15 our charge. How might these be extended from  
16 individual measures to population measures?  
17 Reva's going to go through some things now  
18 that will help us to not spend a lot of time  
19 having a nice discussion about things that  
20 isn't really going to change anything too.

21 She's going to give us the criteria  
22 that all of these measures are evaluated on.

1       So we can really learn the larger process from  
2       that. Then we'll go through and try to apply  
3       this to each one. I think you're going to  
4       share the votes that were done before, and  
5       what we might be able to do is focus our  
6       discussion on things that might need to  
7       change.

8               I mean if the vaccine is available  
9       earlier, well that's something that ought to  
10      be considered, does this need to change. But  
11      these are all pretty well -- today and  
12      tomorrow, pretty well established measures,  
13      and a lot of detailed work has been done.

14             So I think we can maybe focus our  
15      efforts and maybe even save some time, one, so  
16      we don't have to do all the phone calls to get  
17      through the rest of them. But two, maybe if  
18      it will save some time, to continue our other  
19      discussions, but then informed by having  
20      really gone through some of the existing  
21      measures. Is that all fair?

22             DR. WINKLER: It's all fair. So

1       okay.  So as I was saying, our Measure 431,  
2       the Influenza Vaccination Coverage Among  
3       Health Care Personnel, is a measure that's  
4       brought to us from the CDC, and we do have a  
5       representative from CDC on the line.  I've  
6       just asked if they would like to just make any  
7       comments about the measure before we get  
8       started.

9               MS. LINDLEY:  Sure.  This is Megan  
10       Lindley from --

11              DR. WINKLER:  We can hardly hear you,  
12       so you're going to have to really speak up.

13              MS. LINDLEY:  Okay, I will speak up.  
14       Is this any better?

15              DR. JARRIS:  Yes, that's better.

16              MS. LINDLEY:  Okay, great.  So I will  
17       just give some very brief comments about, as  
18       I think was referenced, this is a measure that  
19       had received previously a time-limited  
20       endorsement from NQF.  So what I was going to  
21       do is speak extremely briefly about the pilot  
22       project that we did to test the measure, and

1 just give you an overview of the findings that  
2 caused us to make some changes in the measure,  
3 so that it's what is under consideration  
4 today.

5 So we conducted this pilot during the  
6 past influenza season. We recruited over 300  
7 health care institutions to participate, and  
8 we had 234 of them that completed all of the  
9 surveys that we requested of them. There were  
10 78 acute care hospitals, 59 long-term care  
11 facilities, 16 ambulatory surgery centers, 43  
12 dialysis clinics and 38 physician practices.  
13 So we had a variety of inpatient and  
14 outpatient facilities.

15 I'll go over this briefly, because I  
16 know it's in the application that you all  
17 received. In general, we found that our  
18 inter-rater reliability in looking at the  
19 vaccination status using the measure was  
20 acceptable, and the face validity of the  
21 measure was acceptable.

22 The specifications for the measure

1 are the denominator includes health care  
2 personnel working, as was referenced, between  
3 October 1st and March 31st of the following  
4 year, regardless of their clinical  
5 responsibilities or patient contact, and the  
6 denominator is calculated in three mutually  
7 exclusive groups, the first being employees,  
8 the second being licensed independent  
9 practitioners who are physicians, advanced  
10 practice nurses and physician assistants who  
11 are affiliated with the facility, but are not  
12 employed directly by the facility. Then the  
13 final separate group is students, trainees and  
14 volunteers.

15 The numerator specifications, I think  
16 I don't need to go over, because they were  
17 just discussed. It's those that meet the NQF  
18 consensus standards for measurement. So  
19 vaccination, whether it's received at the  
20 facility or outside the facility, declination  
21 of vaccination for non-medical reasons, or a  
22 medical contraindication.



1           One change that we did make there was  
2           to add a category for unknown vaccination  
3           status. So the findings of our pilots were  
4           that facilities sometimes had difficulty  
5           tracking this in certain non-employee groups,  
6           and we felt that adding an unknown category  
7           would give them actionable data, you know. It  
8           would indicate a need for improvement in their  
9           tracking, and it would be more valid than  
10          calculating the unknown, based on a simple  
11          difference between the reported numerator and  
12          the reported denominator.

13                 The major differences in the  
14          denominator statement between the measure that  
15          NQF had given a time-limited endorsement to  
16          and this measure that's under consideration  
17          now, is that the non-employee groups are more  
18          curtailed. Although we generally had good  
19          agreement in the measure, we did have  
20          facilities, both inpatient and outpatient,  
21          report difficulty in tracking the credentialed  
22          non-employees and their other non-employees,

1 which initially included every single health  
2 care personnel, health care worker in the  
3 hospital who was not an employee.

4 So based on that, we felt that it  
5 would produce a more valid measure to restrict  
6 those groups to, as I mentioned, the licensed  
7 independent practitioners and the students and  
8 volunteers, because those seemed to be easier  
9 for the facilities to track.

10 I think the only other major change  
11 that was made from the measure that had gotten  
12 time-limited endorsements was the time frame.  
13 Initially, it was the health care personnel  
14 who were in the hospital, excuse me, in the  
15 facility for at least one day during the  
16 influenza season, and now it's working for at  
17 least 30 days in the influenza season.

18 That primarily is a concession to  
19 feasibility. We heard from our pilot  
20 facilities that it really wasn't possible for  
21 them to track again, many of the non-employees  
22 who were in for only one day. So the concern

1 was that the data produced by the measure  
2 would not be valid if it were restricted to  
3 one day. I believe that is everything in the  
4 way of background.

5 DR. JARRIS: Could I ask a question?  
6 So in other words, it's employees and  
7 contracted, or health professionals and others  
8 who are in for 30 days or more during  
9 influenza. If a hospital outsources their  
10 food service or custodian services, does that  
11 mean that the food service workers and the  
12 custodians don't have to -- custodial services  
13 do not have to have influenza vaccine?

14 MS. LINDLEY: Well, it doesn't mean  
15 that. It does mean that they would not be  
16 included in this measure, and we did have a  
17 lot of debate about that. The feeling was  
18 based both on sort of the people that were on  
19 our project steering committee, and on the  
20 data that we got from our pilot, that it would  
21 be better to have a measure that was less  
22 inclusive but more valid, than to have a

1 measure that was more inclusive, but included  
2 data on employees that are difficult to track,  
3 and therefore might not be producing data that  
4 is a true representation of how that facility  
5 is doing in their vaccination program. But  
6 yes, your interpretation is correct.

7 DR. STOTO: So I'm curious about that  
8 Category D in the numerator. I understand the  
9 issue there, but it strikes me, if I read it  
10 correctly, that you're counting those unknown  
11 status as if they had been vaccinated.

12 MS. LINDLEY: I'm sorry. Thank you  
13 very much for asking that. I should have  
14 stated specifically each of those categories  
15 is calculated separately. So this would allow  
16 an institution to use Category A and produce  
17 a vaccination rate. Then they could use  
18 Categories B, C and D to produce declination  
19 rates, contraindication rates and rates of  
20 unknown assessment, and that's why it's  
21 actionable data. But thank you. Those would  
22 not be calculated as vaccinated people.

1 DR. WINKLER: All right, thank you.  
2 I believe of our work group members, Linda, I  
3 think you were the person assigned for this  
4 one. I just want to briefly review the  
5 evaluation of measures. The first criteria,  
6 I think, if everybody recalls, is the  
7 important to measure and report criteria. It  
8 has three parts, the high impact.

9 I can honestly say that in years of  
10 doing measure evaluation, I've seen very few  
11 where high impact doesn't pass with much  
12 thought. So I would ask that we won't  
13 separately vote on that. But if you feel that  
14 we're talking about something that doesn't  
15 have a high impact, please call it out.

16 So that the next one is the gap in  
17 performance and the third one is evidence.  
18 Gap in performance can be defined in several  
19 different ways, variability of overall  
20 performance. But here's where disparities is  
21 really critical, and we really do ask for it,  
22 to look on data on disparities, if it's all

1 available, because there are times when that's  
2 where the opportunity is, less so maybe in the  
3 overall performance.

4           You do want to consider the data  
5 that's presented, in terms of distribution and  
6 representativeness. The third thing is  
7 looking at evidence. Key points is we're  
8 looking at the entire body of evidence, and it  
9 would be nice if that measurement or if that  
10 evidence had been graded by one of the  
11 traditional grading systems, like with the  
12 U.S. Preventative Services Task Force or  
13 grade.

14           Expert opinion is not evidence, all  
15 right. It's opinion. So there's still room  
16 for expertise and judgment, that we do want to  
17 try and be as quantitative about the evidence  
18 as possible. We are looking for an assessment  
19 of the quantity, quality and consistency of  
20 that body of evidence, rather than just  
21 calling out one article or one study to base  
22 a measure on.

1           So the work group did preliminary  
2           evaluations, and these are how they rated it,  
3           and Linda, do you want to take the discussion  
4           from here?

5           DR. KINSINGER: Sure. So as you see,  
6           it looks like three of us rated it, and we all  
7           said it was high impact. We all agreed that  
8           there was a performance gap, in terms of  
9           numbers of the percents of health care  
10          employees who, health care personnel who have  
11          been, received influenza vaccination.

12          In terms of the disparities, there  
13          was actually no information about disparities.  
14          So that was a missing piece of information.  
15          I don't know whether it's been looked at or  
16          not, but it's not reported in terms of  
17          disparities among health care personnel, and  
18          you see the rationale there, 63 percent  
19          coverage in the past year. Should I go on?

20          DR. WINKLER: Sure.

21          DR. KINSINGER: In terms of evidence,  
22          quantity, which was five or more studies was

1 all rated as high, although there were four  
2 cluster randomized studies, I'm not sure how  
3 that got high, because I thought high had to  
4 be five or more studies, yeah. I don't know  
5 what I did there.

6 Quality, looks like one rating of  
7 high and two of moderate. In fact, the  
8 information submitted by CDC itself rated the  
9 evidence as moderate, because of some  
10 limitations and the fact that the studies that  
11 are cited are done in long-term care  
12 facilities, as opposed to acute care settings,  
13 and so there's some gaps in the evidence in  
14 terms of effectiveness of immunization of  
15 health care providers in acute care settings.

16 But the studies that have been done  
17 are all internally consistent, and so that  
18 consistency was rated as high.

19 DR. WINKLER: Any comments on the  
20 ratings that the work group presented?

21 MR. BIALEK: Just a question. So  
22 where do -- where does the issue of the data,



1 quality of the data, come into play?

2 DR. WINKLER: That comes under  
3 Scientific Acceptability.

4 MR. BIALEK: Okay, and the data are  
5 self-report or facility verified?

6 DR. KINSINGER: I think, I'm not  
7 totally sure. I would guess these are  
8 verified, but I don't know that for sure.  
9 I'll try to look it up.

10 DR. WINKLER: Our folks from CDC, can  
11 you answer this question about your data  
12 source?

13 MS. LINDLEY: The data source for  
14 these four randomized control trials?

15 DR. WINKLER: No, for your measure  
16 that you tested.

17 MS. LINDLEY: For the measure, there  
18 were different data sources. I will look up  
19 which table it is for you, but it was  
20 dependent on what the facility could provide.  
21 So it could be self-report, it could be  
22 electronic health or medical records. It

1       could be an occupational registry or database  
2       that the facility compiles.  So it's different  
3       sources.

4               DR. WINKLER:  Okay.

5               MS. LINDLEY:  Does that answer the  
6       question?

7               DR. JARRIS:  How do you take into,  
8       and this is a process overall question.  How  
9       do you take into account that there is no data  
10      on disparities provided?  Does that affect the  
11      ranking in any way, or is it just something to  
12      gloss over and say okay?

13              DR. WINKLER:  I think that will  
14      depend on how you want to approach it.  
15      Certainly, lack of information around  
16      disparities could certainly cause your ratings  
17      to be lower.  We've had steering committees in  
18      the past who basically required information  
19      around disparities before they would move a  
20      measure forward.  So it depends on how  
21      strongly the committee feels on that criteria.

22              DR. JARRIS:  The disparity wouldn't

1 necessarily have to be a disparity among the  
2 health care workers. It could be a disparity  
3 among the population served by those health  
4 care workers. It may be that, you know,  
5 lower, facilities serving lower socioeconomic  
6 individuals have lower rates than those  
7 serving the very wealthy. From CDC, can you  
8 respond to that? What would it take to  
9 provide some kind of information on  
10 disparities among influenza -- disparities  
11 among people served by health care facilities,  
12 with regard to immunization rates?

13 MS. LINDLEY: Among the patient  
14 populations, not the health care personnel?

15 DR. JARRIS: Yes, because I think  
16 we're interested in people being protected  
17 when they go into a health care facility.

18 MS. LINDLEY: Right. I know that my  
19 colleague, Dr. Ahmed is on the phone, and he  
20 may want to jump in on that as well. I'm not  
21 aware, based on my knowledge of the  
22 literature, that studies of that manner have

1       been done. I know there have been studies  
2       talking about the quality of care provided to  
3       patients and practices that serve mostly lower  
4       socioeconomic versus higher socioeconomic  
5       patients, in terms of the physician's  
6       education and training.

7               I don't know that studies of that  
8       manner have been done among health care  
9       facilities, particularly hospitals. Is it  
10      necessary that the disparity that's in  
11      question, is that specifically looking at  
12      socioeconomic disparity?

13             DR. JARRIS: It could be racial,  
14      could be ethnic, could be geographic.

15             MS. LINDLEY: I guess the question,  
16      because the interpretation that we had been  
17      thinking of, going through this process, is  
18      that the real disparity that you see, although  
19      this is among the health care personnel and  
20      not their patients, is based on their  
21      occupational categories.

22             We even found in our study data that

1 employees had a higher or significantly higher  
2 vaccination rate versus some of those other  
3 non-employee categories, and also as you know,  
4 physicians will have a higher vaccination  
5 rates than allied health professionals.

6 DR. JARRIS: If you look at unnatural  
7 causes, that film outlines that extremely well  
8 at the university hospital. So that is  
9 another disparity, if that's an easier one to  
10 get at, because it would probably reflect the  
11 disparity in the population being served.

12 MS. LINDLEY: Right. It would  
13 certainly reflect disparities and the amount  
14 of protection given to patients, based on the  
15 type of health care personnel they were  
16 interacting with. But I don't know if that is  
17 exactly what the committee is looking for.

18 DR. STANGE: For approving these  
19 measures, what's more helpful? I mean if the  
20 measure's otherwise sound, is it more helpful  
21 to not approve because we don't have data, or  
22 is it more helpful to approve it, with some

1 suggestions like Paul just made. I mean he  
2 really outlined some very interesting  
3 categories that could be reported on, which is  
4 more helpful to the process.

5 DR. JARRIS: It seems to me this is  
6 far too important a measure not to pass. But  
7 the question is it's got to come around in two  
8 or three years. We may not be here, but can  
9 there be a strong recommendation that when it  
10 comes back around, that there is clearly good  
11 evidence presented about how this is measured  
12 and the impact in disparate, whether it's job  
13 categories in the hospital, which tracks  
14 really well.

15 Those people live in the same  
16 communities. You can draw the line out as  
17 other populations subject to disparities, or  
18 whether it's in the population served. But is  
19 it?

20 DR. WINKLER: Yes, absolutely. You  
21 can certainly make all the recommendations,  
22 and I think that as NQF really pushes this

1 whole issue around disparities, providing very  
2 focused recommendations to a developer on what  
3 those disparities really should -- which ones  
4 should be addressed, I think, is an important  
5 role for this committee to play.

6 DR. KINSINGER: So it seems that it  
7 doesn't affect -- the fact that those data  
8 aren't available doesn't affect the quality of  
9 this measure itself, but it's a recommendation  
10 for use of the measure that we would make. I  
11 mean the measure is still reliable and valid  
12 without, even if we don't know those answers.  
13 Is that not right?

14 DR. JARRIS: Well, if you're looking  
15 at it from the point of view of protecting our  
16 patients in hospitals or a long-term care  
17 facility is probably a much more vulnerable  
18 population, because the vaccine may not even  
19 work on them. But the question is who do you  
20 spend more time with?

21 I mean, you know, if in fact your  
22 doctors and your nurses are vaccinated, but

1 you see a food service worker three times a  
2 day, and your custodian spends 15 minutes or  
3 they're not called -- they're environmental  
4 service, whatever they're called now, spend 15  
5 minutes in your room, you have actually far  
6 more contact with them than you do that  
7 doctor, who you're lucky to see 15 minutes a  
8 day.

9 So it may not be a valid measure of  
10 how well patients are being protected, if  
11 we're not looking at those people who actually  
12 spend more time with you, who are handing you  
13 your food.

14 Then the other thing that really  
15 bothers me is if you're allowed to outsource  
16 that to food service providers or  
17 environmental companies, and therefore wipe it  
18 out of the equation, then you really have  
19 unprotected patients.

20 DR. WINKLER: Okay. I see what  
21 you're saying.

22 DR. BURSTIN: It's also very useful



1 to propose it.

2 MS. LINDLEY: May I just clarify one  
3 thing, the issue about the contracting and  
4 outsourcing is unfortunately absolutely  
5 correct, and it varies a lot by facility, of  
6 course, if those food service or environmental  
7 professionals are directly paid by the  
8 facility. If they're employees, they would be  
9 counted in the employee category.

10 MR. COHEN: Well, I just had a  
11 question about the comment Paul was making,  
12 because I strongly agree, that there needs to  
13 be a stronger equity component in there. I  
14 was just wondering, though, if the responses,  
15 if the studies haven't been done, whether  
16 there's something that has to be addressed now  
17 around some kind of study or some kind of  
18 modeling?

19 Let's just say three years from now,  
20 that's going to have to be dealt with. But  
21 we're recommending to a group it's going to  
22 have to be dealt with, and I imagine they'll

1 get the exact same answer three years from now  
2 as now.

3           So I'm not quite sure what the  
4 implementation, or whether there's a set of  
5 recommendations. But somehow we need some  
6 work to be done, so that we have the resource.  
7 Because the inequities, I mean my experience  
8 is continually, the answer with inequities and  
9 with communities strategies is we don't have  
10 that kind of information.

11           We haven't done that kind of study,  
12 and that's exactly the problem, and that's why  
13 we end up with using the wrong or weaker  
14 information, from a community and equity  
15 perspective, is because the studies are never  
16 done. I would hope we could do something  
17 about that, but I don't know what it is.

18           DR. STOTO: So I'm all in favor of  
19 gathering data on disparities and inequities,  
20 and I'm sure that if we did the kind of thing  
21 that Paul suggested, we'd find them. But on  
22 the other hand, if you look at the measures

1 here about performance gaps, I mean the  
2 licensed providers are less than 50 percent  
3 are vaccinated.

4 It strikes me that that by itself  
5 makes it important enough, that even if there  
6 were no disparities, we'd want to have this  
7 measure.

8 DR. JARRIS: Rhonda.

9 DR. MEDOWS: How strong are our  
10 recommendations? How strong is the influence  
11 of a recommendation from the committee? Is it  
12 a good idea kind of a thing, that may or may  
13 not actually come to pass, or is it something  
14 that we can tie to you are endorsed with the  
15 contingency that this be accomplished by X, Y  
16 and Z date?

17 DR. BURSTIN: So keep in mind all  
18 measures for NQF are evaluated every three  
19 years. So you can make a very clear statement  
20 that by the next time the measure is up for  
21 review, there is an expectation that data  
22 stratified by populations served and/or, I

1 think, the employees, would be required.

2 DR. JARRIS: Then as a matter of  
3 process, I believe, and I'm sorry for the  
4 speaker on the phone. I forgot your name, and  
5 I really apologize, Megan, but I think you  
6 said that this received either a provisional  
7 or a temporary last time around, not a full  
8 endorsement, and what we didn't hear as a  
9 group is why. So we actually are not able to  
10 evaluate what had to change.

11 DR. BURSTIN: Actually, that's a  
12 standard part of our process, which we're not  
13 doing as much anymore. Things are assigned a  
14 time-limited endorsement because they hadn't  
15 yet been fully tested. So the measure is now  
16 fully tested. So it is up for full  
17 endorsement for the next three years.

18 DR. STANGE: So is the question  
19 whether it's fully tested if it hasn't had  
20 these disparity measures? So --

21 DR. WINKLER: The disparities testing  
22 is not a required part of the testing. We're

1 testing for reliability and validity in the  
2 measure properties.

3 MS. MERRILL: Does the committee's  
4 recommendation travel with this, so that the  
5 next committee will see the recommendation?

6 DR. WINKLER: Yes.

7 DR. STANGE: So Bobby, I think --  
8 whose responsibility is it to assure that  
9 those data to allow disparities to be measured  
10 the next time around, are collected? Is it  
11 the person or the entity that's proposing the  
12 measure? So that if in fact those data aren't  
13 available the next time around, then the  
14 measure doesn't get approved?

15 MS. MERRILL: If it's not available,  
16 they just have to say why it's not available.  
17 But I mean if it's not available, they can't  
18 collect it.

19 DR. JARRIS: On the other hand, the  
20 CDC is perfectly capable of commissioning  
21 these studies. So the CDC can assure that it  
22 is available.

1 MS. LINDLEY: You have better faith  
2 in our budget than I do. But I did want to  
3 say one thing, that we would be able to  
4 provide to the Committee, although not  
5 immediately, that we actually do have  
6 addresses for our participant facilities. So  
7 we could fund the zip codes for you and  
8 construct an index of geographic disparity  
9 that way, if that would be useful.

10 We also collected data, for example,  
11 on urban, rural or suburban status. So we  
12 should be able to do some analyses that way if  
13 that would be useful.

14 DR. STANGE: So we're actually doing  
15 two things at once here. We were using this  
16 to actually walk us through the process, and  
17 we're learning a lot about the process, and we  
18 have serious issues raised by this. Do we  
19 want to actually go through the process? We  
20 learn about the process and then make note of  
21 these, and then once finishing the process,  
22 come back and say okay, what are we going to

1 do about this?

2 DR. JARRIS: You know, I'd say from  
3 my point of view, this is such an important  
4 measure, I couldn't go to sleep tonight if it  
5 didn't get passed. So I think that it may be  
6 imperfect, but it's the best we have, and  
7 let's start there with a strong recommendation  
8 that's approved for next time around.

9 DR. BURSTIN: And these disparities  
10 issues come up for every measure that we're  
11 dealing with right now. So this is not  
12 unique. This is an issue where we've got  
13 actually a disparities committee working on  
14 exactly how we should, what should we require  
15 as part of NQF's submission. But we hear you.  
16 This is an important one for this measure as  
17 well.

18 DR. STANGE: Is the way to address  
19 that systemically then, I mean really because  
20 you want to collect these data on everything,  
21 rather than doing it one measure at a time.  
22 So how is that accomplished?

1 MR. PESTRONK: So then the way that  
2 this works is at this point, the measure, if  
3 the measure is adopted, then it goes up as  
4 sort of a formal, on the list of approved  
5 measures from NQF, and things would continue  
6 along. Those who use NQF measures as part of  
7 their, you've got to have, you've got to do  
8 this in order to get that, accrediting bodies  
9 or HEDIS or something else.

10 The way that organizations would be  
11 forced to collect the data that would allow  
12 disparities to be measured is someone like  
13 HEDIS would have to adopt the measure, and  
14 then those entities that needed to demonstrate  
15 that they met the HEDIS measures, would then  
16 have to --

17 Because HEDIS adopted the NQF  
18 measure, would have to collect the data that  
19 would allow them to report on disparities?  
20 That's the cascade of events that NQF  
21 endorsement leads to?

22 DR. WINKLER: NQF endorsement



1 provides a group of measures that any number  
2 of implementers could potentially grab hold  
3 of. We certainly see a lot of it used by the  
4 federal government in a variety of programs.  
5 Often, it's driven by the setting of care. So  
6 we can't totally foresee where and how, but I  
7 think some of the comments on this particular  
8 measure shows that the interests in it likely  
9 being used, perhaps among some of the federal  
10 programs over at the Joint Commission, are  
11 sort of in the works, if you will.

12 DR. JARRIS: We would use it at the  
13 state level, because we would go in and  
14 respond to a dozen deaths in a nursing home,  
15 in you know, several times a year, and in  
16 those nursing homes we found out they had  
17 vaccination rates of their staff of about 30  
18 percent.

19 So if I hadn't had a standard like  
20 this, I would have gone right to the papers  
21 and published, for every nursing home in our  
22 state, what their rates of staff vaccinations

1 were.

2 DR. STANGE: We have Jackie, Ron and  
3 Mike. I'm sorry Madeline, sorry.

4 DR. NAEGLE: Thank you. I just  
5 wanted to point out that there, I see two  
6 components here. One is a workforce issue;  
7 the other's a population issue. I think the  
8 recommendation should be that if you're going  
9 to be measuring immunization for the  
10 workforce, that that should be stratified.  
11 Your population should be stratified there,  
12 and then the population served should be  
13 stratified as well.

14 I think that's really a  
15 recommendation about the science, and I think  
16 it's a good recommendation for us to make,  
17 even though it's setting the bar a little  
18 high. But I think both of those are  
19 important. I mean I would argue for the  
20 workforce, we really want to know if the  
21 nurses aides as well as the registered nurses  
22 and the physicians are being vaccinated, and

1 that there's not discrimination by position  
2 and employment.

3 So I think it's the kind of  
4 recommendation that we can make, but as I  
5 said, I also think it raises the bar, and it  
6 really means that the science has to be  
7 better. I think we certainly can't require  
8 it. It might be a recommendation.

9 DR. STOTO: So I don't think there's  
10 anything about this measure that can't be used  
11 to look at disparities. It's just that they  
12 haven't provided any data on that. So, you  
13 know, we're not saying that -- so we're just  
14 being and saying is this an appropriate  
15 measure, and the fact that they haven't  
16 provided data on disparities strikes me as not  
17 taking away from the quality of this measure.

18 MS. MERRILL: Well, you get into a  
19 terrific can of worms when you try to stratify  
20 the workforce by title. It's very hard to do.

21 DR. BURSTIN: It's actually part of  
22 the measure. They've already put forward.

1 The measure is required to be stratified by  
2 employees, licensed independent practitioners,  
3 and then any students or trainees. So they've  
4 already done that piece. That's already part  
5 of this measure.

6 MS. MERRILL: So that's just  
7 categories. This is title.

8 DR. STOTO: Right, and that's  
9 arguably more important than stratifying it by  
10 race or anything like that, because that's  
11 really actionable. You can say we have to  
12 take an intervention with the doctors and the  
13 nurses, the licensed practitioners, rather  
14 than the employees.

15 MS. MERRILL: Well, the way they've  
16 categorized it, it's not really by title. So  
17 they have given categories that the facility  
18 has to stipulate. The other category they  
19 could do it by is by the EEO category. So  
20 that's professional, administrative, you know  
21 like that, technicians. I don't know if that  
22 would give you the value.

1           It seems like the way they want to do  
2           it is the most pertinent for this measure,  
3           people who are licensed, people who are  
4           actually employed. You've seen that data on  
5           how hard it is to do it by title.

6           DR. STANGE: So we have the  
7           distinction between the reporting on the  
8           population versus the employees. Ron's been  
9           waiting for a long time, and then Reva, I'd  
10          like you to help us tell how we action these  
11          type of concerns for the measures.

12          MR. BIALEK: So not fully  
13          understanding the process, I'm going to ask  
14          the question anyway. I'm a little bit  
15          troubled about the way the data are collected.

16          Let's get beyond the disparities  
17          piece, that some of the data are self-report,  
18          some of the data are based on the facility  
19          record of whether or not they administered the  
20          shot, and so the measure is used by a  
21          facility, and the change in the rate could be  
22          nothing more than a factor related to a change

1 in the way the facility collects the data.

2 If a facility says your continued  
3 employment here is contingent upon you being  
4 vaccinated, and the facility is asking for  
5 self-report, the rate's going to go up. So,  
6 you know, I don't know how that's considered  
7 in this process.

8 DR. WINKLER: Yes. If you could hold  
9 that thought until we move to the section on  
10 Scientific Acceptability, where it's all about  
11 the data and reliability, hold on. It's an  
12 excellent point to be made. Right now, we're  
13 still trying to finish the importance, okay.  
14 Who else wants to talk about importance?

15 DR. JARRIS: Rhonda, your card has  
16 been going up and down. It's like a  
17 windshield wiper.

18 DR. WINKLER: Yes, okay. First time  
19 through, it's always difficult. So if we take  
20 a look at the ratings that were provided by  
21 the work group, does everybody feel this  
22 generally reflects how the entire group? Does

1 anyone have any major issues with the way they  
2 are? Performance gap, there is one. It's  
3 high. On the evidence, the quantity is high,  
4 the quality is moderate to high, and the  
5 consistency is high. Okay.

6 Then as we move to the evaluation of  
7 how we take that information and plug it into  
8 sort of the evaluation algorithm, moderate to  
9 high in quantity, moderate to high in quality,  
10 moderate to high means that it would pass the  
11 evidence criteria. Does anybody have any  
12 objections to that?

13 (No response.)

14 DR. WINKLER: Okay. We don't need to  
15 worry about exceptions. So I guess at this  
16 point, you know, we could do a formal voting  
17 with our little gizmos, or is there anybody in  
18 the room who doesn't think this measurement  
19 meets the importance criteria?

20 (No response.)

21 DR. WINKLER: Okay.

22 MS. SAMPSEL: We're all afraid of

1 Paul.

2 DR. JARRIS: No, but it did occur to  
3 me that if these gizmos don't take a lot of  
4 time, it does respect people's privacy, and  
5 then I don't have to go after anybody.

6 DR. WINKLER: Right. Well, that's  
7 why I was doing it --

8 DR. JARRIS: I want to know who to go  
9 after.

10 DR. WINKLER: Okay. So the next  
11 section is on Scientific Acceptability of the  
12 measure properties, and this is where we're  
13 looking at the specifications themselves. We  
14 are looking at the reliability and the  
15 validity, and we are expecting those to have  
16 been tested and data provided.

17 Again, disparities may come in this.  
18 When we're having, you know, internal  
19 discussions about what criteria disparities  
20 comes under, it seems to come under a lot of  
21 them. Just some guidance points. We are  
22 looking for empirical testing. We don't



1 prescribe what type of testing. We really  
2 want it to be tested on the measure as  
3 specified.

4 I think that CDC has outlined the  
5 testing that they did and the results that  
6 they had. So this is a good version of it.  
7 So this was the evaluation by the work group,  
8 in terms of the scientific acceptability.  
9 Linda, did you want to just summarize?

10 DR. KINSINGER: Sure. So the CDC did  
11 report their study data on reliability and  
12 validity, usability and feasibility, and it  
13 looks like we rated it moderate to high.  
14 Reliability, moderate validity, I think  
15 getting to some of Ron's issues about where  
16 the -- how valid the data are, but I don't  
17 know how you get around self-report.

18 I mean there's not a gold standard,  
19 because people do get vaccines, you know, from  
20 the drug store to the grocery store to lots of  
21 different places, and I don't -- there's just  
22 no way around that. But it does mean it's

1 less valid, I think.

2 Usability was rated high to moderate,  
3 and feasibility, moderate. I believe the  
4 feasibility rating, if I remember here, had to  
5 do with just the challenges to developing, to  
6 figuring out which category employees fit into  
7 or people in the facilities, whether they fit  
8 into which of those categories, and then  
9 collecting the information, I think. At least  
10 that's what my thinking was in terms of  
11 feasibility, that it's not -- those aren't  
12 necessarily data that are routinely collected  
13 for other reasons.

14 They have to be collected  
15 specifically for this, so it challenges  
16 feasibility just a little bit. But there we  
17 are. That's as good as we're going to get, I  
18 think.

19 DR. WINKLER: Is there any comments  
20 or discussion about the reliability or  
21 validity? Ron, I think at this point, that  
22 might be where your comments apply. Did you

1 want to ask CDC their thoughts on that?

2 MR. BIALEK: I'm debating. You know,  
3 I hear, Linda, what you're saying, and I'm  
4 thinking that, you know, for my employees, we  
5 have an employee handbook, and we require if  
6 an employee is out for a certain number of  
7 days, they need to bring in something from a  
8 medical provider, saying what's the issue.

9 If health care workers have a  
10 requirement, they could provide some  
11 documentation, which will get beyond self-  
12 report. But I understand that. I mean there  
13 could be costs related to that, there could be  
14 legal issues related to that, etcetera. So  
15 maybe, you know, CDC, how do you deal with  
16 this issue of the validity of what's being  
17 reported?

18 I mean have you looked at the  
19 difference between self-report and  
20 documentation of vaccination?

21 MS. LINDLEY: We did, and I think  
22 there are two comments, because you bring up

1 an excellent issue, and one that we really ran  
2 into running the pilot, which is there's not  
3 a gold standard, and there are all these  
4 different kinds of documentation and how do  
5 you do this.

6 One, a general comment would be, you  
7 know, that of course, self-report of influenza  
8 vaccination has been studied among adults, and  
9 it's been found to be a highly sensitive and  
10 specific measure. Of course, those are in the  
11 general population, not necessarily in health  
12 care personnel, that may have a job  
13 requirement.

14 But there are not as significant  
15 problems with recall of influenza vaccination  
16 for self-report as there are with other  
17 vaccines. The other thing we did was to do a  
18 comparison between facilities. I took the  
19 three most commonly used data sources, and I'm  
20 sorry that I don't have the quantitative  
21 figures in front of me.

22 But I can tell you that by far, the

1 most common data source reported was actually  
2 paper health records. So although the data  
3 are not available electronically, they are  
4 written down somewhere. The second most  
5 common source was electronic clinical data,  
6 and then we did look at self-report status,  
7 although that was far as less commonly used,  
8 which I find somewhat reassuring personally,  
9 for the reasons that you bring up. So we had  
10 maybe, depending on the categories, say 10,  
11 12, 15 percent say yes, we use self-report.  
12 But most of them did use documentation.

13           When we compared the median  
14 vaccination rate among those institutions  
15 reporting different types of data sources, we  
16 found that although the median did tend to  
17 move around a little, the rates were  
18 comparable, in terms of being, you know,  
19 within the same quartile.

20           So you wouldn't get somebody who had  
21 a 60 percent vaccination rate suddenly  
22 changing their method of reporting and having

1 an 80 percent or a 20 percent vaccination  
2 rate. I know that unfortunately, the table  
3 that's in the Appendix E, which I know that  
4 you all probably didn't necessarily have to  
5 look at, and then there was a brief  
6 explanation of that testing in the Section  
7 2(b)(5).

8 But we did look at that, and the  
9 results that we got suggested to our comfort  
10 that different sources of vaccination data  
11 would still produce acceptably comparable,  
12 although certainly not identical results.

13 DR. STANGE: Mike.

14 DR. STOTO: I just wanted to make the  
15 point that this is an issue. I think all the  
16 influenza vaccines, as indicated we're looking  
17 at, are probably beyond that as well. It's  
18 just an intrinsic problem.

19 DR. WINKLER: Just we do have the  
20 voting gizmos. Everybody's got one in their  
21 hand. We're going to vote first on the  
22 reliability, and then next on the validity.

1 You have the work group's initial ratings. So  
2 what we'll have you do, when Kristin starts  
3 the clock, is pick high, moderate, low and  
4 push the proper button, 1, 2 or 3, or 4 for  
5 insufficient evidence. This will be our  
6 trial, so --

7 MS. CHANDLER: I just have a couple  
8 of notes. So we ask that you please direct our  
9 remotes toward this computer in front of me.  
10 Once you enter your numerical answer on the  
11 keypad, you should briefly receive a green  
12 light. If instead you receive a red light or  
13 no light, we ask you to enter your response  
14 again.

15 You don't need to worry about a  
16 duplicative response. Only one response is  
17 tallied per Steering Committee member. And  
18 then finally, we do have the capability to  
19 revote if the Committee feels that another  
20 vote is necessary.

21 These are just examples to make sure  
22 that everybody's keypad is working. We're not

1 actually voting.

2 DR. SPANGLER: We have a process  
3 question. When we filled out the survey  
4 monkey already, does that count as a vote, or  
5 do we redo it here as an official vote?

6 DR. WINKLER: You redo it here, yes.

7 DR. SPANGLER: Okay, thanks.

8 DR. PACE: Right. But also consider  
9 that part of the voting is having you all  
10 together and raising issues, which could  
11 ultimately change your view one way or another  
12 too.

13 MS. CHANDLER: Okay, so one final  
14 note. There is a small blip in the system,  
15 and it's only allowing a ten second window for  
16 the vote. Can you all get them in in ten  
17 seconds? Let's try now.

18 DR. WINKLER: Okay, great. So we're  
19 going to vote for real this time on  
20 reliability. Ten seconds. Now.

21 Kristin, move on to the next slide.  
22 Okay, the next one is validity, and we're



1 going through this one individually, to see  
2 how this group wants to go as the exercise.  
3 We may be able to streamline this with  
4 subsequent measures. But on validity, you do  
5 see the ratings from the work group, the  
6 discussion from CDC on the voting. So go  
7 ahead and vote on validity.

8 MS. CHANDLER: Please vote again.

9 DR. WINKLER: The votes are 2 high,  
10 11 moderate, 2 low, 4 zero, or insufficient or  
11 zero. Okay.

12 DR. STANGE: One abstention.

13 DR. WINKLER: Okay. In this  
14 particular case, we voted highly for  
15 reliability and moderate to high for validity.  
16 So it does pass the scientific acceptability  
17 criteria. So we're able to move on to the  
18 usability criteria, which is the extent to  
19 which intended audiences, consumers,  
20 purchasers, policymakers, anyone out there,  
21 can understand the results and find them  
22 useful.

1                   This is where we ask about usefulness  
2                   for public reporting. So again, just to go  
3                   back and you've seen this slide before. The  
4                   usability rating of the work group was high to  
5                   moderate one. Comments that it's not  
6                   currently reported, but there's a rule pending  
7                   for CMS and the Joint Commission does require  
8                   it for hospitals.

9                   Linda, did you have any other  
10                  comments around usability? Any other comments  
11                  from the group? So we'll go ahead and vote on  
12                  the usability.

13                  The results are 10 high, 5 moderate  
14                  and low is zero. Okay. So now we'll move on  
15                  to the feasibility, and feasibility, I think,  
16                  is some of the discussion you've had, the  
17                  extent to which the required data are readily  
18                  available, retrievable without undue burden  
19                  and the measure can be implemented. I think  
20                  these are some of the questions you have  
21                  around data sources and collecting and having  
22                  that data. So any discussion around the

1 feasibility?

2 DR. SPANGLER: Comment. One thing I  
3 noticed is 4(b)(1), which is under electronic  
4 sources. It seemed like a common answer for  
5 that was some data elements are in electronic  
6 sources. Then the next question is "If all or  
7 not, then you need to answer this question."  
8 I think that was never answered on any of the  
9 measures.

10 I'm not sure. Is that -- so I had  
11 this question on the call too. Is that  
12 insufficient, does that mean it's moderate?  
13 It seemed like nobody ever answered that  
14 question. I don't know if that's a process  
15 thing or the reasons for that. Do we know?

16 DR. WINKLER: Well again, I think you  
17 balance the various subcomponents of each of  
18 these criteria. But we are certainly trying  
19 to drive, you know, the development of the  
20 data systems, to make this much more feasible,  
21 by using electronic data collection.  
22 Certainly, some types of data will be more

1 advanced in that than others.

2 So it's not -- again, it's a  
3 subcriteria. It's not an all or none kind of  
4 thing, but you balance that subcriteria in  
5 terms of the overall question of feasibility  
6 for the measure.

7 DR. SPANGLER: So I guess my next  
8 question is do they not answer because they  
9 don't have an answer, or they just -- do we  
10 know? Do we have any idea?

11 DR. WINKLER: Can CDC respond to that  
12 question?

13 MS. LINDLEY: The question is there  
14 was a question about the proportion of data  
15 elements in electronic sources, and then there  
16 was a follow-up question that was unanswered.

17 DR. SPANGLER: It's 4(b)(1) and  
18 4(b)(2).

19 DR. WINKLER: Correct.

20 MS. LINDLEY: So 4(b)(2) only appears  
21 if you give a certain answer to 4(b)(1). I  
22 think you said it was all or none, and since

1 we said some, the question didn't appear. It  
2 got skipped out. That's why we didn't answer  
3 it.

4 DR. SPANGLER: Then it's the format  
5 of the question.

6 DR. WINKLER: Yes. That's, and I  
7 didn't -- that's a new one for me. Thank you.  
8 We learned something.

9 MS. LINDLEY: I couldn't figure out  
10 how we would have missed it otherwise.

11 DR. WINKLER: Any further discussion  
12 on feasibility? So let's go ahead and vote on  
13 it. Yes.

14 DR. SPANGLER: So then would all  
15 categories in the numerator and the  
16 denominator, right? So it's collectively how  
17 do we think, and then do we think it's  
18 feasible or not? Yes, okay.

19 DR. WINKLER: Okay. It's high, zero,  
20 moderate 12, low is 3. Okay. So Kristin,  
21 what's the next slide. So this is the overall  
22 vote. This is the do we feel that the measure

1 has met all of the NQF criteria, and is  
2 suitable for endorsement. Any discussion?

3 DR. STANGE: And where do we put the  
4 caveats?

5 DR. BURSTIN: That's a separate  
6 thing.

7 DR. STANGE: Separate?

8 DR. WINKLER: 15 yes, 0 no's. So the  
9 group thinks this measure is suitable for  
10 endorsement. There were some caveats, there  
11 were some recommendations. Do we want to be  
12 sure that we have those captured  
13 appropriately? One was around stratification  
14 for disparities, that we'd like to see  
15 certainly by the time of their next  
16 endorsement cycle, that we want to see data  
17 for disparities, as have been discussed. What  
18 are the other caveats? Is that it? Is that  
19 the only one.

20 Okay, for both the workforce and the  
21 population. All right. So I think CDC is  
22 hearing that message, but we'll certainly also

1 follow up with them.

2 DR. BURSTIN: I'll put out that  
3 Paul's comments directly worked for that  
4 question of how does the measure translate to  
5 the community, so thank you. That's a good  
6 suggestion.

7 Measure 1659

8 DR. WINKLER: All right. The next  
9 measure on our list is 1659, influenza  
10 immunization. This is brought to us from CMS,  
11 and it is a measure for hospitalized patients.  
12 It is the inpatients aged six months and older  
13 discharged during October, November, December,  
14 January, February or March, who are screened  
15 for influenza vaccination status and  
16 vaccinated prior to discharge, if indicated.  
17 Is someone from CMS on the phone to introduce  
18 the measure? Keziah Cook, hello?

19 MS. COOK: On the home health CMS  
20 measure?

21 DR. WINKLER: This is inpatients.

22 MS. COOK: Then I'm not the right

1 person.

2 Measure 522

3 DR. WINKLER: Okay, sorry. Sure. We  
4 can skip to the home health measure, which is  
5 522, and this is the percentage of home health  
6 episodes of care, during which patients  
7 received influenza immunization for the  
8 current flu season. So Keziah, it's now your  
9 turn.

10 MS. COOK: So this measure received  
11 time-limited endorsement in 2009, and we  
12 conducted reliability and validity testing  
13 based on data collected during the first nine  
14 months of 2010.

15 The measure was initially specified  
16 based on the consensus recommendations. So  
17 while the publicly reported measure reports  
18 the number of home health episodes in which  
19 the patient received a vaccine for influenza,  
20 either from the home health agency or from  
21 another provider, which the home health agency  
22 confirmed.



1           The additional measures of vaccine  
2 offered and refused or vaccine  
3 contraindicated, are also calculated and then  
4 reported to the home health agencies  
5 themselves. I can briefly talk about the  
6 reliability and validity testing, or if you'd  
7 like me to talk a little more about the  
8 measure in general, I can do that.

9           DR. WINKLER: I think Jason, you were  
10 the reviewer for this one; correct?

11          DR. SPANGLER: I was.

12          DR. WINKLER: Why don't you -- okay.  
13 Why don't you start with the discussion, and  
14 certainly the developers are available if you  
15 have any questions for them.

16          DR. SPANGLER: Sure. Because this  
17 one is different than the previous measure, I  
18 thought it probably would be good to bring up  
19 what you had discussed earlier, Reva, and  
20 that's this idea of a universal measure. If  
21 you look at all the 16 measures and now we  
22 have eight, a lot of the discussion we had in

1 the work group was why can't we have one  
2 measure that incorporates all of the  
3 denominators together, and so we won't have a  
4 separate one for home health, a separate one  
5 for inpatient, a separate one for different  
6 age groups, high risk populations, etcetera.

7 So I didn't -- we can maybe start  
8 with that discussion, what people feel about  
9 that, because that was one of the -- my  
10 comment on every single measure that I looked  
11 at on flu immunization was this should be  
12 incorporated into the universal measure.

13 DR. STANGE: Can we have some context  
14 for that from what are the possibilities for  
15 that happening, and how would that happen?

16 DR. JARRIS: Can we ask the folks  
17 from CMS, has there been a discussion between  
18 CDC and CMS about how that might be  
19 approached?

20 DR. PACE: I'd like to just put some  
21 context around it, because it's an issue that  
22 comes. I mean it's most dramatically obvious

1 with these measures, but it comes up in other  
2 projects as well, and part of it is when you  
3 start looking at those detailed measure  
4 specifications, you'll see there are some  
5 differences because of the data source. So  
6 that needs to be specified. That's not an  
7 insurmountable issue in terms of having one  
8 measure.

9           Probably the most practical issue is  
10 that currently, we have measure developers  
11 that specify or specialize in a particular  
12 setting or data source, and it's just been  
13 impractical to coax measure developers to  
14 create measure that apply to other settings or  
15 data sources, for which they don't have the  
16 knowledge or information about.

17           So if you have some suggestions about  
18 those things. But those are kind of the two  
19 practical issues that we keep running up  
20 against.

21           DR. STANGE: I wonder if the idea  
22 that care is going to be hopefully

1 increasingly be integrated, that you can make  
2 an argument that you're looking out for the  
3 end user who has this cacophony. I mean is  
4 that a lever point? Bobby's next, but do you  
5 want to answer that?

6 DR. PACE: Well, I think you're  
7 right. I mean there's, you know, the end user  
8 would love that, and NQF, you know, would  
9 certainly like to have that. It's just been  
10 a practical issue, and frankly that's why we  
11 ended up with those standard specifications,  
12 so that even if we had to have different  
13 measures for different settings because of the  
14 unique data elements, that at least they would  
15 be aligned.

16 I don't know if you're experiencing  
17 it here. In the original project, there were  
18 even more divisions of measures. So for  
19 example, physician measures for COPD patients,  
20 and then a separate measure for heart failure  
21 patients, and I think a lot of that has been  
22 resolved and combined. But the different

1 settings and data sources is still a continued  
2 problem.

3 MR. PESTRONK: I wanted Jason to  
4 understand what you're proposing, is would it  
5 be to retain? Well, I'll start from a  
6 different place. It seems to me it's useful  
7 to know what's going in the hospital, what's  
8 going on in the nursing home, what's going on  
9 in different settings, because they are  
10 different settings, and the process perhaps  
11 for making improvement in all those settings  
12 could be different.

13 So when you raise the question about  
14 combining them all into a single measure, I'm  
15 not sure I understood what would -- what that  
16 would look like, and would you lose the  
17 granularity of the current measures if you did  
18 that?

19 DR. JARRIS: Imagine a patient,  
20 though, who is in the hospital, would like to  
21 know their health care provider is vaccinated,  
22 who then gets assessed themselves and then

1 goes out to a rehab facility and then goes to  
2 home health care. Wouldn't it be nice if it  
3 was one measure, so that patient was measured  
4 the same way as they travel through the  
5 system?

6 Or even you could rely upon the  
7 facility transferring the patient to you for  
8 having measured that. That may not work in  
9 this system right now.

10 MR. PESTRONK: Is that a question of  
11 look, so in what you've just described, you  
12 still would want to know what the percentage  
13 was in each of those settings, right? So is  
14 it a question of then, when you say having a  
15 common measure, it's having a numerator and a  
16 denominator for each of those settings, so  
17 that one could do that?

18 It's not that definition of the  
19 numerator and the definition of the  
20 denominator would be the same in each of those  
21 settings.

22 DR. STOTO: So I mean it strikes me

1 that what you might possibly do is have the  
2 definition of the measure be the same in all  
3 those settings. But obviously calculate a  
4 different number for each one. But the  
5 problem is, though, that this one, this home  
6 health one, is based on episodes of care  
7 during the flu season, and the denominator  
8 would be different for other ones.

9 So maybe the numerator can be more  
10 standardized, but the denominator is  
11 impossible.

12 DR. SPANGLER: Yes. We can get to  
13 that later. That's another comment, about  
14 how it doesn't actually fall under the  
15 standard specifications.

16 DR. STOTO: Right. So maybe, you  
17 know, this one could be defined in the same  
18 way that a hospitalization could be defined.  
19 Okay. Right, yes.

20 DR. SPANGLER: I also think, I mean  
21 maybe this is what you were getting at, but  
22 you can stratify within the measure. So I

1 don't think you have to lose that necessarily.  
2 But if you want a whole -- we would have all  
3 these separate measures. How do you even  
4 compare who's getting vaccinated?

5 If you had a whole measure of we know  
6 the percentage of people who are supposed to  
7 get vaccinated. Here's how many are just  
8 total? Where I don't think we can do that at  
9 all now with the different measures. Where I  
10 think you can do that with a universal  
11 measure, but not lose maybe the individual  
12 type of measures. But I don't know. I mean  
13 is that something -- could we do that?  
14 Feasible, not as a practical.

15 DR. PACE: Well, you can suggest  
16 that, but I don't know if you're going to get  
17 any takers of the measure developers. I mean  
18 you don't have that measure in front of you,  
19 and I mean I don't know. It's something that  
20 we'd have to see. I'm just saying from past  
21 experience, we haven't found anyone that was  
22 capable of doing that.



1 DR. BURSTIN: And we do know on the  
2 hospital side, for example, CMS has been doing  
3 work on the CARE tool, which would allow that  
4 transition across the various settings. They  
5 are interested, for example, in at least  
6 trying to get the same data elements across  
7 the different measures, and ultimately if a  
8 CARE tool is available across that full set,  
9 that full continuum, that should get them  
10 closer, and I know they are working on that.

11 DR. SPANGLER: I think one of the  
12 measures, which we'll talk about, I guess, is  
13 trying to get close to that, which we'll talk  
14 about a little bit later, and trying to  
15 incorporate. I think isn't 41 trying to  
16 incorporate every outpatient into one? So I  
17 mean that's probably the closest we have right  
18 now.

19 DR. STANGE: Matt, you saw something  
20 that was relevant?

21 MR. STIEFEL: I hope so. So there  
22 was a slide on this question, right at the

1 beginning of the packet, about harmonization.  
2 It seems to me that the issue is can you  
3 harmonize the numerator, and then the  
4 denominators will be different, depending on  
5 the population. But if the numerator is the  
6 same, then you've achieved that harmony, and  
7 maybe that's the thing that we can look at.

8 DR. WINKLER: And recall that the  
9 prior attempts is to harmonize against that  
10 set of standard specifications, is a way of  
11 making it clear what a numerator should look  
12 like.

13 DR. STANGE: So is the NQF mechanism,  
14 then, to approve these, but give the measure  
15 developers three years to do the harmonization  
16 and come back, and then you decide what to do  
17 about it? Is that what would happen?

18 DR. BURSTIN: I think there's a  
19 difference between harmonization, meaning  
20 saying go back and try to at least align some  
21 of the key elements of the measures, and  
22 asking them to come back with a combined

1 measure. That's not something we can do in  
2 the course of our project.

3 If there are specific questions about  
4 dates of immunizations or something like that,  
5 where they could go back, potentially make a  
6 change and bring it back to you to harmonize,  
7 that's different. I think then really you can  
8 only evaluate the measures before you, and  
9 then make recommendations for additional  
10 measure development.

11 DR. STOTO: Well, to Matt's point,  
12 the standard specifications for immunization  
13 are like the ones we saw before about the  
14 numerator, that it includes contraindications  
15 and declines. There's no contraindications or  
16 decline here, as far as I see. So it's like  
17 it's inconsistent within the standard.

18 DR. SPANGLER: Actually, I would  
19 argue that it's -- the more inconsistency is  
20 the denominator, because the denominator is  
21 always for the standard specifications as  
22 number of persons, and this is not measuring

1 number of persons. This is numbering  
2 episodes, like you mentioned before, Mike.

3 DR. STOTO: Oh, so I assumed, maybe  
4 inappropriately, that if someone had two  
5 episodes during the flu season of home health  
6 care, they would only be counted once. But  
7 then maybe not. Because they do ask about,  
8 you know, if you have been vaccinated on the  
9 previous episode.

10 DR. SPANGLER: That was my big issue  
11 with this, and hopefully maybe the person from  
12 CMS, they can address that, because it didn't  
13 seem to follow the influenza immunization  
14 standard measure specifications because of the  
15 denominator.

16 MS. COOK: This is Keziah Cook. I'm  
17 from the measure developer, Acumen, and all of  
18 the home health quality measures are based off  
19 an episode of care, which is the period of  
20 time between the patient start or resumption  
21 of home health care, and their discharge or  
22 transfer from home health care.

1           So because home health care is a  
2           service that's provided over multiple weeks,  
3           this is the most sensible way to quantify, you  
4           know, what an episode is, would correspond to  
5           a hospitalization or something of that sort in  
6           a different setting.

7           DR. STOTO: But if someone had two  
8           episodes, say one in October and one in  
9           February of the next year, would they be  
10          counted in the database twice?

11          MS. COOK: Yes. In this case, they  
12          would, and the idea here is that the home  
13          health agency goes through a process, you  
14          know, each time they admit a patient to home  
15          health care, of assessing, you know, what are  
16          this patient's needs and what type of care do  
17          we need to provide to that patient.

18          So they do that once in October, the  
19          first time they begin treating this patient.  
20          When that patient comes back in February, they  
21          do that process again. Of course, our item,  
22          you know, one of the responses the agency can

1 give is we did not provide the vaccine to the  
2 patient this time, because we vaccinated them,  
3 you know, earlier this year or this flue  
4 season.

5 But it would be appropriate for the  
6 agency to document, during both episodes, that  
7 they confirmed that the patient had an up to  
8 date vaccine status.

9 DR. PACE: So this, I think this is  
10 an example of one of the issues about the  
11 unique, different data systems that are  
12 operating in nursing homes, home health  
13 agencies, hospitals, and is one of the current  
14 realities that we have to deal with, you know.  
15 So we can try to get things aligned as much as  
16 possible, but then we have to see about what's  
17 possible.

18 DR. STANGE: Bobby and then Madeline,  
19 are you up again? And then Paul.

20 MR. PESTRONK: Just a background  
21 question. If you recall, there was a name for  
22 someone who actually develops the algorithm

1 for producing the measure or producing the  
2 data, that nobody would own that process  
3 sometimes? So you're not able to get the data  
4 developed. What was that person called?

5 DR. WINKLER: Well, we have the  
6 measure developer, who conceptualized and  
7 specified and then tested the measure. So  
8 that's --

9 MR. PESTRONK: Okay. And then  
10 there's a question about whether anybody's  
11 actually collecting that. Once the measure's  
12 defined, it has a numerator and a denominator,  
13 someone has to collect that, which requires  
14 somebody to decide to do that, or to require  
15 that be done, right?

16 DR. WINKLER: Yes. They could be  
17 implemented by any number of potential end  
18 users. In this particular case, with home  
19 health, because it's based on the CMS OASIS  
20 data system, CMS implements these measures.

21 MR. PESTRONK: Okay.

22 DR. STANGE: So what we have here, is

1       because we have a fragmented system, and  
2       there's so many ways for people to fall  
3       through the cracks, we have a number of  
4       different measures that are for these  
5       different opportunities we have. That's the  
6       situation we're in.

7                 DR. JARRIS: So in the National  
8       Quality Strategy, which is an HHS document,  
9       one of the six priorities is provide effective  
10      communication and coordination of care. One  
11      of the goals under that is improve the quality  
12      of care transitions and communications across  
13      care settings.

14                So we just heard from two different  
15      parts of HHS who put this forward as a  
16      priority. We didn't hear from them. But  
17      we've heard that well, they can't work  
18      together. I don't accept that. I think we go  
19      back with another recommendation to them, that  
20      the divisions in HHS, CDC for influenza  
21      vaccine among health care personnel, and CMS  
22      for hospitals and home health, sit down and



1 harmonize these measures across care settings,  
2 for the next time they come back.

3 It's the same umbrella agency coming  
4 to us. We should be able to say that we  
5 recommend you sit down and harmonize.

6 DR. PACE: I think the health care  
7 worker measure, isn't that for any setting?

8 DR. JARRIS: Yes.

9 DR. PACE: Okay.

10 DR. JARRIS: But still, I mean  
11 ideally, hospitals add up to the health care  
12 worker. Or are these patients who are saying  
13 --

14 DR. PACE: There is only the one CDC  
15 measure that covers all settings, I believe.

16 DR. JARRIS: That's really too bad.

17 DR. PACE: And then these are patient  
18 level, or you know, they're for the different  
19 facilities. But it's about the patients being  
20 immunized.

21 DR. JARRIS: Too bad. We need them  
22 for health care workers in those settings.

1 Okay.

2 MS. MERRILL: Is this the measure  
3 where it does list all the other measures that  
4 are similar to it? There's a place for them  
5 to do that, right? I know one of the measures  
6 did list about three or four of them that were  
7 similar to it, and that would be Paul's point.  
8 But I don't, I can never --

9 DR. WINKLER: Well, it would be the  
10 first slide I showed you, essentially would be  
11 the same thing, those eight measures. Except  
12 for maybe the first one, which was the health  
13 care personnel. But the other seven are  
14 essentially the same process of care.

15 MR. BIALEK: Is this the time to ask  
16 about contradictory evidence?

17 DR. WINKLER: Yes.

18 MR. BIALEK: Okay. So the Lancet  
19 article and the Cochrane Review are pretty  
20 compelling, that the impact is not  
21 demonstrated, seen as ineffective. I'm just  
22 wondering the measure developers, how that was

1 addressed?

2 MS. LINDLEY: Is Liz Madigan on the  
3 line?

4 MS. MADIGAN: So I'm not sure what  
5 your question is, in terms of how it was  
6 addressed. So when this was initially  
7 submitted there, I don't know if that  
8 information was included in the initial  
9 submission, because it was receiving a time-  
10 limited endorsement, and because the evidence  
11 has moved forward, I wanted to make sure that  
12 we included the most up to date information on  
13 the effectiveness of this.

14 DR. BURSTIN: It did specifically  
15 reference Lancet in the submission.

16 MS. MADIGAN: Yes, I did.

17 MR. BIALEK: Right, yes my question  
18 really gets to if the new evidence suggests  
19 that this is not effective --

20 MS. MADIGAN: It's very contradictory  
21 evidence. So it's, you know, and all the  
22 articles are different, of course, in terms of

1 what they include. It's the same issues we  
2 have with any systematic reviews or any of  
3 those kinds of issues about what gets included  
4 in the study.

5 So in some cases the study inclusions  
6 are different. I mean it's a hard body of  
7 evidence to evaluate, because you can't RCPs,  
8 of course.

9 MR. BIALEK: Right. I mean  
10 typically, the Cochrane reviews are pretty  
11 rigorous.

12 MS. MADIGAN: Right, exactly. I  
13 think the Lancet, in my estimation, the Lancet  
14 review was as well. So I think that if your  
15 question is are those both showing that these  
16 are ineffective?

17 In some respects, I think that is the  
18 case indeed what it's saying. At the same  
19 time, I think this is why the CDC has  
20 encouraged immunization vaccine among older  
21 people, and the manufacturers are now  
22 providing the high dose influenza vaccine for

1 older people for this exact reason. Does that  
2 answer your question?

3 MR. BIALEK: So, well let me see if  
4 I understand. The way I was reading this is  
5 that the ineffective was that having the  
6 individual vaccinated was not reducing  
7 hospitalization, was not reducing illness. It  
8 sounds like what you're saying is the strategy  
9 for getting them immunized has been  
10 ineffective. I'm trying to understand --

11 MS. MADIGAN: Oh yes. No, no. What  
12 we were trying to do was link this process for  
13 home health care to outcomes, and so if the  
14 outcomes that we were interested in were  
15 hospitalization, and I was trying to provide  
16 the evidence that in fact influenza vaccine  
17 does not necessarily reduce hospitalization.

18 MR. BIALEK: Okay. So the individual  
19 is vaccinated, and it does not necessarily  
20 reduce hospitalization. Okay, thank you.

21 DR. SPANGLER: It does.

22 DR. BURSTIN: It does reduce

1 hospitalization for influenza and pneumonia.

2 DR. SPANGLER: Right. It doesn't  
3 reduce hospitalization rates and deaths from  
4 respiratory disease.

5 MS. MADIGAN: Correct, correct, and  
6 that's what I'm saying, it's a complex body.  
7 So it's a complex body of research to try to  
8 synthesize in a succinct way.

9 DR. WINKLER: So any more comments on  
10 the importance criteria, which are the  
11 performance gap and the evidence?

12 MS. MERRILL: Is this the place to  
13 talk about why the population definition  
14 doesn't agree, because they're saying "all  
15 home health visits," but the evidence is only  
16 for elderly. So every home health visit is  
17 not an elderly visit.

18 MS. COOK: So the measure is  
19 specified to include those home health  
20 patients who meet the age and condition  
21 criteria. So it would be patients who are  
22 over 50 years old, or patients who have one of

1 a number of chronic conditions that, you know,  
2 the CDC recommends they receive annual flu  
3 vaccines.

4 So those are the patients who are  
5 included in the home health measure. Anyone  
6 who meets age or condition guidelines.

7 MS. MADIGAN: In addition, this is  
8 Liz. A large proportion of home health care  
9 patients are 65 and older, and depending on  
10 which source you read, it's somewhere between  
11 75 and 80 percent.

12 MS. MERRILL: Yes, that is true, but  
13 you didn't state it. So you didn't state it  
14 in 2.A.1.1, brief measure information. So  
15 that's why I'm asking the question.

16 MS. COOK: I think if you read  
17 through the numerator specification and the  
18 numerator exclusions, I think it's the  
19 numerator exclusions where it's most explicit,  
20 that all home health episodes during, you  
21 know, the time period, are included, except  
22 those that failed to meet the age or condition

1 guidelines.

2 MS. MERRILL: Okay.

3 DR. WINKLER: Just, I'm just reading  
4 from the denominator exclusions, that say  
5 episodes in which the patient does not meet  
6 the CDC guidelines for influenza vaccination,  
7 and the CDC guidelines for influenza  
8 vaccination have changed, and do apply to  
9 everyone over the age of six months.

10 MS. MERRILL: Okay. So then you need  
11 evidence for why it's efficacious for more  
12 than just the elderly. Do we have that? Is  
13 that evidence there?

14 DR. STANGE: Well so I think we can  
15 just specify that that evidence exists, I  
16 mean, right?

17 MS. MERRILL: Okay.

18 DR. STANGE: I'm just looking at the  
19 number of measures we need to get through. I  
20 think we're, I'm really impressed at the  
21 ability of this group to switch gears just  
22 like that, and go from the big picture about



1 a new thing on population, to really  
2 incredibly detailed comments.

3 So I'm really impressed with the  
4 group, and I think we're learning about the  
5 process. We'll have to, I think we can go  
6 through this maybe one more, depending on how  
7 the time goes, and then we'll kind of reframe  
8 and think about how we're going to develop a  
9 process for getting through the others  
10 tomorrow. So Reva, walk us through the rest  
11 of this, please.

12 DR. WINKLER: So we've looked and  
13 talked about the importance to measure and  
14 report. Go back one, Kristin. So I think  
15 that the question is, voting on importance to  
16 measure and report. If we look at the  
17 evidence criteria, it was rated, sort of there  
18 was a bit of a split there, 1 low, 2 high.

19 The quality, split again between  
20 high, moderate and low, and the consistency  
21 was moderate and low. So Jason, did you want  
22 to have any further comments about the

1 quality, quantity and consistency of the  
2 evidence?

3 DR. SPANGLER: I don't think anymore  
4 than what you just said. I mean I think there  
5 is a difference. I think from my perspective,  
6 I think it was based on the reading of the  
7 evidence, and I honestly think there was  
8 additional evidence that they didn't submit,  
9 kind of what Kurt kind of mentioned, that we  
10 would agree that there is more evidence. So  
11 I kind of -- of the evidence they submitted,  
12 I think there is a certain level.

13 But maybe if you know that there's  
14 actually additional evidence, you may have  
15 scored it differently. But just based on what  
16 they submitted, I can understand, you know,  
17 the score, especially the low and moderate.

18 DR. WINKLER: All right. Given that,  
19 we really are going to have to get a sense of  
20 the Committee, in terms of how you're feeling  
21 about the evidence. I guess we can vote on  
22 those individually.

1 Kristin, can you back it all the way  
2 up? Yes, okay. Back up even -- oh, okay. Go  
3 one more past, one more. Come forward.  
4 There, all right. Did you want to vote on the  
5 performance gap of 1(b)? Why don't we go  
6 ahead and do that, and just everybody can get  
7 on the program here. So we'll vote on the  
8 performance gap.

9 That's 8 high, 2 moderate, 3 low. So  
10 generally the highs have it. Let's go on to  
11 the next one. This is the evidence decision,  
12 and I think we were a little uncertain on how  
13 people feel about quantity, quality and  
14 consistency. So Kristin, go on to the next  
15 one, where we have the consistency of the  
16 evidence, as presented or as you know. How  
17 would you rate that?

18 3 high, 4 moderate, 6 low, 1  
19 insufficient. So it's 7 in the high-moderate,  
20 6 in the low. Okay. So that's going to be  
21 more moderate there. Can we have one more?

22 DR. KINSINGER: Can I just be clear

1 I know what we're voting on? So it's  
2 consistency of the evidence that influenza  
3 immunization works in home health populations?

4 DR. WINKLER: Or in populations that  
5 --

6 DR. PACE: Basically in populations.

7 DR. KINSINGER: Right.

8 DR. PACE: I mean whether they're in  
9 home health or not --

10 DR. KINSINGER: It shouldn't make any  
11 difference, right.

12 DR. PACE: It's people greater than  
13 six months of age.

14 DR. KINSINGER: So I'm puzzled by the  
15 voting.

16 DR. PACE: Because it will affect  
17 every measure that you look at.

18 DR. KINSINGER: So we're just voting  
19 on --

20 DR. SPANGLER: Which makes this more  
21 confusing, because the denominator is not the  
22 person. It's the episodes. That's what I

1 think adds to your confusion, and to the  
2 confusion of people voting. Because it is,  
3 the denominator is everyone above six months.

4 DR. KINSINGER: Yes.

5 DR. SPANGLER: It should be, I think,  
6 but --

7 DR. STANGE: This is a good  
8 discussion for now, because as we go through  
9 the immunization measures, if we're going to  
10 stipulate that everybody six months and older  
11 benefits from it, that's the same for all of  
12 these. So we don't need to vote on this for  
13 each measure. Okay. We can revote this one.

14 MR. BIALEK: Can I just -- point of  
15 information or question. If we're not looking  
16 at the evidence specific to this measure,  
17 which is related to home health, that's what -  
18 - because the evidence related to home health  
19 is a lot different than the evidence related  
20 to does influenza vaccine work? Is it  
21 effective?

22 So I thought we were looking at the

1 evidence related to this specific issue of  
2 home health. That's not the case?

3 DR. PACE: Well, so what is -- so can  
4 you clarify what the difference is?'

5 DR. STANGE: Well actually it's a  
6 good point, because you can make an argument  
7 that if a person's really isolated at home,  
8 and the only people seeing them are home  
9 health workers who are vaccinated, they're at  
10 low risk. So you could make an argument  
11 there.

12 DR. JARRIS: They're still exposed to  
13 children and other vectors.

14 DR. BIALEK: The difference is what's  
15 presented in this information before us, and  
16 I know Jason mentioned that it was related to  
17 hospital admissions for respiratory ailments.  
18 The way I read what is presented, is it says  
19 both the Lancet article and the Cochrane  
20 Review both say that it's ineffective --  
21 ineffectiveness of influenza immunization for  
22 influenza-like illness and pneumonia among

1 community-dwelling older people. It doesn't  
2 say that it -- I mean to me, that includes  
3 influenza.

4 So the research that's presented, the  
5 more current research from Lancet and from  
6 Cochrane, suggest that it's not effective.

7 DR. SPANGLER: I think you need to  
8 read that whole sentence. "It's ineffective  
9 in the prevention of influenza, influenza-like  
10 illness and pneumonia. It does not reduce  
11 hospitalization rates and death, but does  
12 reduce hospitalization for influenza and  
13 pneumonia, and reduce all cause mortality."

14 MR. BIALEK: I'm on page four or page  
15 five?

16 DR. SPANGLER: Yes. I'm on 1.C.14.

17 MR. BIALEK: 1.C.14.

18 DR. SPANGLER: On page five. The  
19 Cochrane says the same thing. "Well-matched  
20 vaccines were associated with reduced  
21 hospitalization from influenza, pneumonia and  
22 all cause mortality." So you're right. It

1 doesn't prevent this, but it does work on  
2 this.

3 DR. WINKLER: I think there was a  
4 desire to re-vote these, now that we've had  
5 this additional discussion. True? Okay. All  
6 righty. Any other comments before we do that?  
7 So we'll go back to the first question on  
8 evidence, and that's the consistency. So how  
9 do you vote on consistency? What's the  
10 matter, Kristin?

11 Okay, all right. The results are  
12 high 4, moderate 8. So that gives us the  
13 high-moderate rating that is needed. The next  
14 one, Kristin, is the quantity of studies.  
15 That's one we didn't vote before.

16 [COMMITTEE VOTING.]

17 DR. WINKLER: Okay. It's 6 high and  
18 6 moderate, so it definitely is high-moderate  
19 there, and 1C is the quality of the body of  
20 evidence. You can vote on that.

21 1 high, 11 moderate, 0 low. So the  
22 moderates win on that. So if we go to the



1 decision, go back one. The quantity was  
2 moderate to high, the quality was moderate,  
3 and the consistency was high-moderate, so it  
4 does pass. Okay.

5 All right, next one. So overall,  
6 we've seen the evidence for performance gap,  
7 and we've seen the evidence. So does this  
8 measure -- no, we don't need this one. Yes.  
9 All of these criteria must be met. Go to the  
10 next one. Wait a minute. Didn't we have one  
11 that's yes and no?

12 DR. PACE: No. If it met those  
13 criteria, you don't -- I mean it's just going  
14 to pass.

15 DR. WINKLER: Yes, okay. So we do  
16 pass. So we'll move on to scientific  
17 acceptability of the measure properties, and  
18 here are the initial ratings by the work  
19 group. Jason, did you want to comment on  
20 scientific acceptability, before we vote on  
21 reliability and validity?

22 DR. SPANGLER: Probably only to say

1       that it's kind of similar to, it seemed like  
2       it was similar to the discussion we had on the  
3       evidence itself, that there was kind of a  
4       range, I think, depending on how people looked  
5       at it.

6                There are specific comments, if you  
7       look at the rationale. I mean there are  
8       specific points that people made, and again,  
9       the discussion about the timing of the  
10      episodes. Again, I think this again comes  
11      back to this issue, for me it comes back to  
12      this issue of the denominator not being a  
13      person or a population to these episodes.

14             DR. WINKLER: Did you have a chance  
15      to look at the testing results for the  
16      reliability and validity that they provided?

17             DR. SPANGLER: Did I?

18             DR. WINKLER: Yes.

19             DR. SPANGLER: Yes, I did.

20             DR. WINKLER: And what's your  
21      assessment?

22             DR. SPANGLER: I mean I thought

1 overall, I thought they were actually okay.  
2 I'm trying to remember what I voted. I think  
3 I voted moderate, but they seem to, from what  
4 I can recall, they seem pretty good, pretty  
5 detailed. Yes, I can't remember anything  
6 specific.

7 The one, oh I know one, actually one  
8 issue I did have is the proxies that they  
9 used. They used acute care hospitalization  
10 and improvement in dyspnea as proxies for  
11 somebody receiving the immunization, and that  
12 there would be improvements in those two  
13 outcomes for those who did receive  
14 immunization, and I'm not sure those were the  
15 best proxies to use. I think that's why I  
16 probably gave it a little bit lower rating.

17 DR. WINKLER: Okay. Any other  
18 comments on reliability?

19 DR. KINSINGER: I'm having a hard  
20 time seeing it, so are episodes of home health  
21 routinely reported? I mean that's a  
22 reportable, I guess because for billing

1 purposes? So that's a routine measure that's  
2 regularly reported, an episode of home health  
3 care?

4 DR. PACE: Right. I think you would  
5 think of it as being analogous to a hospital  
6 stay. It's just in home health, patients are  
7 seen for a longer period of time, you know, 30  
8 days, 60 days, 90 days, and things are  
9 measured over that episode of care.

10 So it is about patients, but it's  
11 their unit of measurement, because that's how  
12 long patients stay in home health care. CMS  
13 may want to add something to that, but I think  
14 that's the reason that they're using episodes.

15 DR. WINKLER: Are you ready to vote  
16 for reliability? Okay, go ahead.

17 For reliability, it's 3 high, 10  
18 moderate. So that's the moderate for  
19 reliability. So the next one is validity.  
20 Any discussion on validity? Comments, Jason  
21 or Linda? Anybody have any --

22 DR. SPANGLER: Sorry. I think my

1 previous comment was related to validity, not  
2 reliability. So sorry about that, the  
3 improvement of dyspnea and acute care  
4 hospitalization.

5 DR. WINKLER: All right. Any other  
6 discussion before voting? Okay. Let's go  
7 ahead and vote.

8 0 for high, 13 moderate, 1 is low.  
9 So moderate there, and both reliability and  
10 validity must be rated moderate or high to  
11 pass a criteria, and they were both rated  
12 moderate, so it does pass. We want to look at  
13 usability. Comments, Jason, on usability of  
14 this measure.

15 DR. SPANGLER: The one comment, and  
16 this was a question, I guess, for the  
17 developer was, there was no answers for  
18 usefulness for quality improvement, and I  
19 wasn't sure if that didn't come up, or there  
20 was a reason they skipped that.

21 MS. COOK: So I think we have an  
22 issue that NQF updated these forms after we

1 completed them. So I think there were just  
2 some items that didn't appear on the initial  
3 forms we filled out.

4 DR. SPANGLER: Okay, thanks. I  
5 didn't have any other comments.

6 MS. MERRILL: So what about this --  
7 this issue may be not good to discuss now, but  
8 this idea of the relevance of these measures  
9 to immunization registries, if we're talking  
10 about relevance for population reporting. I  
11 don't know. I mean I think it's a longer  
12 discussion than maybe we have the time for.

13 But is there any relationship between  
14 this kind of reporting and what actually gets  
15 reported to immunization registries? It's  
16 just no relationship?

17 DR. JARRIS: Very few immunization  
18 registries are recording adult immunizations  
19 now. A couple of states are just beginning  
20 it, but I doubt they get at the level of home  
21 health care.

22 MS. MERRILL: So what's the answer

1 then? I mean I don't know if it's a general  
2 concept, that there should be some  
3 relationship or not. But you'll see that same  
4 comment on all of the immunization ones, and  
5 it's from me. Because it just seems to me  
6 that they're for public reporting, this is  
7 really how you assess population health. Not  
8 in the individual home health care agency;  
9 it's in the population. So that's something  
10 we might want to think about.

11 DR. BURSTIN: CDC does have a BRFSS  
12 survey item on flu vaccination for all,  
13 everybody. That's the population health one  
14 that we know of.

15 MR. COHEN: The question I had about  
16 that has to do with kind of again, the  
17 question of how the -- not so much the value  
18 of the data, but how the data informs action.  
19 I mean the value for me of something like home  
20 health versus overall population is that it  
21 gets a group of people to feel like there's  
22 something specific they can do to move their

1 numbers.

2 I'm not sure I fully understand that.  
3 But that's what feels really important to me,  
4 is that there are all these subgroups that we  
5 need to move their numbers on immunization,  
6 and in a way, just looking at the big picture,  
7 doesn't as well move the subgroups.

8 DR. STANGE: Jackie for you, would a  
9 population measure look different from an  
10 aggregation of the individual measures?

11 MS. MERRILL: That is one of the  
12 things that I wanted to talk about, and that's  
13 why I'm saying maybe now is not the time to do  
14 it. But there doesn't seem to be a link  
15 between what's going on here with this quality  
16 reporting, and then quality of the public  
17 health system in general, and I don't have the  
18 answer to how to create that.

19 But, you know, you've got two  
20 different people looking at it from a  
21 different point of view. It seems like there  
22 should be some efficiencies there.



1 DR. JARRIS: Well optimally, there  
2 would be a vaccine registry to use. But it's  
3 going to be a long time before we get there  
4 practically. But I don't think we could look  
5 at adding up these separate measures as an  
6 indication of population because hopefully,  
7 most people are not in health care. They're  
8 healthy.

9 MR. PESTRONK: So this an example of  
10 why the work that the three subgroups did  
11 today and eventually once they're adopted  
12 would be useful, to provide a structure for  
13 answering that question. Because what we  
14 would do is we would say okay, we have this  
15 clinical measure, which is what this is  
16 basically, and then we'd ask ourselves, walk  
17 ourselves back in the model, and say well is  
18 there some population -- is there some way to  
19 think about this from a population basis, and  
20 if there is, where is it appropriate to be  
21 thinking about that on a population basis, and  
22 what does it mean, then, to be thinking about

1       it at those different steps, right? Isn't  
2       that how we would have a structured way to  
3       think about clinical measures, as well as  
4       whatever we ultimately came up with on  
5       population.

6               MS. MERRILL: Right, but isn't that --  
7       in terms of being aware of the situation --  
8       you have an immunization registry that reports  
9       something, and then you have these other  
10      measures, and they have some relationship to  
11      each other, that tells you something.

12             DR. SPANGLER: Yes. From my  
13      perspective, it's more than just simply adding  
14      them up, because one of the things that was  
15      mentioned at the beginning of the discussion  
16      was that the population measures are not  
17      simply adding up individual measures. They're  
18      conceptually different from simply adding  
19      things up.

20             MS. MERRILL: So that's it. The idea  
21      of the situation so you understand. Well yes,  
22      we have an immunization rate of 80 percent,

1 but among these high risk populations, we know  
2 that these people are more at risk.

3 That's the kind of information that  
4 you need. That's what immunization registries  
5 give now, is just the global figure. But now  
6 we have all these different measures occurring  
7 and these people who are moving the numbers,  
8 as you say. So what's the situational  
9 awareness for the health officer or for the  
10 health authority for that jurisdiction or the  
11 country?

12 MR. STIEFEL: And you're right. It's  
13 a bit late in the day to dive in. But maybe  
14 we can put that on the agenda to talk about  
15 briefly tomorrow, is how does this fit into  
16 the context of the previous conversation? Are  
17 we interested, for example, in influenza or  
18 influenza mortality for a population? Then  
19 you could use the model to say okay, we've got  
20 a number of immunization rates for a bunch of  
21 different populations. What does that add up  
22 to? Not just in the cumulative immunization

1 rate, but in the mortality and morbidity  
2 associated with the flu.

3 DR. STANGE: So we'll put that on the  
4 agenda for tomorrow.

5 DR. WINKLER: So if we could finish  
6 up this measure, and see what you think about  
7 usability, if you're ready to vote. Yes?  
8 Let's vote.

9 The responses are 4 high, 7 moderate,  
10 1 low. So that's a moderate to high rating.  
11 All right, and the next one is feasibility.  
12 Any comments on feasibility before we vote?  
13 No? You ready to vote? Let's vote.

14 4 high, 9 moderate. So again, a  
15 moderate. So we voted on all four criteria.  
16 The overall vote, does this measure meet the  
17 criteria to be suitable for endorsement? Any  
18 further discussion? Ready to vote? Let's  
19 vote.

20 Yes 10, no 1. The yeses have it.

21 DR. STANGE: Does the no person want  
22 to say anything, or protect their anonymity?

1 So this is when we open it up for public  
2 comment, because we're at 5:25.

3 (No response.)

4 DR. WINKLER: If you feel that that's  
5 the end of our agenda for today, yes, we  
6 should take public comment.

7 DR. JARRIS: Is there anyone on the  
8 telephone who would like to make comment from  
9 the public?

10 DR. WINKLER: Anthony, is there  
11 anyone who wants to ask a question?

12 (No response.)

13 DR. WINKLER: Anybody in the room?

14 DR. JARRIS: Very good. Well, that  
15 does wrap up our agenda for the day. I thank  
16 everyone for being here for a very long day,  
17 a lot of hard work. My mind is fried. I  
18 imagine some of yours might be also. Let's  
19 get home, get some rest so we can refry it  
20 again tomorrow.

21 DR. WINKLER: Yes. This is Reva. I  
22 just want to talk to the folks on the phone.

1 I know you've been waiting, and thank you so  
2 much for your patience. Again, the  
3 conversations went longer than expected. We  
4 will be starting again at eight o'clock in the  
5 morning. Please let us know if you're not  
6 going to be able to join us tomorrow.

7 Elisa and Kristin and I will be  
8 monitoring our email for any messages from  
9 you, and we'll see everybody tomorrow at  
10 eight.

11 (Whereupon, the above-entitled matter  
12 went off the record at 5:26 p.m.)

13  
14  
15  
16  
17  
18  
19  
20  
21  
22

<b>A</b>				
<b>abatement</b> 172:16	<b>access</b> 34:9 49:8 64:16 65:18	<b>accredit</b> 94:3	<b>activity</b> 14:10 21:1 213:4,7 214:8	143:1 149:9 177:6
<b>ABCs</b> 38:22 49:3 77:14	103:11 117:15	<b>accreditation</b> 94:2 115:9 201:3 219:4	219:22 224:10	190:15 192:6
<b>ability</b> 84:2 302:12 302:14 432:21	169:13 285:4	<b>accrediting</b> 384:8	245:18 247:19	264:3 285:1 314:8
<b>able</b> 18:21 19:1 43:21 45:22 47:20	<b>accidents</b> 67:14	<b>achieve</b> 22:13 52:5 118:19 130:3,13	249:16,17,20	322:4 327:22
118:12 128:3,15	<b>accompanying</b> 336:1	130:15 271:18	254:8 255:4 256:4	383:18 420:12
128:16 132:11	<b>accomplish</b> 64:1 135:9 295:11	272:3 277:18	258:9 265:5,14	<b>addressable</b> 269:7
144:10,13 158:10	<b>accomplished</b> 379:15 383:22	<b>achieved</b> 72:8,10 418:6	269:3 287:14	<b>addressed</b> 45:7,12
182:9 192:18,19	<b>accomplishing</b> 149:22 150:1	<b>achievement</b> 212:15	295:5 308:2 332:6	45:15 47:22 375:4
209:15 246:6,7	<b>account</b> 331:14 370:9	<b>achieving</b> 72:19 197:1	332:15 333:7	377:16 427:1,6
247:1 294:1 306:1	<b>accountabilities</b> 196:17 197:15	<b>ACIP</b> 344:1	<b>actors</b> 321:22 322:5,9	<b>addresses</b> 382:6
314:8 339:12	222:18 223:3,7	<b>acknowledge</b> 28:17 98:3 159:8 175:13	<b>actual</b> 217:10 287:12	<b>addressing</b> 269:12 269:14
347:15 357:5	<b>accountability</b> 55:6 56:20 90:6,11	<b>acknowledging</b> 42:11	<b>Acumen</b> 2:15 420:17	<b>adds</b> 437:1
380:9 382:3,12	91:12,16 92:1,13	<b>ACO</b> 237:14,18 238:3	<b>acute</b> 359:10	<b>adequate</b> 44:13
401:3,17 423:3	93:10 104:3 110:2	<b>ACOs</b> 56:9 104:7 234:10,17	368:12,15 443:9	<b>adequately</b> 71:15
425:4 454:6	111:19 115:8,16	<b>act</b> 22:10 273:1	445:3	<b>Adjournment</b> 3:22
<b>above-entitled</b> 156:6 242:6 321:7	123:6 130:21	<b>action</b> 79:8 95:2,3 95:9 96:9,16	<b>Adams</b> 2:8 3:8 25:7 27:11 28:4 52:9	<b>adjusted</b> 350:21
454:11	131:8,12,16,19	99:10 209:20	76:16 79:12 80:9	<b>adjustment</b> 153:22 206:2
<b>absence</b> 39:18	138:7,11,14 155:5	389:10 447:18	<b>adapt</b> 327:4	<b>adjustments</b> 352:7
<b>absent</b> 47:17	162:15 174:4	<b>actionability</b> 194:22 347:16	<b>add</b> 16:19 17:12 56:8 57:13 78:9	<b>administered</b> 389:19
<b>absenteeism</b> 47:18	190:22 191:15,16	<b>actionable</b> 328:5 347:12 361:7	123:2 194:18	<b>administration</b> 1:19 9:9 12:1
<b>absolutely</b> 70:16 105:11 107:8	193:6 194:21	364:21 388:11	210:5,14 250:12	277:3
128:5 188:12	196:16,21 202:7	<b>actions</b> 184:6 202:22 261:8	324:17 333:8	<b>administrative</b> 388:20
374:20 377:4	203:3,4,10 212:21	<b>active</b> 16:6 32:17 49:18 50:13	361:2 425:11	<b>admirer</b> 185:18
<b>abstention</b> 401:12	221:10 234:6,12	213:21 214:4	444:13 451:21	<b>admissions</b> 438:17
<b>abuse</b> 10:1 44:16 44:20 287:15	238:2,16,18,21	255:3	<b>added</b> 31:7 117:20 120:12 169:11	<b>admit</b> 114:4 332:5 421:14
<b>abut</b> 239:8	279:7	<b>activities</b> 161:17 162:12 163:2,21	306:3	<b>admittedly</b> 66:5 215:4
<b>ACA</b> 32:2,2 36:16 76:7 129:16,18	<b>accountable</b> 90:20 92:6,10,19 109:7	163:22 165:1	<b>adding</b> 105:20 361:6 449:5	<b>adopt</b> 302:5 309:15 384:13
<b>accept</b> 107:21 424:18	109:19,22 110:7,9	166:6 172:5,13	450:13,17,18	<b>adopted</b> 277:2 384:3,17 449:11
<b>acceptability</b> 105:14 144:7	111:12 112:2	180:16 197:7	<b>addition</b> 202:21 213:20 262:22	<b>adult</b> 446:18
369:3 390:10	129:8,11,19 130:2	204:10,20 258:11	278:4 431:7	<b>adults</b> 396:8
392:11 393:8	131:17 138:5	258:14 280:17,18	<b>additional</b> 31:4 71:6 137:7 306:4	<b>advance</b> 17:15 24:10 55:14 159:4
401:16 441:17,20	166:3 197:14		340:11 409:1	<b>advanced</b> 360:9 404:1
<b>acceptable</b> 148:22 359:20,21	203:2 205:16		419:9 434:8,14	<b>advancing</b> 53:14
<b>acceptably</b> 398:11	213:11 218:18		440:5	<b>advantage</b> 135:22 231:18 250:2
<b>accepted</b> 24:18 49:12	221:8 234:20		<b>address</b> 19:5 40:8 58:5 68:11 69:21	256:8 269:3

<b>advice</b> 212:14	230:10 350:7	319:14 321:10	376:15	<b>annual</b> 52:1 120:16
<b>advise</b> 170:1 185:3	408:20,21 421:13	401:7 402:11	<b>allowing</b> 157:11	431:2
<b>advising</b> 67:12	421:22 422:6	405:12 435:6	158:1 400:15	<b>anonymity</b> 452:22
<b>Advisory</b> 9:12	425:3 447:8	444:16 445:7	<b>alpha</b> 282:20 283:9	<b>answer</b> 18:17,19
<b>advocate</b> 214:19	<b>agenda</b> 3:5 17:10	<b>Ahmed</b> 371:19	<b>alternative</b> 262:8	19:15 37:3 81:4
<b>advocates</b> 170:12	68:8 96:10 98:11	<b>AHRQ</b> 247:5	<b>alternatives</b> 296:16	98:14 215:11
192:10	133:18 189:2	<b>aides</b> 386:21	296:21	221:2 233:18
<b>advocating</b> 187:20	231:10 240:9	<b>ailments</b> 438:17	<b>amazing</b> 195:22	267:11 271:4
<b>affect</b> 43:19 95:5	241:16 301:4	<b>aim</b> 10:11 12:11	344:18	276:3 297:19
95:14 104:2 258:2	332:7 355:10	32:4 33:3 37:13	<b>ambulatory</b> 60:13	301:12 337:15
259:14 323:6,6	451:14 452:4	37:13 53:4 130:8	221:18 359:11	352:12 369:11
324:11 332:21	453:5,15	130:13 271:16,16	<b>amenable</b> 267:17	370:5 378:1,8
349:5 370:10	<b>aggregate</b> 49:5	271:17 333:17	<b>American</b> 143:18	399:10 403:4,7
375:7,8 436:16	<b>aggregated</b> 346:15	<b>aimed</b> 123:21	143:19 268:8	404:8,9,21 405:2
<b>affiliated</b> 360:11	347:13	<b>aiming</b> 207:18	273:1 303:5 354:6	412:5 429:2
<b>affirm</b> 261:1	<b>aggregating</b> 344:10	<b>aims</b> 199:21 200:5	<b>America's</b> 165:17	446:22 448:18
<b>afford</b> 43:6	<b>aggregation</b> 116:22	230:7 263:6,18	<b>Amir</b> 341:1	<b>answered</b> 198:7
<b>affordability</b> 37:17	128:1 251:8	271:19 293:14	<b>amount</b> 60:9,13,15	403:8,13
37:18 51:18	448:10	296:6,8 300:5	240:14 264:11	<b>answering</b> 261:5
<b>affordable</b> 32:4	<b>ago</b> 6:3 29:22 31:3	315:5	305:3 373:13	449:13
38:8 39:3 51:15	93:12 147:10	<b>air</b> 117:17	<b>analogous</b> 444:5	<b>answers</b> 240:20
53:4	157:15,16 175:1	<b>Alabama</b> 153:15	<b>analyses</b> 186:22	336:20 375:12
<b>afield</b> 146:2	202:10 211:17	<b>alcohol</b> 48:16	382:12	445:17
<b>afraid</b> 391:22	248:19 301:21	287:15	<b>analysis</b> 20:5 21:18	<b>Anthem</b> 13:1
<b>Africa</b> 4:16 13:17	316:5 342:12	<b>algorithm</b> 391:8	57:9 141:7 144:10	<b>Anthony</b> 4:6 229:2
13:19	350:15	422:22	206:20 246:18	453:10
<b>African</b> 143:18	<b>agree</b> 85:17 86:21	<b>alien</b> 100:3	326:10	<b>anxious</b> 95:1
<b>African-American</b>	102:11 196:10,14	<b>align</b> 276:10	<b>analyst</b> 15:17	<b>anybody</b> 97:20
268:7 354:5	218:11 219:11	343:12 418:20	<b>analytic</b> 3:12 61:16	227:18 229:6
<b>afternoon</b> 26:17	260:14 264:6	<b>aligned</b> 204:22	159:13 226:7	259:1 295:14
100:6 152:15	266:21 286:6	207:22 343:5,9	<b>analytical</b> 58:15	311:14 338:3
153:7 234:15	298:20 307:8	412:15 422:15	<b>analyzed</b> 247:2	391:11,17 392:5
243:4 246:5 261:3	377:12 430:14	<b>aligning</b> 78:13	<b>Andrew</b> 2:5 82:18	444:21 453:13
319:5	434:10	265:18 349:11	<b>Andy</b> 10:7 82:18	<b>anybody's</b> 423:10
<b>afternoon's</b> 232:20	<b>agreed</b> 327:1 367:7	<b>alignment</b> 30:7	91:3 155:2 194:7	<b>anymore</b> 380:13
239:17	<b>agreement</b> 10:15	32:14 35:1,2,22	219:16,17 278:2	434:3
<b>age</b> 40:15 45:7	162:13 167:13	54:10 76:18,21	<b>Andy's</b> 282:22	<b>anyway</b> 85:5
341:12 350:12	220:1 361:19	77:7 265:10	<b>and/or</b> 24:21 139:6	252:16 313:5
410:6 430:20	<b>agreement's</b>	<b>allied</b> 373:5	379:22	389:14
431:6,22 432:9	114:18	<b>allocation</b> 222:20	<b>Angeles</b> 2:17,21	<b>apologize</b> 76:19
436:13	<b>agriculture</b> 241:12	<b>allocations</b> 222:14	3:16 21:16 334:12	380:5
<b>aged</b> 407:12	<b>AHA</b> 13:12	<b>allow</b> 23:22 28:16	<b>Ann</b> 2:10 3:4 5:17	<b>appear</b> 95:8 106:4
<b>agencies</b> 5:9 94:4	<b>ahead</b> 4:5 16:7	102:6 150:11	<b>annotated</b> 3:13	207:22 405:1
241:10 278:22	25:16 34:8 121:17	291:7 364:15	18:12	446:2
409:4 422:13	128:20 157:17	381:9 384:11,19	<b>announcement</b>	<b>appeared</b> 41:16
<b>agency</b> 78:18,19	158:20 231:17	417:3	94:1	264:12 339:17
160:8 161:3	258:4 263:22	<b>allowed</b> 246:11	<b>annoying</b> 252:19	<b>appears</b> 57:22



404:20	341:14 345:4	266:3 269:4	<b>assent</b> 97:22	<b>attempting</b> 19:21
<b>Appendix</b> 398:3	349:6	273:16 275:8	<b>assess</b> 19:2 167:6	69:20 157:5
<b>apples</b> 93:14	<b>appropriate</b> 79:2	286:15 305:21	294:15 447:7	<b>attempts</b> 418:9
<b>applicability</b>	143:20 144:10	320:18	<b>assessed</b> 349:3	<b>attended</b> 349:4
104:19	205:8 207:16	<b>arena</b> 55:1 171:20	413:22	<b>attention</b> 6:17
<b>applicable</b> 308:13	253:8 313:14	<b>arguably</b> 388:9	<b>assessing</b> 421:15	28:14 36:14 67:4
<b>application</b> 313:21	387:14 422:5	<b>argue</b> 105:19	<b>assessment</b> 47:7	68:6 258:19
359:16	449:20	266:11 386:19	113:2 132:6 195:9	<b>attribute</b> 14:2
<b>applications</b> 57:2	<b>appropriately</b>	419:19	199:9,12 342:20	346:18
115:8	106:5 406:13	<b>argument</b> 412:2	364:20 366:18	<b>attributes</b> 39:19
<b>applied</b> 48:8 53:19	<b>Approval</b> 23:4	438:6,10	442:21	263:13 302:6
54:20 210:22	<b>approve</b> 373:21,22	<b>arrangements</b>	<b>assessments</b> 164:5	306:16 308:4
211:9 233:6	418:14	244:13	169:21	<b>attribution</b> 212:18
235:18 340:14	<b>approved</b> 381:14	<b>arrive</b> 293:19	<b>assets</b> 199:13	<b>audience</b> 182:2
<b>applies</b> 67:7,8	383:8 384:4	<b>arriving</b> 299:10	323:19	233:9 260:1
184:4 322:14	<b>approving</b> 373:18	<b>arrow</b> 336:7	<b>assign</b> 205:8	<b>audiences</b> 233:9
<b>apply</b> 19:3 21:10	<b>approximately</b>	<b>article</b> 366:21	<b>assigned</b> 365:3	401:19
106:22 160:10	11:13	426:19 438:19	380:13	<b>auditorium</b> 348:7
211:1 251:19	<b>April</b> 353:1,17	<b>articles</b> 288:1	<b>assigning</b> 177:2	<b>August</b> 351:9,16
262:19 322:2,15	<b>APRN</b> 1:22	427:22	<b>Assistant</b> 80:4	352:4,18
323:11 337:13	<b>arbitrary</b> 68:1	<b>articulate</b> 151:18	229:16,19	<b>authority</b> 213:11
357:2 394:22	<b>area</b> 4:21 15:7 43:4	<b>articulated</b> 61:12	<b>assistants</b> 360:10	451:10
411:14 432:8	46:21 49:14,16	<b>articulating</b> 286:12	<b>associate</b> 8:21	<b>authors</b> 18:12
<b>appointed</b> 91:7	50:6,12 52:3,8	287:2	<b>associated</b> 33:17	94:18
93:8 301:21	59:12 68:18 73:6	<b>aside</b> 94:8	90:6 107:2 240:22	<b>automatically</b>
<b>appreciate</b> 28:4	93:12 105:5 117:8	<b>asked</b> 6:5 33:1,6	439:20 452:2	255:3
86:11 182:7 217:3	119:9 139:3	57:3 67:9 102:1,5	<b>association</b> 1:23	<b>availability</b> 147:13
230:22 231:2	156:22 157:20	138:4 157:14	5:5 10:9 11:10	351:13
<b>appreciated</b> 198:3	172:6 178:21	211:17,17 294:2	174:11	<b>available</b> 19:15
<b>appreciation</b> 50:19	207:14 235:5	356:11 358:6	<b>assume</b> 155:19	43:6 136:5 141:9
<b>approach</b> 64:9	248:8 264:7,10	<b>asking</b> 18:10 68:20	199:18 287:17	141:18 146:21
65:15 84:4 97:21	268:3 297:21	74:22 212:1,3	<b>assumed</b> 420:3	147:3 172:21
98:12 102:22	310:21 325:15	236:8 238:14	<b>assumption</b> 106:8	173:16 289:14
103:2,11 107:14	<b>areas</b> 20:22 44:17	240:14 262:18	149:15 254:19	351:14 352:11
107:16 112:17	56:9 59:13,22	290:16 364:13	347:3	354:20 357:8
131:21 159:15,22	61:1,4 72:21	390:4 418:22	<b>assumptions</b>	366:1 375:8
174:4 183:21	75:19 78:7,11	431:15	198:17	381:13,15,16,17
190:21 194:13	102:8,16 105:11	<b>ASPE</b> 80:1,9,12,14	<b>assure</b> 352:7 381:8	381:22 397:3
198:5 208:16,17	111:22 120:18	<b>aspect</b> 43:13,13	381:21	402:18 409:14
208:22 212:22	164:2,9 170:17	99:15 123:19	<b>asthma</b> 148:14	417:8
227:10 261:22	180:19 183:2	128:20 182:15	254:15	<b>avenue</b> 148:1
262:10 290:2	217:16 223:10	200:9 346:18	<b>ate</b> 62:22	<b>average</b> 143:6,16
349:9 370:14	230:15 234:3	<b>aspects</b> 69:16	<b>Attachment</b> 104:15	144:20
<b>approached</b> 262:9	235:19 245:17	113:21 124:17	114:8 149:6	<b>avoid</b> 221:20
410:19	248:3 249:10	160:17 251:20	<b>attempt</b> 59:1 196:8	<b>avoidable</b> 291:4
<b>approaches</b> 102:15	250:1,3,5,17,19	275:2	248:14	<b>avoiding</b> 118:21
134:4 288:20	250:21 264:1	<b>aspirin</b> 49:4	<b>attempted</b> 126:2	<b>aware</b> 63:21 81:16

166:10 182:20 371:21 450:7 <b>awareness</b> 451:9 <b>awfulize</b> 144:17 <b>A-F-T-E-R-N-O-...</b> 243:1 <b>a.m</b> 1:10 4:2 18:14 156:7,8 <b>A1C</b> 117:7 235:4	232:13 311:8 327:7 355:5 363:4 422:20 <b>backs</b> 321:11,16 <b>bad</b> 82:12 93:13 110:3 317:10 425:16,21 <b>balance</b> 65:22 403:17 404:4 <b>bar</b> 331:20 386:17 387:5 <b>barely</b> 200:12 <b>bariatric</b> 269:18 <b>base</b> 105:12 122:7 270:2 287:18 366:21 <b>based</b> 5:10 14:17 36:9 37:12 63:16 73:1 74:8 98:2 159:14 185:20 228:10 235:1,7 284:21 306:14 317:1 338:7 343:22 354:17 361:10 362:4 363:18 371:21 372:20 373:14 389:18 408:13,16 415:6 420:18 423:19 434:6,15 <b>basic</b> 343:14 <b>basically</b> 50:8 91:16 210:6 240:2 259:5 319:15 326:17 329:9 370:18 436:6 449:16 <b>basis</b> 102:15 120:16 243:10 274:18 294:21 449:19,21 <b>battles</b> 170:12 225:15 227:3 <b>BC</b> 1:22 <b>bear</b> 223:11 <b>beautifully</b> 115:13 <b>becoming</b> 135:11	352:10 <b>beg</b> 127:10 <b>began</b> 31:2 294:6 <b>beginning</b> 4:18 19:11 32:7 129:6 141:14 211:12 291:13 306:8 342:16 418:1 446:19 450:15 <b>begs</b> 160:13 <b>begun</b> 156:16 197:20 <b>behalf</b> 151:4 <b>behave</b> 46:1 315:22 316:7 <b>behaved</b> 42:18 <b>behavior</b> 41:12 43:2 60:1 62:8 64:8 168:3 190:10 205:2 217:11,21 274:5 <b>behavioral</b> 41:1 45:13 48:9 57:21 58:1 117:15 135:18 190:11 216:2 232:11 243:12,22 257:13 323:14 330:4 332:9,22 <b>behaviors</b> 19:5 20:1,19 21:13 41:10 42:16,16,20 42:22 43:1,12 45:18,21 47:5 61:10 145:8 151:15,19 163:15 167:19 168:11 218:6,6 223:19 224:5 305:4 <b>believe</b> 4:20 11:19 12:17 46:19 69:20 80:19 103:13 113:22 183:12 217:5 243:7,15,16 267:14,15 268:20 285:16 301:17 363:3 365:2 380:3	394:3 425:15 <b>belong</b> 313:18 <b>belt</b> 45:14 <b>bench</b> 108:10 <b>benchmark</b> 174:14 174:15 <b>benchmarking</b> 174:7,12 <b>benefit</b> 102:6 137:8 235:6,10 236:11 276:8 <b>benefits</b> 260:12 304:6 437:11 <b>Bernie</b> 31:18 <b>best</b> 18:4 25:2 36:5 84:3 108:16 133:7 188:13 254:22 255:2 276:5 280:20 354:14 383:6 443:15 <b>beta</b> 282:21 <b>better</b> 10:11,11 32:4 38:4,6 53:4 71:21 84:3 132:3 149:9 153:19,20 156:18 164:11 203:19,22 213:22 228:12 240:8 255:1 295:22 330:13 341:16 351:19 358:14,15 363:21 382:1 387:7 <b>beyond</b> 39:17 92:15 104:10 126:12 184:18 186:19 187:1,1 196:10 220:2 243:11 274:16 278:12 336:2 389:16 395:11 398:17 <b>Bialek</b> 1:14 14:8,8 14:12 71:19 74:5 119:13 120:10 131:14 132:20 137:4 198:2,3	232:19 313:18 321:18 325:11 368:21 369:4 389:12 395:2 426:15,18 427:17 428:9 429:3,18 437:14 438:14 439:14,17 <b>Bialek's</b> 230:22 <b>bias</b> 334:22 <b>bidirectional</b> 36:7 <b>big</b> 52:12 60:4 160:2 177:14 185:18 192:11 222:19 242:2 284:9 300:21 302:22 316:21 344:5 353:17 420:10 432:22 448:6 <b>bigger</b> 181:6 194:2 259:9 304:18 <b>biggest</b> 217:15 251:18 253:9 267:21 <b>billing</b> 443:22 <b>binge</b> 44:21 <b>biology</b> 183:19 <b>Biomedical</b> 8:22 <b>biostatistical</b> 206:3 <b>birds</b> 255:18 <b>birth</b> 246:16 <b>bit</b> 12:5 15:9 21:21 29:11 30:9,13 31:20,22 33:9 41:9 54:21 70:20 71:21 86:7 89:12 115:6 130:7 152:20 170:9 177:20 178:14 183:14 186:3 199:7 200:2 201:19 212:7 221:4 222:4,18 244:21 245:8 247:9,11 254:19 265:21 274:9
--	---	---	---	---

280:11 318:11,19 319:5 320:8 327:20 337:22 338:7 344:9 389:14 394:16 417:14 433:18 443:16 451:13	<b>both/and</b> 116:2,4 116:12,17 131:15 133:12 <b>bottom</b> 38:8 42:7 168:9 169:11 225:11 340:11 <b>bounce</b> 305:19 <b>box</b> 52:19 53:3,7,19 54:6 87:11 163:4 163:13 164:12 166:16,17 171:6 204:10 205:4 271:7 329:19,20 332:9,10 <b>boxes</b> 177:15 332:8 <b>branch</b> 283:22 <b>branches</b> 7:14 <b>brand</b> 250:14 <b>branded</b> 13:1 <b>break</b> 154:3 156:4 168:4 206:21 231:10 242:1 318:10 319:9 320:6 346:1 <b>breakfast</b> 318:11 319:10 <b>breakfasting</b> 318:12 <b>breaking</b> 40:20,21 301:14 <b>breakthrough</b> 206:3 221:3 <b>breakthroughs</b> 37:7 <b>BRFSS</b> 62:5 173:11 173:21 292:8 304:16,18 314:13 447:11 <b>bridge</b> 88:19 223:9 337:11 <b>bridging</b> 33:13 <b>brief</b> 18:18 19:13 25:4 29:17 69:12 158:10 181:15 320:7 321:16 358:17 398:5 431:14	<b>briefly</b> 5:17 59:5 231:19 270:1 355:20 358:21 359:15 365:4 399:11 409:5 451:15 <b>brilliance</b> 217:4 <b>bring</b> 26:22 83:1 96:10 99:14 114:22 141:2 143:14 181:3 187:7 196:9 224:10 245:5 248:22 249:6 270:11 276:18 291:6 327:18 395:7,22 397:9 409:18 419:6 <b>bringing</b> 84:14 85:13 91:1 94:19 245:3 <b>brings</b> 201:12 237:1 247:13 276:13 <b>Briss</b> 31:15 77:5 <b>broad</b> 106:18 122:9 138:8 151:11 184:8 309:2 <b>broaden</b> 266:3 <b>broadened</b> 216:16 <b>broader</b> 30:12 31:8 52:11 54:22 61:12 166:7 186:3,10 215:6 234:10 245:20 249:8 251:4 254:13 255:7 258:21 271:22 332:11,12 335:8 <b>broadly</b> 189:21 190:1 196:10 235:19 255:11 323:15 334:21 337:14 <b>broad-based</b> 41:2 44:12 148:12 281:22	<b>broke</b> 214:1 305:16 <b>broken</b> 87:17 345:21 <b>brought</b> 105:9 115:17 118:5 123:7 141:3,14 179:5 241:3 247:5 248:20 304:4 350:4 358:4 407:10 <b>buckets</b> 263:20 <b>budget</b> 113:6,9 382:2 <b>build</b> 137:4 209:12 209:15 253:18 274:9 288:3 309:15 <b>building</b> 30:1 36:3 54:2 239:21,21 <b>buildings</b> 282:14 <b>builds</b> 55:20 <b>built</b> 54:17 78:10 120:20 168:12 169:9 205:3 <b>bullet</b> 42:8 161:1 194:18 <b>bunch</b> 8:5 451:20 <b>burden</b> 120:1,7 402:18 <b>Burstin</b> 2:8 3:10 5:12,14 15:2,3 58:22 61:18 69:12 69:17 70:16 75:5 75:22 80:17 88:22 89:21 94:16 99:17 103:18 106:16 107:8 108:18 111:8 113:22 117:22 118:20 120:4,14 121:15 124:4 128:5 131:4 137:1 138:15 139:17 144:5 145:3 150:4 152:12 204:6 233:19 245:1 248:1 249:18	250:16 252:6 256:17 263:16 271:3 285:16 290:10 294:5 297:5 308:7 310:10,13 313:9 318:14,20 319:3 319:11 320:20 338:11 376:22 379:17 380:11 383:9 387:21 406:5 407:2 417:1 418:18 427:14 429:22 447:11 <b>bury</b> 347:13 <b>business</b> 2:5 10:8 31:19 83:17,20 84:1,4,7,9,11 99:15 129:21 156:13 192:4,8,13 193:22 219:18 278:7 279:1,15 280:2,12,14 281:6 281:7,12,20 282:3 282:12,14 315:2 323:4,8 <b>businesses</b> 192:19 322:11 <b>busy</b> 93:4 <b>button</b> 399:4 <b>buy</b> 111:1
<b>C</b>				
<b>C</b> 115:4 364:18 <b>cacophony</b> 35:1 60:14 412:3 <b>cake</b> 306:6 <b>calculate</b> 415:3 <b>calculated</b> 352:22 360:6 364:15,22 409:3 <b>calculating</b> 353:6 361:10 <b>calculation</b> 348:22 <b>California</b> 13:18 18:15 91:18 173:12				

<b>call</b> 16:15,16 17:8 21:12 22:2 49:15 69:22 82:1 128:15 234:2 235:15 245:18 246:6 247:13 248:11 249:4 260:6 266:5 270:14,17 286:14 290:13 302:14 310:14 337:21 338:13 365:15 403:11	<b>card</b> 16:7 390:15 <b>cardiac</b> 252:15 259:14 <b>cardio</b> 251:15 252:2,4 <b>cardiovascular</b> 13:10 38:22 48:6 60:17 249:3 252:13 <b>cards</b> 67:22 <b>care</b> 8:1 10:11 12:8 13:9 32:4,5 36:13 37:16 38:6,7,8 39:1,2,3 41:5 49:18,18,21 51:3 51:6,7,8,8,9,13,15 52:2 53:4,4 54:11 81:6,9,10,18 86:13 89:7,17 93:19 104:3 105:12 107:16 109:11 110:3 122:11 123:1,15 123:16,19,22 124:16,21 126:12 126:18 129:11 139:4,6 140:14,15 140:17 152:9 154:6,10,10 161:13,14,14 162:20 164:3 166:3 171:20 173:1 175:9,12 176:10 180:2 186:20 187:11,18 192:12,14,18 194:20 201:1 202:16 203:3 210:11 215:4,5,7 216:3,14 222:20 223:17 229:15 232:11 238:21 247:8 258:11,17 260:20 261:9 266:16 286:21 303:5 329:14 330:14,15 337:12	341:9 343:18 348:4 351:6 355:13,16 358:3 359:7,10,10 360:1 362:2,2,13 367:9 367:10,17 368:11 368:12,15,15 371:2,4,11,14,17 372:2,8,19 373:15 375:16 385:5 395:9 396:12 408:6 411:22 413:21 414:2 415:6 417:3,8 420:6,19,21,22 421:1,15,16 424:10,12,13,21 425:1,6,11,22 426:13,14 429:13 431:8 443:9 444:3 444:9,12 445:3 446:21 447:8 449:7 <b>career</b> 159:21 <b>carefully</b> 202:8 277:8 <b>care-acquired</b> 50:22 <b>carried</b> 20:11 44:2 <b>cascade</b> 55:3 56:16 224:3 384:20 <b>cascades</b> 165:21 180:22 225:17 <b>cascading</b> 55:5 56:21 63:19 72:16 166:9 260:12 <b>case</b> 2:19 7:20 153:2 172:9,13 206:1 207:19 265:17 277:5 324:7 334:19 401:14 421:11 423:18 428:18 438:2 <b>cases</b> 130:12 351:16 428:5 <b>catch</b> 252:17	<b>catch-all</b> 161:10 <b>categories</b> 161:22 167:15 201:5 263:5 344:8 345:2 345:22 347:9 349:22 364:14,18 372:21 373:3 374:3,13 388:7,17 394:8 397:10 405:15 <b>categorize</b> 240:18 <b>categorized</b> 388:16 <b>category</b> 48:7 161:10 168:17 194:9 348:10 361:2,6 364:8,16 377:9 388:18,19 394:6 <b>Caucasian</b> 143:18 143:19 268:7 <b>causal</b> 151:9,17,22 215:21 216:1,7,11 216:18,20 217:14 217:22 218:11 257:10,17 258:7 261:7 264:20 266:18 267:8 268:16 272:16 286:19 288:5,11 288:18 299:12 303:13 332:17 <b>cause</b> 287:12 370:16 439:13,22 <b>caused</b> 359:2 <b>causes</b> 38:21 44:22 45:6 48:4,14,14 75:21 82:15 145:9 145:10 260:5 265:7 287:9,11 373:7 <b>causing</b> 134:17 <b>caution</b> 179:11 <b>caveats</b> 406:4,10,18 <b>CDC</b> 2:16 9:4 10:14 11:4 12:3 13:12 31:15 170:11 210:22	274:22 287:5 291:3 358:4,5 368:8 369:10 371:7 381:20,21 393:4,10 395:1,15 401:6 404:11 406:21 410:18 424:20 425:14 428:19 431:2 432:6,7 447:11 <b>CDP</b> 23:13 <b>center</b> 1:15,17 7:13 7:22 10:3 50:13 187:16 <b>centers</b> 172:19 200:22 269:18 359:11 <b>central</b> 99:5 <b>CEO</b> 10:7 <b>certain</b> 105:3 125:17 165:20 170:1,20 173:8 175:15 176:8 188:8 244:1 361:5 395:6 404:21 434:12 <b>certainly</b> 28:16 29:13 30:16 32:10 34:13 35:2,13,22 36:20 40:2 45:12 46:7 51:4 53:12 53:16 54:1,12,18 56:6,8 58:13 62:19 70:2,11 76:17 147:21 148:1 197:17 208:15 209:2,13 221:20 252:7 256:3,17 264:10 276:14 335:5 341:22 343:3 351:16 352:6 354:15,22 370:15 370:16 373:13 374:21 385:3 387:7 398:12 403:18,22 406:15
---	--	---	--	--

406:22 409:14 412:9 <b>certainty</b> 252:9 <b>certification</b> 94:8 282:18 283:7 284:3 <b>cessation</b> 264:9 <b>cetera</b> 74:13 322:12,13,13 323:6,8 <b>chair</b> 282:22 301:21 310:8 313:8 <b>chairing</b> 311:2 315:16 <b>chairs</b> 133:17 134:7 317:19 338:3 <b>challenge</b> 52:6 62:2 69:6 212:10 215:1 218:2 <b>challenges</b> 60:20 218:22 394:5,15 <b>challenging</b> 4:20 64:16 213:13 <b>championed</b> 193:16 <b>chance</b> 58:14 61:14 88:21 100:1,5 103:19 127:22 155:22 158:8 246:3 442:14 <b>Chandler</b> 2:9 15:16 15:17 399:7 400:13 401:8 <b>change</b> 65:16 66:2 87:19 107:2 120:11 147:13 149:21 170:19 212:17 260:16,17 277:16 306:17 327:21,22 350:10 356:20 357:7,10 361:1 362:10 380:10 389:21,22 400:11 419:6 <b>changeable</b> 239:5	<b>changed</b> 306:3 432:8 <b>changes</b> 114:21 176:6,9 177:8,14 177:17 195:2,2 274:3,4 304:8 359:2 <b>changing</b> 66:1,2 137:14 354:8 397:22 <b>chapters</b> 94:18 <b>characteristic</b> 346:16 <b>characteristics</b> 39:19 201:12 230:8,11 235:13 295:17 343:21 354:18 <b>charge</b> 16:11 69:7 70:7 97:13 212:7 253:3 282:7 305:11 356:15 <b>charged</b> 25:21 102:3 <b>charges</b> 154:7 <b>Charlie</b> 40:10 <b>chart</b> 287:7 336:22 <b>charter</b> 319:20 <b>charts</b> 300:9,10 <b>chasm</b> 55:21 327:17 <b>cheating</b> 329:18 <b>check</b> 86:20 <b>checked</b> 14:13 39:8 <b>chew</b> 304:22 <b>chewed</b> 305:2 <b>chicken</b> 224:15 <b>chief</b> 3:14 8:18 9:7 9:16 10:20 25:20 <b>child</b> 246:14 <b>childhood</b> 183:20 <b>children</b> 46:7 172:8 259:7,11,13 438:13 <b>Children's</b> 246:20 <b>choice</b> 43:12 54:7 136:5	<b>choices</b> 190:11,13 190:17 222:16 312:5 <b>cholesterol</b> 49:4 <b>choose</b> 24:12 42:22 46:1 159:12 161:15 162:2 164:13 173:10 233:13 256:6,10 296:20 310:19 <b>chooses</b> 293:21 <b>choosing</b> 288:4 <b>chose</b> 59:13 252:12 289:8 344:7 <b>chosen</b> 38:22 <b>chronic</b> 46:5 66:17 152:5 210:8 225:5 254:11,14 431:1 <b>chunk</b> 113:8,8,10 115:22 <b>chunks</b> 113:17 <b>cigarettes</b> 85:9 <b>cited</b> 368:11 <b>citizens</b> 251:21 <b>city</b> 1:23 11:10 43:7 63:2 173:14 219:12 281:13,17 <b>clarification</b> 249:14 <b>clarify</b> 17:13 193:9 208:11 377:2 438:4 <b>clarifying</b> 74:22 75:1 <b>clarity</b> 233:11 269:5 307:14 <b>class</b> 18:4 25:3 313:19 <b>classic</b> 191:20 246:22 <b>clean</b> 117:17 <b>clear</b> 71:1 98:6 99:10,19 104:3 109:13 124:13 138:7,14 146:10 154:4 175:8 198:11,12,13	232:2 233:7 238:15 260:11 265:9,17 297:5 379:19 418:11 435:22 <b>clearly</b> 33:11 41:16 49:20 50:3 78:3 112:16 160:1 161:18 213:10 231:21 254:10 265:6,15 346:8 347:8 374:10 <b>Cleveland</b> 7:19 8:2 278:12 <b>Click</b> 45:15 <b>client</b> 166:20 177:10 <b>clinic</b> 8:2 45:8 72:6 72:14 164:22 <b>clinical</b> 11:1 17:19 20:14 27:1 41:1,4 41:19,19 42:1,9 42:10,11 48:21 50:15,18 51:11 57:21 58:2 60:1 60:14 61:9 62:9 72:9,15,22 73:7 73:10,21 74:10,17 75:13 85:21 88:12 89:6 90:5,17 92:3 92:4 93:11 101:11 107:4 108:9 116:7 116:8 117:1,10 119:18,20 120:6 121:7 129:20 133:19,20 134:11 134:15,18 135:11 135:21 137:10,17 146:15,15 149:4 150:5 151:10,13 152:4,10 156:12 161:13 162:20 164:3 168:20 170:21 171:20 175:8,9,17 176:10 176:20 179:1 180:2 183:4 191:1	191:20 193:1 194:19 196:11 201:1 204:21 210:11 213:15 223:10 243:12,21 244:4 249:7 250:6 250:11,18 251:8 256:9,13 263:12 265:10,19 269:6 269:12 273:18,18 278:19 285:1 296:8 312:15,16 323:13 324:6,12 354:21 360:4 397:5 449:15 450:3 <b>clinically</b> 135:2 <b>clinically-based</b> 72:13 <b>clinically-oriented</b> 100:19 260:3 <b>clinicians</b> 104:4 <b>clinics</b> 359:12 <b>clock</b> 399:3 <b>close</b> 27:7 51:19 92:17 204:2 417:13 <b>closely</b> 31:14 76:22 <b>closer</b> 51:20 100:21 339:14 417:10 <b>closest</b> 417:17 <b>Club</b> 93:22 <b>clubs</b> 153:19 <b>cluster</b> 240:19 368:2 <b>clustered</b> 321:3 <b>CMI</b> 50:13 <b>CMS</b> 40:13 342:13 402:7 407:10,17 407:19 410:17,18 417:2 420:12 423:19,20 424:21 444:12 <b>coalition</b> 2:5 10:8 130:19,22 219:18 281:5,8 <b>coalitions</b> 10:10
---	--	--	--	---

169:6 193:13 280:15 282:7 <b>Coast</b> 89:5 <b>coax</b> 411:13 <b>Cochrane</b> 426:19 428:10 438:19 439:6,19 <b>codes</b> 382:7 <b>cogitate</b> 201:19 <b>Cohen</b> 1:15 4:16 13:14,15 63:13 69:14 79:1 96:8 97:4 98:1 121:4 141:3 145:4 185:13,14 212:8 238:13 253:17 260:14 275:16 297:1 302:9 307:4 334:9 338:6 377:10 447:15 <b>cold</b> 348:7 <b>Collaborating</b> 10:3 <b>collaboration</b> 130:15 272:1 <b>collaborations</b> 193:14 <b>collaborative</b> 131:21 271:17 <b>collaboratives</b> 280:13 282:5 <b>colleague</b> 244:12 371:19 <b>colleagues</b> 31:4 59:10 76:22 244:11 <b>collect</b> 54:3 181:8 191:4 381:18 383:20 384:11,18 423:13 <b>collected</b> 329:3 381:10 382:10 389:15 394:12,14 408:13 <b>collecting</b> 394:9 402:21 423:11 <b>collection</b> 34:19 35:6,8 403:21	<b>collectively</b> 162:14 169:18 174:18 176:8 405:16 <b>collector</b> 309:8 <b>collects</b> 390:1 <b>College</b> 1:22 9:21 <b>Columbia</b> 9:1 81:1 <b>column</b> 116:9,13 120:11,13 123:13 137:9 154:15,17 154:21 155:13 172:2 342:1 <b>columns</b> 137:9 <b>combine</b> 342:6 <b>combined</b> 345:12 412:22 418:22 <b>combining</b> 413:14 <b>come</b> 4:16 36:10 37:10 40:1 45:18 55:11 60:10,11 67:1 68:19 69:8 79:13 87:6 88:7 89:10,11 108:21 108:22 110:10 113:13 119:9 136:11,21 142:9 144:6 167:12 207:20 228:5 229:8 233:5 235:17 241:5 258:16 260:9 270:16,18 297:14 302:18 305:22 307:13 317:13 320:6,17 369:1 374:7 379:13 382:22 383:10 392:17,20 418:16 418:22 425:2 435:3 445:19 <b>comes</b> 109:5 118:2 177:7 251:4 266:2 297:19 369:2 374:10 392:20 410:22 411:1 421:20 442:10,11 <b>comfort</b> 63:22	398:9 <b>comfortable</b> 64:13 66:9 <b>comforted</b> 299:9 <b>coming</b> 4:15 56:21 77:9 84:19 85:20 94:13 102:9 115:3 123:6 165:13 239:6 253:4 262:1 287:18 301:10 311:8,19 316:6 349:12 425:3 <b>comment</b> 3:17 17:1 19:10 22:20 26:16 35:3 57:16 58:10 59:6 63:16 73:8 82:20 83:19 97:6 102:18 112:5 119:11 137:5 139:22 151:5 163:1 182:4 206:1 209:13 217:3 225:19 228:16 229:3,5,7 231:6 233:15 239:14 275:17 290:12 302:8 334:8 346:21 377:11 396:6 403:2 410:10 415:13 441:19 445:1,15 447:4 453:2,6,8 <b>commented</b> 335:4 <b>comments</b> 17:11 22:22 58:7 66:19 85:12 88:19 95:6 98:2 113:10,14,18 114:2 136:11,16 146:21 154:2 155:20 163:20 185:15,16 189:8 202:2 215:13 276:1 296:5 301:18 305:13 358:7,17 368:19 385:7 394:19,22 395:22 402:5,10	402:10 407:3 430:9 433:2,22 440:6 442:6 443:18 444:20 445:13 446:5 452:12 <b>commercial</b> 26:1 <b>commission</b> 21:17 68:14 69:15 251:1 385:10 402:7 <b>commissioned</b> 3:13 69:19 70:12 95:4 97:1 100:12 201:10 <b>commissioning</b> 381:20 <b>commitment</b> 197:11 <b>commitments</b> 197:1 <b>committee</b> 1:4,9 6:10,14 7:2,5 9:12 16:13 17:14 18:2 18:10 19:17 20:7 20:13,16 21:7,11 22:10 23:4,9 28:21 31:10 40:11 41:17 69:7 83:2 100:8,15 179:3,9 181:20 188:7 193:22 196:15 198:11 206:18 225:13 252:20 290:18 293:17,20 313:12 315:18 343:11 346:17 349:19 350:15 363:19 370:21 373:17 375:5 379:11 381:5 382:4 383:13 399:17,19 434:20 440:16 <b>committees</b> 12:12 22:9 108:13 316:14 338:3 370:17	<b>committee's</b> 190:5 219:6 381:3 <b>common</b> 38:12 46:5 62:21 84:21 85:2 147:1,7 163:10,21 171:17 197:2 201:17 285:9 348:17 349:15 397:1,5 403:4 414:15 <b>commonality</b> 169:1 <b>commonly</b> 141:8 396:19 397:7 <b>communicate</b> 140:3 316:6 <b>communication</b> 39:2 51:3,4 424:10 <b>communications</b> 424:12 <b>communities</b> 32:6 35:19,19,21 38:9 49:9 66:21 67:3 71:8 129:16 139:11,15,16,20 140:4 142:2 149:1 173:9 189:16 190:3 210:18 214:20,21 234:11 272:21 273:2 274:14,16 275:17 281:15 312:8 315:14 333:17 374:16 378:9 <b>community</b> 7:22 10:17 11:2 35:17 36:8 37:14 40:22 41:18 42:10 43:13 46:20 47:6,8 48:10,12 49:8 51:11,12 56:7 57:21 58:2 60:1,2 61:3,13 62:4,10 64:4,7,14,19,22 65:16,18,21 66:22 68:4,10,11,16,20 72:10 73:8,17
--	--	---	--	---

74:4,6,11 75:14 78:5 82:4,12,21 83:5,14,18 84:1,4 84:7,11 85:16 86:22 87:1,8 88:5 88:6,6,13 89:15 90:13 96:11 97:14 98:15 99:14 100:7 104:11,21 106:11 107:4 110:11 111:4 112:9,12,22 116:10,16 117:2,8 117:16 118:7 119:4,5,11,19,22 121:8 123:3 124:8 124:18,19 125:5,5 125:7 126:16 127:5 128:8,9 129:3 132:6,9,11 134:2,9,12,16,20 135:12,13,22 137:11,19 141:7 145:7,14 146:17 148:12,15 151:21 153:9,20 154:20 154:21 160:3 164:5,9 167:22 168:21 169:13 170:21 171:13,14 176:21 177:22 179:1,7 187:2,20 188:14 189:18,22 190:2,7,9,10,12 190:14 192:3,4,8 192:13 193:16 198:14 199:9,12 199:13 200:18 201:15 202:17 205:11,13 209:3 211:19,20 217:17 218:16 219:14 228:3,13 235:6,10 237:13,20 239:5,8 243:13 245:21 247:2,8 253:22 254:1 258:1 269:7 271:6 273:6 276:8	276:9,19 277:12 278:7 279:1,10,10 280:19 281:2,3,6 281:8 282:4,5,8 283:21 284:1,16 289:17 290:4 291:8,21 303:19 304:4,14 306:12 314:5,7,21 315:1 315:7 323:4,5,6 323:10,14,15,18 323:19 324:4,8,10 324:11,13,15 326:21 333:22 335:19 336:15 337:1,1 351:15 356:13 378:14 407:5 <b>community's</b> 83:21 <b>community-based</b> 166:1 322:12 <b>community-cent...</b> 188:3 214:10 <b>community-dwel...</b> 439:1 <b>community-orie...</b> 62:17 101:17 <b>community-wide</b> 212:17 277:16 279:21 280:13 <b>compact</b> 196:20 <b>companies</b> 11:5 13:12 90:19 376:17 <b>company</b> 26:4 42:4 <b>comparable</b> 397:18 398:11 <b>compare</b> 52:3 115:15 153:17 318:4 416:4 <b>compared</b> 397:13 <b>comparing</b> 345:3 <b>comparison</b> 345:6 396:18 <b>compelling</b> 255:6 426:20 <b>compete</b> 119:16	<b>competence</b> 94:9 <b>competent</b> 51:4 <b>competing</b> 18:1,5 24:22 77:21 118:21 165:10 170:7 173:17 174:7 187:13 208:12 341:19 <b>competing's</b> 165:11 <b>competitive</b> 279:16 <b>competitiveness</b> 279:18 <b>compiles</b> 370:2 <b>complementary</b> 118:18 163:2 169:16 178:9 180:22 181:10 <b>complete</b> 212:14 223:1 233:8 <b>completed</b> 359:8 446:1 <b>completely</b> 100:2 226:19 336:19 <b>completeness</b> 169:7 <b>complex</b> 150:22 156:22 160:16 166:9 175:2 180:21 208:21 209:6 306:15 430:6,7 <b>complexity</b> 208:6 208:14 <b>component</b> 51:16 144:21 207:11 236:19 250:13 251:15 377:13 <b>components</b> 216:11 216:22 260:2 386:6 <b>composite</b> 41:6,8 45:20 47:6 248:20 248:20 249:1 <b>comprehensive</b> 26:12 283:18 344:2 <b>compute</b> 313:3 <b>computed</b> 344:12	<b>computer</b> 399:9 <b>concept</b> 39:12 40:6 40:18,19 41:17 44:1,18 47:12 56:20 67:15 124:3 131:11 135:19 143:3,12,13 149:3 159:10 160:6 195:21 201:13 228:2 265:2,13 266:1 273:15 288:17 289:13 447:2 <b>concepts</b> 27:5,6 33:17 37:21 41:1 44:11,13 51:17 56:3 106:18 156:19 250:9 259:6 <b>conceptual</b> 37:7 107:10 184:10 259:17 <b>conceptualize</b> 44:8 <b>conceptualized</b> 423:6 <b>conceptually</b> 4:19 336:11 450:18 <b>concern</b> 59:19 206:12 248:7 362:22 <b>concerned</b> 219:21 239:11 261:11 <b>concerns</b> 81:20 389:11 <b>concert</b> 176:9 <b>concession</b> 362:18 <b>concise</b> 182:13 183:7 186:5 <b>conclude</b> 231:9 295:10 <b>conclusion</b> 299:10 <b>conclusions</b> 307:18 <b>concrete</b> 307:8 309:4 310:16 <b>concur</b> 68:22 <b>condition</b> 98:21 430:20 431:6,22	<b>conditions</b> 78:4 83:14 84:2 114:12 114:14 183:22 259:11 280:5 431:1 <b>conducted</b> 359:5 408:12 <b>confidence</b> 144:4 248:9 <b>confirmed</b> 408:22 422:7 <b>conflict</b> 7:16 14:2 26:3 75:16 135:7 <b>conflicts</b> 10:13 11:6 11:19 13:13 14:7 14:9 25:14 26:9 26:14 <b>confused</b> 125:3 <b>confusing</b> 137:16 436:21 <b>confusion</b> 217:16 220:20,21 437:1,2 <b>connect</b> 4:10 57:7 261:8 <b>connected</b> 4:9 161:6 <b>connecting</b> 29:14 <b>connections</b> 162:7 <b>connectivity</b> 44:14 <b>consensed</b> 263:5 <b>consensus</b> 20:18 23:3,6 24:5 30:2,5 83:6 97:19 102:2 118:5 132:18 134:8 185:22 199:21 230:5,7 262:10,17 263:9 285:22 293:12 295:19 323:9 327:13 360:18 408:16 <b>consequences</b> 54:19 63:20 64:3 142:15 352:15 <b>consider</b> 20:8 112:13 140:9 157:14 160:9
--	--	---	--	--

163:9 172:10 190:8 196:3 277:8 291:17 292:9 366:4 400:8 <b>consideration</b> 3:20 114:12 198:14 339:2 359:3 361:16 <b>considered</b> 143:11 143:22 147:11 198:19 230:7 231:2 352:5 357:10 390:6 <b>considering</b> 15:7 236:12 259:22 <b>consistency</b> 23:22 366:19 368:18 391:5 433:20 434:1 435:14,15 436:2 440:8,9 441:3 <b>consistent</b> 37:22 96:12 368:17 <b>consistently</b> 354:19 <b>consortia</b> 291:9 <b>consortium</b> 31:18 129:18 273:4 <b>consortiums</b> 196:8 <b>constantly</b> 133:9 <b>constitutes</b> 41:2 <b>Constitution</b> 163:7 <b>construct</b> 72:1 349:7,14 382:8 <b>constructed</b> 348:15 <b>constructing</b> 348:18 <b>constructive</b> 276:19 302:19 334:10 <b>constructively</b> 276:5 <b>constructs</b> 349:17 <b>consultant</b> 8:19 <b>consulting</b> 6:19 <b>consumer</b> 51:18 56:15 112:18 312:13	<b>consumers</b> 31:11 312:14,19,20 328:4 401:19 <b>contact</b> 30:17 114:5 360:5 376:6 <b>content</b> 187:7 <b>context</b> 25:6 29:9 30:9 32:1 42:21 43:10 54:21 60:4 61:4 63:8 64:9 70:19 73:18 104:11 106:21 107:4,4 115:20 137:8 149:10,21 226:9 237:15,16 237:17,21 251:4 260:13 261:7,14 410:13,21 451:16 <b>contexts</b> 125:12 <b>contextual</b> 179:4 <b>context-setting</b> 52:10 <b>contingency</b> 379:15 <b>contingent</b> 390:3 <b>continually</b> 378:8 <b>continue</b> 45:5 104:10 142:19 231:3 357:18 384:5 <b>continued</b> 390:2 413:1 <b>continuing</b> 260:19 260:22 <b>continuum</b> 330:1 417:9 <b>contract</b> 80:12 <b>contracted</b> 363:7 <b>contracting</b> 377:3 <b>contractor</b> 21:15 <b>contractors</b> 318:8 <b>contracts</b> 196:18 <b>contradictory</b> 426:16 427:20 <b>contraindicated</b> 409:3 <b>contraindication</b> 345:11 360:22	364:19 <b>contraindications</b> 344:16 346:3 348:20 419:14,15 <b>contrast</b> 132:11 290:7 <b>contrasting</b> 133:9 <b>contribute</b> 90:20 197:2 237:12 272:18 <b>contributed</b> 28:21 37:8 <b>contributing</b> 214:13 230:12 268:17 <b>contribution</b> 206:6 212:18 272:14 329:13 330:15 <b>contributions</b> 240:4 <b>contributor</b> 267:22 <b>contributors</b> 52:15 266:12 <b>control</b> 7:14 49:4 179:14 238:7 369:14 <b>controlled</b> 109:19 109:21 <b>controlling</b> 192:11 <b>controls</b> 238:9 <b>controversial</b> 204:14 <b>convene</b> 32:16 57:3 <b>convened</b> 30:21 <b>convener</b> 30:10 233:22 <b>convening</b> 230:14 <b>conversation</b> 58:4 68:15 69:3,10 92:12 95:2 96:18 149:11 182:3 189:4 213:17 216:16 230:20 240:2 266:9 267:3 271:14 293:2,3 295:8 298:4 307:2 326:19 338:21	342:9 451:16 <b>conversations</b> 67:8 98:13 132:13 238:12 307:12 454:3 <b>convert</b> 328:13 <b>converting</b> 328:14 <b>Cook</b> 2:15 407:18 407:19,22 408:10 420:16,16 421:11 430:18 431:16 445:21 <b>cooperative</b> 10:14 11:3 <b>coordinating</b> 79:22 80:10 <b>coordination</b> 32:14 39:3 51:3,6,13 424:10 <b>COPD</b> 412:19 <b>copies</b> 34:1 <b>coping</b> 183:19 <b>core</b> 215:2 <b>cornerstones</b> 105:7 105:18 <b>corollary</b> 263:11 296:7 <b>corporate</b> 39:16 82:3,7,13,14 <b>Corporation</b> 39:14 <b>corporations</b> 282:22 <b>correct</b> 217:4 318:5 364:6 377:5 404:19 409:10 430:5,5 <b>correctly</b> 150:2 364:10 <b>correspond</b> 421:4 <b>corresponding</b> 256:13 <b>cost</b> 74:13 145:12 234:20 <b>costs</b> 10:12 52:2 177:10 395:13 <b>Council</b> 219:13 <b>counsel</b> 3:4 5:19	<b>counseled</b> 117:14 <b>count</b> 352:8 400:4 <b>counted</b> 377:9 420:6 421:10 <b>counties</b> 142:5 173:20 <b>counting</b> 364:10 <b>countries</b> 107:11 <b>country</b> 10:10 11:14 12:22 38:2 82:3 85:11 112:15 126:16 163:8 164:2 171:16 174:2 175:11 260:18 265:8,16 451:11 <b>county</b> 1:23 3:16 8:3 11:10 12:15 21:16 142:8 166:1 166:8 173:9,13,18 174:10 180:9 192:15 228:9 292:17 303:6,16 304:12 305:17 306:13 308:1 309:12 314:11 <b>county-wide</b> 142:8 <b>couple</b> 12:12 15:20 16:18 59:13 91:6 92:15 99:12 123:7 154:1 175:1 178:17 198:5 202:13 227:5 243:5 255:5 292:13 333:16 335:18 399:7 446:19 <b>course</b> 29:18 33:16 37:1 48:15 55:18 56:15 76:21 78:4 78:7,13 79:14 101:8 150:14 165:4 168:7 169:2 171:16 172:14 173:3 175:10 184:2 200:20 204:18 224:4
--	--	---	--	---



264:3 377:6 396:7 396:10 419:2 421:21 427:22 428:8 <b>cover</b> 169:4 <b>coverage</b> 355:12 358:2 367:19 <b>covers</b> 425:15 <b>co-chair</b> 1:13,14 3:19,21 28:18 310:7 <b>co-chairs</b> 1:10 23:1 <b>CPPW</b> 276:2,9 <b>crack</b> 193:14 295:14 <b>cracks</b> 424:3 <b>Crawford</b> 244:12 <b>craziness</b> 342:19 <b>crazy</b> 86:3 341:16 343:3 <b>create</b> 43:11 63:9 84:5 170:13 180:14 219:15 234:19,22 279:7 281:8,8 300:20 411:14 448:18 <b>created</b> 159:14,21 162:8 169:4 218:5 294:1 340:20 343:14,17 351:12 <b>creates</b> 219:12 <b>creating</b> 80:2 125:1 147:16 217:19 220:20 236:7 280:4 <b>creation</b> 217:18 <b>creative</b> 193:8 <b>credentialed</b> 361:21 <b>credibility</b> 141:20 215:8 334:17 <b>credit</b> 353:19 <b>crime-ridden</b> 43:4 <b>crisp</b> 246:8 <b>criteria</b> 19:2 21:10 22:16 24:16 25:6 61:16 70:13 95:10	96:4,5 100:17 104:14,19,20,22 106:3,4,9 108:20 111:10 113:6 114:9 120:16,21 121:18 127:8 137:22 141:18 149:8 150:2,10 232:3,4,8 235:17 236:13,16 245:9 255:16,17 282:15 293:7,9,9,12 294:7,9,12,19 295:21 297:7 307:6 314:1 326:20 327:2 328:18 355:20 356:21 365:5,7 370:21 391:11,19 392:19 401:17,18 403:18 406:1 430:10,21 433:17 441:9,13 445:11 452:15,17 <b>criterion</b> 109:1 121:22 <b>critical</b> 33:15,20 35:6,9 36:22 51:15 53:2,14 62:15 66:17,19 77:15 78:12 79:10 105:13 131:10 142:18 151:22 152:3 218:12 365:21 <b>critically</b> 39:21 90:22 <b>criticism</b> 94:8 135:3 175:17 <b>crossing</b> 327:17 <b>cross-cultural</b> 26:21 73:9 <b>cross-cutting</b> 53:11 <b>cross-walk</b> 241:20 285:12,19 <b>Cross/Blue</b> 12:22 <b>crystallized</b> 86:10	<b>culpa</b> 83:20 <b>cultural</b> 112:8 <b>culturally</b> 51:4 <b>culture</b> 15:9 66:3,3 82:3,14 112:9 <b>cultures</b> 107:12 135:7,9 226:16 <b>cumulative</b> 451:22 <b>curious</b> 85:19 131:6 249:17 253:3 364:7 <b>current</b> 23:15 24:6 24:15,20 47:3 98:11 104:14 169:21 191:10 343:13 344:1 408:8 413:17 422:13 439:5 <b>currently</b> 152:16 169:12 247:1 278:18 402:6 411:10 <b>curtailed</b> 361:18 <b>custodial</b> 363:12 <b>custodian</b> 363:10 376:2 <b>custodians</b> 363:12 <b>customers</b> 39:16 283:21 <b>cutting</b> 300:15 325:21,22 <b>CV</b> 6:12 <b>cycle</b> 406:16 <b>cyclical</b> 270:3 <b>C-O-N-T-E-N-T-S</b> 3:1	153:3,12 168:14 171:17 172:16 173:7,10,11,17,21 174:4 177:4 181:8 191:4,6 211:2,22 212:10 214:12,12 214:13,14,14 223:18 240:22 274:20,22 275:2 304:17 314:2,6,12 314:15 349:13,15 354:20,21 361:7 363:1,20 364:2,3 364:21 365:22 366:4 368:22 369:1,4,11,13,18 370:9 372:22 373:21 375:7 378:19 379:21 381:9,12 382:10 383:20 384:11,18 387:12,16 389:4 389:15,17,18 390:1,11 392:16 393:11,16 394:12 396:19 397:1,2,5 397:15 398:10 402:17,21,22 403:5,20,21,22 404:14 406:16 408:13 411:5,12 411:15 412:14 413:1 417:6 422:11 423:2,3,20 447:18,18 <b>database</b> 172:4 370:1 421:10 <b>databases</b> 171:21 <b>date</b> 104:1 200:1 354:16 379:16 422:8 427:12 <b>dates</b> 419:4 <b>Dawn</b> 2:17 3:15 94:17,17 100:1 101:3 156:20 157:12 158:6,16 158:19 178:12	181:13,19 182:6 185:13 188:5 190:20 198:2 200:12 201:22 203:17 207:5 211:15,17 213:12 218:8 220:10 228:1,20 239:14 284:5 285:16 <b>day</b> 16:11 99:19 213:19 243:6 362:15,22 363:3 376:2,8 451:13 453:15,16 <b>days</b> 98:8,10 99:12 178:3 246:21 278:9,10 362:17 363:8 395:7 444:8 444:8,8 <b>deal</b> 21:4 41:4 58:21 65:6 197:9 273:5 314:15,18 315:7,10 316:21 341:4 395:15 422:14 <b>dealers</b> 43:9 <b>dealing</b> 82:10 108:15 302:21,22 336:3,5 383:11 <b>dealt</b> 377:20,22 <b>death</b> 45:1,6 145:9 145:10 260:5 265:7 266:13,15 267:4,6,16,16 287:9,12 328:10 330:21 439:11 <b>deaths</b> 223:22 385:14 430:3 <b>debate</b> 363:17 <b>debating</b> 395:2 <b>decade</b> 146:22 <b>decades</b> 165:16 <b>December</b> 407:13 <b>decide</b> 167:15 168:17,19 171:4 181:2 262:13 270:13 286:4
---	---	--	---	---

289:18 301:13 418:16 423:14 <b>decided</b> 256:6 322:18 <b>deciding</b> 176:7 301:19 <b>decision</b> 54:7 62:13 435:11 441:1 <b>decisions</b> 82:4,6 192:15 222:14,20 <b>decision-maker</b> 223:17 <b>decision-makers</b> 223:14 <b>declare</b> 26:14 <b>declination</b> 360:20 364:18 <b>decline</b> 344:15 347:4 348:19 419:16 <b>declined</b> 345:10 346:2 347:11 348:3,10 <b>declines</b> 419:15 <b>deeply</b> 81:14 <b>default</b> 43:2 206:12 <b>defer</b> 58:3 <b>define</b> 21:5 126:15 126:16 127:11,17 156:18 157:6 159:12 160:14 171:13,14 183:14 189:5 227:8 314:6 319:17 325:12 327:11,19 <b>defined</b> 125:5,18 127:16 159:10 230:13 279:4,12 314:5,22 315:1,2 322:19,20 323:11 323:12,15 326:6 350:8 365:18 415:17,18 423:12 <b>defining</b> 188:13 322:17 <b>definitely</b> 15:7 87:22 88:2 96:17	99:16 159:7,11 178:21 190:6 200:18 205:22 210:4 217:9,11 254:19 342:9 440:18 <b>definition</b> 38:12 98:15 99:14 160:20 182:11,13 183:1 184:10,15 184:17 186:2,3,8 186:9 199:14 228:5,12 255:8 414:18,19 415:2 430:13 <b>definitional</b> 89:13 101:4 105:20 <b>definitions</b> 87:7 126:3 157:1 182:8 182:14,20 183:6 184:12 185:3,7,10 245:11 298:6 <b>degree</b> 297:3 <b>degrees</b> 249:21 <b>delegation</b> 163:7 <b>deliberations</b> 231:3 <b>delineate</b> 240:17 336:15 <b>deliver</b> 161:16 168:21 <b>deliverables</b> 180:13 <b>deliveries</b> 54:12 <b>delivery</b> 33:13 36:12,16 162:3 176:1 216:14 330:15 <b>demands</b> 219:5 <b>demonstrate</b> 384:14 <b>demonstrated</b> 426:21 <b>demonstration</b> 139:1 <b>denominator</b> 49:2 106:13 127:11 325:7,14 348:21 349:1 350:5 352:1	360:1,6 361:12,14 405:16 414:16,20 415:7,10 419:20 419:20 420:15 423:12 432:4 436:21 437:3 442:12 <b>denominators</b> 84:22 104:9 344:6 410:3 418:4 <b>dental</b> 46:3,4 <b>department</b> 2:17 2:21 3:16 11:17 21:16 75:9 89:3 153:15 159:20 175:19 177:12 179:13 204:19 205:21 237:15 244:3 <b>departments</b> 5:9 11:14 12:4 90:12 90:18 94:9 169:3 172:20 175:11 202:16 203:5,6 <b>depend</b> 147:15 370:14 <b>dependent</b> 153:3 369:20 <b>dependents</b> 279:6 283:20 <b>depending</b> 168:14 193:15 224:9 397:10 418:4 431:9 433:6 442:4 <b>depends</b> 334:18 370:20 <b>depth</b> 183:8 189:4 340:21 <b>derive</b> 300:3 304:18 <b>derived</b> 292:18 <b>describe</b> 5:17 26:2 286:10 <b>described</b> 70:13 226:8 297:21 330:21 414:11 <b>describing</b> 93:16	214:22 263:2 <b>desert</b> 43:3 65:20 <b>deserts</b> 49:11 <b>deserve</b> 318:9 <b>design</b> 178:4 230:21 <b>designed</b> 118:19 195:8 210:21 281:14 312:16 <b>designing</b> 230:17 <b>desire</b> 440:4 <b>despite</b> 13:16 64:20 346:11 <b>detail</b> 22:5 34:1 35:11 50:2 56:22 122:8 201:9 348:16 <b>detailed</b> 8:3 18:19 346:19 357:13 411:3 433:2 443:5 <b>details</b> 29:10 197:4 <b>determinant</b> 205:2 255:10,12 270:6 272:19 <b>determinants</b> 43:16 46:11,13 126:19 140:16 151:16,22 161:5 163:16,17 167:20 183:3 186:11 192:1,10,22 215:21 216:2,2,3 216:17 217:10 232:1,6,12 252:21 253:2,12 254:2 257:1,6,7,11,14 264:18 266:18 270:4 272:14 275:9 278:5 284:22 287:2 290:14 291:6 293:2 298:22 300:1 329:11 330:10 332:13,19 <b>determination</b> 25:2 85:9 <b>determine</b> 38:11	258:2 262:21 293:4,8 294:22 <b>determined</b> 322:10 <b>determines</b> 112:12 <b>determining</b> 152:9 <b>develop</b> 16:9 21:17 32:3 51:5 147:18 184:5 220:6 233:17,20 235:7 244:19 283:17 289:10 333:14 433:8 <b>developed</b> 189:11 237:8 295:19 309:10 423:4 <b>developer</b> 13:4 375:2 420:17 423:6 445:17 <b>developers</b> 17:12 19:10 24:1,9 350:21 409:14 411:10,13 416:17 418:15 426:22 <b>developing</b> 76:6 305:6 338:12 394:5 <b>development</b> 20:18 23:6 53:17 79:15 83:11 147:16 183:20 196:1 218:22 241:13 277:1 279:22 403:19 419:10 <b>develops</b> 422:22 <b>devil</b> 197:4 <b>DHHS</b> 295:17 <b>diabetes</b> 213:19 235:3 287:10 <b>diabetic</b> 109:20 123:18 124:6 <b>diabetics</b> 109:21 <b>diagnosed</b> 109:18 <b>diagram</b> 177:2 191:8 207:14 208:2,13 250:4 335:21 <b>diagraming</b> 209:16
--	---	---	--	--

<b>diagrams</b> 187:9	258:15,21 259:11	<b>direction</b> 70:3	406:17 409:19	154:12 168:6
<b>dialogue</b> 302:18	261:9,20 262:1,5	130:18 142:20	<b>discussing</b> 244:17	205:1 210:8
<b>dialysis</b> 359:12	262:5 264:2 268:6	175:20 195:16	276:21 327:3	217:22 225:6
<b>Diana</b> 91:18	270:10 286:18	206:5,8 269:16	329:16	228:11 251:17
<b>dichotomy</b> 216:19	289:1,15 293:7	274:12 338:17	<b>discussion</b> 16:2,6	252:13,16 254:11
<b>diet</b> 287:14 316:8	302:10,11 307:14	<b>directive</b> 342:5	16:10 57:16 69:1	257:15 283:16
<b>differ</b> 232:16	307:21 310:6	<b>directly</b> 218:11	70:18 76:8,10	284:12 287:10
<b>difference</b> 43:21	315:13,14 321:19	292:11 360:12	87:22 88:14 94:13	330:12 331:6
132:12,13,14,21	326:20 331:7,10	377:7 407:3	99:20 100:7 101:3	332:19 342:15
143:7,17 209:21	334:14 338:16	<b>director</b> 3:15 5:5	106:8 108:12	430:4
226:4 258:22	340:19 341:14	8:10 10:2 11:9	120:9 122:20,21	<b>diseases</b> 48:15
288:10 361:11	342:3,8 343:6,7	12:8,14,21 13:6	127:21 134:1,3	223:20,21 254:14
395:19 418:19	344:20 345:4	13:15	136:18 153:6,7	<b>dismissed</b> 93:8
434:5 436:11	348:1 349:6,7,11	<b>directs</b> 163:19	176:4 181:12	<b>disparate</b> 81:22
438:4,14	349:12,13 365:19	<b>dirty</b> 290:22	185:4 191:12	143:9 374:12
<b>differences</b> 117:10	369:18 370:2	<b>disability</b> 45:1 65:4	204:15 211:13	<b>disparities</b> 79:9
133:9,10 144:14	393:21 396:4	145:12 265:8	232:20 234:13	136:13 138:19
361:13 411:5	397:15 398:10	266:13,15 267:4,6	238:2 239:17	139:19 140:8,15
<b>different</b> 27:2	409:17 410:5	<b>disability-related</b>	243:6 245:10	140:16 152:17
32:19 36:15 47:1	412:12,13,22	287:4	246:2 268:13	153:9 168:2 232:8
55:10,12,22 60:11	413:6,9,10,12	<b>disadvantage</b>	269:1 294:7,18	284:22 314:7,14
60:11 67:4 71:7,8	415:4,8 416:9	251:11	295:3 309:2,5	326:5 328:1
79:14,15 84:14,19	417:7 418:4 419:7	<b>disaggregate</b> 41:10	319:6 322:22	331:21 365:20,22
87:14 90:16 98:11	421:6 422:11	<b>disburse</b> 25:14	325:6 328:19	367:12,13,17
103:7 107:11,11	424:4,5,14 425:18	<b>discharge</b> 407:16	333:1,12 347:7,10	370:10,16,19
107:12,14 111:3,4	427:22 428:6	420:21	351:12 354:2,7	371:10,10 373:13
116:5 119:2,3	437:19 448:9,20	<b>discharged</b> 407:13	356:19 357:6	374:17 375:1,3
125:11,12 126:17	448:21 450:1,18	<b>discipline</b> 266:22	367:3 394:20	378:19 379:6
129:3,5 131:8,11	451:6,21	333:4	401:6 402:16,22	380:21 381:9
137:18 139:12	<b>differently</b> 27:3	<b>disclose</b> 6:8,13 7:7	405:11 406:2	383:9,13 384:12
142:2 145:18	131:5 227:12,13	9:2,18 11:7,20	409:13,22 410:8	384:19 387:11,16
146:5 155:16	227:15,16 262:6	12:6,18 14:6	410:17 437:8	389:16 392:17,19
156:11 159:8,9	345:19 434:15	<b>disclosure</b> 6:4 7:9	440:5 442:2,9	406:14,17
160:17,17 163:11	<b>difficult</b> 59:3 64:15	<b>disclosures</b> 3:3	444:20 445:6	<b>disparity</b> 144:21
164:8 166:13	71:3 133:3 177:21	5:14,16 9:10 10:5	446:12 450:15	155:15 314:1
173:16 180:10	291:11 339:7	12:10 14:15,18	452:18	315:4 370:22
185:6 189:10	344:22 364:2	<b>discover</b> 220:17	<b>discussions</b> 50:13	371:1,2 372:10,12
196:16 201:14	390:19	<b>discovered</b> 254:3	75:6 134:22	372:18 373:9,11
203:1,11 205:13	<b>difficulty</b> 125:2	<b>discrimination</b>	152:15 157:5	380:20 382:8
220:9 221:17	361:4,21	387:1	188:19 238:5	<b>display</b> 354:15
223:5,6 226:17,19	<b>diminished</b> 64:6	<b>discuss</b> 14:17 19:17	248:1 357:19	<b>disposal</b> 241:6,15
228:4 232:4,9,9	<b>diminishing</b> 65:5	113:20 167:1	392:19	<b>disseminate</b> 334:20
232:15 235:19	336:10	181:16 325:11,18	<b>disease</b> 1:16,20	<b>disseminated</b> 335:6
238:19,19 239:19	<b>dinner</b> 244:7,11	446:7	7:13 13:7,10	<b>dissemination</b>
240:17 241:10	<b>direct</b> 26:12 196:17	<b>discussed</b> 22:18	39:17,18 48:6,7	335:10
248:8,11 249:5	197:14 280:3	133:22 211:7	48:13 66:17	<b>distant</b> 221:11
256:12 258:10,11	399:8	351:11 360:17	134:14 148:14	<b>distinct</b> 161:22

<b>distinction</b> 218:13 252:21 258:14 331:18 389:7	103:11,16 109:11 109:14 110:20 128:12 132:1	37:4 49:1 52:9 57:12 58:6,7,9,22 61:6,18 62:20	227:20 228:20 229:6,12 231:4,8 231:17 232:18	338:11 339:3 346:21 347:2,3,6 347:17 348:2,11
<b>distinctions</b> 257:20 324:3	135:5 146:22 149:6 150:3,13	67:10 69:5,12,17 70:8,16 71:13	233:14,19 234:16 235:22 236:21	348:13,14 351:7 351:10,14,17,21
<b>distinguish</b> 231:21 232:14 256:22 298:22 300:1 331:3,4	153:19,20 154:6 157:3 158:3,6 162:21 186:13 187:15 194:3	73:4 74:21 75:5 75:20,22 76:1,3 76:16 79:7,12,19 80:6,9,17 82:17	238:1 241:18 243:3,20 244:9,15 245:1 247:16 248:1 249:14,18	352:12,14,19,20 353:3,14 354:2,7 354:10,12 355:4 355:22 357:22
<b>distinguishes</b> 160:1	196:5 202:19	85:6,13 86:5 88:2	250:16 252:6,14	358:11,15 363:5
<b>distribution</b> 258:1 331:22 332:1,3 366:5	205:12 210:1 212:6 215:4 218:19 227:15,17 237:5,12,17 265:1	88:16,22 89:19,21 90:1,2,22 93:3,5 93:11,21 94:16,22 96:6,19 97:5,7,10	253:15 255:21 256:17 257:5 258:4,6 259:22	364:7 365:1 367:5 367:20,21 368:19 369:2,6,10,15 370:4,7,13,22
<b>dive</b> 451:13	283:14,15 284:15	99:17 101:21	261:2 263:11,16	371:15,19 372:13
<b>diversity</b> 288:20	292:3 298:1,11	103:13,18 106:1	263:21 264:1,22	373:6,18 374:5,20
<b>divide</b> 174:12	307:7 312:4	106:16 107:8	267:10 268:1,20	375:6,14 376:20
<b>divides</b> 85:3	313:10 320:11,13	108:4,18 109:3,16	268:22 269:17,20	376:22 378:18
<b>divisions</b> 412:18 424:20	335:1 347:19	110:4 111:8 112:4	271:3 272:21	379:8,9,17 380:2
<b>DNSc</b> 1:21	355:22 364:5	113:3,22 115:21	273:13 274:7	380:11,18,21
<b>doable</b> 60:4 179:11 320:8	365:10 380:13 382:14 383:21	117:4,22 118:15 118:20 120:4,14	275:15 278:1,2 281:4 282:9,17	381:6,7,19 382:14 383:2,9,18 384:22
<b>doctor</b> 124:12 125:15 152:6 347:21 348:8 376:7	392:7 416:22 417:2	121:3,15 123:12 124:4,10,15 125:6	283:7 284:5 285:8 285:16,21 286:14	385:12 386:2,4 387:9,21 388:8 389:6 390:8,15,18
<b>doctors</b> 375:22 388:12	<b>dollars</b> 277:1 283:4	125:9,22 126:8	287:5 288:1,15	391:14,21 392:2,6
<b>document</b> 198:6 199:20 261:19 295:17 422:6 424:8	<b>domain</b> 114:17 328:3	127:1,17,19 128:5 128:19 131:4	290:10 291:19	392:8,10 393:10
<b>documentation</b> 395:11,20 396:4 397:12	<b>domains</b> 61:2 116:18 131:22 201:3 333:5,6	135:15 136:8 137:1 138:2,15	292:12,18 294:5 295:1,7 296:6,11	394:19 398:13,14 398:19 400:2,6,7
<b>documents</b> 40:1 226:9,15 239:19 334:13	<b>door</b> 108:3	139:14,17 140:18 140:19 142:22	297:3,5,12 298:18	400:8,18 401:9,12
<b>dodging</b> 4:17	<b>dose</b> 428:22	144:5,15 145:3 146:19,20 148:5,8	299:13,21 300:19	401:13 403:2,16
<b>doing</b> 5:13 8:6 17:22 18:6 20:3 34:12 35:14 36:3 44:9 57:2,8 58:16 69:20 70:17 73:2 75:17 82:20 85:16 90:13 95:22 100:13 102:14	<b>dots</b> 29:14	149:2 150:4,16 152:3,12 153:13	301:7,9,11,15,19 303:2,3,15 304:20	404:7,11,17,19 405:4,6,11,14,19
	<b>doubt</b> 446:20	154:1 156:2,9 158:18 159:18	305:14,15 306:8 306:21 307:19,20	406:3,5,7,8 407:2
	<b>downstream</b> 287:3 329:10 330:12,19 331:1 332:18 333:20	178:12 181:13 185:12 190:4,20 194:6 195:20	308:6,7 309:6,19 310:10,11,13 311:1 312:11	407:8,21 408:3 409:9,11,12,16 410:13,16,20
	<b>dozen</b> 385:14	197:21 200:7,12 201:20,22 203:14	313:7,9,11 315:15 315:17 316:12,13	411:21 412:6 413:19 414:22
	<b>Dr</b> 4:3,6,10,13 5:12 5:20 7:6,10,16,17 8:9,16 9:5,14,19 10:19 11:21 12:13 14:5,11,22 15:2 15:14,19 16:19 25:11,11,17 26:5 26:10,15 28:4	203:17,21 204:6 205:5 207:2 211:12 215:10 218:8 219:16 220:16 225:18	316:18 317:3,7,10 317:18 318:6,14 318:20 319:3,8,11 319:14,19,22	415:12,16,20 416:15 417:1,11 417:19 418:8,13
			320:3,4,10,18,20 320:22 321:2,10 324:19,22 326:4 326:11,14 328:21 334:7 337:3,19	418:18 419:11,18 420:3,10 421:7 422:9,18 423:5,16 423:22 424:7 425:6,8,9,10,14

425:16,17,21	445:3	30:8 110:17	104:16 397:3	363:6 364:2
426:9,17 427:14	<b>D.C</b> 1:10 5:7,10	192:20 194:1,3	<b>elegant</b> 239:15	367:10 373:1
429:21,22 430:2,9	10:22 11:12	196:2 222:11,21	<b>element</b> 104:18	377:8 380:1 388:2
432:3,14,18	<hr/> <b>E</b> <hr/>	372:6	121:9 141:6	388:14 389:8
433:12 434:3,18	<b>e</b> 116:12 119:14	<b>EEO</b> 388:19	<b>elements</b> 122:3	394:6 395:4
435:22 436:4,6,7	398:3	<b>effect</b> 64:19 127:8	216:17 294:14	<b>employer</b> 7:3
436:8,10,12,14,16	<b>earlier</b> 13:17 67:12	<b>effective</b> 39:2 42:9	403:5 404:15	222:12 279:5
436:18,20 437:4,5	94:10 96:11	48:2 51:2 87:17	412:14 417:6	280:19 281:3
437:7 438:3,5,12	126:10 141:4	87:20 214:17,19	418:21	282:15,18 289:19
438:14 439:7,16	163:1 200:11	240:10 263:13	<b>elevated</b> 172:8	<b>employers</b> 110:22
439:18 440:3,17	213:5 237:2	269:13 424:9	<b>eleven</b> 156:2	203:5 220:12
441:12,15,22	239:14 245:11	427:19 437:21	<b>Elisa</b> 2:11 3:5 8:14	272:2 279:8,13
442:14,17,18,19	263:2 269:21	439:6	61:8 114:1 155:20	280:10,21 283:8
442:20,22 443:17	271:14 276:21	<b>effectively</b> 150:10	159:4 318:16	283:12
443:19 444:4,15	300:11 301:4	189:6	454:7	<b>employer-based</b>
444:22 445:5,15	318:19 332:3	<b>effectiveness</b>	<b>Elisa's</b> 16:10 27:17	10:9
446:4,17 447:11	333:12 335:4	368:14 427:13	<b>ELIZABETH</b> 2:19	<b>employment</b> 46:9
448:8 449:1	339:8 352:9,11,11	<b>efficacious</b> 432:11	<b>email</b> 39:14 155:20	387:2 390:3
450:12 452:3,5,21	357:9 409:19	<b>efficiencies</b> 448:22	454:8	<b>enable</b> 136:4
453:4,7,10,13,14	422:3	<b>efficiency</b> 74:13	<b>emailed</b> 202:13	<b>encounter</b> 118:22
453:21	<b>early</b> 55:20 68:12	151:11	<b>embarked</b> 229:20	<b>encountering</b> 24:21
<b>draft</b> 113:5 123:3	82:21 83:4,9,12	<b>efficient</b> 5:16	<b>embed</b> 328:22	<b>encounters</b> 353:8
124:9 155:19	97:16 168:7	<b>effort</b> 31:17 229:20	<b>embedded</b> 288:5	<b>encourage</b> 50:9
<b>drafted</b> 158:5	183:19 185:4	282:8	<b>embedding</b> 288:18	87:10 199:6 207:9
<b>drafting</b> 96:4	220:17 238:4	<b>efforts</b> 95:13	<b>emerge</b> 62:5	<b>encouraged</b> 428:20
<b>drafty</b> 59:1	352:17	130:14 153:1	230:21	<b>ended</b> 323:21
<b>drag</b> 69:3	<b>ease</b> 134:7	164:21 186:15	<b>emerged</b> 59:17	412:11
<b>dramatically</b> 107:3	<b>easier</b> 225:12 280:9	240:18 274:15	120:18	<b>endorse</b> 82:20
410:22	300:5,20 339:14	275:7 276:8 337:1	<b>emerging</b> 56:9	233:17 293:20
<b>draw</b> 374:16	362:8 373:9	357:15	100:15	294:2
<b>drinking</b> 44:21	<b>easily</b> 224:3	<b>egg</b> 224:15	<b>emphasis</b> 49:17	<b>endorsed</b> 20:13
<b>drive</b> 82:3 142:19	<b>easy</b> 43:1,12 103:11	<b>eight</b> 23:5 170:13	64:3 66:1 186:18	24:18 104:1 234:5
352:15 403:19	175:6 208:16	340:19 409:22	198:13	245:16 246:15
<b>driven</b> 385:5	225:4 243:17,20	426:11 454:4,10	<b>emphasize</b> 6:11	379:14
<b>drivers</b> 55:13 136:3	292:7 336:21	<b>either</b> 217:20	31:1 64:18 65:21	<b>endorsement</b> 1:3
<b>DrPH</b> 2:13	<b>eat</b> 45:19 63:3,12	247:18 274:13	133:20 146:8	17:21 18:22 20:9
<b>drug</b> 43:9 393:20	306:5	296:14 302:5	<b>emphasized</b> 33:12	21:2,8 22:20
<b>due</b> 275:1,2	<b>eating</b> 213:22	305:17 310:1	76:19	23:10,16,21 24:4
<b>Dunn</b> 182:21,22	254:21 255:3,13	380:6 408:20	<b>emphasizing</b> 41:5	29:19 53:20 245:5
183:11	<b>economic</b> 43:15	<b>either/or</b> 131:16	<b>empirical</b> 392:22	351:3 358:20
<b>duplicative</b> 297:9	183:17 196:1	<b>elaborate</b> 130:7	<b>employability</b> 46:9	361:15 380:8,14
399:16	241:13 276:22	<b>elderly</b> 47:20	<b>employed</b> 278:11	380:17 384:21,22
<b>dynamic</b> 210:7,12	279:22	430:16,17 432:12	360:12 389:4	406:2,10,16
<b>dynamically</b> 218:5	<b>ED</b> 45:4	<b>electronic</b> 369:22	<b>employee</b> 362:3	408:11 427:10
<b>dynamics</b> 208:22	<b>educate</b> 87:4	397:5 403:3,5,21	377:9 395:5,6	452:17
209:7 215:13	<b>education</b> 10:1,4	404:15	<b>employees</b> 39:15	<b>endorsements</b>
<b>dyspnea</b> 443:10		<b>electronically</b>	283:18 360:7	362:12

<b>endorsing</b> 30:4	259:13 323:5	<b>establish</b> 37:22	294:18 297:7	441:6,7 442:3
<b>endowment</b> 329:11	324:12 329:12	52:20 133:8	310:10,11 313:8	<b>evidence-based</b>
<b>ends</b> 177:13	<b>environmental</b>	<b>established</b> 37:20	313:12 316:14,19	112:17
<b>energy</b> 197:8 319:8	3:12 21:18 43:15	38:17 68:9 199:2	317:4,4 320:11,12	<b>evidence-recom...</b>
<b>enforcement</b> 219:1	47:6 151:16,21	230:15 287:22	321:3,5 326:19	178:7
<b>engage</b> 51:10 84:11	183:3 192:21	357:12	355:20 365:5,10	<b>evolution</b> 130:8
192:2 193:4	257:12 323:16	<b>establishing</b> 200:16	391:6,8 393:7	147:9 271:15
278:18,21 280:6	376:3,17 377:6	<b>establishment</b>	<b>evaluations</b> 367:2	<b>evolved</b> 186:17,17
297:6 310:17	<b>environments</b>	229:22	<b>evaluator</b> 233:22	<b>evolves</b> 231:3
<b>engaged</b> 71:8 128:4	43:19 66:2 84:6	<b>estimation</b> 428:13	<b>Evans</b> 309:13	<b>evolving</b> 56:1
169:6	168:11 183:17	<b>et</b> 74:13 322:12,12	329:4	<b>ex</b> 31:16
<b>engaging</b> 49:18	<b>episode</b> 420:9,19	322:13 323:6,8	<b>events</b> 384:20	<b>exact</b> 99:21 114:6
192:7 278:6	421:4 444:2,9	<b>etcetera</b> 56:12 65:4	<b>eventually</b> 99:6	336:16 378:1
<b>enhancements</b>	<b>episodes</b> 408:6,18	198:15 291:14	218:19 237:12,22	429:1
176:2	415:6 420:2,5	315:6 325:17	449:11	<b>exactly</b> 75:22 87:2
<b>enormous</b> 254:16	421:8 422:6	395:14 410:6	<b>everybody</b> 103:19	96:15 98:4 118:20
<b>enrolleds</b> 42:3	431:20 432:5	<b>ethnic</b> 372:14	128:21 132:16,22	120:22,22 142:17
<b>enrolls</b> 40:15	436:22 442:10,13	<b>ethnicity</b> 112:10	133:2 147:14	214:21 236:22
<b>ensure</b> 24:5 31:7	443:20 444:14	153:1 168:4	161:8 179:14	239:16 275:6
163:12	<b>equal</b> 346:11	<b>evaluate</b> 20:13	227:8 300:13	280:14 298:11
<b>enter</b> 399:10,13	<b>equation</b> 376:18	22:14 23:9 56:4	344:21 365:6	306:19 307:10
<b>enterprise</b> 52:14,20	<b>equitable</b> 255:20	71:3 122:10	390:21 435:6	373:17 378:12
83:12 280:4	<b>equity</b> 39:21 40:3,8	128:16,18 246:1	437:10 447:13	383:14 428:12
<b>entire</b> 23:14 274:21	66:19 141:5	248:19 274:15	454:9	<b>example</b> 40:14
284:1 323:4 330:1	144:17 155:15	275:7 308:17	<b>everybody's</b> 89:15	41:12 55:9,16
330:18 366:8	168:2,5 182:16	309:7 310:15	227:9 398:20	59:10,14 62:4
390:22	186:9 187:5	311:22 324:20	399:22	65:18 78:1 85:8
<b>entirely</b> 13:21	201:14 254:1,13	328:18 380:10	<b>everyone's</b> 153:18	98:7 107:13
107:14	284:22 336:16	419:8 428:7	<b>evidence</b> 105:12	111:16 117:11
<b>entities</b> 111:4,12	354:11 377:13	<b>evaluated</b> 340:13	106:18 107:22	129:11 139:11
129:11 200:15	378:14	350:17 356:22	122:7 137:2 151:9	142:3,15 145:20
203:11 218:18	<b>equivalent</b> 120:6	379:18	176:18 273:17	151:14 153:11
220:5,9 234:10	144:4	<b>evaluating</b> 310:21	288:7,10 343:14	173:7 179:19
258:21 261:9	<b>ER</b> 67:15	311:5 327:5	344:1 365:17	187:2 205:1
271:16,18 312:9	<b>especially</b> 20:5	<b>evaluation</b> 3:9	366:7,8,10,14,17	212:21 213:2
312:16 384:14	130:16 140:8	17:19 18:3 19:2	366:20 367:21	214:20 238:3
<b>entity</b> 111:12 112:3	161:4 210:8	21:1,9 22:15	368:9,13 374:11	239:2,7 241:1
114:19 129:9,12	300:21 310:13	24:16 25:6 54:16	391:3,11 399:5	245:8 246:13,16
130:1,4,21 131:13	434:17	58:19 61:15 80:4	426:16 427:10,18	246:17 247:6
135:10,12 138:5	<b>ESRD</b> 341:11	96:4 100:17	427:21 428:7	251:1 254:5
155:3 220:8 273:5	<b>essence</b> 134:14	103:15 104:14,18	429:16 430:11,15	255:13 265:9
313:14 381:11	<b>essential</b> 180:9	106:4 113:5 114:9	432:11,13,15	276:9,12 278:8
<b>environment</b> 43:11	219:3 275:8	120:15 137:7	433:17 434:2,7,8	302:13 331:15
63:10 168:12,12	<b>essentially</b> 19:21	139:1 149:8	434:10,11,14,21	346:22 348:3
169:9 190:16	105:6 245:19	150:10 232:3	435:11,16 436:2	382:10 412:19
205:3 217:19,21	263:17 343:13,21	245:9 264:9,14	437:16,18,19	417:2,5 422:10
218:6 239:8	349:21 426:10,14	273:9,10 294:7,12	438:1 440:8,20	449:9 451:17

<b>examples</b> 162:19 167:14 170:2 171:11 194:12 257:2 282:3 328:7 345:5 399:21	<b>expanding</b> 212:7 <b>expanse</b> 249:8 <b>expect</b> 224:21 <b>expectancy</b> 168:1 257:22	358:21 373:7 <b>eyes</b> 38:4 51:19	331:20,21 332:1,9 332:22 336:15,17	362:19 393:12 394:3,4,11,16 402:15,15 403:1 404:5 405:12 452:11,12
<b>excellent</b> 390:12 396:1	<b>expectation</b> 71:9 250:17 251:6 379:21	<hr/> <b>F</b> <hr/>	<b>facts</b> 179:4	<b>feasible</b> 105:17 106:20 122:12 155:10 179:7 403:20 405:18 416:14
<b>exceptions</b> 391:15	<b>expected</b> 273:11 454:3	<b>FAAN</b> 1:22	<b>faculty</b> 7:20 12:10	<b>February</b> 344:21 353:20 407:14 421:9,20
<b>excited</b> 19:20 157:20,21	<b>expecting</b> 237:18 392:15	<b>fabulous</b> 82:22	<b>fail</b> 59:20	<b>federal</b> 11:16 31:13 31:16 32:10 240:7 241:10 385:4,9
<b>exciting</b> 4:18 210:18	<b>experience</b> 37:16 38:7 49:15 73:9 151:11 185:2 213:15 273:8 378:7 416:21	<b>face</b> 245:14 359:20	<b>failed</b> 431:22	<b>federally</b> 7:21
<b>exclude</b> 60:2 61:3 347:21	<b>experiencing</b> 412:16	<b>faced</b> 221:13	<b>failing</b> 51:19	<b>feed</b> 338:14
<b>exclusions</b> 348:19 431:18,19 432:4	<b>experiment</b> 336:19	<b>faces</b> 15:5	<b>failure</b> 412:20	<b>feedback</b> 18:11 28:16 36:5 53:1 54:15 95:15 156:17 206:20 210:12 257:18 331:12
<b>exclusive</b> 360:7	<b>experimenting</b> 333:16	<b>facilities</b> 110:20 359:11,14 361:4 361:20 362:9,20 368:12 371:5,11 372:9 382:6 394:7 396:18 425:19	<b>fair</b> 305:3 357:21 357:22	<b>feeding</b> 178:3
<b>exclusively</b> 230:10	<b>expert</b> 7:5 366:14	<b>facility</b> 350:7 360:11,12,20,20 362:15 364:4 369:5,20 370:2 371:17 375:17 377:5,8 388:17 389:18,21 390:1,2 390:4 414:1,7	<b>fairly</b> 98:5 189:11 197:16 209:4 306:15	<b>feel</b> 13:19 37:5 71:15 86:12 87:15 95:7 96:8,12 98:1 110:11 113:17 128:7 175:19 204:19 239:15,20 240:5,8,13,16 275:22 276:1 279:13 365:13 390:21 405:22 410:8 435:13 447:21 453:4
<b>excuse</b> 9:15 37:18 45:10 72:11 190:12,20 284:5 287:13 362:14	<b>experiment</b> 336:19	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>fairness</b> 143:5,7 182:18	<b>feels</b> 97:20 241:16 302:17,20 370:21 399:19 448:3
<b>executive</b> 5:5 11:9 13:6,15 25:19	<b>explaining</b> 333:16	<b>factor</b> 334:17 389:22	<b>fairs</b> 283:15	<b>fees</b> 6:20
<b>executives</b> 192:16	<b>experimenting</b> 333:16	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>faith</b> 382:1	<b>feet</b> 249:11
<b>exercise</b> 45:20 48:16 59:15 72:1 72:7 75:2 89:18 213:5,9 252:22 260:7 264:11 266:11,17 286:2 299:8 401:2	<b>expert</b> 7:5 366:14	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>fall</b> 28:3,3 32:20 81:13 323:18,19 415:14 424:2	<b>fellow</b> 12:10
<b>exercised</b> 63:1	<b>expertise</b> 366:16	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>falls</b> 52:11 195:20	<b>felt</b> 32:8 214:6 346:17 347:10
<b>exercises</b> 265:4	<b>explain</b> 246:8 334:21,22	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>false</b> 81:10,17	
<b>exist</b> 80:6 210:7	<b>explained</b> 271:10	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>familiar</b> 6:2 15:5 29:4,18 142:7 219:6	
<b>existence</b> 80:1	<b>explanation</b> 398:6	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>family</b> 7:18 9:16 25:18 46:12	
<b>existing</b> 19:22 53:18 95:20 106:4 227:7 250:11,22 275:11 296:14 302:5 308:11 350:17 357:20	<b>explicit</b> 299:18 431:19	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>family-centered</b> 39:1 49:17	
<b>exists</b> 285:6 308:11 432:15	<b>explicitly</b> 130:18 151:18 286:12 325:12	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>far</b> 72:5,8,10 120:2 146:1 200:4 210:14 217:6 232:2 330:17 332:7 374:6 376:5 396:22 397:7 419:16	
<b>expand</b> 19:22 29:22 73:14 221:4	<b>explode</b> 258:5	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>farce</b> 214:2,6	
<b>expanded</b> 342:7	<b>explore</b> 59:17 68:19 119:10	<b>fact</b> 40:18 62:11 64:20 68:7 70:17 84:7 91:8,13 99:20 106:19 114:1 118:9 120:5 120:7 124:1 149:20 150:1 247:20 279:14 343:1 353:5 368:7 368:10 375:7,21 381:12 387:15 429:16	<b>fast</b> 79:17	

350:15 361:6 362:4 <b>field</b> 34:21 92:21 92:22 186:16 335:3 <b>figure</b> 88:10,15 153:8 175:6 183:13 185:5 188:22 194:2 222:17 223:10 294:21 405:9 451:5 <b>figurehead</b> 91:15 <b>figures</b> 396:21 <b>figuring</b> 394:6 <b>fill</b> 53:13 78:6 <b>filled</b> 400:3 446:3 <b>film</b> 373:7 <b>final</b> 51:14 93:6 97:5 102:18 180:12 360:13 400:13 <b>finalize</b> 337:22 <b>finally</b> 19:4 399:18 <b>Finance</b> 159:20 <b>financial</b> 9:9 10:13 11:6 12:9 <b>financially</b> 12:17 <b>find</b> 39:18,22 93:17 101:1 185:6,8 195:17 197:5 204:22 306:2 320:14 327:10 378:21 397:8 401:21 <b>finding</b> 84:21 93:13 153:3 184:20 <b>findings</b> 359:1 361:3 <b>fine</b> 314:9 319:2,3 319:4 320:21 325:21,22 <b>finish</b> 243:6 301:4 390:13 452:5 <b>finished</b> 244:20 <b>finishing</b> 382:21 <b>fire</b> 155:8 317:17	<b>fired</b> 91:9 <b>first</b> 13:22 20:12 52:18 53:2 59:11 63:15 68:13 70:22 79:13 96:7 98:18 114:11 121:17,18 122:4 128:11 132:5,18,19 133:7 146:18 156:21 157:14 182:7 244:6 246:12 248:14 250:15 261:2 262:15 275:19 283:13 287:6 329:13,17 337:10 340:7,17 342:1 345:7,21 346:6 355:10 360:7 365:5 390:18 398:21 408:13 421:19 426:10,12 440:7 <b>fit</b> 47:3 52:17 54:22 71:1 137:21 150:6 175:15 224:7 232:16 245:10 294:9 299:12 327:9,10 338:10 349:22 394:6,7 451:15 <b>fits</b> 100:14 142:17 153:9 239:16 263:4 269:1 <b>five</b> 19:14 94:5 109:20 156:4 225:14 227:4 231:14,19 263:13 296:6 301:16 317:8 367:22 368:4 439:15,18 <b>fix</b> 267:18 <b>fixed</b> 69:8 <b>flagged</b> 129:5 <b>flat-out</b> 224:2 <b>flesh</b> 158:14 <b>fleshed</b> 201:9 202:10	<b>flexibility</b> 337:4 <b>flip</b> 39:4 277:19 <b>flips</b> 238:21 <b>floating</b> 86:8 <b>Florida</b> 45:9 <b>Floridian</b> 45:11 <b>flow</b> 53:6 62:17 <b>flu</b> 344:18 348:6,9 349:4 350:11 353:22 408:8 410:11 415:7 420:5 431:2 447:12 452:2 <b>flue</b> 422:3 <b>focal</b> 64:22 <b>focus</b> 33:9 53:3 59:12 75:2 78:3 90:8 95:13 103:3 122:7 151:13 161:12 163:4 164:13,14 191:1 248:16 267:20 273:14 302:12 324:4,5 335:20 342:3 347:9 357:5 357:14 <b>focused</b> 10:10 199:16 220:8 247:22 280:15 290:20 344:2 375:2 <b>focuses</b> 11:1 183:22 <b>focusing</b> 171:7 273:22 314:20 316:11 <b>Foege</b> 288:2 <b>fold</b> 64:8 <b>folded</b> 230:20 <b>folder</b> 104:16 <b>folks</b> 5:1 26:22 69:19 89:3 156:3 156:11 204:12 229:13 284:8 289:4 297:4 319:12 321:14 322:7 337:20 338:15 369:10	410:16 453:22 <b>follow</b> 4:14 61:7 70:9 235:12 297:8 407:1 420:13 <b>following</b> 23:5 109:7 360:3 <b>follows</b> 16:3 215:12 <b>follow-up</b> 230:14 255:22 404:16 <b>food</b> 43:3,5 49:11 65:19,19,21 213:22 255:12 276:15,16,20 302:13 363:10,11 376:1,13,16 377:6 <b>foods</b> 49:7,9 85:14 <b>footprint</b> 85:15 <b>foray</b> 59:11 248:10 <b>force</b> 9:12 144:18 144:19 209:4 341:18 366:12 <b>forced</b> 343:11 384:11 <b>forcing</b> 144:16 152:20 <b>foresee</b> 385:6 <b>foreshadow</b> 57:16 <b>forget</b> 54:14 56:14 286:5 <b>forgive</b> 121:4 <b>forgot</b> 380:4 <b>form</b> 6:4 <b>formal</b> 94:1 384:4 391:16 <b>format</b> 19:8 405:4 <b>former</b> 8:18 45:11 <b>formerly</b> 284:14 <b>forming</b> 337:16 <b>forms</b> 445:22 446:3 <b>forth</b> 33:3 56:4,21 88:13 150:19 170:5,8 172:18 204:13 212:2 <b>fortunate</b> 34:14 <b>forum</b> 1:1,19 13:7 15:18 27:13 225:13 230:1	<b>forward</b> 5:1 15:11 29:12 36:20 60:6 86:15 88:14 102:2 157:4 158:12 159:11 163:12 170:18 171:9 178:11 181:11 193:2 229:1 240:9 241:17 243:11 248:17 301:5 310:14 337:6 370:20 387:22 424:15 427:11 435:3 <b>foster</b> 20:4 <b>found</b> 38:14 141:8 185:17 210:17 220:22 359:17 372:22 385:16 396:9 397:16 416:21 <b>foundation</b> 1:14 9:2 10:15 11:4,18 12:5 14:13 21:14 150:18 274:13 <b>foundational</b> 20:16 79:11 128:13 246:12 319:13 <b>foundations</b> 8:6 <b>four</b> 29:22 31:3 105:7,18 109:5 127:7 165:15 180:18 223:19,21 224:5 225:14 317:8,8 368:1 369:14 426:6 439:14 452:15 <b>fragmented</b> 424:1 <b>frame</b> 16:11 59:7 61:14 68:5,11,16 68:20 87:1,8 89:8 89:16 131:18 182:3 212:5 226:7 253:8 260:3 262:22 277:8,10 298:13 350:2,9 353:4,7 362:12
---	---	---	---	---



<b>framed</b> 89:6 133:19 216:20 219:20 227:1,2 234:14	291:5 298:1 <b>Frank</b> 1:17 26:7,10 85:19 88:3 276:21	283:2 336:13 342:13	113:14 115:22 136:12 147:4 185:15,16 186:1	226:18 229:9 231:14 318:17 348:3 356:21 358:17 359:1 361:7 388:22 404:21 418:14 422:1 451:5
<b>frames</b> 68:5 107:10 256:4 262:2 344:20	<b>frankly</b> 38:13 98:19 150:19 354:18 412:10	<b>funder</b> 212:13 <b>funding</b> 7:12 9:3,3 10:1 11:4,5,18 14:3 193:17 247:20	206:15 291:7 312:20 342:5 353:8 359:17 396:6,11 409:8 447:1 448:17	<b>given</b> 60:15 64:19 68:7 75:8 106:2 113:5 125:15,20 139:13 244:2 295:16 296:18 299:17 324:2,2 339:8 361:15 373:14 388:17 434:18
<b>framework</b> 3:12 33:2 34:17 58:15 60:22 61:16 71:20 72:12 78:10,11 80:2 112:7 151:7 159:13 160:11,19 164:7 203:7 216:9 224:7 225:16 237:6 248:19 259:17 267:1,7 270:14,17 286:9 286:12 287:20 288:5,12,18 293:19 298:21 299:3,11,22 300:3 300:12 301:6 302:4,7 303:7,11 305:6,18 306:15 308:2,10 309:7,15 315:18 316:14,16 316:19 317:1 320:11 321:6 329:7 330:18 331:13 332:4,5,12 334:2 335:11 338:22	<b>free</b> 37:5 113:17 <b>freedoms</b> 225:15 <b>freely-associated</b> 5:8 <b>frequently</b> 287:7 <b>fried</b> 453:17 <b>Friedman</b> 159:16 160:7 162:8 167:4 170:11 217:5 <b>Friedman's</b> 166:17 185:19 186:12 190:22	<b>funds</b> 13:11 <b>funny</b> 118:11 <b>further</b> 5:13 18:3 21:14 36:18 39:13 66:4 69:15 119:10 122:11 149:12,21 330:12 331:1 405:11 433:22 452:18	<b>generally</b> 105:1 361:18 390:22 435:10 <b>generated</b> 306:5 <b>genesis</b> 70:10 <b>genetic</b> 257:12 329:11 <b>gentleman</b> 159:14 <b>geographic</b> 228:8 324:2 325:15 326:1,9 372:14 382:8	<b>gives</b> 25:4 55:16 349:7 353:18 440:12 <b>giving</b> 150:7 240:13 <b>gizmos</b> 339:18 391:17 392:3 398:20 <b>glad</b> 150:22 180:7 185:19
<b>frameworks</b> 304:19 308:11 309:9,11 310:6	<b>front</b> 18:8 23:11 32:22 54:18 59:2 79:16 396:21 399:9 416:18	<b>furthest</b> 4:15 276:17	<b>geographically</b> 314:22 322:19 323:11 325:13 <b>geographically-d...</b> 325:9	<b>global</b> 139:22 140:13 451:5 <b>gloss</b> 370:12 <b>glucose</b> 330:7 <b>go</b> 4:5 6:2,8 7:6,7 16:6 17:17 22:4 25:15,15 29:10,16 34:5 35:12 42:13 48:10,19 50:1 53:6,22 68:2 71:5 73:17 74:20 76:4 81:3 95:18 103:21 104:18 109:2 113:8,16 121:20 122:8 125:3 132:5 150:3,19 157:17 158:20 165:22 172:2,12 177:15 177:19,22 187:1,1 193:10 196:10 203:12 204:3,4
<b>Framework's</b> 321:2	<b>fuel</b> 317:17 <b>full</b> 43:9 47:20 140:5 380:7,16 417:8,9	<b>futures</b> 211:3	<b>George</b> 77:4 <b>Georgetown</b> 2:4 12:2 <b>Georgia</b> 93:2 <b>Geriatric</b> 10:4 <b>Gersh</b> 333:13 <b>getting</b> 4:11 34:7 45:13 99:1 101:10 110:12 124:7,16 140:5 162:13 164:8 171:13,22 204:8 236:20 261:4 264:13 270:22 393:15 415:21 416:4 429:9 433:9	
<b>framing</b> 57:19,20 58:1 62:19 81:10 82:21 83:5 89:2 100:11 106:17 119:10 121:2 122:9,19 139:12 161:12 215:15 216:6 231:20 256:3 261:16,21	<b>function</b> 152:21 154:9 <b>functional</b> 257:15 267:6 289:9,22 291:10 330:22 331:9 332:19	<b>gain</b> 50:19 <b>gained</b> 60:16 <b>gaining</b> 39:13 <b>gains</b> 123:15 <b>Gallup's</b> 303:22 <b>gap</b> 21:18 78:7 122:6 138:20 139:2,13 144:22 236:15,15,18 253:13 365:16,18 367:8 391:2 430:11 435:5,8 441:6	<b>Georgetown</b> 2:4 12:2 <b>Georgia</b> 93:2 <b>Geriatric</b> 10:4 <b>Gersh</b> 333:13 <b>getting</b> 4:11 34:7 45:13 99:1 101:10 110:12 124:7,16 140:5 162:13 164:8 171:13,22 204:8 236:20 261:4 264:13 270:22 393:15 415:21 416:4 429:9 433:9 <b>give</b> 16:10 18:18 19:13 31:22 71:6 103:2,9 119:3 134:10 155:21 174:16 185:9 204:11 220:10	
	<b>functioning</b> 47:15 331:8 333:14	<b>Gary</b> 333:13 <b>gather</b> 258:19 292:7 <b>gathering</b> 378:19 <b>gaze</b> 126:18 <b>gears</b> 432:21 <b>general</b> 3:4 5:18 9:6 38:15 106:17		
	<b>functions</b> 52:14 <b>fund</b> 224:2 273:2 283:4 382:7 <b>fundamental</b> 65:14 141:6 213:3 277:17 <b>fundamentally</b> 299:4 317:15 <b>funded</b> 12:3 212:16			

225:10 231:17	271:13 303:20	246:1 247:14	75:14 80:21 83:5	<b>graded</b> 366:10
233:12 241:8	329:20 384:3	248:17 252:4,8	85:16 86:18 87:3	<b>grading</b> 366:11
247:11 250:11	414:1,1 421:13	255:8 256:6	87:9 94:21 95:7	<b>graduate</b> 148:19
253:8 256:5 258:4	433:7	259:16 260:11	96:6 106:9,14	278:14
260:19 263:21	<b>going</b> 4:19 16:10	261:19,21 265:20	113:18 116:2,21	<b>grandchildren</b> 93:4
300:4 301:2 302:1	22:18 23:9 27:9	267:20 269:2	119:9 126:4	<b>grant</b> 6:17 10:2
303:4 306:5 309:3	28:12 33:9 36:22	276:4,7,18 277:3	142:15 157:4	11:3 211:1
319:14 321:10	37:22 39:17 47:16	277:21 281:9	158:21,22 163:9	<b>granted</b> 176:15
333:3 336:1 337:6	58:18 60:5,21	282:20 289:10,12	163:10,22 194:12	198:18
337:9 340:1	61:22 63:14 66:2	289:21 290:1,1,10	198:4 201:16,17	<b>grants</b> 8:5 10:15
348:16 355:9	66:4 69:22 73:2	292:4 294:4,14,16	226:20 227:21	11:15 193:17
356:17 357:2	74:1,3 75:10	294:21 295:12,13	234:13 238:13	276:10
359:15 360:16	77:14 79:17 80:19	296:20 297:4,6,17	254:4 265:12,20	<b>granular</b> 144:13
367:19 371:17	90:2 91:15 92:13	297:18 298:13	266:1,11 273:17	<b>granularity</b> 413:17
382:19 383:4	95:11,14,19 97:7	303:18 304:21	283:9 289:5,5	<b>graphical</b> 331:18
385:13 390:5	99:22 100:7,13	305:10 307:2	293:5,8 294:22	<b>grass</b> 91:5
392:5,8 401:2,6	101:16 104:7	308:22 309:1,12	308:6 320:1	<b>gray</b> 60:16
402:2,11 405:12	105:4 108:11,21	309:20 312:1,18	343:15 347:4	<b>great</b> 4:22 21:4
418:20 419:5	108:21 110:13	315:11 316:13	350:15 354:13	37:6 65:6 87:5
424:18 432:22	111:13 113:7	320:15 321:1,19	361:18 374:10	103:18 135:16
433:5,14 435:2,5	115:2 117:9	321:21 327:12,19	379:12 386:16	157:9 158:19
435:10,14 437:8	121:16 126:5,5,6	327:21 336:1	393:6 394:17	159:6 184:9
440:7,22 441:1,9	127:1,10,20,20	337:9 338:16	407:5 409:18	198:19 206:8
444:16 445:6	128:2,3 129:9	339:4,19 341:5	437:7 438:6 443:4	219:19 233:7,19
<b>goal</b> 29:21 43:13	130:2,6 132:22	344:8 346:22	446:7 453:14	245:1 252:5 315:7
84:8 85:2 97:13	133:4 134:6	348:16 349:12	<b>goodness</b> 143:4,6	316:12 317:22
111:5 146:11	138:17 140:20	355:11 356:11,17	144:20 182:17,18	318:1 358:16
203:11 237:21	142:11 144:22	356:20,21 357:3	332:2	400:18
245:2,7,15 294:10	145:2,19 147:20	358:12,20 372:17	<b>Goodrich</b> 80:11	<b>greater</b> 72:5,8,10
342:5	148:8 149:13,16	377:20,21 382:22	<b>gorilla</b> 86:14	120:3 201:9
<b>goals</b> 22:13 30:2,7	155:10 158:3,9,13	386:8 389:13	<b>gotten</b> 138:3	265:15 350:12
33:7,16 34:11,15	158:15 167:11	390:5,16 394:17	265:16 362:11	436:12
35:21 37:2,20	173:11,12 175:6,7	398:21 400:19	<b>government</b> 11:16	<b>greatest</b> 72:20,21
39:16 41:13,13	175:13 176:5	401:1 411:22	91:8 93:9 191:2	74:8,9,19 75:11
44:2 48:8,18 50:1	188:12 191:22	413:7,8,8 416:16	220:2 240:7	75:18
51:6 52:5,21	192:2 193:4,15	433:8 434:19	278:22 329:22	<b>green</b> 53:19 164:12
53:15 55:15 56:5	197:12 200:10	435:20 437:9	385:4	168:19 204:10
77:17 160:2,5	201:4 202:3 206:4	441:13 448:15	<b>governmental</b>	399:11
191:7 258:19	212:6 215:11	449:3 454:6	130:10 156:13	<b>greener</b> 91:5
276:14 346:8	220:18 222:19,19	<b>gold</b> 393:18 396:3	161:16 164:1	<b>grocer</b> 85:11
424:11	223:5,9,11 224:2	<b>good</b> 4:3,14 5:14,20	178:1 216:15	<b>grocery</b> 43:7
<b>God</b> 301:11	224:18 225:5	5:21 8:9,13,16,20	230:10	393:20
<b>goes</b> 35:10 50:20	226:22 227:6	9:5,14,19 10:6	<b>governments</b>	<b>ground</b> 15:20
102:7 120:7	230:21 233:3	11:21 12:19 14:21	322:11	234:17
132:16 140:1	235:22 236:4,9	26:15 47:10 49:3	<b>governors</b> 192:15	<b>grounding</b> 150:17
153:18 186:19	237:9,12,14,16	49:5 54:5 57:12	<b>grab</b> 385:2	<b>group</b> 4:22 10:14
215:2 249:12	243:5 245:20,22	61:19 67:11 73:4	<b>grade</b> 366:13	16:15 22:3 28:22

31:7,20 39:20 41:15,16 44:9 51:15 58:7 68:8 68:17 78:18,19,21 79:4 81:3 87:10 87:15 97:13 125:14 126:2 127:9,12,16,21 128:4 136:17 141:17 143:9 149:19 150:15 151:8,12 155:6 181:20 185:1,5 188:5 193:20 210:13 212:11 215:18 241:7 253:4 261:21 283:1 285:13 290:5 295:3,5 296:13,17 297:10 298:10 300:4,21 301:16 305:10 308:9,12,16,22 309:14 319:18 320:5 321:11,13 321:18,21 322:6 322:18 323:9,21 323:21 324:16 325:10,19 326:1 326:18 329:17,21 337:18,20 338:1,4 338:22 339:22 340:22 341:1,21 348:5 355:6 360:13 365:2 367:1 368:20 377:21 380:9 385:1 390:21,22 393:7 401:2,5 402:4,11 406:9 410:1 432:21 433:4 441:19 447:21 <b>groups</b> 32:15 68:18 126:19 129:1 130:13 131:9 138:12 139:7	156:13 157:4 170:8 191:17 192:3,5 193:7 195:1,11 196:3 197:5 207:22 221:1 238:5 289:16 302:10,11 302:16 304:22 305:11,16,22 307:14 309:6 310:5,9 318:12,13 319:16 321:15,16 335:16 337:17 338:20 340:20 360:7 361:5,17 362:6 410:6 <b>group's</b> 399:1 <b>grow</b> 63:11 <b>growth</b> 52:1 <b>guess</b> 47:9 61:19 109:3 145:21 148:22 184:22 195:17 204:1,2 216:19 224:14 229:9 254:18 286:22 298:19 303:4 306:5 308:21 318:7 353:22 369:7 372:15 391:15 404:7 417:12 434:21 443:22 445:16 <b>guidance</b> 71:6 105:21 120:19,20 137:7,16 138:1 149:20 150:2 179:17 199:14 206:17 220:10 318:17 392:21 <b>guide</b> 124:18 176:20,22 177:18 179:1,1 187:2 198:14 209:3 210:2 324:13,14 <b>guideline</b> 235:14 <b>guidelines</b> 343:13	344:1 431:6 432:1 432:6,7 <b>guides</b> 170:21,22 <b>guilty</b> 26:6 <b>gun</b> 45:10 <b>guru</b> 217:7 <b>guys</b> 234:1 291:16 320:16 <hr/> <b>H</b> <hr/> <b>hairs</b> 60:16 <b>half</b> 93:6 152:7 278:13 302:16 304:21 307:16 309:5 <b>hall</b> 15:21 348:5 <b>Hammersmith</b> 2:10 3:4 5:17,21 14:4,14,20 <b>hand</b> 16:1 51:7,13 148:15 227:1 242:2 302:21,22 314:11 335:12 378:22 381:19 398:21 <b>handbook</b> 395:5 <b>handed</b> 339:9 <b>handing</b> 376:12 <b>handle</b> 164:8 <b>hands</b> 133:2 316:17 317:2,6,9 322:7 <b>hang</b> 178:18 298:21 299:22 332:6 <b>hanging</b> 93:2 <b>happen</b> 95:15 107:20 110:12 135:14 145:2 164:22 224:4 289:6 410:15 418:17 <b>happening</b> 147:8 354:19 410:15 <b>happens</b> 194:10 228:11 304:7 345:8,17 348:21 <b>happily</b> 204:12	<b>happy</b> 33:22 37:3 58:2 66:12 78:15 78:22 183:9 309:17 <b>hard</b> 66:5,7 129:10 145:15 170:14 213:12 241:4 273:11 296:17 300:17 318:9 387:20 389:5 428:6 443:19 453:17 <b>harder</b> 66:5 225:10 334:1 <b>harmonization</b> 18:3 20:4 25:1 56:18 60:8 62:16 117:5 118:2,3,18 119:15,21 120:7 120:13 121:6 146:2 341:19 343:3 418:1,15,19 <b>harmonize</b> 250:9 418:3,9 419:6 425:1,5 <b>harmonized</b> 60:19 117:19 119:17 342:8 <b>harmonizing</b> 60:22 <b>harmony</b> 418:6 <b>hate</b> 188:20 <b>Hayes</b> 182:22,22 183:11 <b>head</b> 62:21 92:22 131:18 214:5 315:11 <b>heads</b> 154:4 <b>health</b> 1:3,14,16,18 1:23,24 2:5,18,22 3:7,10,16,18 4:22 5:6,9 7:12,18,22 8:1,2 9:8,16 10:3 10:8,9,11,16,21 11:10,14,17 12:1 12:2,4,15,16,20 13:2 14:13 18:11 19:1,3 21:8,11,17	21:19 25:10 26:17 27:1 28:8,15,19 31:5,8,11,20 32:1 33:12,14,14 35:8 37:15 38:13,19,22 39:10,15,21 40:3 40:8,18,21 41:3,4 41:5,18,22 43:17 44:16,19 45:2 46:3,4,13 47:1 50:21,22 52:2 53:9,15 54:5 56:7 56:12 60:12 61:10 64:4,5 65:1 66:22 71:11 73:12 78:6 79:8 81:6,7,8,9,10 81:18,19 83:14 84:3,8 85:3 86:13 88:5 89:3,7,16,17 90:10,12,18 92:17 93:16,19 94:2,4 98:16,20 100:9 101:18 103:4,15 104:3,5 105:5 107:15 108:8 109:10,13 110:6 110:22 112:12 116:10 123:1,15 123:16,19,22 124:2,16,19,21 125:16 126:12,14 126:18,19 127:8 129:10 130:16 131:2,10 132:3,7 137:6 140:17 141:5 143:3 144:17 145:7 149:10,17 150:21 152:9 153:15,19 154:10,11 156:12 160:2,9,21 161:1 161:4,5,13,17,19 162:10,15,21 163:5,8,10,14,18 163:22 164:2,5,22 165:9,14,17,19 166:5,20 167:18
--	--	---	---	---

167:19,22 168:3	253:1,2,5,6,7,10	368:15 369:22	<b>health-care-orie...</b>	<b>Helen's</b> 95:11,11
169:2,18,21 170:3	253:22 254:7	371:2,3,11,14,17	123:14	96:3,22 113:7
170:18 171:2,19	255:9 256:11	372:8,19 373:5,15	<b>heap</b> 215:20	<b>hello</b> 13:5 407:18
172:11,19,20	257:1 258:1,11,12	395:9 396:11	<b>hear</b> 34:21 76:9	<b>help</b> 15:10 36:1
173:1,12,13,19	258:15,21 259:11	397:2 407:19	85:22 88:20 92:2	37:6,6 53:13 69:1
174:8 175:10,18	260:20 261:4,6,9	408:4,5,18,20,21	92:4,7 102:1	88:15,18 101:5
177:11,12 178:2	261:10,15 262:18	409:4 410:4	200:3,12 203:19	103:1,20 127:13
178:11 179:13,19	263:7 265:10,18	413:21 414:2	203:20 297:17	134:3 169:20
180:3 181:4	266:15 267:2,18	415:6 420:5,18,21	300:7 358:11	170:22 180:13
182:11,16 183:9	268:2,14 269:22	420:22 421:1,13	380:8 383:15	191:13 192:19
183:15,16,18,20	270:3 271:21	421:15 422:12	395:3 424:16	208:11 210:7
183:21 184:1,6,13	272:2 274:10,13	423:19 424:21,22	<b>heard</b> 86:22 92:15	211:2,6,16,17
186:16,18,20	274:22 275:3,5,8	425:6,11,22	95:3,10 99:18	212:1,4,6 219:7
187:11,11,17,18	275:9,9,12 278:5	426:12 429:13	154:7 155:2	233:11 243:15
187:21 188:3,9,14	278:20 279:11,16	430:15,16,19	159:17 163:19	247:12,15 259:4
189:11,13,14,15	279:17 280:10,15	431:5,8,20 436:3	247:17 273:10	269:15 271:11
190:1,1,3,7,15	282:19 283:14	436:9 437:17,18	316:19 362:19	295:6 296:1
191:2,20 192:1,11	284:10,13,19,22	438:2,9 443:20	424:14,17	297:10 301:12
192:12,14,17,22	286:11,20 287:3,8	444:2,6,12 446:21	<b>hearing</b> 106:7,10	308:3,16 356:18
193:2,12 194:19	287:17,21 289:9	447:7,8,13,20	116:15,20 156:15	389:10
194:19 195:21	289:20,22 291:2	448:17 449:7	158:12 159:11	<b>helpful</b> 26:19 58:12
196:4,11,12 199:1	291:10 292:6,8,10	451:9,10	406:22	59:11 89:10
199:5,12,21	292:11,13,14,15	<b>healthcare</b> 25:21	<b>heart</b> 1:19 13:7	102:22 104:13
200:18 201:15,17	292:17 293:13	31:1 52:1 271:8	134:14 148:13	119:1 121:1 123:4
202:14,16,16	294:9,15 295:18	272:17 279:9	251:17 287:9	153:5 159:22
203:3,5,9 204:19	296:7 299:18	322:10	412:20	161:11 185:9,18
205:21 206:7	300:13 303:5,6,16	<b>healthful</b> 46:1 47:8	<b>Hearts</b> 77:13	187:3 191:12
210:10 212:22	303:21 304:12,12	<b>healthier</b> 281:9	<b>HEDIS</b> 275:4	206:22 207:1
214:10 215:6,22	304:14 305:3,17	<b>healthiest</b> 143:8	384:9,13,15,17	211:18,22 212:10
216:3,14,15,17	306:13,13,14	<b>Healthways</b> 303:22	<b>HEIDI</b> 2:9	215:18 232:18
217:16,20 218:6,7	308:1,20 309:12	<b>healthy</b> 19:5 20:1	<b>held</b> 42:6 92:6	235:5 240:10,17
219:4,9,15,18	311:8,14,20,22	20:19 21:13 32:5	129:19 130:2	241:21 246:10
220:2,14 221:6	312:3,19 315:2,21	32:5 38:9,9 39:5	150:7 218:18	249:22 256:19,22
222:8,12,20,21	316:1 323:3,7,8	40:7 41:11 42:16	234:20 235:2,9	285:7 290:21
223:16 224:11	326:21,21 327:5	42:19,20,22 43:1	238:3,7,10	373:19,20,22
225:2,2,7 229:15	327:14 328:3,8	43:5,11,22 45:21	<b>Helen</b> 2:8 3:10 5:14	374:4
229:17,19 230:1,2	329:14,14 330:6	47:5,7 49:7,9 53:5	14:22 15:3 31:19	<b>helping</b> 70:18
230:6,9,10,13,17	330:15,18,20,21	62:8 63:1,10 65:2	58:10 83:10	216:6 232:14
231:22,22 232:5,6	330:22 331:5,8,19	65:19,21 66:3	103:13 113:16	<b>helps</b> 61:5 299:18
232:11,12 235:14	331:22 332:8,13	88:6 107:17 136:5	127:19 136:9	<b>hey</b> 252:1
236:10,18 237:13	333:15 341:9,11	143:8 144:1	138:4 142:17	<b>HHS</b> 7:14 32:3,15
237:15 238:20	343:18 348:4,5	165:14 170:4	149:5 181:15	34:9 37:9 38:14
243:13,22 244:3	350:9 351:6	174:9 190:17	211:13 233:15	40:2 48:4 50:6,13
244:17 245:4,12	354:11 355:13,16	205:19 237:20	244:21 255:22	56:1 57:3 59:10
245:16 246:14,20	358:3 359:7 360:1	254:20 255:3,12	263:1 275:17	67:12 75:6 76:22
246:22 248:15	362:1,2,13 363:7	255:13 282:8	278:8 288:22	77:2 78:21 79:14
250:13,20 251:7	367:9,10,17	284:8 316:4 449:8	327:3	80:5 156:14 201:6

247:20 248:2 256:2 260:2 262:16 263:5 266:1 285:9,11 289:4 315:5 424:8 424:15,20 <b>HHS-wide</b> 229:22 <b>Hi</b> 7:17 12:7,13 13:14 26:10 76:3 185:13 198:2 207:5 <b>hierarchy</b> 122:14 259:17 283:12 <b>high</b> 59:13 67:5 111:22 122:4 142:10 148:19 154:5 168:20 173:4 245:3 278:14 284:2 365:8,11,15 367:7 368:1,3,3,7,18 386:18 391:3,3,4 391:5,9,9,10 393:13 394:2 399:3 401:9,15 402:4,13 405:19 410:6 428:22 433:18,20 435:9 435:18 440:12,17 440:21 441:2 444:17 445:8,10 451:1 452:9,10,14 <b>higher</b> 61:4 372:4 373:1,1,4 <b>highest</b> 61:1 75:9 <b>highlight</b> 16:18 <b>highlighted</b> 23:15 53:8,20 <b>highly</b> 193:15 333:9 396:9 401:14 <b>highs</b> 435:10 <b>high-impact</b> 123:19 <b>high-moderate</b> 435:19 440:13,18 441:3	<b>hinge</b> 176:18 <b>historical</b> 329:4 <b>historically</b> 73:10 107:13 108:2 328:12 <b>history</b> 29:19 83:8 <b>hit</b> 48:17 182:22 190:18 221:1 296:9 <b>hits</b> 40:15 <b>hodgepodge</b> 130:9 <b>hold</b> 92:19 109:1 155:8 197:13 203:1 213:10 385:2 390:8,11 <b>holding</b> 90:16 92:9 <b>holds</b> 133:2 <b>holes</b> 59:4 <b>home</b> 51:9 56:12,12 60:12,12 91:19 172:15 214:10 221:20 340:15 341:10 385:14,21 407:19 408:4,5,18 408:20,21 409:4 410:4 413:8 414:2 415:5 420:5,18,21 420:22 421:1,12 421:14 422:12 423:18 424:22 429:13 430:15,16 430:19 431:5,8,20 436:3,9 437:17,18 438:2,7,8 443:20 444:2,6,12 446:20 447:8,19 453:19 <b>Homer</b> 40:11 210:21 333:13 <b>homes</b> 56:10 168:11 188:3 385:16 422:12 <b>honestly</b> 365:9 434:7 <b>Honore</b> 80:17 229:11,14,15 <b>hope</b> 14:1 15:10 20:17 80:15 84:14	148:9 158:7 186:6 187:22 188:15 240:14 248:17 378:16 417:21 <b>hopefully</b> 126:6 158:16 182:2,9 234:3 248:16 306:17 307:13 411:22 420:11 449:6 <b>hoping</b> 18:1,6,21 19:4 28:1,2 <b>horrible</b> 142:12 <b>hospital</b> 1:25 8:1 12:15 42:2 51:1,8 60:12 78:3 88:8 117:7 124:12 221:19 251:3 341:10 348:6 362:3,14 363:9 373:8 374:13 413:7,20 417:2 438:17 444:5 <b>hospitalization</b> 145:13 247:7 415:18 421:5 429:7,15,17,20 430:1,3 439:11,12 439:21 443:9 445:4 <b>hospitalized</b> 407:11 <b>hospitals</b> 56:11 129:13 235:7 359:10 372:9 375:16 402:8 422:13 424:22 425:11 <b>hotel</b> 1:9 231:14 <b>hour</b> 100:6 152:7 295:7,8,11,12,14 301:3,4 302:16 304:21 307:16 309:5 315:12 337:21 <b>hours</b> 243:5 301:21 <b>housekeeping</b> 16:18 244:6	<b>housework</b> 102:5 <b>housing</b> 197:8 <b>Howard</b> 229:17 <b>how-to</b> 295:4 <b>HRSA</b> 9:17 <b>huge</b> 35:2 85:15 155:6,11 240:14 252:12 280:9 285:15 304:6 <b>human</b> 7:12 11:17 28:9 183:19 <b>hundreds</b> 180:5 <b>hymnal</b> 118:11 <b>hypertension</b> 109:18 <b>hypertensive</b> 123:18 <b>hypothetical</b> 345:16 <hr/> <b>I</b> <hr/> <b>idea</b> 68:4 75:17 82:1,12 87:3,9 93:13 116:3,12 126:10 128:12 138:8 140:20 147:10 168:5 175:4,22 180:20 191:12,15 202:6 202:14 205:6 207:7 208:3,20 226:21 237:2 259:9,21 278:3 284:16 288:16 311:16,19 312:3 317:22 318:1 320:2 347:8 379:12 404:10 409:20 411:21 421:12 446:8 450:20 <b>ideal</b> 56:16 274:22 <b>ideally</b> 13:22 41:7 425:11 <b>ideas</b> 86:7 116:19 158:11 259:9 302:19,22 305:19	306:4 <b>identical</b> 163:3 345:17,18 398:12 <b>identification</b> 83:13 <b>identified</b> 53:9 56:5 117:14 145:15 <b>identifies</b> 112:16 184:2 <b>identify</b> 18:2,7,21 19:4 21:7 148:2 171:17 220:15 326:7 347:15 <b>identifying</b> 53:7 68:10 145:17 187:19 <b>idle</b> 96:18 <b>ignored</b> 64:6 <b>ignoring</b> 273:21 <b>IHI</b> 12:11 38:14 <b>IHI's</b> 130:8 271:16 <b>ill</b> 40:16 <b>illegal</b> 45:9 <b>illness</b> 40:17 65:3 149:4 152:5 429:7 438:22 439:10 <b>illnesses</b> 46:6 <b>illustrative</b> 55:18 <b>imagine</b> 60:18 111:3 125:17 377:22 413:19 453:18 <b>immediate</b> 166:6 <b>immediately</b> 382:5 <b>immensely</b> 150:21 <b>immunization</b> 9:13 17:20 19:12 20:15 101:11 339:6 340:9,14 341:10 342:13,18 343:18 343:19,20 349:20 351:5 368:14 371:12 386:9 407:10 408:7 410:11 419:12 420:13 428:20 436:3 437:9
--	---	--	---	--

438:21 443:11,14 446:9,15,17 447:4 448:5 450:8,22 451:4,20,22 <b>immunizations</b> 3:21 46:14 243:17 337:10 419:4 446:18 <b>immunized</b> 425:20 429:9 <b>impact</b> 72:2,5,8,21 74:8,9,20 83:21 84:2 122:5 126:11 126:12,13 127:3 154:5 170:16 176:11 178:10 199:4 213:3 233:1 233:2,7 236:15 252:4,13 279:11 333:19 337:2 365:8,11,15 367:7 374:12 426:20 <b>impacts</b> 72:20 75:18 87:14 <b>imperative</b> 84:9 279:15 281:12 <b>imperfect</b> 383:6 <b>implement</b> 180:16 184:5 222:6 <b>implementation</b> 284:15 378:4 <b>implemented</b> 176:9 402:19 423:17 <b>implementers</b> 385:2 <b>implements</b> 423:20 <b>implication</b> 96:13 214:11 <b>implications</b> 98:6 99:2 212:20 <b>implicit</b> 99:7 109:9 299:15 <b>implied</b> 305:8 <b>importance</b> 36:12 41:6 44:11 105:7 106:18 109:1,6 122:1,2,18 123:14	138:18 142:18 390:13,14 391:19 430:10 433:13,15 <b>important</b> 4:4 16:16 22:8 23:13 23:18 27:4 28:10 30:6 32:13 35:15 39:20,22 40:6 41:14 42:12 44:17 45:17 46:4 50:3,6 51:5 52:15,19 57:7 58:5 63:9 66:16 67:14 74:2 77:18 78:5 83:9 83:15 91:1 92:13 103:3,8,9 104:10 105:11 109:4,15 122:13,19 125:19 130:20 131:2 136:7,19 137:3 141:1,12,21,22 145:9 146:6,8 148:11,17,18 155:1 198:16 206:22 221:5,6 222:1 241:19 244:15 248:6 253:5 257:19 264:15 265:11 266:21 267:15,16 271:13 288:6 294:15 299:4 307:11 316:2 319:6 331:3,4,13 335:9 336:3,4 346:8,16,17 347:19 349:10 365:7 374:6 375:4 379:5 383:3,16 386:19 388:9 448:3 <b>importantly</b> 31:2 32:5 36:5 66:18 332:21 <b>impossible</b> 415:11 <b>impractical</b> 411:13 <b>impressed</b> 432:20	433:3 <b>improvable</b> 267:21 <b>improve</b> 162:14 169:18 171:1 174:17 184:6 224:22 225:5 315:22 424:11 <b>improved</b> 219:9 <b>improvement</b> 3:15 10:16 34:21 38:1 43:14 54:13,13 115:10 131:10 133:6 162:10,19 164:6,21 165:2,10 165:19 166:5 169:22 174:6 179:12 181:9 225:7 230:16 279:11,17 328:17 361:8 413:11 443:10 445:3,18 <b>improvements</b> 443:12 <b>improving</b> 25:21 74:12 122:22 123:16 160:9 <b>inappropriately</b> 420:4 <b>incentives</b> 54:11 147:17 <b>inch</b> 193:2 <b>incidence</b> 235:2,3 <b>Incidentally</b> 38:10 <b>include</b> 17:19 20:21 21:18 82:13 97:14 139:3 151:14,15,18 183:4 200:19 216:21 222:7 241:10 254:15 270:4 344:3 345:8 428:1 430:19 <b>included</b> 22:5 80:3 121:11 139:18 362:1 363:16 364:1 427:8,12 428:3 431:5,21	<b>includes</b> 30:22 74:3 155:5 186:8,10 360:1 419:14 439:2 <b>including</b> 6:19 23:14 40:2 90:19 104:21 138:11 153:12 193:20 261:9 279:9 292:8 296:2 309:11 <b>inclusions</b> 428:5 <b>inclusive</b> 363:22 364:1 <b>income</b> 46:12 168:5 <b>inconsistency</b> 419:19 <b>inconsistent</b> 142:1 419:17 <b>incorporate</b> 79:6 121:12 294:13 417:15,16 <b>incorporated</b> 130:4 410:12 <b>incorporates</b> 410:2 <b>Incorporating</b> 40:22 <b>increase</b> 176:11 277:1 346:9 <b>increasing</b> 24:19 <b>increasingly</b> 111:14 279:15 412:1 <b>incredibly</b> 137:15 336:4 433:2 <b>incremental</b> 61:7 <b>inculcated</b> 81:14 <b>independent</b> 360:8 362:7 388:2 <b>independently</b> 196:5 <b>index</b> 12:20 45:19 274:22 303:20 304:1,13 382:8 <b>indicate</b> 141:21 361:8 <b>indicated</b> 27:20 285:17 398:16	407:16 <b>indicates</b> 141:11 <b>indication</b> 449:6 <b>indicative</b> 188:1 <b>indicator</b> 165:11 215:19 268:17 <b>indicators</b> 62:4,6 62:17 64:14 141:9 141:10 145:17,19 170:4,6 179:19 183:16 187:22 189:17 207:19,20 207:21 215:16,20 216:7,10,21 224:19,22 225:6 247:6 268:15 <b>individual</b> 7:2 45:8 49:8 56:13 104:4 118:16 126:18 183:18 189:12,17 190:13 203:10 205:11 220:8 249:1 277:13,15 304:3 305:20 322:21 323:2,3 330:3,11 331:19 337:11 356:16 416:11 429:6,18 447:8 448:10 450:17 <b>individually</b> 346:4 401:1 434:22 <b>individuals</b> 30:18 194:10 322:15 323:7 371:6 <b>indoor</b> 117:17 <b>industry</b> 31:12 279:19 <b>ineffective</b> 426:21 428:16 429:5,10 438:20 439:8 <b>ineffectiveness</b> 438:21 <b>inequities</b> 121:10 142:12 335:14,15 335:20 336:4 378:7,8,19
---	--	--	---	---

<b>inequity</b> 145:12 335:22	<b>informatics</b> 9:1 259:4	407:21	<b>inter</b> 78:18	134:18 168:21
<b>infant</b> 143:16	<b>information</b> 16:14	<b>input</b> 21:12 29:1	<b>interacting</b> 373:16	172:11 209:5,20
<b>infection</b> 221:15	87:12 194:5	32:9,12,18,22	<b>interaction</b> 145:21	217:17 219:1,9
<b>infections</b> 50:22	241:15 338:14	33:2,7,15 57:6	209:9	273:18 280:21
<b>influence</b> 58:14,20	346:19 367:13,14	71:12 212:3 230:1	<b>interactions</b> 208:7	388:12
70:14 100:11	368:8 370:15,18	<b>inside</b> 163:13	<b>interchange</b> 181:15	<b>interventions</b> 43:14
163:17 184:1	371:9 378:10,14	<b>instance</b> 71:21 72:3	<b>interconnect</b> 77:20	72:17 88:11
209:9 217:14,20	391:7 394:9	198:12	<b>interest</b> 3:3 6:4	116:11 137:12
218:5 226:12	411:16 427:8,12	<b>instant</b> 91:9	25:14 26:3 80:2	171:1 176:21
253:10 286:10,20	431:14 437:15	<b>Institute</b> 1:15 8:8	281:2,22 310:12	177:13 178:7
294:8 330:12	438:15 451:3	13:16 160:20	328:14	179:10 210:10,17
331:16 333:6	<b>informed</b> 54:7	185:14 202:9	<b>interested</b> 156:15	211:20 217:13
379:10	169:5 236:3	335:17 336:13	156:17 244:10	223:4 288:9
<b>influenced</b> 183:16	357:19	<b>institution</b> 348:4	275:16,21 282:14	<b>intervention/com...</b>
330:9	<b>informs</b> 447:18	364:16	371:16 417:5	323:17
<b>influences</b> 208:8	<b>informs</b> 447:18	<b>institutions</b> 275:19	429:14 451:17	<b>Interview</b> 173:12
332:16 333:19	<b>infrastructure</b>	359:7 397:14	<b>interesting</b> 40:19	<b>inter-agency</b> 78:20
<b>influencing</b> 179:22	35:17 36:3	<b>instructive</b> 277:22	51:17 82:17 89:1	<b>inter-rater</b> 359:18
207:13 332:17	<b>inherent</b> 112:7	<b>instrumental</b> 29:14	115:4 144:12	<b>intricate</b> 257:17
<b>influenza</b> 19:13	<b>initial</b> 59:14 66:10	<b>insufficient</b> 399:5	250:7 290:7,8	<b>intrigue</b> 291:16
339:6 340:9,13	80:22 157:19	401:10 403:12	300:10 312:11,15	<b>intrinsic</b> 398:18
341:8 342:14,17	245:9 399:1 427:8	435:19	317:14 336:12	<b>introduce</b> 7:8 14:6
343:17,18 349:20	441:18 446:2	<b>insurance</b> 26:4	374:2	15:1,15 25:13
351:5 354:4	<b>initially</b> 362:1,13	27:1 42:4 156:12	<b>interests</b> 208:12	26:8 27:11 40:5
355:12,17 358:2	408:15 427:6	<b>insureds</b> 42:3	385:8	124:2 143:13
359:6 362:16,17	<b>initiate</b> 20:16	<b>insurer</b> 124:13	<b>interface</b> 73:7	171:18 407:17
363:9,13 367:11	<b>initiative</b> 4:18	129:13	75:11 191:21	<b>introduced</b> 17:16
371:10 396:7,15	12:11 29:15 32:11	<b>insurers</b> 130:11	<b>intermediate</b>	39:13 44:1 47:13
398:16 407:9,15	50:9,18 77:12	322:11	151:10 222:8	143:2
408:7,19 420:13	130:9	<b>insurmountable</b>	331:5	<b>introductions</b> 3:2
424:20 428:22	<b>initiatives</b> 77:3	411:7	<b>internal</b> 7:19 167:8	5:4,15
429:16 430:1	112:14 129:16	<b>integrate</b> 35:7	199:15 274:20	<b>intuit</b> 190:21
432:6,7 436:2	230:19 239:19	51:12 165:6 200:1	335:5 392:18	<b>intuitive</b> 296:22
437:20 438:21	<b>injured</b> 146:18	200:4 201:18	<b>internally</b> 368:17	<b>invariably</b> 147:3
439:3,9,12,21	<b>injuries</b> 45:4,5	224:6	<b>internist</b> 9:6	<b>invested</b> 270:22
451:17,18	254:17	<b>integrated</b> 36:15	<b>interpretation</b>	<b>investigation</b>
<b>influenza-like</b>	<b>injury</b> 65:3 66:14	79:10 171:22	364:6 372:16	172:15
438:22 439:9	67:13,19 330:13	174:3 198:20	<b>interrelated</b> 183:22	<b>investigations</b>
<b>inform</b> 41:15 68:15	331:6	225:17 412:1	<b>interrupt</b> 178:13	169:8
69:1,16 170:22	<b>inner</b> 43:6 63:2	<b>integration</b> 176:7	<b>intersecting</b> 76:13	<b>Investment</b> 273:1
181:19,22 210:8	<b>innovating</b> 35:20	<b>intended</b> 115:6	<b>interval</b> 144:4	<b>investments</b> 174:20
237:19 290:9	<b>Innovation</b> 50:14	124:5 336:8	<b>intervene</b> 127:7	280:10
297:17 334:19	187:17	401:19	219:14 289:6	<b>invited</b> 17:11
337:5	<b>inordinate</b> 60:9	<b>intending</b> 118:1	348:2	<b>inviting</b> 73:11
<b>informatic</b> 259:3	<b>inpatient</b> 359:13	<b>intends</b> 247:21	<b>intervening</b> 187:20	<b>involve</b> 61:13
<b>informaticist</b> 259:2	361:20 410:5	<b>intent</b> 120:5,5,8	<b>intervention</b> 40:10	<b>involved</b> 29:6
	<b>inpatients</b> 407:12	124:8	48:3 72:15 116:7	49:21 76:6 77:5

157:12 236:14  
 238:12 259:4,20  
 280:12 310:22  
**involvement** 80:7  
 281:2,3  
**involves** 213:7  
 305:5  
**IOM** 94:11 108:12  
 189:8 196:15  
 263:18  
**Iowa** 129:21 281:5  
**iPhone** 303:14  
**irks** 265:4  
**IRS** 235:8  
**Isham** 77:4  
**isolated** 438:7  
**issue** 65:14 67:6  
 76:18 105:20  
 108:7,10 110:1  
 139:9 142:18  
 143:1 144:12  
 147:20 177:7  
 208:20 221:22  
 245:13 254:6  
 300:7 308:17  
 313:22 314:16,19  
 315:4,4 353:1,18  
 354:11 364:9  
 368:22 375:1  
 377:3 383:12  
 386:6,7 395:8,16  
 396:1 398:15  
 410:21 411:7,9  
 412:10 418:2  
 420:10 438:1  
 442:11,12 443:8  
 445:22 446:7  
**issues** 3:18 24:22  
 26:18 56:19 66:20  
 71:16 76:21 85:4  
 99:2,3,21 104:8  
 105:9 108:21  
 111:14 118:4  
 128:15 140:10  
 147:14 180:6  
 197:10 221:13  
 224:9 246:21

254:13 261:16  
 268:19 269:15  
 273:6 275:18  
 280:1,11 285:1,2  
 285:4 291:14  
 297:11 335:20  
 382:18 383:10  
 391:1 393:15  
 395:14 400:10  
 411:19 422:10  
 428:1,3  
**item** 421:21 447:12  
**items** 446:2  
**iteration** 318:3  
**iterations** 128:2  
**i.e** 105:15

---

**J**


---

**Jack** 210:21 333:13  
**Jackie** 207:3,4,5  
 208:5 210:3 218:4  
 282:9 296:11,12  
 386:2 448:8  
**Jackie's** 215:13  
 315:19  
**Jacobson** 2:17 3:15  
 158:6,21 159:19  
 178:16 184:11  
 193:9 195:3 200:6  
 200:8,14 203:12  
 203:15,18 204:1,7  
 205:17 210:3  
 217:2 218:21  
 223:13  
**Jacqueline** 1:21  
 8:21 98:17 207:3  
 236:22 341:1  
**January** 27:18 28:1  
 353:16 407:14  
**Jarris** 1:10,13 3:8  
 3:19 4:3,13 5:4,20  
 7:6,10 14:5,11,22  
 15:14,19 23:1  
 25:11 26:5,15  
 28:17 37:4 57:12  
 58:6 62:20 67:10  
 69:5 73:4 74:21

75:20 76:1 79:7  
 79:19 80:6 82:17  
 85:6,13 88:16  
 89:19 90:1,22  
 93:5,21 96:6 97:5  
 97:10 101:21  
 103:13 108:4  
 109:16 117:4  
 118:15 121:3  
 123:12 124:10  
 125:6,22 128:19  
 135:15 138:2  
 139:14 140:18  
 142:22 144:15  
 146:19 148:5  
 149:2 150:16  
 152:3 153:13  
 156:2,9 178:12  
 181:13,14 185:12  
 190:4 195:20  
 197:21 200:7,12  
 201:20 203:14,17  
 203:21 207:2  
 215:10 219:16  
 220:16 225:18  
 227:20 228:20  
 229:6,12 231:4,8  
 231:17 232:18  
 233:14 234:16  
 235:22 238:1  
 241:18 243:3,20  
 244:15 247:16  
 249:14 252:14  
 253:15 257:5  
 258:4 259:22  
 261:2 263:11,21  
 264:22 267:10  
 268:1,20 269:17  
 272:21 274:7  
 275:15 278:1  
 281:4 282:9,17  
 283:7 285:8,21  
 286:14 287:5  
 292:12,18 295:7  
 296:6 297:12  
 298:18 299:21  
 300:19 301:9,15

301:19 303:2  
 305:14 306:8  
 307:19 308:6  
 309:6,19 310:11  
 311:1 312:11  
 313:7,11 315:15  
 316:12 317:18  
 320:3,10,18,22  
 324:22 326:4,11  
 326:14 328:21  
 334:7 337:3,19  
 351:7,14 352:14  
 354:2,10 358:15  
 363:5 370:7,22  
 371:15 372:13  
 373:6 374:5  
 375:14 379:8  
 380:2 381:19  
 383:2 385:12  
 390:15 392:2,8  
 410:16 413:19  
 424:7 425:8,10,16  
 425:21 438:12  
 446:17 449:1  
 453:7,14  
**Jason** 2:2 10:19  
 28:20,22 37:5  
 57:12 58:6 282:6  
 341:1 409:9 413:3  
 433:21 438:16  
 441:19 444:20  
 445:13  
**JD** 2:10 3:4  
**job** 46:10 153:19  
 153:20 374:12  
 396:12  
**jobs** 63:9 148:19  
 192:19  
**John** 292:2  
**Johnson** 142:4  
**join** 21:19 454:6  
**joined** 271:17  
**joining** 5:2 80:20  
 156:10  
**Joint** 251:1 385:10  
 402:7  
**jointly** 197:13

203:8  
**joke** 170:10  
**journey** 5:2  
**judgment** 366:16  
**July** 344:21 351:15  
**jump** 16:4 63:14  
 121:17 136:16  
 371:20  
**jumping** 267:9  
**jumps** 57:19  
**jurisdiction** 451:10  
**justification** 153:11  
**justify** 342:7

---

**K**


---

**Kaiser** 2:4 12:9  
 88:17 166:4  
 270:18 271:1,21  
 276:8 314:4  
**Kaiser's** 276:2  
**Karen** 2:8,12 3:8  
 25:7 27:11 37:5  
 52:7 58:11 351:17  
**Kate** 80:11  
**keep** 26:19 40:20  
 86:19 93:3 121:16  
 126:6 129:2  
 138:17 171:5  
 180:9 184:13  
 205:18 236:1  
 244:22 309:2  
 316:3 337:8  
 379:17 411:19  
**keeping** 161:21  
**keeps** 86:15 123:6  
**Keith** 1:19 13:6  
 337:14 338:7  
**kept** 316:5  
**key** 79:4 84:21,22  
 145:8 154:9  
 294:14 366:7  
 418:21  
**keypad** 399:11,22  
**Keziah** 2:15 407:18  
 408:8 420:16  
**kid** 43:7  
**kids** 47:16 63:2,11



148:19	80:3 82:8 98:13	157:22 159:1,5	275:20 276:14,22	431:1,21 434:13
<b>kill</b> 255:18	98:13 100:20	160:15 161:7	277:5,18 279:3,4	434:16 435:16
<b>killer</b> 48:7	104:8 129:13	164:5 165:13	279:5,21 280:8,20	436:1 438:16
<b>killers</b> 251:18	134:4 186:14	166:4,10,22 167:1	282:5,11,17 284:8	443:7 444:7
<b>killing</b> 251:21	196:16 209:18	167:4 168:8 169:3	284:12,17,20	446:11 447:1,14
<b>kind</b> 28:12 34:17	223:2,6 240:21	169:8 171:11	285:3,8 287:5,9	448:19 451:1
34:22 52:10 59:3	249:5 255:17	172:1,14 173:15	288:9,12 292:2	454:1,5
59:20 78:7 79:15	276:14 285:3	173:19,21 174:14	295:3,9 297:21	<b>knowing</b> 204:14
81:20 82:13 88:11	354:20 396:4	176:10 177:6,9,12	298:4 299:6,13,15	<b>knowledge</b> 49:19
90:10 93:14,17,18	428:3	177:16,17 178:4	301:9 302:3	70:2 184:5 259:5
96:9 100:13,21	<b>Kinsinger</b> 1:15 9:5	178:20 179:4,8	303:12 306:11	371:21 411:16
101:16 107:19	9:6 76:3 268:22	180:4,7,8,14,20	309:16,19,22	<b>knowledgeable</b>
128:13,14 141:5	367:5,21 369:6	180:21 184:15	311:6,21 312:1,3	64:12 68:18
141:18 148:21	375:6 393:10	185:1,5,10,22	314:19 315:9,9	<b>known</b> 343:16
154:8 164:10	435:22 436:7,10	186:13,13 187:2,8	317:1,12,17	<b>knows</b> 92:18,19
177:16 186:1	436:14,18 437:4	187:9,21 189:1,11	318:12,14 320:22	298:11
187:12 188:1,11	443:19	193:10,14,18	321:1 322:7,9	<b>Koh</b> 229:17
188:15,20 189:3,6	<b>knew</b> 214:2,3,6	194:4 195:7,18,21	326:16 327:1,2	<b>Kristin</b> 2:9 15:14
191:14 197:14,18	<b>know</b> 13:21 17:6	196:6 200:16,20	328:7 329:3,8,16	15:14,16 17:15
203:7 205:4	22:10 26:2,8 34:2	201:8,9,13 204:10	329:18 332:4	22:7 399:2 400:21
207:18 209:13	34:13 35:13,18	204:11 205:3,8,19	334:17,18 335:7,7	405:20 433:14
227:9 236:16	42:17 47:13 52:3	206:2,10,11	336:7,14 339:7	435:1,14 440:10
241:13 245:14	52:19 56:8,11,15	208:20 209:1	341:3,15 344:20	440:14 454:7
255:19,22 258:10	56:17 57:7 58:3	210:9,19 212:3	347:14,17,20	<b>Kurt</b> 1:10,14 3:21
260:17 273:17,21	61:18 62:19,22	217:6,10 219:5,11	350:6 352:9,10	7:17 23:2 61:19
274:18 277:5,6	63:7,22 64:10	220:7,12,14 223:4	353:6 354:18,22	71:11 89:12 98:2
282:16 289:1	65:19 67:10 69:7	223:16 224:12,14	359:16 361:7	100:11,16 105:22
291:21 296:18	69:9,14 74:17	224:16,21,22	367:15 368:4	151:3 157:10
299:16,19 300:15	75:20 76:22 78:2	225:5,9,15 226:18	369:8 371:4,18	158:17 181:14
302:14,16 303:3	78:6 80:7 81:4	226:20 227:18	372:1,7 373:3,16	190:21 202:5
307:12,13,17	82:22 83:16,19	228:6,11 231:12	375:12,21 378:17	275:15 278:1
308:18 312:17	84:5 85:3,6,20	232:1 233:14	383:2 385:15	298:10 317:20
319:17 329:18	89:10,21 90:15	234:4,9,18 237:10	386:20 387:13	434:9
335:21,21 336:22	91:6 92:16 93:1	238:1,20 239:12	388:20,21 390:6,6	
336:22 338:9	94:14 96:15 97:18	239:16 240:12,18	391:16 392:8,18	<b>L</b>
341:7 342:18	98:17 100:4,18	241:3,15 248:13	393:17,19 395:2,4	<b>LA</b> 69:19 79:4 89:2
343:2 344:22	101:7,22 105:6	248:14,18 250:2	395:15 396:7	90:8 126:2 153:18
353:10 356:1	108:5,13 110:11	251:12 252:8	397:18 398:2,3	156:3 172:4 173:9
371:9 377:17,17	113:18 115:16	254:6 255:11,12	403:14,15,19	173:13 180:9
378:10,11,20	118:10,12 123:11	255:20 256:6	404:10 412:7,8,16	212:12 240:11
379:12 387:3	123:12 128:18,22	258:20 259:15	413:7,21 414:12	261:18 268:13
404:3 411:18	129:9 135:4,21	260:4 261:18	415:17 416:5,12	285:13 297:3,11
433:7 434:9,9,11	140:8 141:16	263:15 265:13	416:16,19 417:1	297:13 335:1
442:1,3 446:14	142:16,22 143:14	266:3,20 268:1,12	417:10 420:8	338:15
447:16 451:3	143:21 145:21	269:11,14 270:2	421:4,14,15,22	<b>labeled</b> 135:18
<b>Kindig</b> 182:21	147:16 148:16	271:10 272:16	422:3,14 425:18	<b>lack</b> 370:15
<b>kinds</b> 64:14 71:3	150:19 153:21	274:12 275:1,2,5	426:5 427:7,21	<b>lacking</b> 141:22

<b>ladies</b> 114:3	<b>laws</b> 72:4 117:17	<b>led</b> 31:17 67:17	108:16 115:15	388:13 389:3
<b>lag</b> 353:10	<b>lawsuit</b> 91:20 93:6	112:5 129:19,21	116:13,14,16,21	<b>licensing</b> 51:1
<b>laid</b> 72:19 145:14	<b>lawsuits</b> 91:18 93:1	246:13	116:22 117:13,15	<b>lien</b> 91:19
230:6	<b>lay</b> 21:14 131:19	<b>LEED</b> 282:13,19	117:16 127:5,9	<b>life</b> 40:10 42:10
<b>Lancet</b> 426:18	197:17 212:8	<b>leeway</b> 204:11	141:7 142:8 144:9	43:22 47:20 99:15
427:15 428:13,13	262:8 296:18	<b>left</b> 38:9 93:8	144:13 154:19	132:8,8 152:8,8
438:19 439:5	336:22	102:12 120:11	164:17 165:12,18	168:1,1 184:2
<b>land</b> 193:12 296:19	<b>lays</b> 203:7	136:14 148:7	166:15 167:18	232:7 254:12
332:14	<b>lead</b> 84:4 130:22	154:17 160:22	168:13,16 171:12	257:16,22,22
<b>landed</b> 349:19	157:8 162:13	167:3,17 175:18	172:9 174:14,15	259:15 268:5,11
<b>language</b> 123:4,10	172:8,15,16 173:2	214:1 218:14,15	178:11 179:2	270:7,8,9 331:2
124:9 131:12	216:3 223:21,21	224:4 248:5 321:5	189:17 190:10,14	331:11
137:14 257:8	239:7,9 251:12	335:12	194:4 199:6	<b>lifestyle</b> 47:5
262:4 267:3 298:6	257:13,14,15,16	<b>legal</b> 130:4 395:14	205:11 206:10	<b>lifted</b> 298:19
327:22 328:1	260:8 282:19	<b>legislation</b> 32:2	211:3 235:11	<b>light</b> 194:15 399:12
<b>lap</b> 188:21	330:4	<b>length</b> 232:7	236:8,9 240:2,12	399:12,13
<b>large</b> 12:16 49:17	<b>leader</b> 27:15	<b>lens</b> 263:2	241:21 246:15,17	<b>liked</b> 264:19
88:4 161:2 172:19	<b>leaders</b> 222:15	<b>lenses</b> 114:5	247:3 249:1 269:8	<b>limit</b> 51:22 64:1
212:13 273:3	280:3,12 281:20	<b>Leone</b> 1:17 26:10	271:2,6 272:10,11	180:8
281:5 295:3	281:21	26:11 86:5	273:7 280:7 281:3	<b>limitations</b> 368:10
296:18 347:7	<b>leadership</b> 85:7	<b>let's</b> 73:20,21	284:17 290:4	<b>limited</b> 41:21
431:8	129:20,22 282:4	105:21 106:10,11	291:8 304:3,4	139:19 314:12
<b>largely</b> 7:13 283:2	<b>leading</b> 38:20	113:9,17,18 114:9	326:2 333:11	427:10
<b>larger</b> 112:14	44:22 48:4 49:21	121:20 125:22	385:13 425:18	<b>Linda</b> 1:15 9:6 76:2
281:1 337:18	145:9,10,11	126:3 132:4	434:12 446:20	76:16 266:4
338:1 357:1	152:22 170:3	138:16,17 143:18	<b>levels</b> 20:5 48:18,20	268:20 341:2
<b>largest</b> 85:10,13	223:19 224:5	148:7 150:22	51:7 55:7,12,14	365:2 367:3 393:9
<b>Larry</b> 1:15 13:15	239:6 257:13	153:15 156:4	55:22 59:17 73:20	395:3 402:9
63:12 67:11 96:6	287:8 330:3,8	212:2 221:4 240:1	91:22 104:20	444:21
96:19 97:9 99:18	<b>leads</b> 132:13	242:4 266:3 289:7	119:3 136:6 160:3	<b>Linde-Feucht</b> 1:18
121:3 136:7 138:2	172:14 219:9	301:2 302:1 305:9	164:9 166:13	9:14,15 284:5
140:18 142:22	277:13 288:6	316:15 321:10	167:12 171:4	<b>Lindley</b> 2:16 358:9
148:10 185:12,13	299:7 384:21	337:8 345:17	173:16 174:13	358:10,13,16
189:21 253:15	<b>leap</b> 280:11	377:19 383:7	189:10 190:18	363:14 364:12
266:5 275:15	<b>learn</b> 21:5 27:5	389:16 400:17	206:18 210:17	369:13,17 370:5
329:17 334:7	46:8 98:20 227:14	405:12 435:10	211:18,21 212:9	371:13,18 372:15
<b>Larry's</b> 97:10	248:10 256:14	445:6 452:8,13,18	271:4 279:3	373:12 377:2
146:21 256:1	290:8 337:13	453:18	289:16 331:7	382:1 395:21
<b>lastly</b> 199:19	356:6 357:1	<b>level</b> 10:17 20:6,8,9	<b>level's</b> 116:20	404:13,20 405:9
<b>late</b> 159:15 318:11	382:20	20:19 21:2 29:15	<b>lever</b> 113:4 209:19	427:2
320:8 451:13	<b>learned</b> 88:3	35:8 41:19 45:8	412:4	<b>line</b> 4:7,8 21:22
<b>latency</b> 274:4	184:13 405:8	45:13,15,22 46:16	<b>leverage</b> 84:1	22:1 27:21 90:3
<b>Laughter</b> 86:4	<b>learning</b> 86:6 243:9	46:20 48:10 49:6	<b>levers</b> 43:18,19	92:10 95:6 117:9
108:6 325:4	256:15 382:17	55:9 56:2,7,11	207:15 218:3,4	231:5 311:4
<b>launched</b> 50:17	433:4	57:8 64:14 65:3	<b>liaison</b> 9:11	335:13,13 358:5
77:14	<b>leave</b> 66:7 340:4	65:22 67:4 82:4,7	<b>licensed</b> 360:8	374:16 427:3
<b>laundry</b> 299:6	<b>leaves</b> 253:13	91:11,16 92:11	362:6 379:2 388:2	<b>linear</b> 208:4,21

209:4 331:14	219:21 222:4,17	220:5 226:5	240:1 243:8,11,20	158:12 173:5
<b>linearly</b> 210:1	242:3 243:3	251:19 252:3	249:5 250:12,18	186:2 189:15,18
<b>lines</b> 4:11 117:16	244:21 245:8	264:20 316:4	251:3 252:8	192:7 194:14,15
140:13 226:3	254:18 265:21	340:16 389:9	263:12,19 264:18	196:11 215:14
<b>lining</b> 170:12	274:9 291:11	444:12 449:3	264:22 273:2	223:18 232:3,7
<b>link</b> 80:11 173:6	302:20 303:14	453:16	274:16 284:18	234:11 236:1
195:19 197:8	318:11,19 319:5	<b>longer</b> 319:5 444:7	289:21 294:20	241:11,12,13
222:5 335:18	320:6,8 327:20	446:11 454:3	295:19 300:17	248:14 250:19
336:12 429:12	337:22 339:14,14	<b>long-standing</b>	301:16 303:7,14	263:3 269:3
448:14	339:18,19 344:8	29:19	304:14 309:21	274:10 277:9
<b>linkage</b> 162:10	386:17 389:14	<b>long-term</b> 51:9	310:6,14 326:20	288:8 302:4
267:8	391:17 394:16	222:8 359:10	327:19 340:20	306:12,19 307:5
<b>linkages</b> 217:9	397:17 409:7	368:11 375:16	342:1,13 343:15	312:12 322:18,19
276:6	417:14 435:12	<b>look</b> 21:9 26:18	345:18,20 346:6,7	326:5 327:7,13,16
<b>linked</b> 187:18	443:16	27:2 37:20 38:3	348:17 355:5,11	328:11 339:5
<b>linking</b> 300:16	<b>livable</b> 148:18	40:16 42:7,16	365:22 369:9,18	341:5 354:22
<b>links</b> 77:2 80:19	281:15	44:7,12 46:6 47:2	373:6 378:22	359:18 366:7,8,18
160:5 271:11	<b>live</b> 13:19 42:21	48:5,13 50:10	387:11 390:20	372:11 373:17
<b>lions</b> 4:17	43:4,20,21 45:9	52:18 54:18 55:12	397:6 398:5,8	375:14 376:11
<b>lion's</b> 158:4	47:20 63:8 125:17	55:14 57:4 62:9	409:21 413:16	392:13,14,22
<b>list</b> 16:8 30:16	374:15	69:18 70:5 71:15	414:11 418:7,11	398:16 411:3
91:17 161:8 168:9	<b>lived</b> 214:3	71:17 72:2,20	433:16 436:17	412:2 432:18
185:6 220:5 299:6	<b>lives</b> 254:10	73:6 79:5 84:8	442:7,15 445:12	437:15,22 448:6
336:17 338:5	<b>living</b> 13:17 43:3	85:8 86:18 89:2	448:9 449:4	448:20
384:4 407:9 426:3	255:3 283:21	90:15 95:2 96:3	<b>looked</b> 67:15 88:13	<b>looks</b> 58:11,12
426:6	312:2,4,8	97:12 98:10 99:22	116:1 145:6,10	148:13 188:19
<b>listed</b> 31:14 138:20	<b>Liz</b> 427:2 431:8	101:10,14 102:4,7	189:10 196:21	199:13 231:10,13
152:2 205:4	<b>local</b> 11:13 12:4	108:11 111:14	199:4 268:6	255:10 355:16
<b>listen</b> 182:9	94:3 171:12 194:4	114:13 115:2	321:19,22 335:19	367:6 368:6
<b>listening</b> 319:1	205:21 206:10,11	116:8 119:20	341:21 343:12	393:13
<b>lists</b> 184:19	206:13,19 211:2	122:14 127:4	346:15 351:7,22	<b>look-back</b> 352:3
<b>literally</b> 59:1 124:7	<b>located</b> 11:12	133:1,19 134:9	354:16 355:6	<b>loop</b> 36:5 54:15
249:19	<b>locked</b> 45:1	135:17 136:2	367:15 395:18	95:15
<b>literature</b> 264:12	<b>locus</b> 111:21	138:19 139:10,19	410:10 433:12	<b>loops</b> 257:18
371:22	<b>logic</b> 72:1 75:17	142:11 144:18	442:4	331:12
<b>little</b> 12:5 21:21	103:1 126:10	150:8,11,16 152:4	<b>looking</b> 5:1 36:14	<b>loosely</b> 161:6
29:11 30:9,13	127:2 128:6 175:2	152:14 153:21	37:9 38:1,13	223:15
31:20,22 33:9	176:13 180:21	154:22 155:9	41:11 44:11,18,22	<b>Los</b> 2:17,21 3:16
34:7 40:4,14 41:8	207:8,10 208:1,21	159:11 169:3,20	45:18 48:11 53:17	21:16 334:12
54:21 63:11 70:20	237:11 239:13	174:8 177:8	74:7,12 78:21	<b>lose</b> 24:12 83:2
71:21 86:5 89:12	252:11 333:11	181:11,21 183:5	83:11 86:2 97:15	281:17 413:16
98:3 115:5 136:17	334:3	184:20 187:4	99:3 112:17 113:2	416:1,11
138:4 155:14	<b>logical</b> 59:22 251:3	192:14 199:6	123:12 124:1	<b>loses</b> 182:14,15
170:9 178:13	<b>logically</b> 106:22	209:2 222:9,11	126:13 134:13,19	<b>losing</b> 319:12
183:14 187:10	<b>long</b> 93:12 157:13	223:3 227:15	136:6 142:5,7	<b>lost</b> 254:12 268:5
199:7 200:2 202:7	159:21 183:14	228:1,22 232:10	147:6 148:3	268:12 270:8,9
212:7 215:14	184:9 202:10	234:2 238:18	149:14,16 154:9	281:18

<b>lot</b> 26:16 27:8 34:2 36:13 44:14,15 46:18 49:10 60:6 81:22 83:6 85:1 85:20 87:11 90:5 96:13 103:8 104:6 107:1 114:3 119:8 140:10 141:5 144:8 159:8,9 163:21 165:10 166:5 173:19 177:21 186:7,17 186:22 193:8 195:2,2 198:8 204:14 212:19 213:7 249:21 258:18 264:2,4 265:19 271:4 279:12 280:16 284:15 300:8,19 303:1 304:8 310:19 312:7 313:5 327:15 329:3 335:2,6 341:3 351:12 354:19 356:18 357:13 363:17 377:5 382:17 385:3 392:3,20 409:22 412:21 437:19 453:17	354:6 370:17 371:5,5,6 372:3 443:16 <b>lucky</b> 173:20 376:7 <b>lump</b> 256:7 <b>lunch</b> 87:4 231:10 231:15 242:1 <b>lung</b> 1:17 274:2 <b>luxury</b> 246:11	259:5 283:16 <b>Manager</b> 8:14 <b>managers</b> 225:3 <b>managing</b> 203:15 204:4 315:20 <b>manner</b> 46:2 371:22 372:8 <b>manufacturers</b> 428:21 <b>map</b> 34:9 <b>March</b> 33:5 344:18 350:1 352:2 360:3 407:14 <b>mark</b> 159:16 162:7 166:16 167:4 185:19 186:12 217:5 324:8 <b>marketplace</b> 280:6 <b>Mark's</b> 186:12 <b>Marriott</b> 1:9 <b>MARY</b> 2:13 <b>Maryland</b> 159:20 <b>Mason</b> 1:19 13:5,6 27:16 250:10 251:14 300:6 319:15,20 320:1 325:20 326:8 337:15 <b>match</b> 118:7 142:5 <b>matches</b> 295:2 <b>material</b> 30:15 <b>materials</b> 34:2 55:4 68:22 <b>matrix</b> 180:14 <b>Matt</b> 2:4 12:7 28:20,22 37:5 57:12 61:5 88:16 130:4 131:5 136:7 138:2 148:5 151:4 155:2 194:7 197:21,22 201:20 215:10,10 217:3 218:10 231:17 237:10 255:22 256:19 266:4 268:14 275:6 280:13 286:7	288:3 298:18 320:10 325:21 328:21 329:1 417:19 <b>matter</b> 70:17 101:8 118:15 156:6 224:16 242:6 244:5 264:20 321:7 380:2 440:10 454:11 <b>Matt's</b> 58:9 59:5 274:9 278:3 419:11 <b>maximize</b> 256:14 288:19 <b>maximum</b> 176:11 <b>mayor</b> 281:13 <b>mayors</b> 312:22 <b>MBA</b> 1:13 2:9 3:8 3:19 <b>McELVEEN</b> 2:10 <b>McGinnis</b> 288:2 <b>MD</b> 1:13,14,15,17 1:18,21 2:2,8,13 3:8,10,14,15,19 3:21 <b>mea</b> 83:20 <b>mean</b> 42:17 47:7,16 60:13 61:2 67:5 85:14 86:6 96:8 98:14,15 102:11 110:2,2,6 111:13 112:9 114:15 117:5,6 119:8 124:11,14 125:5 125:10,11,20 127:14 131:1,16 134:11 135:18 151:19 152:4 179:6 184:22 185:21 195:5 201:3 208:16 211:4,20 215:19 219:2,7,10,22 220:4,11 223:15 227:12 228:2 243:22 246:8	248:17 253:17 254:10 260:9 266:20 270:16 275:12 280:16 282:5 291:5,20 294:5 295:4 296:17 297:13 300:6 302:3,4 304:2,7,10 306:21 307:4 308:3,8 312:2 315:13 316:3 324:10 326:2 343:4 352:6 352:21 353:14 354:9 357:8 363:11,14,15 373:19 374:1 375:11,21 378:7 379:1 381:17 383:19 386:19 393:18,22 395:12 395:18 403:12 410:22 412:3,7 414:22 415:20 416:12,17,19 417:17 425:10 428:6,9 432:16 434:4 436:8 439:2 441:13 442:7,22 443:21 446:11 447:1,19 449:22 <b>meaning</b> 311:12 312:7,9 418:19 <b>meaningful</b> 171:22 176:6 311:7 314:17 <b>meaningless</b> 125:7 <b>means</b> 42:20 61:2 68:17,21 87:2,8 97:21 106:11,12 117:9 123:17 155:12,15 163:5 211:19 228:4 387:6 391:10 <b>meant</b> 38:12 60:2 176:4 311:17 <b>measurable</b> 179:7
	<b>M</b>			
<b>lot</b> 26:16 27:8 34:2 36:13 44:14,15 46:18 49:10 60:6 81:22 83:6 85:1 85:20 87:11 90:5 96:13 103:8 104:6 107:1 114:3 119:8 140:10 141:5 144:8 159:8,9 163:21 165:10 166:5 173:19 177:21 186:7,17 186:22 193:8 195:2,2 198:8 204:14 212:19 213:7 249:21 258:18 264:2,4 265:19 271:4 279:12 280:16 284:15 300:8,19 303:1 304:8 310:19 312:7 313:5 327:15 329:3 335:2,6 341:3 351:12 354:19 356:18 357:13 363:17 377:5 382:17 385:3 392:3,20 409:22 412:21 437:19 453:17	<b>machine</b> 86:14 <b>Madeline</b> 1:22 9:20 263:21 386:3 422:18 <b>Madigan</b> 2:19 427:2,4,16,20 428:12 429:11 430:5 431:7 <b>main</b> 146:7 186:20 <b>mainstream</b> 120:22 <b>maintain</b> 114:20 351:3 <b>maintained</b> 206:16 <b>maintaining</b> 24:4 64:5 65:1,2,3 <b>maintenance</b> 1:4 23:17,21 24:8,10 351:1 <b>major</b> 45:6 46:13 81:11 113:10 185:10 206:3 230:2 260:4 265:7 266:12 282:21 361:13 362:10 391:1 <b>making</b> 54:8 123:15 142:20 174:21 180:21 209:18 222:13,16 222:19 260:16 290:11 377:11 413:11 418:11 <b>manage</b> 12:21 316:10 <b>management</b> 172:9 172:13 210:8	259:5 283:16 <b>Manager</b> 8:14 <b>managers</b> 225:3 <b>managing</b> 203:15 204:4 315:20 <b>manner</b> 46:2 371:22 372:8 <b>manufacturers</b> 428:21 <b>map</b> 34:9 <b>March</b> 33:5 344:18 350:1 352:2 360:3 407:14 <b>mark</b> 159:16 162:7 166:16 167:4 185:19 186:12 217:5 324:8 <b>marketplace</b> 280:6 <b>Mark's</b> 186:12 <b>Marriott</b> 1:9 <b>MARY</b> 2:13 <b>Maryland</b> 159:20 <b>Mason</b> 1:19 13:5,6 27:16 250:10 251:14 300:6 319:15,20 320:1 325:20 326:8 337:15 <b>match</b> 118:7 142:5 <b>matches</b> 295:2 <b>material</b> 30:15 <b>materials</b> 34:2 55:4 68:22 <b>matrix</b> 180:14 <b>Matt</b> 2:4 12:7 28:20,22 37:5 57:12 61:5 88:16 130:4 131:5 136:7 138:2 148:5 151:4 155:2 194:7 197:21,22 201:20 215:10,10 217:3 218:10 231:17 237:10 255:22 256:19 266:4 268:14 275:6 280:13 286:7	288:3 298:18 320:10 325:21 328:21 329:1 417:19 <b>matter</b> 70:17 101:8 118:15 156:6 224:16 242:6 244:5 264:20 321:7 380:2 440:10 454:11 <b>Matt's</b> 58:9 59:5 274:9 278:3 419:11 <b>maximize</b> 256:14 288:19 <b>maximum</b> 176:11 <b>mayor</b> 281:13 <b>mayors</b> 312:22 <b>MBA</b> 1:13 2:9 3:8 3:19 <b>McELVEEN</b> 2:10 <b>McGinnis</b> 288:2 <b>MD</b> 1:13,14,15,17 1:18,21 2:2,8,13 3:8,10,14,15,19 3:21 <b>mea</b> 83:20 <b>mean</b> 42:17 47:7,16 60:13 61:2 67:5 85:14 86:6 96:8 98:14,15 102:11 110:2,2,6 111:13 112:9 114:15 117:5,6 119:8 124:11,14 125:5 125:10,11,20 127:14 131:1,16 134:11 135:18 151:19 152:4 179:6 184:22 185:21 195:5 201:3 208:16 211:4,20 215:19 219:2,7,10,22 220:4,11 223:15 227:12 228:2 243:22 246:8	248:17 253:17 254:10 260:9 266:20 270:16 275:12 280:16 282:5 291:5,20 294:5 295:4 296:17 297:13 300:6 302:3,4 304:2,7,10 306:21 307:4 308:3,8 312:2 315:13 316:3 324:10 326:2 343:4 352:6 352:21 353:14 354:9 357:8 363:11,14,15 373:19 374:1 375:11,21 378:7 379:1 381:17 383:19 386:19 393:18,22 395:12 395:18 403:12 410:22 412:3,7 414:22 415:20 416:12,17,19 417:17 425:10 428:6,9 432:16 434:4 436:8 439:2 441:13 442:7,22 443:21 446:11 447:1,19 449:22 <b>meaning</b> 311:12 312:7,9 418:19 <b>meaningful</b> 171:22 176:6 311:7 314:17 <b>meaningless</b> 125:7 <b>means</b> 42:20 61:2 68:17,21 87:2,8 97:21 106:11,12 117:9 123:17 155:12,15 163:5 211:19 228:4 387:6 391:10 <b>meant</b> 38:12 60:2 176:4 311:17 <b>measurable</b> 179:7

209:15 344:5	289:10 290:1	433:16 436:17	51:22 53:11,18	246:7,15,19 247:1
<b>measure</b> 3:9 13:4	291:3,21 292:10	437:13,16 441:8	54:20 56:3 57:5	247:7,13,22
17:11 18:3,4 19:2	293:1 294:22	441:17 444:1	60:8,10,18 62:9	248:12,15,20,21
19:10,12 21:9	299:1,3 302:12	445:14 448:9	62:12,12 70:22	248:22 249:1,4,5
22:15 23:22 24:12	303:11 311:15	449:15 452:6,16	71:4 72:21 73:10	249:6 250:6,12,14
24:14,22 33:17	313:14 314:3,9,16	<b>measured</b> 167:21	73:20 74:10 75:12	250:18,20,20
37:21 41:11 44:10	326:3 327:7 328:8	183:15 190:9	75:13 79:6 90:7	251:2,7,8,11,15
44:20 45:20 46:16	328:13 331:22	272:10 278:17	95:20 96:22	251:19 252:9,15
47:9,10 48:22	333:2,7 339:2	313:14 330:5	100:20 101:9,12	253:1,1,4,6
49:7 51:5 53:7,8	342:6 343:15	343:4 374:11	101:14,17 102:4	255:18 256:9,13
53:14,17 56:3	345:21 346:12,18	381:9 384:12	103:4,15,22 104:2	257:7 259:14,20
57:2,5 65:15 66:5	348:22 349:5,7	414:3,8 444:9	104:20 105:13	261:15 263:12,19
66:6,7 67:15	350:16,20 353:12	<b>measurement</b> 3:18	106:19 109:10	264:3 266:12,16
83:11,13 88:10	353:15 354:9	18:22 21:7 24:13	110:5 111:15,17	266:21 267:13,13
93:18 96:3 100:19	355:3,10,11,15	29:20 34:19 36:4	111:18 113:2	268:16 270:14,15
103:14 105:8	358:1,3,7,18,22	37:21 46:19 48:20	114:13,20,22	270:17,20 271:1
106:4 114:8 115:7	359:2,19,21,22	49:12 58:18 70:13	115:3,11 116:5	272:15 273:22
116:3 117:12,20	361:14,16,19	71:9 94:11 95:10	117:1 118:19	275:11 278:4,5,6
118:16 119:16,21	362:5,11 363:1,16	96:5 97:15 105:14	119:2,18 121:7,8	279:7,21 280:18
119:22 120:2,6	363:21 364:1	106:6 121:9	122:10 126:14	282:1,11,12
122:1,2,7,15	365:7,10 366:22	128:14 140:22	128:9,16,18	284:11,19 286:9
127:3,6 134:9,18	369:15,17 370:20	144:7 147:22	141:18,22 146:15	286:21 287:3
134:20 137:7	374:6 375:9,10,11	159:15 165:2	146:21 147:2,13	289:11,13,15,17
139:13 142:13	376:9 379:7,20	171:2 172:21	147:17,18 148:2	289:18 291:2,2,7
143:4,5,5,7,15	380:15 381:2,12	178:10 179:12	148:12,21 149:18	293:5,18 294:15
144:20 147:11,15	381:14 383:4,10	189:9 195:13	150:4,11 152:11	294:20 298:14,22
149:10 153:4	383:16,21 384:2,3	196:14 200:22	152:21 157:13	299:7,15,22
154:19,19 165:20	384:13,18 385:8	217:7 223:14	166:18 168:6	302:11 303:12
167:11,16 168:22	387:10,15,17,22	232:8 245:21	169:16 172:10	305:8 310:15,19
169:3 172:11	388:1,5 389:2,20	272:6 274:18	176:16,17 179:13	310:20,21 311:6
173:5 177:3,4,5	392:12 393:2	277:10 328:2	180:4,5,8 187:14	311:17 312:6,16
178:8 179:21	396:10 402:19	332:6 345:4 346:9	187:14 189:22	312:19 313:21
180:16 182:19	404:6 405:22	360:18 366:9	196:19 197:19	315:3,13,20 317:5
195:15 197:3,13	406:9 407:4,7,9	391:18 444:11	204:17,18 210:11	319:7 320:12
202:18,22 203:8	407:11,18,20	<b>measurement-ba...</b>	215:16 216:4,10	322:2,3,16 323:10
211:6 217:19	408:2,4,10,15,17	34:20	216:13 218:14	323:13,13,14,14
221:14,16 222:1	409:8,17,20 410:2	<b>measures</b> 3:10 8:11	220:7 221:6 223:6	324:4,9,10,11,16
224:19 232:3	410:10,12 411:3,8	13:3 15:4 17:14	231:22 232:1,5,5	326:22 327:5,8
233:1 239:3	411:10,13,14	17:21 18:1,5,8,8	232:7,10,15,21,22	330:20 331:4
246:17 251:20	412:20 413:14	19:1,3,4,13,18	233:6,9,17,18,21	333:5,18 337:2
253:20 260:11	414:3,15 415:2,22	20:2,5,8,10,15,20	233:22 234:3,5,11	338:13 339:5
261:4,6,13 262:22	416:5,11,17,18	20:21 21:2,8,12	235:9,15,16 236:7	340:7,12,14,19,21
263:3 267:17,19	418:14 419:1,10	21:19 22:15,16,18	236:8 237:4,6,7	341:4,8,20,22
268:4,10 269:19	420:14,17 423:1,6	23:10 24:7,18,19	238:6 239:1,10	342:2,4,8,11,14
271:2 272:6,14,18	423:7 425:7,15	24:20 25:1,2 33:8	241:4,6,9 243:8	342:17,19,20
272:20 274:11	426:2,22 430:18	41:6,8 47:2,11	243:12,13 244:17	343:2,8,10 344:3
275:13 278:17	431:5,14 433:13	48:17 49:6 50:1	245:4,16,19 246:5	344:19 345:5

348:15,18 349:11	275:19 276:17	<b>mental</b> 44:16,19	<b>meta-questions</b>	<b>Milstein</b> 210:21
350:4,17,19,22	277:14 330:14	266:14 292:14	302:15	333:13
353:7,12,15	360:22 369:22	<b>mention</b> 40:3	<b>method</b> 397:22	<b>mind</b> 26:20 71:2
354:14,17 355:6	395:8	138:21 230:22	<b>methodological</b>	201:7 205:7,18
356:7,9,16,16,22	<b>Medicare</b> 26:1	284:20 303:18	56:18	230:19 244:22
357:12,21 365:5	187:17	351:21	<b>methodologically</b>	253:7 255:7
373:19 378:22	<b>medication</b> 213:21	<b>mentioned</b> 16:20	4:20	311:19 316:3
379:18 380:20	<b>medicine</b> 7:19 9:7,8	19:8,19 21:3,20	<b>methodologists</b>	337:8 341:6
384:5,6,15 385:1	12:14 108:9	30:20 65:7 66:11	243:14	379:17 453:17
389:11 401:4	160:20 202:10	66:12 75:1 76:5	<b>methodology</b> 47:4	<b>minds</b> 15:9 280:2
403:9 409:1,21	265:19 296:8	94:14 100:16	150:18 243:10	<b>mine</b> 38:4 182:10
411:1 412:13,18	<b>Medows</b> 1:21 25:11	105:2 197:6	337:13	<b>minimized</b> 64:10
412:19 413:17	25:17,18 93:3	198:22 200:15	<b>methods</b> 210:5,15	<b>minimum</b> 142:1
416:3,9,12 417:7	97:7 301:7,11	202:5 220:12,13	211:5 320:12	<b>minute</b> 69:4 156:4
417:12 418:21	305:15 306:21	220:14 269:20	<b>metric</b> 179:15	163:15 211:17
419:8 420:18	379:9	270:1 282:6 284:6	<b>metrics</b> 163:2	318:4 321:11
423:20 424:4	<b>meet</b> 27:7 127:7	293:16 310:9	167:6 168:7,8	344:9 441:10
425:1 426:3,5,11	158:14 252:10	329:2 362:6 420:2	169:10 175:15	<b>minutes</b> 19:14 29:9
432:19 437:9	297:15 360:17	434:9 438:16	199:2 200:17	103:16 133:22
446:8 448:10	430:20 431:22	450:15	262:20	136:14 148:7
449:5 450:3,10,16	432:5 452:16	<b>Merrill</b> 1:21 8:20	<b>Metro</b> 8:2	229:9,10 231:14
450:17 451:6	<b>meeting</b> 4:5 6:1	8:21 79:20 80:15	<b>mic</b> 85:12 296:5	231:19 305:9
<b>measure's</b> 114:17	14:21 16:22 17:18	80:21 94:10,21	301:18 302:8	306:7 309:17
373:20 423:11	19:7 23:4 37:7	99:13 124:22	305:13 329:1	310:1 320:5,20
<b>measuring</b> 93:14	79:13 198:7 262:8	126:21 127:13	<b>Michael</b> 2:4 90:1	321:12 376:2,5,7
118:6 141:10	310:4 340:22	144:3 207:4,5	140:18 197:22	<b>mirror</b> 306:22
162:17 167:14	<b>meetings</b> 6:1 22:3	208:9 209:14	201:21 241:22	307:15
172:7 203:3,4	26:20,21 80:4	211:11 235:12	264:19 315:16	<b>misguided</b> 277:12
292:10 340:18	150:14 181:22	236:6 255:15	346:19 352:19	<b>missed</b> 25:17 236:5
346:14 350:7	317:19	259:1 270:11	<b>microphone</b> 17:3	246:21 278:9,10
386:9 419:22	<b>meets</b> 320:5 391:19	271:9 272:5,9	204:1	324:17 405:10
<b>meat</b> 40:4	431:6	282:10 283:5	<b>microsystem</b> 55:22	<b>missing</b> 321:17
<b>mechanism</b> 70:15	<b>Megan</b> 2:16 358:9	295:16 311:4	<b>middle</b> 22:4 27:8	329:6 367:14
418:13	380:5	313:2 381:3,15	38:18 121:21	<b>mission</b> 30:1,12
<b>mechanisms</b> 71:14	<b>member</b> 12:10	387:18 388:6,15	300:18	161:20 230:9
71:16,18 274:14	188:7 324:16	426:2 430:12	<b>Mid-America</b>	<b>mistake</b> 277:11
<b>MEd</b> 1:24	399:17	431:12 432:2,10	282:7	<b>mitigated</b> 330:13
<b>median</b> 46:12	<b>members</b> 17:8 19:8	432:17 446:6,22	<b>Mike</b> 11:22 112:5	<b>mitigation</b> 172:15
397:13,16	22:21 24:1 228:18	448:11 450:6,20	146:19 202:1	<b>mix</b> 206:1
<b>Medicaid</b> 25:22	252:20 322:6	<b>mesh</b> 302:19	218:9 219:7 258:4	<b>mode</b> 112:20
50:14,14 187:16	340:22 365:2	<b>message</b> 35:2 78:12	273:12 307:19	<b>model</b> 72:2 75:17
<b>medical</b> 10:20 14:1	<b>membership</b> 22:11	119:3 406:22	341:1 386:3	126:10 127:3
25:20 56:10 81:2	22:19 274:17	<b>messages</b> 454:8	398:13 420:2	131:19 176:13
98:18,21 107:15	<b>Member/Public</b>	<b>met</b> 1:9 114:14	<b>Mike's</b> 91:1	180:21 207:8
161:14 184:18	3:17	213:16 350:19	<b>milestone</b> 349:10	208:1,21 209:4,15
186:20 187:18	<b>memo</b> 106:2	384:15 406:1	<b>million</b> 77:13 283:3	210:13 216:6
188:10 215:4,7	<b>men</b> 123:9	441:9,12	<b>millions</b> 281:16	237:11 253:13

266:14 286:9	<b>morning</b> 4:3,14	<b>movement</b> 104:7	<b>N</b>	299:17
298:21 331:15	5:14,21 8:9,13,16	111:17 188:8	<b>NACCHO</b> 11:11	<b>navigate</b> 49:20
333:10,11,14,15	8:20 9:5,14,19	<b>moves</b> 214:16	11:15	<b>NCQA</b> 12:12 13:4
334:1,3 449:17	10:6 11:21 12:19	329:9	<b>Naegle</b> 1:22 9:19	<b>nearing</b> 22:4
451:19	86:10 88:3 89:4	<b>moving</b> 36:20	9:20 112:4 264:1	<b>nearly</b> 67:1 244:1
<b>modeling</b> 175:2,3	157:3 158:7,21	52:16 86:15	386:4	<b>necessarily</b> 73:2
377:18	163:1 182:9 190:6	121:16 138:15	<b>nail</b> 156:22 296:19	131:1 135:20
<b>models</b> 36:16 56:10	191:12 194:8	149:2 169:9	<b>nailed</b> 298:17	251:13 254:22
209:7,12,18 210:7	200:11,15 202:5	171:10 174:3,6	<b>name</b> 13:5 15:16	371:1 394:12
210:20 239:13	202:14 231:1	206:5 240:9 451:7	78:16 159:16	396:11 398:4
329:3 334:5	233:4 241:2 246:3	<b>MPA</b> 2:4	221:14 380:4	416:1 429:17,19
<b>model-based</b>	251:10 268:14	<b>MPH</b> 1:15,21,23	422:21	<b>necessary</b> 6:11
207:10	269:21 318:13	2:2,2,8,9,10,11,13	<b>narcosis</b> 305:14	14:1 74:18 372:10
<b>moderate</b> 368:7,9	327:3 454:5	3:5,10,14,15	<b>narrow</b> 112:10	399:20
391:4,8,9,10	<b>mortality</b> 38:21	<b>MPP</b> 1:14	140:15 189:11	<b>need</b> 35:18 37:6
393:13,14 394:2,3	48:4 143:16 168:7	<b>MSN</b> 2:9	249:7	40:9 49:3 51:5,10
399:3 401:10,15	168:7 264:3	<b>MSW</b> 1:15	<b>nascent</b> 197:17	54:15 70:4 71:10
402:5,13 403:12	267:17,17 268:11	<b>multi</b> 130:14,21	<b>nation</b> 40:20 48:7	71:17 74:19 77:8
405:20 433:20,21	270:7 291:4	194:22 196:7	224:1 325:17	77:15 81:16 83:22
434:17 435:9,18	439:13,22 451:18	<b>multiple</b> 91:14	<b>national</b> 1:1,15,19	91:2 93:17 101:9
435:21 440:12,18	452:1	128:2 207:13	1:23 2:5 3:6 8:8	101:10 110:22
440:21 441:2,2	<b>mortality-related</b>	208:8 209:8	10:7,9 11:9 13:7	111:6 113:6 114:4
443:3 444:18,18	287:4	246:19 254:4	15:18 25:8 27:12	114:19 115:5
445:8,9,10,12	<b>motion</b> 97:8	421:2	27:13 28:6,18	116:5 124:2
452:9,10,14,15	<b>mouth</b> 203:19	<b>multiples</b> 338:20	29:6,15 30:2,3,11	125:10 126:9
<b>moderates</b> 440:22	<b>move</b> 70:3 73:13	<b>multiplicity</b> 342:11	30:14,20 31:19	128:10 139:5
<b>modifiable</b> 69:9	92:14 100:14	<b>multi-sectoral</b>	32:3,10,11,21,22	143:4 145:19
<b>modified</b> 105:2	102:2,16 103:14	186:19	33:4,6 34:18 35:5	148:4 149:21
149:8,9	111:15,18 113:12	<b>multi-stakeholder</b>	36:1 37:10,11	154:3 158:13
<b>modify</b> 158:14	163:12 168:19	22:11 32:9 130:19	38:1 44:4 48:2	181:21 186:8,22
<b>moment</b> 137:5	170:17 171:2,8	138:12 155:6	52:21,22 53:1	187:6 191:11
163:5 178:1	175:2 178:5,8,10	191:17 192:5	55:8,21 56:2,2	193:3 196:6
321:20	195:16 206:7	193:7 195:18	57:8 67:12 76:4,6	202:21 206:14
<b>moments</b> 36:19	214:17 217:17	272:1	77:7,10 79:3,8	208:18 220:10,15
<b>money</b> 25:15 82:4,6	241:16 249:12	<b>mundane</b> 95:19	80:13 93:22 99:4	228:12 237:10
88:7 108:5 173:3	262:14 269:16	<b>municipalities</b> 82:5	165:12,18 173:11	238:15 241:16
215:9 222:22	276:4 279:20	<b>Munthali</b> 2:11 3:5	174:9 187:4,5	244:19 245:18
<b>monies</b> 6:17	295:11 301:5	8:13,14 16:12	198:22 205:20	246:7 260:17
<b>monitoring</b> 349:2	334:8 337:6 339:4	27:22 228:19	206:14,19 219:18	264:10,16 265:15
454:8	349:15 370:19	229:2 231:13	225:12 239:19	266:22 274:16,17
<b>monkey</b> 400:4	390:9 391:6	243:19 317:22	246:20 263:17	275:4 276:3 288:3
<b>months</b> 24:9	397:17 400:21	318:18,22 320:9	277:7 292:7 328:9	290:15 295:13
350:13 407:12	401:17 402:14	320:15	424:7	297:15 301:1
408:14 432:9	441:16 447:22	<b>must-pass</b> 121:22	<b>nationwide</b> 277:4	306:11 308:2
436:13 437:3,10	448:5,7	122:13	<b>Native</b> 143:19	309:20 310:14,17
<b>morbidity</b> 168:6	<b>moved</b> 33:15 93:12	<b>mutually</b> 360:6	354:5	334:22 342:10
452:1	130:17 427:11		<b>nature</b> 135:4 197:9	343:3 351:2 357:6

357:10 360:16 361:8 378:5 391:14 395:7 399:15 403:7 421:17 425:21 432:10,19 437:12 439:7 441:8 448:5 451:4 <b>needed</b> 31:3 34:18 71:5 202:18 306:2 306:3 342:8 384:14 440:13 <b>needle</b> 113:13 <b>needless</b> 40:11 <b>needs</b> 35:1 91:4 100:14 108:3 110:15,17,18,21 116:9 120:20 126:22 138:14 149:12 151:18 158:15 185:5 199:13,16 205:10 214:7,12,14 227:8 237:19 238:16 271:22 290:3 296:21 377:12 411:6 421:16 <b>negative</b> 83:21 <b>negotiating</b> 151:3 <b>neighborhood</b> 214:3,8 <b>network</b> 160:21 161:16 <b>neutral</b> 233:21 <b>never</b> 100:20 145:2 196:3 378:15 403:8 426:8 <b>new</b> 1:22 15:6,7 21:3 24:18,20 78:16 98:5 102:8 102:16 114:5 129:16 143:12,13 147:7 165:13 173:5,13 234:7 235:7 241:18 250:14,21 251:2 264:16 356:2,9	405:7 427:18 433:1 <b>newer</b> 120:18,18,20 234:10 <b>newly</b> 20:13 <b>newspaper</b> 91:10 <b>NHLBI</b> 13:12 <b>nice</b> 95:1 174:16 234:18 291:5 303:6 337:11 349:16 356:19 366:9 414:2 <b>nicely</b> 160:6 175:15 184:16 204:22 <b>nickels</b> 153:16 <b>Nicole</b> 2:10 113:22 152:22 <b>NIDA</b> 10:1 <b>night</b> 304:7 <b>NIH</b> 8:6 <b>nine</b> 170:13 199:20 201:5,11 230:6 295:20 300:5 315:5 408:13 <b>Nishimi</b> 2:12 8:16 8:17 <b>nitty-gritty</b> 236:20 <b>nobody's</b> 131:17 <b>nodding</b> 214:5 <b>noise</b> 34:22 <b>nomenclature</b> 140:10 <b>nominated</b> 7:4 <b>non</b> 235:6 273:17 <b>non-clinical</b> 269:14 <b>non-employee</b> 361:5,17 373:3 <b>non-employees</b> 361:22,22 362:21 <b>non-health</b> 281:7 <b>non-linearity</b> 207:7 207:11 <b>non-medical</b> 360:21 <b>non-profit</b> 10:22 161:6 164:4 <b>non-voting</b> 31:17	<b>normal</b> 356:2 <b>normative</b> 113:1 <b>norms</b> 65:16 66:1 112:8 136:3 <b>note</b> 142:16 340:3 382:20 400:14 <b>noted</b> 352:19 <b>notes</b> 339:16 399:8 <b>notice</b> 24:2 340:10 <b>noticed</b> 55:3 191:8 403:3 <b>notified</b> 24:9 <b>notion</b> 40:13 41:2 48:5 51:10 63:18 63:19 64:11,21 65:12 112:8 129:8 131:7,9 186:4 257:10 286:1 <b>notional</b> 301:6 <b>notions</b> 276:13 <b>November</b> 407:13 <b>no's</b> 406:8 <b>NPP</b> 25:9 31:21 34:12 57:8 59:18 135:18 143:2,11 282:15 304:2 <b>NPP's</b> 28:6 <b>NQA</b> 356:2 <b>NQF</b> 2:6 3:17 8:11 8:15,18 15:4,8 17:8 21:4 22:11 22:21 26:20 29:4 29:17 30:10,21 32:8,16 44:6 47:3 50:7 57:2 60:6 73:9,13,13 83:8 84:15,17 91:3 92:16 102:3,7,15 103:22 104:14,22 108:1,2 109:10 113:5 114:8 115:18 120:14,21 121:22 125:13 135:10 146:22 149:7 150:17 157:14 205:9 221:12 228:16	230:18 233:16,20 243:10 247:20,21 260:1 262:22 265:2 266:1 271:1 282:15 293:10 294:7,13 295:21 299:15 306:11 308:19 312:15 324:3 337:13 340:12 342:5,11 358:20 360:17 361:15 374:22 379:18 384:5,6,17 384:20,22 406:1 412:8 418:13 445:22 <b>NQF's</b> 19:2,22 22:19 46:21 106:3 339:4 341:18 383:15 <b>NQF-endorsed</b> 24:4,13 <b>NQP</b> 32:16 <b>number</b> 24:19,21 32:17 34:15 48:6 65:13 79:21 121:20 188:17 259:10 274:11 277:1 313:20 335:16 344:18 346:10 350:5 356:3 385:1 395:6 408:18 415:4 419:22 420:1 423:17 424:3 431:1 432:19 451:20 <b>numbering</b> 420:1 <b>numbers</b> 170:13 367:9 448:1,5 451:7 <b>numerator</b> 344:7 344:10 345:2,9,22 347:8 349:21 360:15 361:11 364:8 405:15 414:15,19 415:9	418:3,5,11 419:14 423:12 431:17,18 431:19 <b>numerical</b> 399:10 <b>numerous</b> 246:15 <b>nurses</b> 360:10 375:22 386:21,21 388:13 <b>nursing</b> 1:22 8:22 9:21 10:4 51:9 56:12 60:12 221:20 340:15 385:14,16,21 413:8 422:12 <b>nutrition</b> 48:16 249:16 252:22 258:9 260:6 265:5 265:14 266:10,17 267:9 269:4 273:14 276:15 287:13 299:8 302:13 314:4 332:15 333:3 <b>NYU</b> 9:21 <b>NYU's</b> 9:20 <b>N.W</b> 1:10 <hr/> <b>O</b> <hr/> <b>Oakland</b> 13:18 142:12 143:22 <b>Oakland/Alameda</b> 142:8 <b>OASIS</b> 423:19 <b>Obama</b> 277:3 <b>obesity</b> 20:22 59:15 62:12 71:22 72:7 75:2 134:13 177:20 235:3,20 245:17 247:19 249:15,20 254:20 256:3 258:8 259:15 260:6 265:3 273:3,14 275:12 276:12 277:6,6 281:10 286:2 <b>objections</b> 391:12
--	--	---	--	---



<b>objective</b> 160:10 161:4 221:16	229:15,16,18,18 284:12	400:18,22 401:11 401:13 402:14	251:16 252:7 301:20 307:11	224:21 272:15,17
<b>objectives</b> 17:18 74:12	<b>officer</b> 3:14 8:18 9:17 10:20 25:20	405:18,19,20 406:20 408:3	453:1	<b>organizational</b> 30:19 164:15
<b>obligations</b> 133:14	80:10,11 451:9	409:12 415:19	<b>opened</b> 108:3	223:16 225:1
<b>obscurity</b> 217:6	<b>official</b> 44:5 91:21	423:9,21 425:9	<b>opening</b> 76:20 106:2	<b>organizations</b> 13:9
<b>observation</b> 119:14 225:21	400:5	426:1,18 429:18	<b>operating</b> 8:18 422:12	30:16,22 31:10
<b>observational</b> 108:13	<b>officials</b> 1:23 5:6 11:11 91:7	429:20 432:2,10	<b>operational</b> 164:20	90:12,16,17,19
<b>observer</b> 221:12	<b>officio</b> 31:17	432:17 435:2,2,20	<b>Operator</b> 4:8	111:11 130:10
<b>obvious</b> 46:15 209:22 340:18	<b>offs</b> 51:8	437:13 440:5,11	228:19 229:2,4	166:22 200:21
410:22	<b>oftentimes</b> 111:10 112:2 164:18	440:17 441:4,15	<b>opinion</b> 366:14,15	202:17 220:5
<b>obviously</b> 158:9 170:20 173:16	<b>oh</b> 99:6 121:13,14 225:4 229:14	443:1,17 444:16	<b>opportunities</b> 33:8	230:3 322:12,14
175:17 177:18	240:1 244:8,9	445:6 446:4	33:10,19 34:5,10	322:21 323:12
193:13 200:8	313:11 322:6	449:14 451:19	34:14 37:2 118:8	384:10
209:11 215:19	323:20 420:3	<b>Oklahoma</b> 281:12	252:10 340:2	<b>organization's</b> 164:19
219:22 245:2	429:11 435:2	<b>old</b> 71:2 93:17 101:10 261:1	424:5	<b>organization-spe...</b> 160:4
248:5 252:12	443:7	430:22	<b>opportunity</b> 15:12	<b>organized</b> 222:12 281:5
273:10 294:19	<b>okay</b> 7:10 8:4 10:17 14:4,14,20 15:19	<b>older</b> 407:12 428:20 429:1	17:9 19:9 28:5	<b>organizing</b> 34:17
312:14 327:15	26:6 58:6 80:21	431:9 437:10	35:5 54:10 62:7	<b>orient</b> 102:22 107:10,15
331:15 333:9	94:21 95:20 97:4	439:1	62:15 70:1 82:22	<b>orientation</b> 16:15
347:18 353:21	114:3 120:10	<b>once</b> 33:6 59:8 136:5 171:14	83:3 84:10 87:16	22:2 65:7 85:21
415:3	121:14 130:1	233:8,22 245:22	100:10 190:17	107:18,19
<b>occasionally</b> 9:3	132:17,21 133:1	382:15,21 399:10	250:7 251:9,22	<b>oriented</b> 28:15 135:2
<b>occasions</b> 241:3	136:3 138:2,15	420:6 421:18	254:16 256:5	<b>original</b> 286:2 412:17
<b>occupational</b> 370:1 372:21	147:5 156:1,2,9	423:11 449:11	262:12 355:19	<b>ostensibly</b> 149:14 235:15
<b>occur</b> 392:2	158:21 200:14	<b>ones</b> 15:6 40:2 53:22 75:10	366:2	<b>other's</b> 386:7
<b>occurrence</b> 184:4	207:2 225:18	101:15 110:10	<b>opposed</b> 65:4 190:2	<b>ought</b> 89:21 152:10
<b>occurring</b> 165:1 451:6	227:2,6 231:8	132:3 136:10,20	209:6 220:20	263:9 312:20
<b>occurs</b> 51:13	241:22 243:3	150:8 181:10	221:9 239:22	351:8 357:9
<b>ocean</b> 59:20	244:15 258:16	218:15,17 220:7	250:13 272:20	<b>outbreak</b> 169:8
<b>October</b> 32:21 344:17 350:1	266:6 289:3	252:12 283:20	368:12	<b>outcome</b> 41:6 90:21 134:15
351:8 352:2	301:20 311:1,5	375:3 415:8	<b>opt</b> 24:11	147:11 168:3
353:21 360:3	313:11 317:8,8,13	419:13 447:4	<b>optimally</b> 449:1	180:1 205:1,2,3
407:13 421:8,18	318:16 319:14	<b>One's</b> 95:4	<b>order</b> 67:21,22	206:7 209:6 216:4
<b>offer</b> 28:12 71:6	320:10,13 322:8	<b>one-time</b> 249:9	68:2 130:12	216:4 217:11
<b>offered</b> 342:21 349:4 409:2	325:5 326:11	<b>ongoing</b> 54:15 273:9	148:21 149:12	219:2 241:4,5,9
<b>offering</b> 118:10 352:16,16	339:3,18 347:2	<b>onset</b> 335:9	274:15,17 277:15	244:18 256:11
<b>office</b> 80:18 221:18	352:19 358:1,13	<b>open</b> 4:10 17:8,8 22:21 62:19 71:11	384:8	257:1 259:14
	358:16 369:4	100:17 107:6	<b>organic</b> 85:11,14	266:16 267:12,19
	370:4,12 376:20	108:1,1,2 181:5	<b>organics</b> 92:8	270:6,13 272:20
	382:22 390:13,18	184:11 229:4	<b>organization</b> 7:11	
	391:5,14,21		10:3,22 11:12	
	392:10 400:7,13		13:9 73:11 129:12	
			141:4 143:3 155:7	
			162:11 166:2,4,15	
			166:19 167:7,8	

278:4,17 286:20 287:3 289:2 295:2 299:16 306:9 347:4 <b>outcomes</b> 90:10 123:1,16 132:4 134:17 140:16 141:1 151:10,10 163:14 167:19 179:20 199:5 202:15 203:9 215:22 222:8 225:22 227:5 231:22 232:5 240:21,22 252:21 253:7,21 257:8,11 258:3 261:11 264:18 266:19 267:2 271:21 272:4 273:22 277:17 286:11 288:6 290:14 291:9,18 293:2 299:1 300:2 331:5 332:13 333:21 429:13,14 443:13 <b>outline</b> 3:13 18:12 18:13,20 23:18 69:18,21 70:5 89:3 158:5 <b>outlined</b> 17:18 374:2 393:4 <b>outlines</b> 23:5 373:7 <b>outpatient</b> 359:14 361:20 417:16 <b>outpatients</b> 341:11 <b>output</b> 95:8 166:18 <b>outputs</b> 70:11 <b>outreach</b> 30:8 <b>outside</b> 50:15 63:5 72:9 87:11 92:21 244:12 360:20 <b>outsource</b> 376:15 <b>outsources</b> 363:9 <b>outsourcing</b> 377:4 <b>overall</b> 37:9 44:5 54:5 65:21 90:21	93:14 120:15,21 122:21 182:17 189:15 269:13 279:22 365:19 366:3 370:8 404:5 405:21 441:5 443:1 447:20 452:16 <b>overarching</b> 80:2 98:22 141:15 336:5 <b>overlap</b> 59:22 169:14 175:14,22 176:3 187:11 256:2 259:19 264:4 327:16 <b>overlapping</b> 191:6 191:9 <b>oversees</b> 80:12 <b>overview</b> 3:5 28:13 29:17 200:9 359:1 <b>over-specifying</b> 289:14 <b>owners</b> 163:20 204:13 <b>ownership</b> 165:6 175:5,5,20 177:3 204:9 <b>owns</b> 178:4 <b>oxygen</b> 86:16 <b>o'clock</b> 156:3 243:7 318:15 454:4 <hr/> <b>P</b> <hr/> <b>PACE</b> 2:12 351:21 354:7,12 400:8 410:20 412:6 416:15 422:9 425:6,9,14,17 436:6,8,12,16 438:3 441:12 444:4 <b>package</b> 111:1 <b>packaging</b> 82:8 <b>packet</b> 22:6 104:15 114:7 418:1 <b>page</b> 17:4 89:14	101:6 121:21 138:16 151:7 152:16 199:19 439:14,14,18 <b>paid</b> 377:7 <b>pair</b> 288:1 <b>panel</b> 259:2 <b>paper</b> 3:13 21:17 68:14 69:19 70:12 90:9 97:1 99:22 100:12 156:16 157:15 181:16 182:6 188:2 199:8 201:10 213:13 232:13 284:7 285:20 397:2 <b>papers</b> 95:4 385:20 <b>paper's</b> 202:3 <b>paradigm</b> 146:8 150:6 177:14 188:9 191:1 277:15 <b>parallel</b> 79:17 93:19 162:22 187:13 285:10 292:22 <b>parameters</b> 109:20 220:11 235:1 <b>paraphrase</b> 97:11 <b>pardon</b> 323:20 <b>parent</b> 259:10 <b>parenthetical</b> 138:10 <b>parents</b> 259:6 <b>park</b> 1:9,9 126:1 <b>parking</b> 114:3 <b>Parkland</b> 1:24 12:15 <b>parks</b> 203:6 312:21 <b>part</b> 4:4 19:6 23:16 52:20,21 60:5 62:1 69:5 70:6 71:9 79:5 80:14 81:7,8,18 82:9 83:10,15 84:13 87:21 101:12 111:1,6 114:20	120:16 125:14 128:6 138:22 141:20 152:10,21 154:4 158:22 161:19 164:4,7 166:11 179:16 182:3,10 200:19 211:1,4 214:9,18 234:14 238:18 239:3 240:8 245:7 250:16 272:22 285:5,17,19 288:4 288:7,11 290:13 294:6 300:6 323:1 323:2 335:7 340:8 347:7 351:19 356:14 380:12,22 383:15 384:6 387:21 388:4 400:9 411:2 <b>participant</b> 382:6 <b>participants</b> 17:7 49:19,19 <b>participate</b> 271:22 359:7 <b>participated</b> 229:21 <b>participating</b> 18:13 53:21 88:14 <b>participation</b> 154:20 <b>participatory</b> 192:3 <b>particular</b> 6:16 7:15 28:6,14 65:15 182:10,15 186:17 238:20 314:16 338:22 354:17 385:7 401:14 411:11 423:18 <b>particularly</b> 6:13 28:10 32:1 34:22 46:20 53:10 79:3 83:7 94:22 187:4 240:6 269:9 279:1 372:9	<b>parties</b> 26:6 196:9 205:16 <b>partners</b> 31:13,16 160:22 178:2 181:4 193:12,21 196:4 224:12,17 272:7,12 278:18 279:8 <b>partnership</b> 2:2 3:6 10:20 12:3 25:8 28:7,19 29:7 30:4 30:11,14,21 32:21 33:6 44:5 50:7 53:1 56:2 57:3,4 77:11 78:2 80:13 84:18 131:19,20 155:5 164:3 191:16 276:2 <b>partnerships</b> 84:21 132:2 193:5 277:20 <b>parts</b> 52:17 84:15 219:14 258:15 298:9 326:13 365:8 424:15 <b>party</b> 170:1 <b>pass</b> 15:12 365:11 374:6 379:13 391:10 401:16 441:4,14,16 445:11,12 <b>passed</b> 383:5 <b>passing</b> 201:21 <b>path</b> 15:11 29:12 74:3 247:9 262:12 262:13 <b>pathway</b> 151:9,17 152:1,4 215:21 216:1,7,11,18,20 217:14,22 218:11 257:10,17 258:7 261:8 264:21 266:18 267:8 272:17 299:12 303:13 332:17 <b>patience</b> 15:8 454:2 <b>patient</b> 27:4 37:16
---	--	---	--	---

38:6 39:1 42:2	374:1 377:11	222:13 231:11	<b>perception</b> 62:21	315:22 352:3
49:14 50:5,9,16	378:21 392:1	240:6 246:3	<b>perfect</b> 143:15	365:3 381:11
50:20 140:3,9,11	422:19	258:17 266:9	176:4	408:1 420:11
140:14 146:5	<b>Paul's</b> 123:10	270:22 277:13	<b>perfectly</b> 381:20	423:4 436:22
151:11 152:5	124:16 407:3	278:11 281:9,17	<b>perform</b> 211:6	442:13 452:21
154:10 166:21	426:7	284:8 286:6	<b>performance</b> 3:15	<b>personal</b> 93:7
169:15 190:10,12	<b>pay</b> 6:16 112:19	289:22 295:4,9	8:11 15:4 18:7	183:18 303:20
215:5 291:12	115:9	304:22 309:21	25:22 29:20 54:14	348:3
360:5 371:13	<b>payers</b> 322:11	310:17 312:8,22	93:15,18 106:6	<b>personality</b> 80:16
408:19 413:19	<b>payment</b> 36:11	313:1 316:4 317:4	115:9 122:6	<b>personally</b> 114:15
414:3,7 420:20	54:10,11 57:5	319:8 331:6,9	138:20 139:2,13	227:20 277:9
421:14,17,19,20	<b>payments</b> 196:19	336:10 349:3	140:21 143:6	397:8
422:2,7 425:17	<b>PDF</b> 33:22	352:8 363:18	157:13 164:15	<b>personnel</b> 341:9
432:5	<b>pediatrics</b> 40:12	364:22 371:11,16	167:12 171:21	343:18 351:6
<b>patients</b> 50:7 77:11	<b>peek</b> 134:10	374:15 376:11	172:6,12 174:16	355:13,17 358:3
78:2 109:12	<b>Peggy</b> 80:17 229:8	389:3,3 393:19	178:10 179:21	360:2 362:2,13
154:13 341:10,11	229:10,15 231:4	394:7 410:8 416:6	195:8 196:18	367:10,17 371:14
342:21 344:11	<b>pegs</b> 59:4	424:2 428:21	199:1,4 200:17,22	372:19 373:15
345:7,9 346:10,12	<b>pejoratively</b> 42:17	429:1 435:13	202:22 215:16	396:12 424:21
349:21 350:6	<b>pen</b> 123:11	436:12 437:2	216:10,13,22	426:13
372:3,5,20 373:14	<b>pending</b> 402:6	438:8 439:1 442:4	220:6 225:1,2	<b>persons</b> 419:22
375:16 376:10,19	<b>Penn</b> 1:17	442:8 447:21	236:15,17 264:8	420:1
407:11 408:6	<b>Pennsylvania</b> 1:18	448:20 449:7	264:14 268:15	<b>person's</b> 438:7
412:19,21 425:12	26:12	451:2,7	272:11,15,18,19	<b>perspective</b> 46:21
425:19 430:20,21	<b>people</b> 29:4 32:5	<b>people's</b> 46:8 47:15	327:7 328:2	74:16 86:22
430:22 431:4,9	38:9 40:17,20	190:13 213:3	346:12,15 365:17	134:16 146:11
444:6,10,12	42:6,18,21 43:20	215:6 267:3 392:4	365:18,20 366:3	186:1 188:7
<b>patient's</b> 421:16	45:7,14,21 47:17	<b>People-Commun...</b>	367:8 379:1 391:2	205:20 206:13
<b>patient-centered</b>	47:20 49:18 50:15	39:5	430:11 435:5,8	213:14 253:21
56:9 263:14	62:22 63:8,10	<b>people/community</b>	441:6	336:9 378:15
<b>patient-oriented</b>	65:2 73:12 79:13	53:5	<b>performing</b> 167:7	434:5 450:13
146:3 238:22	85:14 86:3 91:7	<b>perceive</b> 7:15	230:9	<b>perspectives</b> 86:16
239:3	92:4,6,17 95:6	<b>perceived</b> 292:6,14	<b>period</b> 22:20 35:3	86:17,19
<b>patient-reported</b>	96:13 98:18,21	330:22	173:22 228:15	<b>pertinent</b> 389:2
291:20 292:1	109:18 110:8	<b>percent</b> 109:17,20	274:4 333:21	<b>Pestronk</b> 1:23 11:8
<b>patterns</b> 184:3	113:19 117:13,15	152:7,8 172:7	353:11 420:19	11:8 68:3 102:19
<b>Paul</b> 1:10,13 3:8,19	125:2,14,16	206:6 223:22	431:21 444:7	107:6,9 132:19
5:4 15:13 16:8	126:20 127:22	318:5 367:18	<b>periodically</b> 159:5	149:5 150:12
23:1 25:18 28:17	128:7 132:9	379:2 385:18	<b>periodicity</b> 275:1	225:20 261:17
29:3,10 31:6	135:22 136:4,20	397:11,21 398:1,1	<b>Permanente</b> 2:4	292:16,20 297:20
33:16 36:22 53:7	146:1,17 147:4	431:11 450:22	12:9 88:18 270:18	384:1 413:3
55:10 57:10 58:12	148:13 149:17	<b>percentage</b> 52:1	271:2,21 314:4	414:10 422:20
61:22 63:17 65:17	154:11 165:15	145:22 169:5	<b>person</b> 4:16 27:15	423:9,21 449:9
74:5 77:4 88:1	167:1 169:5 170:4	328:10 355:16	39:1 49:17 158:3	<b>Peter</b> 31:15 77:5
89:12 135:6	174:9 186:7	408:5 414:12	204:21 228:10,18	<b>pharma</b> 13:12
181:14 211:13	188:17 190:3,16	416:6	229:8 266:6 300:7	<b>pharmaceutical</b>
212:22 225:21	192:9 205:19	<b>percents</b> 367:9	311:2 312:4	11:5

<b>phase</b> 19:6 20:10 20:12,15,17 21:6 21:13,15 27:17,19 27:19,20,22 28:2 42:15 61:9,10,11 62:14 128:17 138:4 220:17,20 245:6 247:12 251:5	<b>physiological</b> 257:14 <b>physiology</b> 332:18 <b>Ph.D</b> 241:18 285:14 <b>pick</b> 170:11 179:18 216:14 225:8,14 227:5 234:12 249:10 263:4 265:12 286:3 325:5 333:2 350:2 399:3 <b>picked</b> 234:6,9 286:19 332:8 <b>Pickens</b> 1:24 12:13 12:13 88:2 148:8 269:20 303:3 348:2,13 <b>picking</b> 243:7 <b>picture</b> 52:12,12 54:5 102:21 160:2 174:16 269:11 432:22 448:6 <b>pictured</b> 187:10 <b>pictures</b> 91:6 <b>piece</b> 74:18 119:15 121:11 291:9 336:1 367:14 388:4 389:17 <b>piecing</b> 300:16 <b>pilot</b> 358:21 359:5 362:19 363:20 396:2 <b>pilots</b> 361:3 <b>pioneering</b> 229:20 <b>PITTMAN</b> 2:13 <b>placard</b> 133:16 <b>place</b> 13:22 55:11 64:5 75:15 107:19 125:17 144:1 146:18 153:21 209:19 226:19 252:5 254:22 255:2 265:17 284:4 286:5 352:17 354:21 413:6 426:4	430:12 <b>places</b> 36:13 107:7 145:11 187:6 241:8 393:21 <b>plan</b> 56:7 79:8 110:6,8 125:14 165:21 168:13 250:10 289:20 311:14 312:1 315:2 323:3,8 350:9 <b>planning</b> 80:5 162:13,16 163:19 163:22 165:4 166:11,15 167:7 <b>plans</b> 12:22 26:1,2 31:11 164:6,19,20 164:21 166:4 169:22 177:11 274:10,13 279:9 <b>platform</b> 153:4 193:6 <b>platforms</b> 54:3 193:3 <b>plausible</b> 211:3 <b>play</b> 43:8 67:1 176:15 179:9 206:11 369:1 375:5 <b>played</b> 28:13 36:17 55:17,19 <b>players</b> 186:21 203:1 238:19 <b>playground</b> 43:9 63:6,12 <b>playing</b> 30:6 36:21 187:19 <b>plays</b> 30:12 115:20 <b>please</b> 4:10,11 29:17 30:13 34:6 37:5 41:12 44:10 46:17 48:1 50:5 51:2,14 123:11 157:8 159:12 160:12 162:6 165:7 166:13 167:9 169:19	171:10 174:5,19 176:14 178:19 180:12 203:17 340:3 365:15 399:8 401:8 433:11 454:5 <b>pleased</b> 87:21 <b>pleasure</b> 5:11 301:15 <b>plenty</b> 282:2 <b>plug</b> 391:7 <b>pneumococcal</b> 342:14 343:19 <b>pneumonia</b> 430:1 438:22 439:10,13 439:21 <b>pocket</b> 177:10 <b>point</b> 18:16 46:6 59:15 64:22 67:11 73:4 74:2 75:11 79:22 80:20 81:21 90:4 91:1 130:7 131:15 135:5 140:19 145:5 173:21 209:17 221:2 237:1 253:18 261:18 266:9 269:1,2 271:7 273:16 286:7 295:9 299:11 315:19 327:10 334:4 336:12 337:7 339:21 351:9 375:15 383:3 384:2 386:5 390:12 391:16 394:21 398:15 412:4 419:11 426:7 437:14 438:6 448:21 <b>pointed</b> 213:12 <b>pointing</b> 149:7 <b>points</b> 17:10 97:15 113:4 122:17 136:12 155:1 262:1 366:7	392:21 442:8 <b>poisoning</b> 239:7,9 <b>policies</b> 55:11 169:4 184:5 186:18 212:22 219:12 323:5,17 329:22 <b>policy</b> 10:21 43:18 43:18 45:15 91:17 176:8 177:11 195:21 196:12 198:13 217:18,20 218:22 270:2,3 324:12 335:17 336:12 <b>policymakers</b> 401:20 <b>political</b> 129:20 223:16 281:20 <b>politicians</b> 222:15 <b>poor</b> 63:11 85:14 287:14 <b>pop</b> 248:15 <b>population</b> 1:3 3:6 3:10,18 4:22 10:16 12:1,14 18:11 19:1,3 20:6 20:9,19 21:2,8,10 21:19 25:10 26:17 28:15,19 31:5 33:11,14 35:7 37:15 38:13 40:7 41:18,22 42:2 45:22 46:16,20 48:12,20 49:6 53:9,15 71:10 72:22 78:6 85:2 98:16,20,22 100:8 101:17 103:4,15 104:20 105:5 106:5 107:17 108:16 109:13 116:10,14,16,21 116:22 117:2 118:17 119:16,21 120:2 123:2,17 124:2,5,11,12
--	---	--	--	--

125:1,4,16 126:13 127:5,16,18 129:2 129:10 130:16 131:2,10 137:6 139:7 140:6 143:20 146:13 149:10,14,17 150:21 153:8,17 160:2,9 162:10,14 163:5,10 165:9,19 166:5,7,8 167:18 168:13,16 169:5 169:18 170:16,18 173:6 174:13 178:11 179:18,19 182:11 183:8,14 183:15,21 189:10 206:1 210:9 215:15,18,22 216:21 221:6 223:9 225:2,7 228:13 234:22 235:11 236:11 239:12 243:22 244:17 245:4,12 245:16 246:22 247:21 250:13,19 251:7,19,20 252:15 255:9 261:3,6,10,15 266:15 267:2,18 269:8,19 271:2,20 272:11 275:8 279:5,12 284:10 284:18 286:10,20 287:3 291:2 293:17 299:17 300:13 312:18,21 314:19,21 315:21 322:1,17 324:3 325:7,8,10,13,15 326:5,21 327:5 330:18,20 331:19 333:15 337:12 340:15 341:12 342:7 347:18 348:1 350:8 352:1	354:17 356:7,8,16 371:3 373:11 374:18 375:18 386:7,11,12 389:8 396:11 406:21 418:5 430:13 433:1 442:13 446:10 447:7,9,13 447:20 448:9 449:6,18,19,21 450:5,16 451:18 <b>populations</b> 104:9 139:20 140:11 154:18 155:17 163:18 184:2,7 268:7 314:20 322:20,20 341:12 342:3 343:7 344:4 354:3 371:14 374:17 379:22 410:6 436:3,4,6 451:1,21 <b>population-based</b> 210:10 241:5,9 <b>population-health...</b> 150:9 <b>pore</b> 103:7 <b>portfolio</b> 19:22 24:20 115:18 340:12 <b>portion</b> 6:1 <b>posing</b> 323:22 <b>position</b> 7:19 44:6 93:8 387:1 <b>positions</b> 156:14 <b>possibilities</b> 410:14 <b>possible</b> 42:22 161:22 177:5 241:17 256:16,18 362:20 366:18 422:16,17 <b>possibly</b> 64:6 143:22 415:1 <b>post</b> 194:15 <b>posted</b> 17:4 <b>Postprandial</b> 305:14	<b>potential</b> 64:2 192:3,6 205:16 254:12 268:11 270:8 329:13 330:14 423:17 <b>potentially</b> 59:16 61:11 70:2 75:12 120:14 135:6 139:5 193:21 234:19 308:22 314:22 347:11 385:2 419:5 <b>pound</b> 86:13 <b>pounds</b> 281:17,18 <b>power</b> 192:2 <b>powerful</b> 43:17 80:16 <b>practical</b> 68:9 270:21 282:10 411:9,19 412:10 416:14 <b>practically</b> 210:16 270:12 449:4 <b>practice</b> 112:18 117:6 184:13 280:20 350:8 360:10 <b>practices</b> 9:13 36:6 48:3 183:18 188:13 359:12 372:3 <b>practitioners</b> 162:1 360:9 362:7 388:2 388:13 <b>precise</b> 105:16 249:19 318:15 <b>precision</b> 144:8 <b>predators</b> 63:4,5 <b>predictive</b> 292:6 <b>predispose</b> 40:17 <b>predominantly</b> 11:16 <b>prefaced</b> 106:3 <b>prefer</b> 213:6 319:12 <b>prefers</b> 112:20 <b>preliminary</b> 33:2	174:22 355:8 367:1 <b>premature</b> 220:19 328:10 <b>premium</b> 283:14 <b>preparation</b> 340:21 <b>prepare</b> 20:17 <b>prepared</b> 278:15 <b>preparing</b> 21:6 97:16 <b>prescribe</b> 393:1 <b>present</b> 1:12 2:14 58:18 226:7 296:15 338:1 <b>presentation</b> 158:7 182:5 185:17 198:4,9,20 219:19 284:6 328:22 <b>presentations</b> 15:22 <b>presented</b> 58:12 366:5 368:20 374:11 435:16 438:15,18 439:4 <b>presenteeism</b> 47:19 <b>PRESENT(Cont'...</b> 2:1 <b>president</b> 10:7 15:3 25:19 27:12 <b>presiding</b> 1:11 <b>Press</b> 93:22 <b>pressure</b> 49:4 330:6 <b>pretend</b> 152:6 <b>pretty</b> 92:17 103:16 147:12,21 184:8,8 213:19 265:9 273:17 281:22 284:2 302:4 323:9 357:11,12 426:19 428:10 443:4,4 <b>prevent</b> 440:1 <b>preventable</b> 247:6 268:4 <b>preventative</b> 9:11 17:20 20:1,14	41:19 42:1,9,12 46:16 48:9 61:9 190:9 273:6 366:12 <b>preventing</b> 50:22 <b>prevention</b> 1:3,15 1:17,20 2:3 10:21 11:1,2 13:8,10,16 13:22 36:14 38:20 48:3 65:13 66:14 66:15 76:7,10 77:7,10 78:8 79:3 99:4 129:17 180:16 185:14 187:5 213:17 241:2 247:5 253:22 260:22 261:13 272:22 284:13 329:14 332:8 335:17 336:13 439:9 <b>preventive</b> 9:7,8 101:11 124:19 133:20 137:10,11 137:17,19 175:8 209:3 324:4,13,15 <b>previous</b> 264:5 346:17 409:17 420:9 445:1 451:16 <b>previously</b> 13:3 87:17 263:18 358:19 <b>pre-existing</b> 87:12 <b>pre-read</b> 75:3 <b>pre-reading</b> 57:22 <b>primarily</b> 104:1 140:22 164:14 215:4 362:18 <b>primary</b> 36:13 51:8 160:10 175:12 247:8 <b>principles</b> 3:12 18:22 21:7 61:17 236:2,3 <b>printed</b> 339:8 <b>prior</b> 50:2 198:7
---	--	---	--	---

350:10 407:16 418:9 <b>priorities</b> 3:6 25:8 27:12 28:7,18 29:6 30:2,4,14,21 32:21 33:6 37:11 37:14,15,17,19 38:17 52:21 71:22 75:9 80:13 165:13 165:18 206:11 224:18 225:8,12 424:9 <b>prioritization</b> 170:14 211:8 <b>prioritize</b> 168:16 171:1,3 179:10 180:11,15 210:16 211:2 299:2 300:2 <b>prioritized</b> 164:10 234:3 245:17 248:3 299:2 <b>prioritizing</b> 166:12 <b>priority</b> 30:11 37:18 44:4 48:2 53:1 59:13 61:1,4 67:5 78:11 111:22 168:20 170:15 180:19 230:15 245:4 424:16 <b>privacy</b> 392:4 <b>private</b> 9:21 35:18 43:18 77:3 283:3 <b>privileges</b> 8:1 <b>proactive</b> 255:20 315:6 <b>probably</b> 4:15 22:3 36:10 46:12,19 47:14 64:21,22 73:5 81:4 91:2 101:5 105:19 116:15,17 119:9 122:18 138:3 139:22 140:1 142:6 177:5 178:14 191:9 221:5 224:11 228:14 252:19	269:6,13 271:14 276:6,13 288:21 299:14 309:13 314:6 317:12 318:16 332:20 334:8,18 351:8,19 373:10 375:17 398:4,17 409:18 411:9 417:17 441:22 443:16 <b>problem</b> 124:22 139:2 188:21 207:7 378:12 398:18 413:2 415:5 <b>problematic</b> 286:13 <b>problems</b> 191:18 194:16 254:5 335:11 396:15 <b>procedure</b> 85:20 <b>proceed</b> 5:13 24:14 <b>proceeding</b> 241:14 <b>process</b> 23:6,14,17 23:19,21 24:11,14 24:17 27:9 38:10 39:8 53:20 57:14 68:8,14 80:14 94:4 98:4 101:12 113:2 121:5 128:4 133:3,6,8,12 136:8 140:22 143:2 166:18 211:1 231:3 243:9 264:17 278:5 282:18 283:8 284:4 294:11 295:2 296:13 298:15 299:16 301:20 356:3,6 357:1 370:8 372:17 374:4 380:3,12 382:16 382:17,19,20,21 389:13 390:7 400:2 403:14 413:10 421:13,21	423:2 426:14 429:12 433:5,9 <b>processes</b> 29:4 48:13 102:8 221:12 222:7 <b>procrastinate</b> 318:7 <b>produce</b> 132:3 362:5 364:16,18 398:11 <b>produced</b> 226:16 230:4 363:1 <b>producing</b> 364:3 423:1,1 <b>product</b> 92:10 244:19 <b>productive</b> 47:18 <b>productivity</b> 47:12 84:9 279:16,17 280:11 <b>products</b> 84:5 285:9 <b>professional</b> 93:7 174:11 388:20 <b>professionals</b> 363:7 373:5 377:7 <b>professor</b> 8:22 9:20 11:22 81:1 <b>profile</b> 173:4 <b>profit</b> 235:7 <b>program</b> 165:1 199:1,7 364:5 435:7 <b>programs</b> 26:13 30:8 77:1 283:18 329:22 385:4,10 <b>program-specific</b> 160:5 <b>progress</b> 142:21 <b>project</b> 3:5 8:14 15:17 17:4 19:6 19:20 20:7,10,18 22:12 23:2 25:5 42:15 59:7 60:17 80:9,11 157:11 159:1 194:2 230:17 245:6	246:14 248:21 249:9,11,13 250:8 281:14 282:8 291:13 340:8 342:13,16 358:22 363:19 412:17 419:2 <b>projected</b> 355:15 <b>projects</b> 24:3 62:6 105:1,3 147:2 181:10 248:16 411:2 <b>prominent</b> 152:17 <b>promote</b> 14:3 39:10 260:17 <b>promotes</b> 47:8 <b>promoting</b> 30:7 48:2 263:10 <b>promotion</b> 1:16 284:13 329:15 332:9 <b>proof</b> 265:2,13 266:1 273:15 288:16 <b>proper</b> 399:4 <b>properties</b> 105:15 144:8 381:2 392:12 441:17 <b>property</b> 274:6 <b>proportion</b> 404:14 431:8 <b>propose</b> 162:4,11 204:9 217:12 310:5 377:1 <b>proposed</b> 159:13 160:7,19 171:6 201:5 293:7,18 <b>proposing</b> 381:11 413:4 <b>pros</b> 103:8 <b>protect</b> 452:22 <b>protected</b> 371:16 376:10 <b>protecting</b> 375:15 <b>protection</b> 353:22 373:14 <b>prove</b> 273:12	<b>provide</b> 18:11 19:9 32:18 33:1,7,22 110:21 115:16 137:16 172:21 179:17 190:16 192:19 240:15 309:20 346:19 369:20 371:9 382:4 395:10 421:17 422:1 424:9 429:15 449:12 <b>provided</b> 30:15 32:22 240:21 276:2 370:10 372:2 387:12,16 390:20 392:16 421:2 442:16 <b>provider</b> 20:6,8,18 56:11,13 93:20 116:13,15,20 117:2,13 119:4,6 160:4 164:17 169:13 174:15 279:10 345:13 346:13,13 395:8 408:21 413:21 <b>providers</b> 104:4 111:11 129:13 130:11 139:6 160:14 162:1,5 202:16 203:4 220:3 261:10 322:10 345:7,16 346:6 352:15 368:15 376:16 379:2 <b>provider-level</b> 167:5 <b>provides</b> 385:1 <b>providing</b> 17:1 156:17 312:9 375:1 428:22 <b>provisional</b> 283:10 380:6 <b>proxies</b> 443:8,10,15 <b>proximal</b> 222:9
---	---	--	--	--

257:7	295:18 296:7	452:3	247:5 257:16,22	311:13 313:3,4,20
<b>proximately</b> 208:1	308:20 311:8,10	<b>puts</b> 167:4 184:17	262:17 263:17	315:16 323:22,22
<b>proxy</b> 22:11	311:13,16,18,20	184:19	270:7,9 280:1	324:1,2 325:1,3
<b>public</b> 1:14 2:18,22	311:21 316:7	<b>putting</b> 42:7 128:7	293:13 295:17	326:13 338:7,19
5:9 7:18 9:16,22	327:14 328:3,8	129:17 178:6	327:14,17 331:2	343:12 346:20
14:12 17:9 19:9	402:2 447:6	185:2 210:18	331:10 336:6	352:13,20 354:13
21:16 22:21 24:1	448:16 453:1,6,9	222:22 272:22	366:19 368:6	363:5 368:21
27:1 31:5 33:11	<b>publications</b> 40:1	337:4,17	369:1 372:2 375:8	369:11 370:6,8
33:13 35:3,17	<b>publicly</b> 408:17	<b>puzzle</b> 82:10	387:17 391:4,9	372:11,15 374:7
36:4 43:18 47:1	<b>publish</b> 287:6	<b>puzzled</b> 311:11	420:18 424:8,11	375:19 377:11
50:20 54:5 57:6	<b>published</b> 385:21	313:4 436:14	433:19 434:1	380:18 389:14
73:11 81:7,8,18	<b>pull</b> 236:4 341:17	<b>pyramid</b> 166:1	435:13 440:19	400:3 403:6,7,11
88:4 89:3,7,16	<b>pulled</b> 175:1	<b>P-R-O-C-E-E-D-...</b>	441:2 445:18	403:14 404:5,8,12
92:2,17 93:16	<b>pulmonologist</b>	4:1	448:15,16	404:13,14,16
94:2,3 107:15	26:11	<b>p.m</b> 231:16 242:7,8	<b>quantify</b> 228:6	405:1,5 407:4
108:8 114:17	<b>purchasers</b> 401:20	243:2 321:8,9	421:3	413:13 414:10,14
115:7 124:19	<b>purely</b> 50:15	454:12	<b>quantitative</b>	417:22 422:21
156:12 159:21	123:21		366:17 396:20	423:10 427:5,17
160:7,21 161:1,3	<b>purpose</b> 181:16,17	<b>Q</b>	<b>quantity</b> 366:19	428:15 429:2
161:17 162:20	243:9 334:13	<b>QI</b> 115:12	367:22 391:3,9	431:15 433:15
163:9,22 164:1,22	<b>purposeful</b> 247:11	<b>qualified</b> 7:22	434:1 435:13	437:15 440:7
166:20 167:21	<b>purposes</b> 151:20	301:22	440:14 441:1	445:16 447:15,17
169:2 171:19	211:14 234:6	<b>qualifying</b> 228:6	<b>quarter</b> 8:7 136:15	449:13 453:11
172:10 174:8	331:18 334:15	<b>quality</b> 1:1 12:9	152:6	<b>questioning</b> 254:18
178:1 179:13	444:1	15:18 25:22 27:13	<b>quartile</b> 397:19	254:21
180:3 181:4	<b>purview</b> 141:16	33:1,5 36:1 37:10	<b>question</b> 17:2	<b>questions</b> 6:5 14:16
184:13 186:16,20	<b>push</b> 135:9 145:2	37:16 38:1,7	27:17 58:10 59:7	16:1 17:13 18:17
187:11,17 188:9	222:3 399:4	49:16,16 52:11,14	61:19 63:14 65:10	18:19,20 19:16
189:14 191:2,20	<b>pushes</b> 374:22	52:20,22 54:13,22	65:20 66:10 67:7	37:3 58:7 98:14
193:2,12 194:19	<b>pushing</b> 135:12	55:21 67:13 74:13	69:6 70:10 75:1	135:20 136:9
196:4,11 199:1,5	<b>put</b> 16:7 19:18 33:3	76:4 78:18,20	81:4 88:22 97:3	189:19 198:8
199:21 200:18	45:4 56:4 59:2,4	93:12 95:10	107:22 109:6	245:14 292:13
201:15,16 210:10	70:19 91:19 94:7	115:10 123:1,16	110:5 123:2,5	301:12,17 304:20
217:16 219:4	123:8 148:5	124:16,17,20	127:11 128:22	305:1 324:21
220:2,14 222:12	152:18 161:9	126:12 127:4	145:18 160:13	328:22 334:11,16
222:21 224:11	163:13 166:1,3	132:8 133:5 139:4	198:1 205:7 210:4	341:7 402:20
225:1 228:16,17	167:14 170:5,8,9	139:4,6 145:20	211:22 212:9	409:15 419:3
229:3,4,22 230:2	172:18 173:7	162:18 164:21	226:13,14 233:20	<b>queue</b> 16:5
230:5,9,10,13,16	177:1,16 201:7	168:1 179:12	234:8 238:14	<b>QuIC</b> 78:15,17,18
231:6 235:13	204:13 220:4,11	181:9 188:13	244:16 250:15	<b>quick</b> 102:20 148:9
236:10,18 258:12	240:19 247:14	201:5 214:14,16	253:5 255:21	165:8 198:6
262:17 263:6	251:11 266:6	225:13 229:16	256:1 260:15	273:13 290:22
265:10,18 272:2	273:4 283:3 303:7	230:1,5,8,14,16	261:2,6 267:5,11	327:15
274:18 275:3,5,8	303:11 311:15	232:7 234:21	275:19 277:17	<b>quickly</b> 54:1 137:1
275:12 278:20	387:22 406:3	235:1,8,13 236:10	278:3 288:22	138:16,17 179:14
283:5 287:7,16,21	407:2 410:20	236:18 238:6	292:5 297:9	180:5,6 271:17
293:13 294:9,15	424:15 451:14	239:12 246:14	307:22 311:7,9,11	323:10 355:21

<b>quiet</b> 306:6	368:1,8,18 393:13	304:6 314:15	196:15,21 197:9	141:3 149:18
<b>quit</b> 117:15	394:2 433:17	324:8,8 333:14	199:2 201:7 204:7	195:6 273:19,20
<b>quite</b> 27:9 71:1	445:10,11	353:13 372:18	218:3,12,13 220:7	429:1 444:14
86:7 101:10	<b>rates</b> 364:19,19,19	400:19	224:6,15 225:10	445:20
109:13 162:18	371:6,12 373:5	<b>realities</b> 422:14	227:11 233:7,21	<b>reasonable</b> 61:1
178:22 204:22	385:17,22 397:17	<b>reality</b> 191:10	234:13 238:15	296:3
273:11 295:2	430:3 439:11	<b>realized</b> 130:13	239:13 242:4	<b>reasons</b> 146:7
309:4 314:12	451:20	271:18	243:20 247:17	264:2 274:11
316:4 331:10	<b>rate's</b> 390:5	<b>realizing</b> 188:2	248:6 249:12	360:21 394:13
341:15 378:3	<b>rating</b> 368:6 394:4	<b>really</b> 27:18 34:16	252:3 255:10	397:9 403:15
<b>quo</b> 260:20	402:4 440:13	39:10 40:5,16	256:10 260:17,21	<b>reassuring</b> 397:8
<b>quote</b> 92:18 143:12	443:16 452:10	47:10 55:19 56:1	260:21 262:13	<b>recall</b> 268:2 396:15
287:9,19 292:2	<b>ratings</b> 355:8	60:7 61:8,12 64:9	264:15,19 265:12	418:8 422:21
	368:20 370:16	64:17 65:8,16	269:5,10,15	443:4
	390:20 399:1	71:22 72:2 74:17	275:16 276:3,7	<b>recalls</b> 365:6
<b>R</b>	401:5 441:18	76:9,19 77:18	277:21 279:11	<b>receipt</b> 42:8
<b>race</b> 112:10 153:1	<b>rationale</b> 288:4	78:14 79:5 81:11	283:10 288:11	<b>receive</b> 11:18 298:2
168:4 388:10	323:1 367:18	81:19 82:14 84:10	289:3,4,5 290:20	344:14 399:11,12
<b>racial</b> 228:10	442:7	86:8 87:8 91:2,5	294:14 296:12,19	431:2 443:13
372:13	<b>RCPs</b> 428:7	95:3 99:1 100:9	297:15,16 300:17	<b>received</b> 6:3 16:13
<b>raise</b> 16:1 148:15	<b>reach</b> 111:5 134:8	100:18,18 102:17	303:6 304:1,2,11	58:19 154:8
302:15 322:7	262:10 276:6	105:13,20 111:20	306:10 310:21	169:14 198:7
413:13	283:22 306:10	112:6 113:12	311:11 312:7	260:13 346:1
<b>raised</b> 133:15	<b>reached</b> 107:13	116:2 118:2,18	313:4 314:13,14	352:4,5,9 355:17
137:3 382:18	146:12 272:10	120:8 123:22	315:3,6 316:9,10	358:19 359:17
<b>raises</b> 387:5	<b>react</b> 123:10	124:13 134:17	317:7 321:20	360:19 367:11
<b>raising</b> 76:17 79:18	300:20 309:22	136:2 142:14	322:14,18 324:5	380:6 408:7,10,19
126:17 400:10	<b>reaction</b> 190:5	143:1 146:6	326:12 327:18	<b>receives</b> 11:15
<b>ran</b> 396:1	<b>read</b> 49:22 50:4	147:15 152:10	333:10 335:19	13:11
<b>random</b> 299:6	51:17,21 156:1	153:17 154:5	336:7 339:11	<b>receiving</b> 427:9
<b>randomized</b> 368:2	183:9 339:7,12,15	155:1 156:18	343:11 345:3	443:11
369:14	364:9 431:10,16	159:14 160:8,19	346:7 347:9,14	<b>recognize</b> 15:10
<b>range</b> 442:4	438:18 439:8	161:18 162:8,19	349:2,5 356:20	16:8 42:5 59:3
<b>ranking</b> 370:11	<b>readily</b> 402:17	164:1,9,17 165:2	357:1,20 358:12	63:8 75:7 85:5
<b>rankings</b> 173:19	<b>reading</b> 118:10	166:10,14 167:6	362:20 365:21,21	132:9 283:20
268:2 269:22	429:4 432:3 434:6	168:3,9,19,22	374:2,14,22 375:3	<b>recognized</b> 31:3
292:13,17 303:5,6	<b>readmission</b>	169:12 170:17	376:14,18 380:5	67:13 71:5 115:11
303:16 304:12,13	111:16	172:5,18 173:4,8	383:19 386:14,20	352:10
305:18 306:13,14	<b>readmissions</b> 78:3	174:1 175:9 177:9	387:6 388:11,16	<b>recognizing</b> 40:9
306:14 307:6,7	<b>ready</b> 128:8 231:11	178:9 180:14	393:1 396:1 419:7	43:16 133:10
308:1 309:12	321:13 444:15	181:7,16,19 182:1	425:16 427:18	<b>recommend</b> 23:10
<b>rare</b> 353:12	452:7,13,18	183:8 184:18	432:20 433:1,3	71:18 179:20
<b>rate</b> 148:14 270:19	<b>real</b> 52:6 85:7	185:17,17,19	434:19 438:7	180:18,19 344:11
364:17 373:2	91:11 93:9 121:17	186:3 187:6 189:5	447:7 448:3	425:5
389:21 397:14,21	133:5 150:14	189:9,14,16,17	<b>realm</b> 32:1 109:13	<b>recommendation</b>
398:2 435:17	174:3 194:16,17	191:11 192:17	<b>reason</b> 62:20	176:19 307:9
450:22 452:1	234:8 302:18	193:4,8 195:1	107:18 133:14,15	374:9 375:9
<b>rated</b> 142:9 367:2,6				



379:11 381:4,5 383:7 386:8,15,16 387:4,8 424:19 <b>recommendations</b> 22:19 28:15 29:11 36:21 350:11 355:1 374:21 375:2 378:5 379:10 406:11 408:16 419:9 <b>recommended</b> 176:21 177:18 344:3 <b>recommending</b> 57:4 377:21 <b>recommends</b> 431:2 <b>reconcile</b> 308:18 <b>reconciling</b> 215:15 216:9 <b>reconfiguration</b> 188:16 <b>reconsidering</b> 96:10 <b>reconvene</b> 231:16 <b>record</b> 156:7 242:7 321:8 389:19 454:12 <b>recording</b> 16:21 17:4 446:18 <b>records</b> 173:15 369:22 397:2 <b>Recovery</b> 273:1 <b>recreation</b> 312:21 <b>recruited</b> 359:6 <b>red</b> 399:12 <b>redo</b> 400:5,6 <b>redoing</b> 252:2 <b>reduce</b> 342:10 429:17,20,22 430:3 439:10,12 439:13 <b>reduced</b> 439:20 <b>reducing</b> 177:10 235:16,18 429:6,7 <b>refer</b> 52:13 55:2 236:6 <b>reference</b> 94:12	427:15 <b>referenced</b> 199:10 358:18 360:2 <b>referencing</b> 55:5 <b>referral</b> 352:17 <b>referred</b> 125:13 287:7 <b>reflect</b> 111:18 162:3 236:10 246:4 247:8 373:10,13 <b>reflected</b> 112:6 164:18 354:12 <b>reflects</b> 118:4 191:9 204:20 390:22 <b>reform</b> 32:2 36:12 165:14 <b>refrain</b> 252:18 <b>reframe</b> 117:3 155:7,12 289:8 433:7 <b>refry</b> 453:19 <b>refused</b> 409:2 <b>regard</b> 36:9 199:7 354:4 371:12 <b>regarding</b> 182:5 355:1 <b>regardless</b> 343:5 360:4 <b>regards</b> 19:7 35:12 77:11 <b>regional</b> 36:8 <b>registered</b> 63:4 386:21 <b>registries</b> 446:9,15 446:18 451:4 <b>registry</b> 370:1 449:2 450:8 <b>regular</b> 24:3 <b>regularly</b> 444:2 <b>regulations</b> 235:8 <b>rehab</b> 414:1 <b>reinforcing</b> 78:1 <b>reining</b> 220:21 <b>reiterate</b> 22:9 <b>relate</b> 10:16 145:8	236:21 237:21 333:6 <b>related</b> 14:9 18:1 161:5 187:16 279:18 317:14,15 336:15 341:19,22 342:4 389:22 395:13,14 437:17 437:18,19 438:1 438:16 445:1 <b>relates</b> 63:16 83:8 122:20 189:20 <b>relationship</b> 57:18 208:4 280:3 446:13,16 447:3 450:10 <b>relationships</b> 208:7 <b>relative</b> 87:14 217:6 <b>relatively</b> 21:3 <b>released</b> 28:8 33:5 78:14 189:9 285:10 <b>relevance</b> 206:15 446:8,10 <b>relevant</b> 6:9,13,17 6:22 90:4 148:10 168:18 275:22 278:11 417:20 <b>reliability</b> 106:19 122:15 199:3 359:18 381:1 390:11 392:14 393:11,14 394:20 398:22 400:20 401:15 408:12 409:6 441:21 442:16 443:18 444:16,17,19 445:2,9 <b>reliable</b> 105:15 122:12 292:6 375:11 <b>rely</b> 414:6 <b>remain</b> 24:6 105:7 <b>remarks</b> 76:20 <b>remedial</b> 313:19	<b>remember</b> 79:12 79:19,20 281:16 394:4 443:2,5 <b>remind</b> 7:1 244:10 284:8 <b>reminded</b> 206:14 <b>reminder</b> 165:8 167:19 201:2 <b>reminds</b> 238:4 <b>remission</b> 274:6 <b>remotes</b> 399:9 <b>remove</b> 348:20 <b>repeat</b> 16:17 <b>replace</b> 140:13 <b>replacing</b> 146:4 <b>report</b> 9:10 28:8,13 33:21 34:1 35:10 36:13,18 56:22 76:5,9,10 78:13 94:11,19 105:8 122:1,2 165:20 181:8 189:9 198:11 202:9 205:9 231:20 306:1 320:7 321:11,16 326:17 328:9,20 334:12 346:3 349:22 354:16 361:21 365:7 384:19 393:11 395:12 433:14,16 <b>reportable</b> 443:22 <b>reported</b> 67:7 291:12 344:12 361:11,12 367:16 374:3 395:17 397:1 402:6 408:17 409:4 443:21 444:2 446:15 <b>reporting</b> 34:20 36:4 54:6 57:6 115:7 283:6 311:10,13,16,18 321:14 389:7 397:15,22 402:2	446:10,14 447:6 448:16 <b>reports</b> 76:13 167:12 291:21 341:18 408:17 450:8 <b>represent</b> 5:7 11:13 23:2 88:4 335:13 <b>representation</b> 31:4 82:13 84:18 350:16 364:4 <b>representative</b> 7:3 83:17 312:13 358:5 <b>representativeness</b> 366:6 <b>representatives</b> 30:19 31:9 36:9 82:11 <b>represents</b> 52:13 87:15 <b>reputable</b> 135:10 135:11 <b>requested</b> 32:16 359:9 <b>require</b> 145:1 273:3 337:2 383:14 387:7 395:5 402:7 423:14 <b>required</b> 130:14 188:12 370:18 380:1,22 388:1 402:17 <b>requirement</b> 119:22 138:22 395:10 396:13 <b>requirements</b> 172:1 <b>requires</b> 32:12 97:18 99:10 119:16 423:13 <b>requiring</b> 120:13 <b>research</b> 6:17 10:22 12:3 145:6 181:20,22 264:12 287:18 336:20
---	--	---	---	---

430:7 439:4,5 <b>researcher</b> 206:4 <b>reserve</b> 2:19 7:20 133:22 <b>reside</b> 83:7 <b>resilience</b> 44:15 330:8,9 332:18 <b>Resolution</b> 13:2 <b>resolved</b> 412:22 <b>resonate</b> 71:7 <b>resonating</b> 86:1 87:22 <b>resource</b> 70:21 105:3 274:12 335:3 378:6 <b>resources</b> 1:18 69:15 191:5 222:5 222:10 223:11 239:22 240:13 279:10 <b>respect</b> 316:8 392:4 <b>respects</b> 428:17 <b>respiratory</b> 430:4 438:17 <b>respond</b> 22:22 59:5 69:17 82:6 99:18 146:20 205:6 245:21 255:16 275:18 371:8 385:14 404:11 <b>responding</b> 185:16 275:21 <b>response</b> 14:19 69:13 83:19 231:7 238:6 274:9 391:13,20 399:13 399:16,16 453:3 453:12 <b>responses</b> 6:6 112:13 377:14 421:22 452:9 <b>responsibilities</b> 205:9 360:5 <b>responsibility</b> 52:4 90:9 110:12 112:1 131:22 155:4 191:16 202:7,15	202:20 203:9 212:15 213:15 215:6 218:16 222:2 381:8 <b>responsible</b> 109:11 109:14 114:19 155:3 177:9 205:12 279:13 322:8 <b>rest</b> 15:20 121:18 257:18 272:3 357:17 433:10 453:19 <b>restrict</b> 362:5 <b>restricted</b> 363:2 <b>result</b> 43:14 258:10 274:2 <b>resulted</b> 345:2 <b>resulting</b> 184:4 <b>results</b> 190:22 193:6 258:16 349:5,8 393:5 398:9,12 401:21 402:13 440:11 442:15 <b>resumed</b> 156:7 242:7 321:8 <b>resumption</b> 420:20 <b>retail</b> 46:10 <b>retain</b> 413:5 <b>retired</b> 197:22 <b>retirees</b> 283:20 <b>retirement</b> 47:21 <b>retrievable</b> 402:18 <b>return</b> 114:2 152:14 246:2 <b>Reva</b> 2:13 8:10 60:16 146:19 244:7 246:13 356:1 389:9 409:19 433:10 453:21 <b>Reva's</b> 356:17 <b>Revenue</b> 199:15 <b>review</b> 3:5 23:8,9 24:8,10 158:8 245:9 290:22	294:12 327:15 351:1 365:4 379:21 426:19 428:14 438:20 <b>reviewed</b> 6:6 24:15 55:3 327:8 <b>reviewer</b> 409:10 <b>reviewing</b> 13:2 62:14 <b>reviews</b> 170:21 246:4 428:2,10 <b>revise</b> 189:2 <b>revision</b> 149:12 <b>revisit</b> 155:22 <b>revitalization</b> 281:14 <b>revote</b> 399:19 437:13 <b>re-ask</b> 97:2 <b>re-look</b> 102:13 120:15 252:1 <b>re-vote</b> 440:4 <b>Rhonda</b> 1:21 25:18 45:10 92:22 97:5 101:22 268:1 321:12 379:8 390:15 <b>right</b> 4:17 15:21 22:3 23:7 29:1 38:8 42:18 45:19 47:11 62:2,18,22 63:3 68:11 69:11 73:17 82:16 83:7 93:21 96:21 97:12 112:15 116:9,13 120:12 121:15 124:4 126:7 128:9 132:17 133:1 138:15 146:9 153:6 154:15,21 155:13 165:11 172:2 175:21 185:22 196:13 201:7 203:18 204:2 205:17 209:2 218:14,17 219:10 223:11	225:6 232:22 233:1,6 241:19 248:9 250:1 253:21 259:7 274:3 275:10 280:9 281:22 286:6 294:19 300:17 317:16 319:16,18,22 320:16,22 321:5 331:17 337:16 338:11 339:3 340:6 345:14,15 347:6,17 353:1,3 353:4 355:15 365:1 366:15 371:18 373:12 375:13 383:11 385:20 388:8 390:12 392:6 400:8 405:16 406:21 407:8,22 412:7 414:9,13 415:16,19 417:17 417:22 423:15 426:5 427:17 428:9,12 430:2 432:16 434:18 435:4 436:7,11 439:22 440:11 441:5 444:4 445:5 450:1,6 451:12 452:11 <b>righty</b> 440:6 <b>right-hand</b> 257:21 <b>rigid</b> 191:14 <b>rigorous</b> 428:11 <b>rise</b> 170:2 248:3 <b>rising</b> 115:14 <b>risk</b> 153:22 206:1 223:20 235:15,17 270:3 330:3,4,5 330:11 332:9,22 410:6 438:10 451:1,2 <b>risks</b> 270:6 <b>risk-reducing</b>	235:20,21 236:16 236:19 <b>RN</b> 1:21 2:12 <b>road</b> 1:10 275:13 <b>Robert</b> 1:23 126:9 142:4 155:2 194:7 <b>robust</b> 173:9 181:12 283:10 <b>Robyn</b> 2:12 8:17 152:22 <b>role</b> 22:9 30:6 32:18 33:11 36:20 50:15 56:6 187:19 244:4 269:6 282:4 375:5 <b>roles</b> 53:12 196:22 <b>roll</b> 56:16 <b>Ron</b> 1:14 14:8 74:22 136:7 197:21 198:3 201:2 230:22 232:18 311:5 320:12 386:2 394:21 <b>Ron's</b> 202:1 389:8 393:15 <b>room</b> 5:1 7:8 26:6 86:14 95:12 96:3 150:20 156:10 214:2 229:8,21 312:12 336:2 366:15 376:5 391:18 453:13 <b>rooms</b> 15:20 <b>root</b> 82:15 <b>roots</b> 329:4 <b>Rosof</b> 31:18 <b>rotten</b> 46:10 <b>round</b> 59:4 139:5 <b>routine</b> 444:1 <b>routinely</b> 394:12 443:21 <b>row</b> 342:2 345:7,20 345:21 346:7,8 347:14 348:17 <b>rub</b> 153:16 <b>rule</b> 82:14 292:1
--	--	--	--	---

402:6 <b>rulemaking</b> 57:6 <b>rules</b> 15:20 <b>run</b> 274:21 <b>running</b> 16:9 69:2 396:2 411:19 <b>rural</b> 43:7 382:11 <b>RWJ</b> 269:21	210:1 214:5 218:4 227:6 236:17,22 239:4,22 255:17 259:12,18 267:1 267:14 270:21 286:18 289:3,7,15 303:8 307:21 318:20 319:4,16 338:8 358:1 376:21 387:13,14 395:3,8 416:20 418:20 425:12 428:18 429:8 430:6,14 448:13 <b>says</b> 98:9 116:2,6 116:13 129:4 132:17 133:1 139:18 183:15 227:3 237:10 266:2 290:12 331:20 390:2 438:18 439:19 <b>scale</b> 118:16,17 284:3 <b>scan</b> 3:12 21:18 164:10 172:18 174:1 200:10,19 210:5,14 <b>scanned</b> 211:5 <b>scared</b> 313:15 <b>scary</b> 92:1 <b>schedule</b> 24:3 252:8 <b>scheduled</b> 24:10 338:2 <b>schematic</b> 23:12 175:17 176:3 <b>school</b> 43:8 46:8 47:16 63:2,4,6 148:19 178:3 246:21 278:9,14 280:1 <b>schools</b> 161:2 203:6 272:1 <b>science</b> 3:14 107:7 107:9,10 108:10 108:14 114:21	118:4 122:14 386:15 387:6 <b>sciences</b> 108:8,9 <b>scientific</b> 105:14 336:18 369:3 390:10 392:11 393:8 401:16 441:16,20 <b>scope</b> 99:21 102:13 181:5 194:1 219:22 220:18 224:20 247:17 309:1,7 310:10,11 313:10,11,13 315:15 316:15,20 317:8 319:17 320:13 321:4,4,13 321:18,21,22 322:3,3 323:13,19 324:2 325:6 <b>score</b> 311:6 347:14 434:17 <b>scored</b> 434:15 <b>scores</b> 345:17,18 <b>screen</b> 114:4 339:13 <b>screened</b> 407:14 <b>screening</b> 110:16 169:14 <b>script</b> 4:13 <b>se</b> 248:5 312:14 <b>search</b> 140:13 <b>searching</b> 154:9 <b>season</b> 359:6 362:16,17 408:8 415:7 420:5 422:4 <b>seat</b> 45:14 339:18 340:5 <b>second</b> 35:16 48:1 64:20 85:10 97:8 122:5 128:8,17 132:20 152:13 172:3 245:5 251:5 251:14 293:14 316:22 330:14 342:1 345:20 346:7 360:8 397:4	400:15 <b>secondarily</b> 221:7 <b>secondhand</b> 72:4 <b>Secondly</b> 322:1 <b>seconds</b> 400:17,20 <b>Secretary</b> 28:8 33:21 80:4,18 229:17,19 <b>section</b> 140:1 210:5 231:9 244:16 337:9 390:9 392:11 398:6 <b>sector</b> 27:1 31:1 33:14 41:5 50:16 50:21 51:12 60:15 77:3 92:2,3,5 159:21 265:11 283:3 <b>sectors</b> 27:6 32:12 32:19 60:12 104:2 238:19 258:12,12 278:21 287:8 <b>see</b> 15:11 30:1 31:8 31:14 38:3,5,18 38:19 39:9 44:15 45:21 53:3 70:5 71:15 72:19 75:3 77:17,22 79:16 81:12 86:18 94:14 98:18 103:19 104:19 108:19 110:10 111:9 123:3 125:15 126:3 142:20 144:10,13 158:16 159:1 160:22 162:8 163:13 169:12,22 174:9 177:21 187:21 198:22 211:9 216:19 227:16 236:16 244:14 247:14 249:7,11 256:14 260:18 271:9 274:3,4 281:11,20,21 283:12 289:7	300:8,9,18 316:15 332:11 336:9 341:8 345:16,17 346:5,11 348:21 349:6 367:5,18 372:18 376:1,7,20 381:5 385:3 386:5 401:1,5 406:14,16 411:4 416:20 419:16 422:16 429:3 447:3 452:6 454:9 <b>seeing</b> 120:17 207:12 218:2,22 280:9 327:4 333:4 438:8 443:20 <b>seeking</b> 193:21 244:18 <b>seen</b> 135:10 147:9 147:21 179:22 205:20 261:14,15 365:10 389:4 402:3 426:21 441:6,7 444:7 <b>sees</b> 152:5 <b>select</b> 18:4 167:11 272:5 298:14 352:1 <b>selected</b> 21:15 <b>selecting</b> 233:10 286:11 287:1 <b>selection</b> 54:7 211:6 232:22 298:16 <b>self</b> 292:5 330:21 395:11 <b>self-determinants</b> 190:15 <b>self-perceived</b> 331:8,10 <b>self-report</b> 369:5 369:21 389:17 390:5 393:17 395:19 396:7,16 397:6,11 <b>sell</b> 85:8 91:19 <b>selling</b> 92:8
---	---	--	---	--

<b>send</b> 113:19 127:22 338:5	102:17 117:8 187:2 199:15	200:21 221:19,19 348:1 356:4 385:5	<b>short</b> 184:14 186:4 260:15 340:15	173:14 199:18 290:11 303:16
<b>sending</b> 297:13	209:3 363:10,11	386:17 411:12	<b>shortly</b> 100:2	426:4,7 442:1,2
<b>Senior</b> 8:10,14 12:8 15:3	376:1,4,16 377:6 421:2	421:6 425:7	<b>shot</b> 148:20 348:6,9 353:19 389:20	<b>similarities</b> 154:16
<b>sense</b> 76:2 86:1 127:20 147:5	<b>services</b> 1:19 7:13 9:11 11:17 14:1	<b>settings</b> 42:11 343:6 349:13	<b>show</b> 173:8 180:15 208:6 217:13	<b>similarly</b> 72:8 88:16
186:9,10 190:5	17:20 20:1,14	368:12,15 411:14	224:6 225:16	<b>simple</b> 81:10,16 182:13 183:7
191:3 195:5 208:2	28:9 41:20 42:1,9	412:13 413:1,9,10	299:1 316:17	309:3 361:10
227:17,19 265:1	42:12 48:9 61:9	413:11 414:13,16	317:2,6,9 331:18	<b>simpler</b> 239:14
266:2 337:20	101:11 124:20	414:21 415:3	332:16 339:20	<b>simplified</b> 333:10 334:2
342:5 434:19	137:10,11,18,19	417:4 424:13	<b>showed</b> 426:10	<b>simply</b> 42:17 43:5 45:1 162:7 172:2
<b>sensible</b> 421:3	162:3 175:8,12	425:1,15,22	<b>showing</b> 142:13 162:7 217:9 218:2	172:7 190:2 450:13,17,18
<b>sensitive</b> 396:9	183:20 187:18	<b>seven</b> 117:7 170:13 426:13	428:15	<b>simulation</b> 333:14
<b>sent</b> 104:16 202:12	190:9 219:4 272:3	<b>sexual</b> 63:4,5	<b>shown</b> 330:3	<b>Simultaneous</b> 313:17 324:18
<b>sentence</b> 439:8	312:10 323:17	<b>shake</b> 62:20	<b>shows</b> 23:13 160:18 385:8	<b>simultaneously</b> 292:21
<b>separate</b> 121:11 162:22 171:5	324:13,14,15	<b>shaking</b> 92:22	<b>shrift</b> 64:20	<b>singing</b> 321:20
187:13 216:12	363:10,12 366:12	<b>shame</b> 297:16	<b>shrink</b> 349:1	<b>single</b> 108:20 207:14 271:16,18
218:2 305:16	<b>servicing</b> 7:5 53:13 371:5,7	<b>shaped</b> 32:9	<b>shrinking</b> 133:11	273:5 292:5 304:7
336:19 360:13	<b>SES</b> 153:1	<b>share</b> 22:8 27:5 64:21 111:22	<b>shy</b> 90:11	362:1 410:10 413:14
406:5,7 410:4,4,5	<b>session</b> 38:16 113:15	158:4 188:4 202:1	<b>sick</b> 66:3 146:17 153:17	<b>sit</b> 84:16 87:6 225:3 286:10 303:13
412:20 416:3	<b>set</b> 41:13 52:5 59:21 61:1,14	298:5 338:17	<b>side</b> 134:21 135:11 135:12,13 168:19	424:22 425:5
449:5	71:2 99:20 114:12	355:8 357:4	177:22 215:19	<b>site</b> 161:2 193:22 221:15
<b>separated</b> 344:12	121:17 135:21,22	<b>shared</b> 22:1 29:3 36:17 52:19 55:6	222:9 257:21	<b>sites</b> 178:3
<b>separately</b> 336:14 344:13 350:1	137:22,22 145:18	56:10,19 90:9	269:10 275:5	<b>sits</b> 332:16
364:15 365:13	168:14 170:15	111:18,21 131:7	276:17 308:19,20	<b>sitting</b> 63:5 218:9
<b>separating</b> 68:4 73:1 74:14,14	179:10 216:12	131:16,18 133:13	320:17 324:6	<b>situation</b> 64:18 424:6 450:7,21
345:12	231:15 234:1	147:5 155:4	335:12 417:2	<b>situational</b> 451:8
<b>September</b> 1:6 28:9 33:22 344:20	236:2 245:14,15	162:15,15 174:3	<b>sides</b> 153:13	<b>six</b> 37:11 38:18 103:16 152:16
<b>series</b> 177:13 251:2	246:6 248:4	191:15 202:15,19	<b>signal</b> 83:9	170:11 225:14
<b>serious</b> 116:8 147:14 213:19	251:11 261:7	203:8 220:8 226:2	<b>signed</b> 114:18	227:4 290:18
288:16 382:18	262:20 264:20	238:16 307:5,18	<b>significance</b> 23:18	317:3 340:7
<b>seriously</b> 97:12	291:18 293:11	<b>shares</b> 218:16	<b>significant</b> 21:12 96:12 123:15	350:12 355:6
<b>serve</b> 7:2,4 9:10 10:2 12:12 28:17	296:15 298:5	<b>sharing</b> 309:11	396:14	407:12 424:9
30:18 32:18 167:2	299:1,3 332:13	<b>Sheila</b> 244:12 339:9	<b>significantly</b> 37:8 373:1	432:9 436:13
308:1 372:3	378:4 417:8	<b>she'd</b> 5:18	<b>signs</b> 144:6	437:3,10
<b>served</b> 371:3,11 373:11 374:18	418:10	<b>she'll</b> 158:6	<b>sign-on</b> 338:5	
379:22 386:12	<b>sets</b> 64:8 103:4 159:3 165:11	<b>Shield</b> 12:22	<b>Silence</b> 97:21	
<b>service</b> 6:10,14 9:22 12:8 42:3	172:17 173:7,10	<b>shift</b> 101:16 146:8 146:14 187:21	<b>similar</b> 24:21 104:8 114:16 136:11	
	173:17 187:14	188:1	140:20 171:20	
	293:7	<b>shifts</b> 177:14		
	<b>setting</b> 29:9 30:10 72:9 125:21	<b>shocking</b> 192:8		
		<b>shop</b> 85:14		

<b>skills</b> 183:19	<b>smoke</b> 72:4	237:2,16 241:20	216:9 217:7,8,9	420:10 429:21
<b>skinny</b> 153:18	<b>smokers</b> 117:14	256:20 320:17	217:11 218:4	430:2 434:3
<b>skip</b> 408:4	<b>smoking</b> 20:22	397:20 423:14	219:8,20 222:5	436:20 437:5
<b>skipped</b> 405:2	26:13 49:5 59:15	443:11	224:14 226:2	439:7,16,18
445:20	62:11 71:22 72:3	<b>somebody's</b> 114:21	248:18 253:13	441:22 442:17,19
<b>sleep</b> 383:4	72:4 75:2 118:6	<b>Someone's</b> 239:6	257:17 259:16,21	442:22 444:22
<b>sleeping</b> 18:16	235:21 245:17	<b>something's</b> 214:15	270:2 285:12	445:15 446:4
<b>slide</b> 17:16,17 22:5	249:20 251:2	<b>somewhat</b> 98:10	290:22 292:22	450:12
22:7 29:17 30:13	252:22 264:8,9	191:6 250:3 397:8	293:3 294:3 299:9	<b>speak</b> 28:5 29:15
34:6,7 38:4,5 39:5	265:3 266:10,17	<b>soon</b> 108:22 276:9	309:10 331:17	33:16 34:4 52:12
41:12 44:10 46:17	267:9,15,20,21	<b>sooner</b> 274:5	332:17 339:4	56:21 88:21
48:1,11 49:13	273:14 274:2,5	<b>sophisticated</b> 81:3	342:4 343:14	203:17 214:7
50:5 51:2,14 52:7	286:1 299:8 333:3	283:19 334:1,5	344:22 363:18	244:21 311:3
52:13 55:1 159:3	333:7,19,20	<b>sorry</b> 14:10 51:18	384:4 385:11	319:19 340:9
159:4,12 160:12	<b>social</b> 43:15,16	70:8 108:7 157:22	391:8 421:5	351:19 358:12,13
160:18 162:6	44:13,14 46:11	172:20 178:12	433:17	358:21
165:7 166:13	136:3 145:20	229:14 244:8	<b>sorting</b> 109:15	<b>speaker</b> 380:4
167:9 169:19	151:16,21 161:5	263:21 301:8	<b>sorts</b> 179:8	<b>speaking</b> 6:20
171:10 174:5,19	163:15 167:20	334:9 364:12	<b>sound</b> 192:12	16:22 178:14
176:14 177:20	168:11 169:9	380:3 386:3,3	373:20	186:7 266:10
178:18 180:12	183:2,17 186:10	396:20 408:3	<b>sounds</b> 193:19	313:17 324:18
193:11 198:8	192:1,10,20,21	444:22 445:2	313:13 429:8	<b>speaks</b> 76:18 81:20
203:13 204:3,5	205:2 216:1	<b>sort</b> 4:21 83:11	<b>source</b> 284:18	<b>spec</b> 351:4
215:14 284:6	217:19 219:2	86:13,15,21,21	369:12,13 397:1,5	<b>special</b> 28:14
400:21 402:3	232:11 257:6,12	87:6,11 88:17	411:5,12 431:10	<b>specialize</b> 411:11
405:21 417:22	270:4 272:2	111:7 121:18,20	<b>sources</b> 171:17	<b>specialty</b> 51:8
426:10	284:21	128:7 151:9 160:1	174:8 177:4	175:12
<b>slides</b> 27:17 29:9	<b>society</b> 67:2 312:2	160:4,10,12,22	207:20 314:12	<b>specific</b> 6:5 41:10
51:20 158:9,17,17	312:4	161:3,10,15 162:4	349:13,16 369:18	48:12 63:14,15
159:2 162:9	<b>socioeconomic</b>	162:9,22 163:6,9	370:3 396:19	65:10 68:6 123:17
178:18 202:12,13	228:10 329:12,19	163:21 164:8,15	397:15 398:10	123:19 124:4,11
203:16 204:4	331:16 354:6	165:5,18 166:5,12	402:21 403:4,6	125:4,10,20
339:7	371:5 372:4,4,12	166:17 167:3	404:15 411:15	127:14,15 129:8
<b>slightly</b> 105:2	<b>socioeconomics</b>	168:4,15,17	413:1	130:21 131:12
345:19	323:16	169:12,15 170:2,7	<b>south</b> 4:16 13:17,19	132:1 133:14
<b>slow</b> 147:10	<b>socio-environme...</b>	170:10,15 171:3,5	244:3	138:7,11 148:2
<b>small</b> 9:3 173:19	184:19	171:6,12 172:18	<b>space</b> 75:13,14	160:5 164:20
266:8 291:18	<b>solution</b> 68:10	174:7,13 175:5,20	115:12,13 234:7	166:22 205:8
300:4 304:22	254:4 259:3	177:14,16 178:22	342:12	223:4,4 224:18
305:10,11 321:15	277:14	179:17 184:15	<b>span</b> 40:10 42:10	237:6,7 396:10
321:16 335:12	<b>solutions</b> 194:17	185:9 189:12,20	<b>Spangler</b> 2:2 10:19	419:3 437:16
400:14	276:19	193:11,20 195:8	10:19 28:20	438:1 442:6,8
<b>smaller</b> 295:5	<b>solve</b> 127:2 191:19	195:18 200:16,20	303:15 400:2,7	443:6 447:22
<b>smart</b> 289:3,4	<b>solves</b> 254:4	200:21 201:4,15	403:2 404:7,17	<b>specifically</b> 32:20
<b>smarter</b> 27:8	<b>somebody</b> 87:4	202:18 203:8	405:4,14 409:11	40:7 48:5 66:11
<b>smiling</b> 71:2	92:9,20,21 110:18	206:6,9,15 210:2	409:16 415:12,20	67:16 122:22
<b>Smith</b> 292:3	219:11 227:15	210:6,7,12 215:15	417:11 419:18	138:19 139:3,9,18

140:1 182:4 263:15,19 274:21 297:6 302:12 325:8,18 345:22 364:14 372:11 394:15 427:14 <b>specification</b> 431:17 <b>specifications</b> 25:1 105:16 144:9 343:5,16,17,22 349:20 355:14 359:22 360:15 392:13 411:4 412:11 415:15 418:10 419:12,21 420:14 <b>specificity</b> 303:1 <b>specifics</b> 113:12 133:13 184:17 198:21 <b>specified</b> 106:5 150:2 393:3 408:15 411:6 423:7 430:19 <b>specify</b> 106:13 131:5 344:7 411:11 432:15 <b>specifying</b> 131:3 347:8 <b>spectrum</b> 50:12 <b>spend</b> 29:8 36:19 45:2 82:6 89:12 90:5 91:2,4 115:5 192:14 304:21 356:18 375:20 376:4,12 <b>spending</b> 192:17 <b>spends</b> 376:2 <b>spent</b> 60:9 82:5 84:16 88:9 <b>sphere</b> 73:14 <b>split</b> 317:10 433:18 433:19 <b>spoke</b> 55:21 119:19 199:20 202:4 <b>spot</b> 320:14	<b>spring</b> 28:2 <b>square</b> 59:4 <b>stab</b> 156:21 157:7 182:7 <b>staff</b> 2:6 14:22 22:13 27:14 96:17 133:17 134:7 135:1 172:12 228:16 231:14 290:21 351:18 385:17,22 <b>stages</b> 79:15 <b>stakeholder</b> 32:15 130:15,22 131:8 195:1,11 196:8 230:2 <b>stakeholders</b> 52:16 84:19,22 85:1 138:13 169:6 196:22 322:1,5,9 <b>stalled</b> 302:20 <b>standard</b> 87:7 109:10 293:12 343:16,17,22 350:3 351:4 355:14 380:12 385:19 393:18 396:3 412:11 415:15 418:10 419:12,17,21 420:14 <b>standardization</b> 350:20 <b>standardize</b> 21:5 <b>standardized</b> 119:1 344:17 349:19 415:10 <b>standardizing</b> 249:12 349:9 <b>standards</b> 3:20 23:3,8 24:5 30:5 199:1 200:17 234:1 264:14 360:18 <b>standing</b> 266:5 <b>stand-alone</b> 172:4 195:8	<b>Stange</b> 1:10,14 3:21 7:16,17,17 16:19 23:2 49:1 58:8,9 61:6 70:8 71:13 94:22 96:19 106:1 113:3 115:21 124:15 126:8 127:1,19 136:8 154:1 158:18 159:18 190:20,21 194:6 211:12 255:21 278:2 288:15 291:19 295:1 296:11 304:20 316:13,18 317:3,7 317:10 318:6 319:8,14,19,22 320:4 321:2,10 324:19 355:22 373:18 380:18 381:7 382:14 383:18 386:2 389:6 398:13 401:12 406:3,7 410:13 411:21 417:19 418:13 422:18 423:22 432:14,18 437:7 438:5 448:8 452:3 452:21 <b>start</b> 44:18 63:21 64:12 66:8 67:1 69:2 73:13,20 74:6,7 75:15 97:15 102:14 113:12 126:13 149:15 154:14 157:4 173:4 174:2 174:20 176:16 177:2 180:20 185:2 189:5 192:6 194:10 196:11 204:17 206:5 207:12 224:16,17 226:15,19 235:9 238:17 243:16	252:16 253:6 254:22 255:2 267:19 268:12 279:20 283:13,14 283:15,17 298:3 300:12,15 303:10 318:13,18 320:7 321:20 326:8 327:2 352:16 383:7 409:13 410:7 411:3 413:5 420:20 <b>started</b> 4:11 130:9 133:8 226:5 294:17 318:10 327:3 328:6,19 358:8 <b>starting</b> 22:17 50:18 55:2 59:14 72:12,14,15 74:17 81:13 146:14 151:1 154:17,21 221:9 225:22 226:13 249:2 253:11 255:16 262:11 273:19,21 286:7 326:19 329:10 454:4 <b>starts</b> 146:16 166:11 178:3 226:4,8 300:14 399:2 <b>state</b> 5:5,7 12:4 56:7 94:3 117:9 126:16 159:19 164:5 165:21 166:8 170:5 174:10 192:15 194:3 206:19 211:3 228:9 244:2 244:3 246:15,17 247:2 289:18 304:12 305:17 325:16 331:6 385:13,22 431:13 431:13 <b>stated</b> 151:20	364:14 <b>statement</b> 138:11 199:21 230:5 262:17 324:1,8 327:13 335:8 361:14 379:19 <b>statements</b> 260:16 <b>states</b> 5:8 234:11 244:1 330:20 446:19 <b>statistical</b> 93:18 <b>Statistics</b> 328:9 <b>status</b> 24:13 132:7 132:8,8,8,10 183:16 257:16 260:20 267:7 268:15 289:22 291:10 330:22 331:7,9,16 332:19 333:19,20 354:6 359:19 361:3 364:11 382:11 397:6 407:15 422:8 <b>stay</b> 340:15,16 444:6,12 <b>steeped</b> 312:17 <b>steering</b> 1:4,9 16:13 17:13 19:17 22:9,10 179:3 206:17 219:5 349:19 350:14 363:19 370:17 399:17 <b>stem</b> 259:21 <b>step</b> 23:7,15 92:1 96:9,16 99:10 103:14 132:19,20 218:1 294:2 300:22 301:13,14 307:2 310:2 <b>steps</b> 23:6,13 29:12 53:2 57:5 61:7 68:13 95:3,3,9,22 96:2,21 290:9 337:7 338:12 450:1
--	--	---	---	--

<b>Steve</b> 2:21 94:17 100:1 101:3 156:20 178:20 181:18 188:5 189:7 198:2 202:1 204:11 205:18 206:12 211:15 218:8 228:1,20	127:17 140:19 201:22 202:1 205:5 218:8,9 236:21 258:6 273:13 288:1 297:3 299:13 307:20 315:17 346:21 347:3,17 352:20 353:14 364:7 378:18 387:9 388:8 398:14 414:22 415:16 419:11 420:3 421:7	<b>stream</b> 290:17 <b>streamline</b> 401:3 <b>streams</b> 54:4 <b>Street</b> 92:9 <b>streets</b> 223:1,1 <b>stressful</b> 84:6 <b>stretch</b> 4:21 102:8 156:18 213:13 265:21 269:10 <b>strikes</b> 74:11 93:15 119:15 120:1 364:9 379:4 387:16 414:22 <b>striking</b> 306:19 <b>strive</b> 56:19 <b>stroke</b> 1:20 13:8 251:17 287:10 <b>strong</b> 42:6 374:9 379:9,10 383:7 <b>stronger</b> 187:19 377:13 <b>strongly</b> 32:8 97:20 370:21 377:12 <b>struck</b> 186:11 <b>structure</b> 65:8 166:18 299:16 449:12 <b>structured</b> 293:19 450:2 <b>struggle</b> 216:9 <b>struggled</b> 208:15 351:18 354:14 <b>struggling</b> 200:2 226:3,21 260:21 264:17 303:4 313:19 <b>stuck</b> 39:9 133:6 <b>student</b> 285:14 <b>students</b> 81:2 278:13 360:13 362:7 388:3 <b>studied</b> 199:3 396:8 <b>studies</b> 108:14 367:22 368:2,4,10 368:16 371:22 372:1,7 377:15	378:15 381:21 440:14 <b>study</b> 366:21 372:22 377:17 378:11 393:11 428:4,5 <b>stuff</b> 58:19 154:6 155:11 193:8 197:17 217:14 262:5 291:11 300:8 304:17 <b>subcommittee</b> 28:19 39:6 189:5 <b>subcomponents</b> 403:17 <b>subcontractor</b> 58:15 <b>subcounty</b> 206:20 <b>subcriteria</b> 404:3,4 <b>subgroup</b> 309:18 310:3,8 326:1,9 <b>subgroups</b> 296:14 297:2 300:22 448:4,7 449:10 <b>subject</b> 374:17 <b>subjected</b> 356:10 <b>submission</b> 383:15 427:9,15 <b>submit</b> 245:22 326:14 434:8 <b>submitted</b> 20:14 22:14 33:21 62:13 150:8 368:8 427:7 434:11,16 <b>submitting</b> 270:15 <b>subsequent</b> 68:15 317:19 401:4 <b>subset</b> 141:16 <b>substance</b> 10:1 44:16,20 <b>substantial</b> 7:12 <b>suburban</b> 382:11 <b>successful</b> 132:2 135:8 280:5 <b>succinct</b> 430:8 <b>sucking</b> 192:11 <b>sucks</b> 86:15	<b>suddenly</b> 346:5 397:21 <b>Sue</b> 1:24 12:13 85:19 148:6 303:2 <b>sued</b> 91:13 <b>sufficient</b> 24:2 106:15 138:12 151:8 <b>suggest</b> 95:12,22 103:6 113:3 115:22 135:17 154:2 207:15 209:19,19 211:14 296:13 416:15 439:6 <b>suggested</b> 97:9,17 99:9 126:10 134:5 211:13 267:10 378:21 398:9 <b>suggesting</b> 74:6,7 96:20 97:11 208:6 208:9,10 296:12 <b>suggestion</b> 134:21 135:16 138:5 208:19 209:21 407:6 <b>suggestions</b> 133:16 205:15 355:1 374:1 411:17 <b>suggests</b> 266:14 427:18 <b>suitable</b> 295:21 406:2,9 452:17 <b>sum</b> 189:12 190:2 <b>summarize</b> 6:12 393:9 <b>summarizing</b> 154:2 <b>summed</b> 189:17 <b>supermarkets</b> 277:2 <b>support</b> 36:2 39:13 44:13 266:10 299:19 307:14 <b>supports</b> 34:20 <b>suppose</b> 108:4 <b>supposed</b> 78:20 124:7 149:22
--	---	--	---	---

228:15 247:7	40:18 197:7	316:11 327:14	109:19 118:16	<b>talked</b> 54:2,9 55:10
335:13 416:6	<b>sweet</b> 184:14 186:4	330:6,16 400:14	128:2 134:3	59:9 61:8 126:1
<b>sure</b> 17:2 39:7	<b>switch</b> 432:21	414:5,9 423:20	135:22 148:14	155:4 168:2
44:20,22 61:20	<b>sync</b> 159:5	424:1 448:17	150:20 153:15	213:18 241:1
67:6 75:16 89:14	<b>synching</b> 77:6,17	<b>systematic</b> 170:21	154:3 156:4 168:3	257:9 268:14
89:15,19 95:17	77:19 78:12 79:17	184:3 428:2	178:22 183:5	294:8 298:3 304:2
100:14 101:5	<b>synergistic</b> 210:9	<b>systemically</b>	184:15 193:5	327:20 332:3
112:22 114:16	<b>synergy</b> 77:19	383:19	194:13 198:18	333:1,2 335:22
118:9 121:10	180:15	<b>systems</b> 1:25 8:2	212:14 224:5	341:3 356:5
136:15 138:8	<b>synopsis</b> 158:10,11	12:1 87:16,19	231:18 241:22	433:13
142:6 151:6 159:3	<b>synthesis</b> 309:10	93:15 104:5	243:8 274:1 278:3	<b>talking</b> 38:16 41:22
161:8 198:10,17	<b>synthesize</b> 430:8	160:15,17 161:3,7	290:2 295:12,14	47:14,15 66:13
199:11 200:6	<b>system</b> 8:3 12:15	161:13,18 162:4	296:14 301:16	82:15 86:3 94:14
214:21 225:20	12:16 33:13 36:12	163:11 165:3	305:9 309:14	100:9,22 106:21
244:13 251:10	49:20 55:7 81:7,7	169:1,17 171:7	319:4 320:5	107:3 118:13
256:20 257:3	81:8,9,11,11,19	172:22 173:6	324:22 331:14	119:14 126:11
268:22 285:19	86:13 88:5 89:7,7	174:18,21 175:3	340:2,4 348:18	129:3,4 140:11
295:1 296:9 297:8	89:17 93:20 104:3	175:16 176:1	355:19 367:3	151:19 152:1
298:8 304:16	107:16 109:11	178:6 180:17	370:7,9 371:8	157:6 182:17,18
306:18 334:9	112:14 117:21	181:11 188:10	388:12 390:19	188:22 199:11
338:15,17 358:9	144:18,19 160:8	191:4,20,21	391:7 392:3 453:6	203:2 208:12
367:5,20 368:2	160:13,14,21	194:13 195:5,7,9	<b>taken</b> 107:13	212:20 213:1
369:7,8 378:3,20	161:1,13,14,14	195:19 208:2	281:13	216:5 228:7
393:10 399:21	162:4,11,20,21	209:7 210:20	<b>takers</b> 416:17	231:12 237:14
403:10 406:12	164:2,3,4,13	215:13 220:13	<b>takes</b> 64:5 146:1	239:18 254:7,7,8
408:3 409:16	171:21 173:1	269:6 278:20,20	255:13	254:11 256:1,21
413:15 427:4,11	174:15,18 175:9	290:2 293:13	<b>talk</b> 15:12 21:21	259:6 261:13
443:14 445:19	176:5,10 177:8,14	366:11 403:20	25:9 26:17 41:8	262:3,5 268:9
448:2	177:17 178:2,2	422:11	48:22 60:5 61:15	270:5 271:15,20
<b>surfaced</b> 34:16	180:3,3,4 181:1,4	<b>system's</b> 194:3	84:6 95:11 100:1	292:9,20 297:22
<b>surgery</b> 269:18	188:9,10 191:2,3	<b>S-E-S-S-I-O-N</b>	144:6,8 145:20	298:5,12 315:8,12
359:11	191:10,13 192:12	243:1	146:2 153:10,14	326:18 329:21
<b>surgical</b> 221:15	193:12 194:1		163:14 180:7	330:17 332:7
<b>surprise</b> 36:11	199:5 201:1	<b>T</b>	185:7 195:9,12,13	356:8 365:14
<b>surprised</b> 98:19	208:22 210:6	<b>t</b> 240:11	196:15 199:10	372:2 446:9
<b>surprising</b> 15:6	211:7 214:17	<b>table</b> 6:8 29:5	214:12 218:10	<b>talks</b> 345:8
192:9	215:4,7 216:3,14	73:12 86:18 96:21	225:3 244:7 254:5	<b>tallied</b> 399:17
<b>surveillance</b> 169:7	216:15 217:1	132:16 133:2	254:14,17,20,20	<b>tardy</b> 14:10
172:3 219:8	222:11 224:11,17	138:13 152:18	255:8 259:8	<b>target</b> 39:14 82:2
328:12	225:11 226:12	196:6 238:11	260:10 276:20	85:8 167:5 174:9
<b>survey</b> 173:13,13	227:7 230:6,12,17	241:20 278:19	302:1 304:22	233:8 234:18
246:20 400:3	235:14 258:15,22	290:3 305:2 313:1	317:21 324:20	281:16 342:3,7
447:12	262:18 263:7	341:17 343:10	325:6 340:7 344:8	<b>targeting</b> 166:19
<b>surveys</b> 118:7	275:3 276:16,16	369:19 398:2	355:20 390:14	<b>targets</b> 92:7 284:10
292:8 359:9	276:20 280:2	<b>take</b> 60:10 70:4	409:5,7 417:12,13	346:9
<b>suspect</b> 252:14	283:11 295:18	87:16 88:21 97:21	430:13 448:12	<b>Target's</b> 283:3
<b>sustainability</b>	311:20 315:21	105:11 107:19	451:14 453:22	<b>task</b> 9:11 150:22



209:4 341:18	79:2,6 82:7 83:14	15:8,19 16:12	366:6 376:14	280:1 281:10
355:5 366:12	83:18,20 85:2,16	34:7 37:4 74:22	377:3 378:20	285:4,13 288:4
<b>taxation</b> 72:3	94:8 98:7,16 99:3	76:16 79:18 114:3	379:12 382:3	289:5,6 292:21
<b>taxes</b> 117:18	99:21 122:15	156:9,20 157:7,9	396:17 403:2,15	293:22 297:21
<b>teach</b> 81:1,1	141:15,17 156:19	181:12,13 182:5	404:4 406:6 418:7	299:7,19 300:15
<b>teaching</b> 347:1	189:12 195:22	189:8 200:5	426:11 433:1	305:1 310:16
<b>tears</b> 213:16 214:1	199:4 202:19	201:20 215:10	439:19	311:21 315:13,17
<b>tease</b> 238:17	212:21 232:21	225:18 228:20,22	<b>things</b> 6:13 16:18	316:5 317:14
314:13,14	236:11 238:13,22	231:4 242:5	47:19 48:17,21	324:11 327:9,11
<b>technicians</b> 388:21	240:21 254:10,11	328:21 337:3	55:13 58:17 61:13	328:2 330:7
<b>tee</b> 152:12	260:4 282:10	364:12,21 365:1	63:20 79:14,21	332:15,20,21
<b>teenagers</b> 238:10	291:1 301:14	386:4 405:7 407:5	81:17 82:8 85:16	339:22 340:2
<b>teeth</b> 46:9	313:13 314:2	429:20 453:15	87:14 91:14 98:12	345:14,19 347:20
<b>teleconference</b>	321:22 322:3	454:1	99:3 102:4,15	348:19 352:22
18:14	333:3 335:10	<b>thanks</b> 4:14 68:3	106:1 109:14	356:17,19 357:6
<b>telephone</b> 453:8	354:8 366:5 367:8	76:3 103:18	111:5 112:11	380:13 382:15
<b>telephonically</b>	367:12,16,21	157:10 158:1	117:18 125:12	384:5 411:18
310:3	368:14 372:5	201:2,22,22 245:1	127:5,6,22 129:3	422:15 444:8
<b>tell</b> 28:22 136:21	393:8 394:10	279:2 334:9 337:3	129:5,14 132:1	448:12 450:14,19
143:15,17 207:2	397:18 404:5	400:7 446:4	136:4,19 140:14	<b>think</b> 4:17 6:9,21
226:17 229:12	411:7 427:5,22	<b>theme</b> 68:16 147:1	141:8,10 142:19	9:1 10:17 12:6
389:10 396:22	434:20 450:7	147:7 277:7	145:21 147:13	17:16 18:15 22:2
<b>telling</b> 35:20	<b>terrible</b> 277:11	<b>themes</b> 39:6	154:12 155:9	27:3 33:18,19
213:18	<b>terribly</b> 191:9	<b>theoretical</b> 305:7	162:21 164:16	35:6 38:15 41:14
<b>tells</b> 328:15 450:11	<b>terrific</b> 387:19	<b>thesis</b> 241:18	165:12,20 167:13	42:14 44:3,6,7,11
<b>temporary</b> 380:7	<b>Territorial</b> 5:6	<b>they'd</b> 63:1	167:15,20 168:10	46:14,22 47:22
<b>ten</b> 136:13 145:10	<b>Territories</b> 5:8	<b>thing</b> 57:19 65:11	170:9 176:12,17	48:22 49:11 52:7
145:11 147:10	<b>test</b> 283:9 358:22	71:10,14 84:15	179:8 180:11	53:10 54:19 55:8
170:3,8,13 179:18	<b>tested</b> 369:16	89:9 101:20 105:4	181:21,21 187:3	57:11 58:4 59:6,9
179:20 185:6	380:15,16,19	114:7,11 115:18	190:8 192:9	59:19 60:2,3,20
195:13 219:3	392:16 393:2	115:22 118:11,14	195:14 196:19	61:3,21 62:1,3,8
400:15,16,20	423:7	124:15 129:7	197:9 201:14	62:16,16 63:18
<b>tend</b> 234:5 397:16	<b>testing</b> 110:20	133:7 135:16	202:4 207:5	64:20 67:14,19,22
<b>tendency</b> 189:1	282:20,21 380:21	136:9 140:7 154:5	209:10,13 212:5	69:10,18 70:1,1,4
<b>tends</b> 50:17 64:5,9	380:22 381:1	168:15 184:12,22	213:8 218:15,17	70:18 73:1,5,16
175:19	392:22 393:1,5	194:6 205:18	219:8 221:9 223:5	74:1,18 75:10
<b>tent</b> 298:20	398:6 408:12	215:17 218:12	223:8 227:4 228:4	76:2 77:8,15,17
<b>term</b> 135:19 161:15	409:6 442:15	222:1 224:13	231:2 252:6 253:9	78:11 79:4 80:8
162:2 228:2	<b>Teutsch</b> 2:21 3:14	227:22 231:20	253:11 254:3	81:12,15 82:22
260:16	157:9 158:19	233:16 247:16	255:5,18 256:21	83:4,5,8,10,16,22
<b>terminologies</b>	189:7 196:13	262:16 268:8	257:20 258:2,17	83:22 84:3,13
159:9	208:5 209:1 222:3	273:20 289:2	259:16 260:10	85:1,6,17 86:17
<b>terminology</b> 71:7	228:22	296:4 301:22	261:12 262:6	87:3,11 89:1,5,9
268:18	<b>Texas</b> 12:16	303:17 304:5	265:6,22 267:18	89:11,18 90:4,8
<b>terms</b> 45:13 47:13	<b>thank</b> 4:12 7:16	308:21 333:8	269:10,16 273:12	90:11,14 91:3
63:18,19 65:8	8:11,15 10:18	340:17,18 345:14	273:13 274:1	92:6 93:12 95:5
66:17,18,19 72:4	14:4,14,20 15:2,4	345:15 353:18	278:21 279:22	95:13 96:2,18

97:1,2 99:1,5,18	208:17,20 209:1	299:13,18 300:6,9	443:2,15 444:4,5	59:11 75:8 80:22
99:19 100:10,16	209:11,16 212:19	300:11 301:2	444:13,22 445:21	86:9 101:13
100:21 101:5,6,15	213:7,9 214:11	302:6 304:11	446:1,11 447:10	104:12,17 109:4
101:19,20,21	215:2,12,17 216:5	306:21 307:4,10	449:4,19 450:3	123:7 137:20
102:1,5,16 103:3	216:16 217:4,15	307:11 308:3,7,8	452:6	161:11 187:8
103:20 104:7,9	218:21 219:3	308:10,12,15,16	<b>thinking</b> 60:22	198:19 213:8
105:4,8,10,19	220:1,16,18	309:1,11 310:2,18	61:20 67:18,18	219:19 226:6
106:7,9,10,11,12	221:11 223:7	312:12 313:18	74:19 75:18 81:14	244:20 248:2
106:16,21 107:5	224:8 225:21	315:3,19 316:2,9	81:17 82:2,11	249:10,22 250:6
108:19 109:9,12	226:1 227:20	316:10 318:16,21	83:7 90:6 104:6	255:1 257:6 283:9
110:5,6 111:6,13	231:8,20 232:4,13	319:4,11 320:1	112:6,21 117:1	291:1 303:17
111:14,20 112:1	232:21 233:2,12	325:14,20 329:17	119:5 141:11	306:2 311:16
112:15 113:6,11	233:19 234:8,12	331:3 334:1,14,19	146:6,16 150:13	334:10 365:12
114:15 115:5,18	234:13,16 235:22	335:4,6,8,11,20	154:11 155:13	368:3 390:9
115:19 116:14,19	237:4,5,10 238:21	336:2,7,21 337:5	157:2 174:20	409:18 437:22
117:4 118:8 119:7	239:2 240:5,12	338:6,11,13,22	186:14 187:15	442:22 443:1
119:8 120:16,19	242:2 243:21	339:13 340:17	189:6 194:21,22	<b>thoughtful</b> 246:12
121:1,13 122:19	244:16 245:2,10	341:6,21 347:6,22	198:4 199:22	<b>thoughts</b> 85:22
123:3 125:9 128:8	245:13 246:4	351:8,11 353:3	202:6 207:6,9,17	131:6 157:19
128:10,14 130:19	247:10 248:6,7,13	356:4,12,14 357:3	210:2 211:19,21	198:6 200:4
131:9,15 134:11	248:15 249:2,2,19	357:14 358:18	215:3 221:3 233:4	299:21 300:2
134:16 135:14	249:21 252:11	360:15 362:10	233:13 237:5	395:1
136:6,14 137:2,13	253:6,12,17,19	365:3,6 369:6	253:19 257:4	<b>thousand</b> 269:18
137:17,19 138:6	254:13,15 256:18	370:13 371:15	259:3 261:1,20	<b>thousands</b> 237:3,3
139:8,21 140:4,22	256:20 257:2,11	374:22 375:4	262:15,16 271:11	<b>threads</b> 82:1
141:1,19 142:14	257:19 258:6,7,13	380:1,5 381:7	276:11 277:16	<b>three</b> 8:1,6 19:14
142:18 145:4	258:20 259:22	383:5 385:7 386:7	278:3,12,19	24:8 34:8,16
146:6,16 148:10	260:7,10,15 261:4	386:14,15,18	299:16 306:9	37:12,15,20 41:13
149:17 150:4,6,16	264:4,7,15 265:14	387:3,5,7,9	313:20,22 314:21	44:2 48:18 59:16
151:7,17 153:5	266:22 268:12,14	391:18 393:4,14	315:21 328:10	59:17 61:21 73:20
154:15,18,20	268:18 269:2,9,15	394:1,9,18,21	334:19,21,22	75:21 81:2 93:5
155:12,16 156:17	269:17 270:8	395:21 398:15	335:2 336:11	115:1 116:18
159:22 163:6	271:3,5,6,13	402:15,19 403:8	345:3 356:5	122:2 136:6
165:9 170:17	272:16 274:5,8,10	403:16 404:22	372:17 394:10	138:16 157:15,16
172:19 178:9	276:3,4,7 277:7	405:17,17 406:21	395:4 449:21,22	161:21 162:4,5
179:2 182:12,13	277:11,18,20	409:9 412:6,21	<b>thinks</b> 406:9	171:6 178:6
182:19 184:9,12	279:3,4,21 280:6	415:20 416:1,8,10	<b>third</b> 36:10 42:8	180:18 181:3
184:15 185:4,21	280:8 281:1,21	417:11,15 418:18	43:13 85:10 122:6	182:19 190:8,18
186:2,22 188:6,16	282:2,12 285:4,11	419:7 422:9	161:1 190:11,14	223:20,20 243:7
189:19 190:4,18	286:3,8,13,14,18	424:18 425:6	191:13 194:18	250:1,2,17 251:17
191:13,13 193:6	287:15 289:1	428:13,14,17,19	266:6 297:20	251:21 256:7
194:8 195:1,3	290:15,16,20	431:16,18 432:14	308:21 313:7	258:17 260:10
196:7,14 197:6,16	291:10,14,16,22	432:20 433:4,5,8	365:17 366:6	264:1 265:22
198:16 201:16,17	292:12,15 294:5,6	433:14 434:3,4,5	<b>thirdly</b> 322:2	276:16 289:5
201:18 202:2,5,12	294:10,14,16	434:6,7,12 435:12	<b>thought</b> 16:16 22:8	293:6 298:9
204:13,16,21	295:10,20 296:8	437:1,5 439:7	23:17 29:8 34:16	302:10,10 304:11
205:6,17 206:2	297:12,18 298:20	440:3 442:4,10	45:17 52:9 59:6	305:3,16,22 310:5

316:14 317:7	260:20 296:9	80:20 122:20	<b>tracks</b> 374:13	38:20 48:3 112:20
318:9,15 319:1	301:5 304:6	149:13 150:5,13	<b>traction</b> 338:9	169:14 177:18
320:7 321:12,15	307:17 314:15	204:3 245:7 249:7	<b>traditional</b> 101:15	184:18
321:19 326:13	316:5 324:7 336:5	294:18 297:16	128:14 339:5	<b>tremendous</b> 60:15
337:17 342:12	344:17,20 350:2,9	308:14 318:19	366:11	264:11
345:14 349:22	350:10,21 351:11	319:13 327:8	<b>traditionally</b>	<b>trial</b> 399:6
350:15 360:6	353:4,5,6,13	340:5 355:5	103:22 115:17	<b>trials</b> 369:14
365:8 367:6 374:8	356:18 357:15,18	357:11 359:4	125:13 152:19	<b>tricky</b> 219:2
376:1 377:19	362:12 375:20	449:11 453:5	167:21 188:11	<b>tried</b> 77:16 111:8
378:1 379:18	376:12 379:20	<b>toes</b> 155:8	189:13 213:8	143:1 150:20
380:17 396:19	380:7 381:10,13	<b>told</b> 157:17 194:8	293:10 354:3	180:8 196:15
418:15 426:6	383:8,21 389:9	351:1	<b>trainees</b> 360:13	<b>trigger</b> 66:17,19
449:10	390:18 392:4	<b>tomorrow</b> 93:22	388:3	<b>triple</b> 10:11 12:11
<b>three-part</b> 29:21	400:19 406:15	318:11,13 319:12	<b>training</b> 372:6	32:4 37:13 53:4
33:3 37:13 57:20	420:20 421:14,19	327:9 357:12	<b>transcribing</b> 16:21	130:8,13 271:15
325:2	422:2 425:2	433:10 451:15	<b>transcript</b> 17:3	271:16,17,19
<b>throw</b> 137:20 201:3	426:15 427:9	452:4 453:20	<b>transfer</b> 420:22	333:16
<b>throwing</b> 300:14	428:19 431:21	454:6,9	<b>transferring</b>	<b>triplicate</b> 326:15
<b>thrown</b> 87:1	433:7 443:20	<b>tomorrow's</b> 232:20	154:16 414:7	<b>trouble</b> 87:2
<b>Thursday</b> 347:1	444:7 446:12	<b>ton</b> 88:3 155:18	<b>transformation</b>	215:14 321:21
<b>Ticket</b> 45:16	448:13 449:3	<b>tonight</b> 244:8,11	276:10	<b>troubled</b> 389:15
<b>tie</b> 379:14	<b>timeliness</b> 169:7	383:4	<b>transformative</b>	<b>troubles</b> 141:13
<b>tied</b> 277:6	<b>times</b> 81:2 91:14	<b>tool</b> 208:11 210:2	155:11 194:17	<b>true</b> 81:9,16 86:12
<b>tiers</b> 44:2 190:8	120:19 123:8	211:8 241:17	<b>transformatory</b>	106:9 243:18
<b>ties</b> 57:1	175:7 254:15	417:3,8	193:4	316:9 364:4
<b>tight</b> 290:15	354:20 366:1	<b>tools</b> 315:20 339:20	<b>transition</b> 99:11	431:12 440:5
<b>tightened</b> 23:20	376:1 385:15	<b>top</b> 34:16 38:5	349:16 417:4	<b>Truly</b> 118:1
<b>till</b> 157:16	<b>time-limited</b>	43:12 75:20	<b>transitions</b> 424:12	<b>Trust</b> 165:17
<b>time</b> 7:9 8:7 21:22	358:19 361:15	122:22 165:22	<b>translate</b> 134:2	<b>try</b> 44:8 45:18
21:22 24:2 26:16	362:12 380:14	170:2,8 248:4	328:16,17 356:13	59:12,21 73:13
27:20 35:12 45:3	408:11	<b>topic</b> 19:12 20:21	407:4	87:18 99:17
60:10 68:19 70:22	<b>timing</b> 28:10 442:9	170:16	<b>translated</b> 96:16	102:16 114:20
84:16 89:13 90:5	<b>title</b> 387:20 388:7	<b>topical</b> 286:15	264:13	119:10 150:19
91:3,4 95:18	388:16 389:5	<b>topics</b> 170:1	<b>translates</b> 54:12	156:22 159:3
113:7,9 115:6	<b>tobacco</b> 48:16	<b>toss</b> 188:20	<b>translation</b> 328:2	176:12 191:21
133:10 134:3	55:10,17 117:12	<b>total</b> 416:8	<b>transparency</b>	193:2 197:19
136:17 143:17	117:17 177:1,19	<b>totally</b> 99:7 217:2	201:13	217:13 227:7
144:21 145:15	224:12 247:18,19	344:19 369:7	<b>transparent</b> 328:5	242:4 250:8
147:9 157:13	249:15,16 255:4	385:6	<b>transportation</b>	252:10 256:22
164:10 165:7	255:14 260:5	<b>touch</b> 200:9 228:21	196:2 197:8 213:2	305:19 354:16
173:2 174:17	265:18 273:2	<b>touched</b> 42:14	213:10 220:13	357:2 366:17
180:9 202:10	281:10 287:12,13	<b>trace</b> 329:4	222:22 241:11	369:9 387:19
221:13 224:8,12	<b>tobacco's</b> 265:9	<b>track</b> 79:18 224:22	312:22	400:17 418:20
227:22 228:14	<b>today</b> 6:7 18:9	263:16 362:9,21	<b>travel</b> 381:4 414:4	422:15 430:7
229:5 230:4	22:17 28:5 35:12	364:2	<b>treat</b> 239:9	<b>trying</b> 20:3 39:18
248:11 251:19	39:14 46:15 57:17	<b>tracking</b> 274:19	<b>treating</b> 421:19	48:13 51:22 60:3
254:9 255:14	69:22 70:17 77:13	361:5,9,21	<b>treatment</b> 26:13	60:10 69:3 81:22

86:19 88:9,15	269:9 273:13	293:20 298:11	<b>unfair</b> 240:12	288:8 329:9,10,15
89:6,13 96:20	279:3 292:21,21	333:20 349:15	<b>unfit</b> 327:10	330:2,10
103:7,10 105:10	293:6 295:8	400:11 417:7	<b>unfortunately</b>	<b>uptake</b> 234:4
111:15,17,20	297:21 310:8,16	450:4	292:3 377:4 398:2	<b>urban</b> 172:19
119:7 133:7	315:17,19 321:11	<b>umbrella</b> 91:17	<b>unhappy</b> 258:8	178:4 382:11
137:21 139:19	326:2 331:5,8	425:3	<b>unhealthy</b> 84:5	<b>urging</b> 213:20
152:19 183:13	332:8,12 340:10	<b>unacceptable</b>	<b>unintended</b> 54:19	<b>USA</b> 170:6
191:19 195:17	340:11 345:6,16	239:11	63:20 64:2 142:15	<b>usability</b> 393:12
220:17 226:12	346:5 352:21	<b>unanswered</b>	352:14	394:2 401:18
227:9 250:3	357:17 368:7	404:16	<b>unintentional</b>	402:4,10,12
253:14 271:7	374:7 382:15	<b>uncertain</b> 435:12	66:14	445:13,13 452:7
306:10,22 308:13	386:5 395:22	<b>uncomfortable</b>	<b>unique</b> 20:7 383:12	<b>usable</b> 105:17
327:18 342:10	411:18 420:4	287:1	412:14 422:11	106:20 122:12
390:13 403:18	421:7 424:14	<b>underline</b> 69:6	<b>unit</b> 444:11	<b>use</b> 49:2 55:9 59:16
417:6,13,14,15	443:12 448:19	<b>underlying</b> 48:14	<b>United</b> 25:20 268:2	70:21 105:3 115:6
429:10,12,15	<b>two-part</b> 58:1 67:2	69:10 75:21 145:7	283:4 292:12,19	140:2 161:15
443:2	<b>type</b> 32:11 55:6,12	255:11 260:5	306:13,14	166:19,21 172:1
<b>TUESDAY</b> 1:6	55:13 67:17 91:5	265:7 267:14	<b>UnitedHealthcare</b>	173:11,12 176:6
<b>turn</b> 25:7 36:22	228:9 268:8	287:11 335:19	1:21	197:19 208:18
57:10 106:14	274:11 289:9	<b>understand</b> 51:11	<b>units</b> 57:9 161:16	213:6 225:16
158:15 231:11	303:16 315:7	71:20 74:3,16	<b>universal</b> 409:20	228:7 233:3
240:11 273:10	328:3 350:16	89:6 99:8 102:9	410:12 416:10	240:20 253:14
336:21 408:9	373:15 389:11	103:10 118:13	<b>universe</b> 290:17	270:9 271:2 286:4
<b>Turnock</b> 182:12	393:1 416:12	121:5 125:11	<b>university</b> 1:18,22	289:16,18 293:18
184:16	421:16	132:7 139:9	2:4,20 7:21 9:22	293:21 298:6,15
<b>twice</b> 421:10	<b>types</b> 20:4 36:15	164:11 172:5	12:2 26:11 373:8	301:5 303:8 307:1
<b>two</b> 6:18,21 20:12	47:1 119:18	174:2 181:18	<b>unknown</b> 361:2,6	307:6 310:20
37:14,17 61:21	160:14 162:5,12	208:3 209:8	361:10 364:10,20	314:9 322:15
71:14 76:12 78:17	162:16,17 163:20	226:10 240:3,7	<b>unleash</b> 193:8	329:1 334:2
88:17 95:3 96:21	167:13,20 172:13	259:18 335:9	<b>unnatural</b> 74:15	339:20 343:6
98:8,10 117:10	176:11 177:16	364:8 395:12	373:6	346:22 364:16,17
119:1 121:21	191:18 201:14	401:21 413:4	<b>unprotected</b>	375:10 384:6
122:17 137:9	204:9,18 210:6	429:4,10 434:16	376:19	385:12 397:11,12
139:15 148:7	223:5 232:10,15	448:2 450:21	<b>unreadable</b> 114:5	443:15 449:2
153:13,16 157:15	288:20 327:11	<b>understanding</b>	<b>unrolling</b> 94:2	451:19
161:13,18 164:14	344:11 397:15	64:11 87:2 98:4	<b>unsatisfying</b>	<b>useful</b> 84:11 89:11
167:12 171:4,7	403:22	113:7 165:5	102:12	101:1,7,13 104:17
174:13 175:16	<b>typical</b> 149:7 210:9	166:12 170:17	<b>unusual</b> 207:20	118:6 123:8 135:1
180:17 181:2,10	328:1 345:4 353:7	178:8 199:19	<b>upcoming</b> 24:2	149:13 155:10
183:12 186:20	353:11	212:17 233:16	<b>update</b> 18:18 19:14	208:14 214:13
187:12 188:10	<b>typically</b> 13:1	243:9 262:6	25:5 114:22	216:8 224:8 226:1
189:10 191:22	221:1 428:10	389:13	<b>updated</b> 350:12	226:15 231:21
196:16 216:13		<b>understood</b> 73:19	445:22	232:14 274:6
229:9 230:18	<b>U</b>	265:6 413:15	<b>upstream</b> 36:14	280:19 308:8,9,15
232:15 248:18	<b>ultimate</b> 258:19	<b>under-served</b>	53:16 78:14	309:5,13 329:8
249:3 251:16,18	<b>ultimately</b> 217:21	354:4	163:16 168:10	332:14 339:1
252:2,17 256:6	248:17 283:19	<b>undue</b> 402:18	217:10 223:2	376:22 382:9,13

401:22 413:6 449:12 <b>usefulness</b> 311:9 402:1 445:18 <b>user</b> 412:3,7 <b>users</b> 282:11 423:18 <b>uses</b> 104:22 263:1 289:14 <b>usual</b> 150:6 252:7 <b>usually</b> 147:3 263:1 353:8,10 <b>U.S</b> 5:7 9:11 163:6 209:3 226:10,11 226:12 251:21 366:12	428:20,22 429:16 437:20 449:2 <b>vaccines</b> 393:19 396:17 398:16 431:3 439:20 <b>valid</b> 105:16 292:6 361:9 362:5 363:2 363:22 375:11 376:9 393:16 394:1 <b>validity</b> 122:15 199:3 359:20 381:1 392:15 393:12,14 394:21 395:16 398:22 400:22 401:4,7,15 408:12 409:6 441:21 442:16 444:19,20 445:1 445:10 <b>valuable</b> 202:2 335:2 <b>value</b> 168:20 179:6 311:20 388:22 447:17,19 <b>variability</b> 365:19 <b>variable</b> 193:15 <b>variation</b> 139:10 139:10 <b>variations</b> 123:20 184:3 <b>varies</b> 205:22 377:5 <b>variety</b> 203:1 259:16 343:2 359:13 385:4 <b>various</b> 31:9 32:15 52:16 54:4,11 55:19 57:9 77:1 86:19 104:2 109:14 160:3 200:20 210:17 222:7,7 403:17 417:4 <b>vary</b> 171:15 315:7 <b>vectors</b> 438:13 <b>Venn</b> 177:2 187:9 191:8 250:4	<b>verified</b> 369:5,8 <b>version</b> 294:11 339:9,15 393:6 <b>versus</b> 65:19 107:4 116:14,17 119:5 208:21 222:20,21 222:21 257:1 258:2 260:16 264:18 276:14,15 372:4 373:2 389:8 447:20 <b>Veterans</b> 9:8 <b>VHA</b> 9:10 <b>vice</b> 15:3 25:19 27:11 <b>view</b> 31:8 42:6 46:7 74:2 92:20 245:3 249:7 273:16 375:15 383:3 400:11 448:21 <b>viewing</b> 41:21 <b>views</b> 27:2 262:1 <b>vigilant</b> 315:5 <b>violence</b> 66:13,15 <b>violent</b> 67:19 <b>virtually</b> 260:22 <b>vision</b> 161:19 164:19 307:5 <b>visit</b> 430:16,17 <b>visits</b> 45:4 67:15 430:15 <b>visual</b> 23:12 300:7 336:8 <b>visuals</b> 321:13,17 <b>vital</b> 173:15 328:9 <b>voice</b> 178:13 301:10,11 <b>Volume</b> 203:14 <b>voluntary</b> 278:22 <b>volunteers</b> 321:12 360:14 362:8 <b>vote</b> 19:17 97:9,19 102:1 193:19 316:22 339:22 340:2 365:13 398:21 399:20 400:4,5,16,19	401:7,8 402:11 405:12,22 434:21 435:4,7 437:12 440:9,15,20 441:20 444:15 445:7 452:7,8,12 452:13,13,16,18 452:19 <b>voted</b> 401:14 443:2 443:3 452:15 <b>votes</b> 357:4 401:9 <b>voting</b> 146:1 339:19 391:16 398:20 400:1,9 401:6 433:15 436:1,15,18 437:2 440:16 445:6 <b>vulnerable</b> 375:17	54:14 56:4,14 57:13 59:5 73:3 74:22 77:6 81:13 82:20 83:2 84:20 95:4 98:3 99:14 105:11 109:1 112:3,22 113:13 114:16 115:19 128:6 136:2,15 138:21 142:16 143:12,13 144:11 147:4 152:18 154:18 156:20 157:6 161:9 164:16 166:15 170:8,9 174:1 176:12 181:3 188:4 189:22 190:6,18 192:8 195:14 198:10 199:11,17 200:18 204:8 206:21 207:18 212:8 216:18 218:20 220:2 221:20 226:10 227:11 237:22 238:17 240:11 241:8 244:7 246:6 247:14 251:9 253:17,19,20 258:13 260:6 262:14 270:19 277:10,18 286:4,4 288:14 291:17 292:2 294:2 295:14 296:9 298:8 301:12,13 302:1,6,14 309:3 315:18 316:21,22 318:16,18 320:13 324:19 327:21 328:13 335:21 338:14,16,20 339:12 341:7 347:21,22 348:8 351:21 355:19
<b>V</b>			<b>W</b>	
<b>vaccinated</b> 342:22 345:10 364:11,22 375:22 379:3 386:22 390:4 407:16 413:21 416:4,7 420:8 422:2 429:6,19 438:9 <b>vaccination</b> 341:9 344:19 345:10,11 355:12,18 358:2 359:19 360:19,21 361:2 364:5,17 367:11 373:2,4 385:17 395:20 396:8,15 397:14 397:21 398:1,10 407:15 432:6,8 447:12 <b>vaccinations</b> 244:2 385:22 <b>vaccine</b> 344:15,15 346:2,10,13 349:4 350:11 351:13 352:5,9,16,17 354:4 357:8 363:13 375:18 408:19 409:1,2 422:1,8 424:21			<b>wage</b> 148:19 <b>wait</b> 318:3 353:4 441:10 <b>waiting</b> 206:3 319:1 389:9 454:1 <b>walk</b> 43:8 63:3 73:21 88:17 104:13 105:22 108:19 114:9 144:1 227:7 382:16 433:10 449:16 <b>walkability</b> 254:6 260:8,11 <b>walkable</b> 214:20,21 259:12 281:15 <b>walked</b> 348:5 <b>walking</b> 149:6 <b>wall</b> 92:9 300:14 303:8 <b>Walmart</b> 85:10 92:8 <b>Walmarts</b> 92:8 <b>want</b> 6:10,12 7:1 8:4 14:5,17 15:15 15:22 16:5 34:3 35:22 36:18 44:7	

365:4 366:4,16	93:17,19 96:12	450:2	264:6 287:16	64:12,13 66:8,13
367:3 370:14	98:12 99:5,19	<b>ways</b> 26:20 45:16	<b>Well-matched</b>	68:13,20 71:20
371:20 379:6	103:2,7 112:5,10	55:19 61:22 62:1	439:19	72:12,14,14,16
382:2,19 383:20	117:3 118:5	84:12 104:5 118:7	<b>well-represented</b>	73:2,5 74:12,14
386:20 389:1	128:20 133:18	120:8 125:18	40:12	78:22 79:17 81:17
392:8 393:2,9	134:12,12 137:17	126:17 159:9	<b>went</b> 77:16 91:16	82:10 89:14 95:1
395:1 406:11,16	137:18 140:2	165:20 167:1,11	156:7 227:16	100:6,21 101:6,16
412:5 414:12	141:19 146:5	180:10 261:20	242:7 283:8 321:8	101:19 102:9,14
416:2 433:21	148:20 162:6	262:8 269:12,14	348:7 454:3,12	103:2,10,16,16
435:4 441:19	169:15 171:8	276:18 365:19	<b>West</b> 89:5	105:4 106:7,10,16
444:13 445:12	173:3 184:20	424:2	<b>Western</b> 2:19 7:20	108:11,21 110:7,9
447:10 452:21	187:9 189:2,6	<b>weaker</b> 378:13	<b>wet</b> 249:11	111:20 112:21
453:22	195:6,17 201:18	<b>wealthy</b> 371:7	<b>we'll</b> 15:11 16:8,9	114:7 116:15,20
<b>wanted</b> 16:17 17:6	203:7 210:16	<b>wear</b> 45:14	18:21 26:16 27:7	118:13 119:7
21:21 25:7 39:7	211:9 214:17	<b>weave</b> 81:22 111:9	29:11 38:15 41:8	121:15 124:1
39:10 40:5 42:5	217:8 226:1 227:1	134:22	46:15 60:5 64:7,8	126:5 127:1,19,20
42:15 44:19,21	227:14 230:20	<b>Webber</b> 2:5 10:6,7	66:8 71:10 95:7	128:2,4,7,20
48:5 65:10 66:10	236:12,14 237:4	82:19 219:17,17	99:6 100:21 101:2	129:4 130:2
76:4 112:4 139:9	239:20 240:10,16	268:13 279:2	102:16 114:13	132:10 134:6,19
171:18 244:9	240:19 243:17	282:2	122:8 126:6 139:5	135:7 140:5
252:14 274:8	246:10 247:13	<b>webinar</b> 23:3 159:2	142:19 155:22	142:20 145:16,19
278:2 316:20	248:8,18 249:2	310:3,4	163:14 164:7	147:6 149:1,2,13
334:4 352:7 386:5	252:2 253:8	<b>website</b> 30:17	195:3 217:17	149:16,22 150:13
398:14 413:3	255:20 256:7,12	311:15	227:1 228:21,22	150:22 151:19
427:11 448:12	257:4 258:7,10	<b>week</b> 91:14 157:16	229:9 231:15,15	152:1 153:2 154:5
<b>wanting</b> 261:20	261:1,5,16 262:7	340:19	234:2 243:16	156:15 157:20,21
<b>wants</b> 112:19	264:22 275:7,22	<b>weekend</b> 55:4	246:2 252:10	158:12 159:5
192:13 308:10	276:5,11 280:17	<b>weeks</b> 6:3 17:5	261:13 285:19	169:8 173:10,11
311:3 390:14	282:13 298:7	157:15,16 421:2	298:14,15 307:10	174:21 178:16,17
401:2 453:11	301:5 307:21	<b>weigh</b> 34:3 296:21	310:17 317:13	181:5 184:11
<b>Wardman</b> 1:9	309:3,14 310:15	<b>weight</b> 246:16	328:20 338:13,17	186:2 188:12
<b>Ware</b> 292:2	313:3 316:6 322:6	<b>weighted</b> 306:16	339:20 355:8	191:18,22 192:2
<b>warrant</b> 24:22	327:12 328:4	<b>welcome</b> 3:2 25:12	357:2 399:2	193:3 199:11,18
<b>Washington</b> 1:10	337:10,12 339:21	28:16 29:1 85:17	402:11,14 406:22	200:10 202:19
5:10 11:12	343:4 348:14,17	228:17	417:12,13 433:5,7	203:2 204:8,12
<b>wasn't</b> 67:18 98:6	349:2 351:22	<b>welfare</b> 163:8,18	435:7 440:7	207:18 212:6,20
157:16 198:12,13	354:10,15 356:6	<b>wellness</b> 65:1	441:16 452:3	220:1,16,17 223:5
214:4 341:15	363:4 370:11	161:19 282:18	454:9	223:8,10,18 224:2
362:20 445:19	382:9,12 383:18	283:11	<b>we're</b> 4:11,18 5:9	224:4,18 225:5
<b>waste</b> 82:7	384:1,10 388:15	<b>WellPoint</b> 2:2	5:13 10:8 13:18	226:11,12,22
<b>watch</b> 190:4	389:1,15 390:1	12:21 281:6	16:1,6 18:1,6,10	227:6,6,22 228:7
<b>Watching</b> 130:8	391:1 393:22	<b>well-being</b> 39:12	18:20 19:4,21	235:22 236:4,4,7
<b>way</b> 38:1 41:21	400:11 414:4	39:15,20 41:3	20:3 22:3,4 24:21	236:8,12 237:5,12
50:21 59:17 70:5	415:18 418:10	47:14 149:3	28:1,2,12 33:22	239:11,18 240:13
70:14 73:2 74:14	421:3 429:4 430:8	189:18 303:22	44:8 49:14 52:7	240:14 243:5
81:14 84:3,17	435:1 438:18	304:13 331:1,15	53:17 54:2 55:2	244:18,19 249:2
89:16,17,18 93:17	448:6 449:18	<b>well-established</b>	57:7 60:3 62:19	250:19 252:8

253:14,19 254:6,7	111:11,15 115:10	384:22 390:8,18	228:3,7,12,13	171:4,5 178:3
254:8,11 255:8	120:17,17,18	391:14,21 392:6	276:12,15,15	179:2 180:6
256:20 257:3	122:20 128:21	392:10 394:19	<b>wording</b> 120:11,12	181:17,18 185:11
259:5 261:4,11,22	136:12 145:14	398:19 400:6,18	<b>words</b> 41:2 86:22	185:19 186:12,12
262:3,4,11 265:1	147:21 154:8	401:9,13 403:16	107:1 125:7 154:9	186:19 191:21
267:14,20 271:7	180:8 189:13	404:11,19 405:6	172:17 249:15	193:22 195:22
271:20 274:14,19	213:1 216:15	405:11,19 406:8	270:16 286:1,2,3	196:5 200:2 201:8
276:4 277:9 280:9	219:22 220:12,12	407:8,21 408:3	286:5 344:5	201:10 209:17
288:15 289:3,10	220:13 223:8	409:9,12 418:8	345:13 363:6	210:19 211:15,16
289:12,21,22	232:2 236:14	423:5,16 426:9,17	<b>wordsmith</b> 128:3	217:8 223:14
290:1,16 292:9	246:8 247:4,4,9	430:9 432:3	<b>wordsmithing</b>	226:1 233:8 236:2
294:1 296:20	248:5 254:3 257:9	433:12 434:18	137:15	241:4 246:9,12
297:8 298:1,4,12	268:18 280:16	436:4 440:3,17	<b>work</b> 7:21 12:5	247:12 251:5
298:13 301:19	292:20 296:18	441:15 442:14,18	13:21 14:11,12	252:3 253:8 254:1
302:4,20,21,22	297:22 304:1	442:20 443:17	16:15 20:11,16	259:15 261:22
306:9,19 307:5	305:2 308:19	444:15 445:5	22:2,12 25:9 26:4	264:5,11,16
308:13 309:20	313:15 315:12	452:5 453:4,10,13	28:6,7,11,21 29:7	265:20 269:21
312:14,18 315:8	317:3 318:9 332:7	453:21	29:13 30:3 31:2	272:22 276:21
318:5,5,16 319:11	339:8 354:15	<b>winnable</b> 170:12	31:14 33:19 34:12	277:21 278:10
321:14 322:17	356:7 370:17	225:14 227:3	35:14,19 36:2	280:16 284:9,14
327:12,16,19,20	383:12 424:17	<b>wipe</b> 376:17	41:15 46:10 47:17	284:15,21 285:15
330:17 332:6	433:12 440:4	<b>wiper</b> 390:17	49:10 50:19 52:22	286:15 287:17
333:15 336:5	441:6,7 451:19	<b>wise</b> 133:21	55:20 57:1,7,18	293:16 296:3,14
337:8 339:4 340:5	<b>whichever</b> 106:20	<b>wish</b> 51:20 322:15	57:18,20 58:11,13	296:15,22 297:11
340:18 341:5	161:14	324:17,17	60:16 65:12 67:12	298:11 305:20
344:8 347:19	<b>Whoa</b> 321:13	<b>wishing</b> 231:5	69:15 70:6 73:14	306:4 307:12
348:16 354:22	<b>Whoever's</b> 203:15	<b>wonder</b> 68:7	78:15,22 79:5,16	309:18 310:19
355:11,22 356:11	<b>who've</b> 5:22	136:10,13 244:4	80:13 82:21 83:4	312:17 317:11
365:14 366:7	<b>wide</b> 71:11 100:17	251:22 288:15,21	83:13,15 84:6	319:13 324:6
371:16 376:11	<b>wilderness</b> 241:14	290:6 302:9	87:13 88:10,12	333:12 335:1,14
377:21 380:12,22	<b>win</b> 440:22	411:21	89:13 90:15 95:19	336:11 337:5
382:14,17 383:10	<b>window</b> 344:17	<b>wondered</b> 220:9	96:22 98:7,9	338:10 339:5
387:13,13 390:12	400:15	<b>wonderful</b> 27:14	99:11,15 100:13	340:20,22 343:8
391:22 392:12,18	<b>windshield</b> 390:17	84:15,17	100:20 101:4	348:4 355:6 356:2
394:17 398:16,21	<b>Winkler</b> 2:13 4:6	<b>wondering</b> 58:17	103:10 105:19,21	357:13 365:2
399:22 400:18,22	4:10 8:9,10	72:11 76:12	115:13 125:13,16	367:1 368:20
401:17 424:6	146:20 244:9	107:20 137:6	126:9 128:13	375:19 378:6
432:20 433:4,8	339:3 347:2,6	199:22 314:18	129:17 135:4	390:21 393:7
436:1,18 437:9,15	348:11,14 351:10	377:14 426:22	141:5,6 142:3	399:1 401:5 402:4
446:9 453:2	351:17 352:12,19	<b>Wood</b> 142:4	149:22 150:3,15	410:1 414:8 417:3
<b>we've</b> 17:11,16,18	353:3 355:4	<b>Woodley</b> 1:9	151:8,12,17	424:17 437:20
28:7 36:7 59:9	357:22 358:11	<b>word</b> 125:1,6	155:18 156:16	440:1 441:18
60:9 62:13 64:11	365:1 367:20	127:14 129:2	157:3,11,19,20,21	449:10 453:17
70:20 73:12 75:6	368:19 369:2,10	140:3 146:4	158:4 160:15,16	<b>worked</b> 27:13
77:16 84:10 94:5	369:15 370:4,13	155:14 165:11	161:2 162:16	46:22 63:2 151:2
97:1 100:5 103:20	374:20 376:20	166:19,21 179:11	163:11 164:20	159:19 171:19
104:6 105:2 111:8	380:21 381:6	185:22 213:5,6	168:18 170:15	173:18 178:21

202:8,9 205:19 253:22 284:14 316:3 342:11 407:3 <b>worker</b> 362:2 376:1 425:7,12 <b>workers</b> 363:11 371:2,4 395:9 425:22 438:9 <b>workforce</b> 278:15 279:6,17 280:10 386:6,10,20 387:20 406:20 <b>working</b> 36:8 50:8 60:6 62:7 76:21 88:5 94:5 114:7 145:16 157:14 171:11,15 179:12 194:11 195:4 204:12 214:15 229:1 274:14 279:8 285:18 290:18 318:9 360:2 362:16 383:13 399:22 417:10 <b>works</b> 87:13 98:5 100:18 121:5 133:15 140:21 334:14,20 384:2 385:11 436:3 <b>worksite</b> 280:17,18 280:22 285:5 <b>world</b> 10:3 27:2,3 56:16 90:5 140:21 143:2 147:16,22 227:21 287:21 <b>worlds</b> 83:1 88:17 <b>worms</b> 387:19 <b>worries</b> 65:6,8 66:6 <b>worry</b> 166:16 297:13 391:15 399:15 <b>worse</b> 330:14 <b>worth</b> 131:2 211:18 <b>worthwhile</b> 188:18 289:1	<b>worthy</b> 89:18 296:2 <b>wouldn't</b> 128:17 187:12 201:6 254:19 370:22 397:20 414:2 <b>woven</b> 293:3 <b>wrap</b> 52:10 60:3 453:15 <b>wraps</b> 57:11 <b>wrap-up</b> 29:12 <b>wrestle</b> 223:8 <b>write</b> 113:19 166:17 245:18 247:12 <b>writing</b> 149:1 176:16 204:17 300:12 <b>written</b> 190:1 198:6 199:20 326:17 339:15 397:4 <b>wrong</b> 138:6 142:20 378:13 <b>wrote</b> 188:2 194:7	251:16,18 252:2 252:17 254:12 268:4,11 270:7,9 290:19 333:21 342:12 350:15 365:9 374:8 377:19 378:1 379:19 380:17 418:15 430:22 <b>yellow</b> 177:15 <b>yeses</b> 452:20 <b>York</b> 1:22 173:14 <b>Young</b> 182:21 <b>youth</b> 44:16	<b>103</b> 3:10 <b>11</b> 401:10 440:21 <b>11:00</b> 18:14 156:5 <b>11:12</b> 156:8 <b>12</b> 242:2 397:11 405:20 <b>12:34</b> 242:7 <b>13</b> 1:6 145:13 445:8 <b>14</b> 12:21 <b>15</b> 229:9 239:18 309:17 310:1 376:2,4,7 397:11 406:8 <b>157</b> 3:13 <b>16</b> 3:5 342:17 343:10 345:5 359:11 409:21 <b>1659</b> 407:7,9 <b>17</b> 241:10 <b>18</b> 88:9 <b>19</b> 20:13 22:16 23:10 340:7	<b>2011</b> 1:6 <b>2012</b> 28:3 <b>2020</b> 284:8 <b>229</b> 3:17 <b>234</b> 359:8 <b>243</b> 3:18 <b>25</b> 109:20 156:11 320:5 <b>2660</b> 1:9 <b>28</b> 3:7 <b>28th</b> 353:20	
	<b>X</b>	<b>Z</b>	<b>2</b>	<b>3</b>	
<b>works</b> 87:13 98:5 100:18 121:5 133:15 140:21 334:14,20 384:2 385:11 436:3 <b>worksite</b> 280:17,18 280:22 285:5 <b>world</b> 10:3 27:2,3 56:16 90:5 140:21 143:2 147:16,22 227:21 287:21 <b>worlds</b> 83:1 88:17 <b>worms</b> 387:19 <b>worries</b> 65:6,8 66:6 <b>worry</b> 166:16 297:13 391:15 399:15 <b>worse</b> 330:14 <b>worth</b> 131:2 211:18 <b>worthwhile</b> 188:18 289:1	<b>X</b> 379:15	<b>Z</b> 379:16 <b>zero</b> 401:10,11 402:14 405:19 <b>zip</b> 382:7 <b>zone</b> 63:22	<b>2</b> 2 19:6 20:10,17 21:6,13,15 27:19 27:20 28:2 42:15 61:10 346:13 399:4 401:9,10 433:18 435:9 <b>2C</b> 136:12 <b>2nd</b> 353:16 <b>2(b)(5)</b> 398:7 <b>2(c)</b> 152:14,16 <b>2,700</b> 11:13 <b>2.A.1.1</b> 431:14 <b>2:23</b> 321:8 <b>20</b> 109:20 227:10 239:18 295:4 333:21 398:1 <b>200</b> 225:6 <b>2000</b> 316:4 <b>2002</b> 143:3 <b>2008</b> 229:11,18 <b>2009</b> 408:11 <b>2010</b> 230:15 350:10 408:14	<b>0</b> <b>0</b> 406:8 440:21 445:8 <b>02</b> 152:7	<b>3</b> 3 23:7 61:11 348:17 399:4 405:20 435:9,18 444:17 <b>3-4-50</b> 223:20 <b>3:08</b> 321:9 <b>30</b> 173:2 227:10 316:22 320:20 362:17 363:8 385:17 444:7 <b>300</b> 359:6 <b>31st</b> 360:3 <b>32</b> 34:14 <b>35</b> 45:7 <b>358</b> 3:21 <b>37th</b> 227:21 <b>38</b> 359:12
	<b>Y</b>	<b>1</b>	<b>4</b>	<b>4</b>	
<b>works</b> 87:13 98:5 100:18 121:5 133:15 140:21 334:14,20 384:2 385:11 436:3 <b>worksite</b> 280:17,18 280:22 285:5 <b>world</b> 10:3 27:2,3 56:16 90:5 140:21 143:2 147:16,22 227:21 287:21 <b>worlds</b> 83:1 88:17 <b>worms</b> 387:19 <b>worries</b> 65:6,8 66:6 <b>worry</b> 166:16 297:13 391:15 399:15 <b>worse</b> 330:14 <b>worth</b> 131:2 211:18 <b>worthwhile</b> 188:18 289:1	<b>Y</b> 2:12 379:15 <b>yeah</b> 101:21 147:5 219:10 256:18 263:18 266:2 268:18 368:4 <b>year</b> 8:7 33:4 60:17 81:2 94:10 125:15 283:4 306:17,17 353:2,9 360:4 367:19 385:15 421:9 422:3 <b>years</b> 6:19,21 24:8 29:22 31:3 32:17 47:21 60:7 65:14 88:9 92:16 93:4,6 94:6 115:1 147:10 173:2 175:1 227:10 230:18 248:18 249:3	<b>1</b> 20:15 27:18,19,20 27:22 61:9 129:8 346:14 347:14 399:4 433:18 435:18 440:21 445:8 452:10,20 <b>1C</b> 440:19 <b>1st</b> 28:9 33:21 353:17,21 360:3 <b>1(b)</b> 435:5 <b>1(c)</b> 151:6 <b>1,000</b> 224:19,22 <b>1.C.14</b> 439:16,17 <b>1:00</b> 231:16 242:1,5 <b>1:09</b> 242:8 243:2 <b>10</b> 397:10 402:13 444:17 452:20 <b>10:51</b> 156:7 <b>100</b> 225:6 318:5 345:7	<b>4</b> 4 3:2 104:15 114:8 149:6 399:4 401:10 435:18 440:12 452:9,14 <b>4(b)(1)</b> 403:3 404:17,21 <b>4(b)(2)</b> 404:18,20 <b>40</b> 109:17 <b>41</b> 417:15 <b>43</b> 359:11 <b>431</b> 355:3,11 358:1 <b>45</b> 291:4 <b>454</b> 3:22 <b>48</b> 30:22		
			<b>5</b>	<b>5</b>	
				<b>5</b> 3:3 402:13	



**5:25** 453:2  
**5:26** 454:12  
**50** 5:7 109:17  
 223:22 273:2  
 341:13 379:2  
 430:22  
**501(c)(3)** 7:11  
 11:11 13:8,11  
**522** 408:2,5  
**59** 359:10

---

**6**

---

**6** 435:18,20 440:17  
 440:18  
**60** 397:21 444:8  
**63** 367:18  
**64** 291:4  
**65** 40:15 431:9

---

**7**

---

**7** 203:13 204:3  
 215:14 435:19  
 452:9  
**75** 431:11  
**78** 359:10

---

**8**

---

**8** 193:11 435:9  
 440:12  
**8:39** 1:10 4:2  
**80** 398:1 431:11  
 450:22  
**800** 86:13  
**800,000** 281:18

---

**9**

---

**9** 452:14  
**90** 444:8  
**90's** 159:16  
**99** 183:1,11  
**99.98** 152:8

C E R T I F I C A T E

This is to certify that the foregoing transcript

In the matter of: Population Health and Prevention  
Endorsement Maintenance

Before: NQF

Date: 09-13-11

Place: Washington, DC

was duly recorded and accurately transcribed under  
my direction; further, that said transcript is a  
true and accurate record of the proceedings.



-----  
Court Reporter

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701